<SEC-DOCUMENT>0001558370-24-002861.txt : 20240311
<SEC-HEADER>0001558370-24-002861.hdr.sgml : 20240311
<ACCEPTANCE-DATETIME>20240311083052
ACCESSION NUMBER:		0001558370-24-002861
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240311
DATE AS OF CHANGE:		20240311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAPRICOR THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34058
		FILM NUMBER:		24736653

	BUSINESS ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211
		BUSINESS PHONE:		(310) 358-3200

	MAIL ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nile Therapeutics, Inc.
		DATE OF NAME CHANGE:	20070920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>capr-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:capr="http://capricor.com/20231231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" xs:nil="true" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" name="us-gaap:CommitmentsAndContingencies" id="Hidden__wfulCvmzkqblGrCoRiYMg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" xs:nil="true" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" name="us-gaap:CommitmentsAndContingencies" id="Hidden__16vxDQry0ijRuuleSYUWw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" xs:nil="true" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" name="us-gaap:PreferredStockValue" id="Hidden_csn4ML-U40qMKF0mNA918w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" xs:nil="true" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" name="us-gaap:PreferredStockValue" id="Hidden_gJAaLp8guEGZnxuR63MXJg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" sign="-" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_3fnBnzAAkUyQ2u5GgMTsEw">0.83</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Fem3QWtdUEWo4L6QdPIeUA">1.18</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Mxnah5-F00iP0zO9JTsDfw">26778360</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_tpsH8HWT8EuA-vvpMBjc_Q">24552688</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" name="capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" id="Hidden_inwFgsXzk0-bGk5MAURUnA">0.00</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityCentralIndexKey" id="Tc_lsCwHlMnQ0iAdGiQ_cSp1A_2_1">0001133869</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentFiscalYearFocus" id="Tc_HHfAbv4-Eki0H5yts5x5RA_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentFiscalPeriodFocus" id="Tc_8gnU6p36rEWmljlmt1QgTw_6_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:AmendmentFlag" id="Tc_03iAY4OVIEu9nYnOMWKkmg_7_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_4gDhwQPilEiomiZ2dYjYrQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_84EccO4aFU65I4npzyIOcw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_RycXJw99TkuhZ4oIC-N0ZA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_6QYLGWLrVE2j2Tqkh4daXw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_hQRFCNamYUa9BA896rhzWg">31148320</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_sJHoZlsetECWy9vfmM5zoA">25241402</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_uhAlupWMJEW3mHzcohO-jA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_4p8iOFeSNEmdNJAChajhxw">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_aR2fiAmS1k-ZXTjTa9frtQ">31148320</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_ncn7a3kMgkO12NbLrZBVLA">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="capr-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_10_3_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_-rsa000sD0a8m5UVTffp1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_3_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_bQCWtMxE70i-06Cl52c_Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_CaliforniaFranchiseTaxBoardMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_t5-jJPzGkk-S3fnBbEiOcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_hIIPvdfnnkWCVs4dZrEouA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_666ZzRUp-EqzLeKGKVR3Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2021_To_3_15_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_UJ-PEwE3u0eQNWZSzusEPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2024-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2021_To_12_31_2023_fcukxm__uEiN61L1wZ0xDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4X-qf24Pnkim2ijfGAzOrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_QonEck6FD0KdgFPM0l4WBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6T-zyWrrmkSBVCPBt8HidA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tf5OikZQFUONNK7Iknfs5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_E2rfLuwSdkG6a9ykiY4nqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J8eFa0zA6kGN_euvLuaNqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HU_mvTo810KMf88JbAhomA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ec85mF__lkWbIVrr9-VJSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i1t2nRzziUyi6BVPUlI6Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_qp1o0pSjSEynST8Sz742XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9vSuYHyy80Soi04pDnBeCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">capr:EmployeesNonEmployeeConsultantsAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_MichaelKelliherMember_What73q3UE2-6pZFUmISsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:MichaelKelliherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_m81pZxvbV0ifPEk3pIVFTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:AdvisoryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:DrEduardoMarbanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_R17I3foYh02N_TLWyWcP4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:AdvisoryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:DrEduardoMarbanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_60dARrLHYEG7PVahuY09wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_eiRHIQU2P0-iE89u76MZug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_FGAMc8suqEKYI1VbJay2BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_cQDaPBIGKkWSfcAzIJL2Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_11_2021_To_6_11_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member__c5YnH6Py0aKqf8BOj9xog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-11</xbrli:startDate><xbrli:endDate>2021-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_DBWOt4gfCES-rIx3f5YORA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_B-Y637VwK06PJ8NRgj159g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_3hggLcl2wEOMWMDA2p08QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__dhbnCoFj0mFXSecYuidNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:OverduePaymentObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_YSrt3eyVpUyrEiyR3LkflQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_7DiFd0JLoUiEm79PuGWQEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_uhAlupWMJEW3mHzcohO-jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_bqLzk-PKtkyrIwepnUrEfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_xpiwJvCFFEONVOfrrGbCGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5ZNv_wjOyUmsCoYiegAY_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pKISfRGyWUC5dXwS0_Kalw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RmDL9OhBUESyNzJ0kgQcWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_9P99ospyIU6YpKdhtGl_Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_H_E_Lr6_YUepovFiKb6S1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GkllSxdfAUuGq58nSnX8Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_aYVKDRCxe0SMDBzgeTcNdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:TransactionOtherThanSubawardAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__Feo3dGKN0Sy2w8lAyM8Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:TransactionOtherThanSubawardAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_0FeZ1sWYakOU07ed4P8ELw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_zfDRweqJO0KyY-n8-mOXUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_KTrLvd7n_kW3fJkJoMqk2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="capr:UnrelatedPartyAxis">capr:UnrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="capr:UnrelatedPartyAxis">capr:UnrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_ztBgOe6LO0utYsvlcIn3LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5BsNuYaQz02q8UT51aO1_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BT9Hpe-z3EmOCGA9Ohlt9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_srt_RangeAxis_srt_MaximumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_pZgkKv4xj0G4O10XC-Wx9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_RangeAxis_srt_MinimumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_khGZ9fyPC02WUrVz7NyC4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_5EcEBXyvWkCaPP71aV_17g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_FacilitiesLeaseMember_X5iGALpimEK3OkzCpCCfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_gO-91n0nUE2kR2Y9RTTwLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_QldM9U_12EOep7ZCnuvYiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_1YjBI06wLU-zMo3y3uhc5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_us-gaap_VariableRateAxis_capr_LiborMember_bGOtzNXAZUys8V9CVS72yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">capr:LiborMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_oeC63qvRMkKBhVSqouykUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_qQnWowdCk0ycTDEN3vYiFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_d-yKIQOYmUyiV6A4kVWmVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_xrETY022i06_Ku6R6SeboQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2030TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2030TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lcBRc0KVsUmNSWtqubCDrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4jUtqUF9xUW3YXYFwchNdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_b5u34GlNrU6qAr1zibPqjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_b4udqpao7UWs4Wn0sMDiOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P0GvjWMIp0OgB3_UoJ_50A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tpwrEaOXFkyl_lEK9GeKjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ur1NlChm70CaqH2aI7vchQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rSWNvsGxUkyv-s30zMi0YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_381IvcRiHkGNroOTc9xh6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2024_locdSCvZGUSg9uuiWZPwEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:RomeLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_JVh39f55SEWCSfGr2sFfwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_hcCGu4aCq0aWdI1ic9gMFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_r9pBOG-cqUSu0_0p-X_SUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_hUhoFzMYxU2y08SvRW_3Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_l8hYv85mhkiSnt-G1Lj7Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_p6GoxGGgcE2JSpPe0-Rv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:NonPaymentOfRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_G6HBLmII80uwt4M0Xn301w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:MaterialBreachHasNotBeenCuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_fHaPByLkFEWmMCmmItdYUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_Xt587NoPDES43nwHwu-1Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToCureBreachAfterNoticeFromCsmcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2RTneoE4LUiql_wj_gb_WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_oHpjOTKGoUykLnbV-fTRSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_GyIsPMRQwEid4EesUv_0_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_24_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_f49c96jOM0qAScvbNEBu5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_raj702HzaEWCiJY45rn1UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_I1LoZTPxAU2_UBJz6muQiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_qFit8CulBkqXDIzMZnp4pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ZlaNNG4xJUeX586mgmAzAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_W4VghYTqKU60Dmy4MPpb1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_MLcvLvWUPEyWrlR72udH3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_2oh6xrIk3U6oGA7dPrVBkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-16</xbrli:startDate><xbrli:endDate>2016-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ConsultingAgreementWithFrankLitvackMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_X7Uz7GC3XUmBUEPTyo0nPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_CwHLfODuHEWscaDC4mM3SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="capr:MilestonePaymentsInPhasesAxis">capr:CompletionOfPhaseTwoDueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_-d6RYF7mlUWi4_x3ZsGV7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:OverduePaymentObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_jFLITrcimUyqsFvsZebRCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="capr:MilestonePaymentsInPhasesAxis">capr:CompletionOfPhaseTwoDueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:LicenseAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_e9bkzfMXvE6M55FAWBdCdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2023_To_9_30_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_S7NB6S2w7UatfWnNM-rVaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_7_1_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_1IeDcw5S-Emny3Ah0glf7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_gQ0jiQuHOkO7EnvSiVT1AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_gpq9drB0NkmE4zplTZT6kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_bD2EIdyBUUuS0qgSmQHcbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_RVq8CNEcHEiNiTlY9gUr_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_8kCOk0e360iW2gA4XW8iYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_t8_RP8tgw0mTuYIP9tOUPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_HyvjpaP4ukelUP5RqqGhUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2021_To_6_22_2021_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_uDaog7QSQEmqbstoEX4SJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_ZkaD9BdX-Ue4UjbW-P8o9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_nwrh_aVVjkGtRzSmUAp6Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:RomeLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_bybMKDXxsEWCLX8wsTPgbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:NonPaymentOfRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_kNOGvDAtg0KsQmmw19rGSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:MaterialBreachHasNotBeenCuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_vjuMg_ZNqkuHDVxlRGx3Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_2-wubRxozEmpbQcL1C0TJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToCureBreachAfterNoticeFromCsmcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_EUR_1WG7i0WyeU6pv6Zueih0aw"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_49COgzvYRkSizuPr91icIw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_16395vBjAEypAKpz4atoug"><xbrli:measure>capr:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_rMuzb-X9s06FnUhxCkVIgQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d798985d_9207_4cd6_b027_53a8e8f8f6ca"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:5pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentType" id="Narr_iqlCdMbC8UyzoF4XxRiqBw"><b style="font-size:8pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:5pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_47687315_48da_45f8_ad9b_be26dc796191"></a><a id="Tc_FXZRiuJqekKlalnF24XoUA_1_2"></a><a id="Tc_PVmUZiyy5kyCmG2ugsTHfw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentAnnualReport" id="Tc_RuWiYAgRQ0uhGqIspXBYVg_1_1"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:87.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annual Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">for the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentPeriodEndDate" id="Narr_f6pPLlAsPkuxBCBPIYcmxQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:CurrentFiscalYearEndDate" id="Narr_xlO9V5oZqESmretmDmSezQ"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2023</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_f3ee1360_a31e_4d84_8b9f_d5b712f0152b"></a><a id="Tc_GISAYZSGtE-oYAVY3LSIIw_0_2"></a><a id="Tc_D_TXi4xFLk-6Q0Hb-ckcNQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentTransitionReport" id="Tc_b6-Y49QCqE2g1UFFLTKoLg_0_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:87.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Transition Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">for the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:3pt 0pt 0pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityFileNumber" id="Narr_by3vsobKXEWgT8LPlPqPwQ"><b style="font-size:8pt;font-weight:bold;">001-34058</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityRegistrantName" id="Narr_wbjybtmheUmCLYfZ7gow8g"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact Name Of Registrant As Specified In Its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:5pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_d2f2cdd3_844d_49cb_bb5f_4e9b0150ea86"></a><a id="Tc_hrdelqg4M0WABy_tBUB_lQ_2_0"></a><a id="Tc_2wwa1B4SO0qw_-2IOu1rfg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityIncorporationStateCountryCode" id="Tc_nJQ9dHkT8kyhhKelcG9nxw_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityTaxIdentificationNumber" id="Tc_kCwj3Lgq4kucP3mho1Auqw_1_2"><b style="font-size:8pt;font-weight:bold;">88-0363465</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b><br/><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityAddressAddressLine1" id="Narr__xI94C7R50SWBFrIChcgwg"><b style="font-size:8pt;font-weight:bold;">10865 Road to the Cure, Suite 150</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityAddressCityOrTown" id="Narr_ru8q-HkmEUWGLF0SaggG0w"><b style="font-size:8pt;font-weight:bold;">San Diego</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityAddressStateOrProvince" id="Narr_oyFSLuD_1UCyRJ5N8mIDfw"><b style="font-size:8pt;font-weight:bold;">California</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityAddressPostalZipCode" id="Narr_JQDWT5MlxEaNb1kuk86YrA"><b style="font-size:8pt;font-weight:bold;">92121</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices including zip code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:CityAreaCode" id="Narr_buM7vwKmFk6hJwTtFW8Xmg"><b style="font-size:8pt;font-weight:bold;">858</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:LocalPhoneNumber" id="Narr_4vCPIhc7qkefF-Rr2QBZEw"><b style="font-size:8pt;font-weight:bold;">727-1755</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_293c08fb_e8bb_4946_b8b9_b334468efd20"></a><a id="Tc_NB7RmE4wp0awmOot9n1s0A_0_0"></a><a id="Tc_ICZcpi8I3kSPQT9Fy-Rzhw_0_2"></a><a id="Tc_vTW8RZpM-kS6glri9M9Dbg_0_4"></a><a id="Tc_uec28xOgJ0aV5uYVK2xOKA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:middle;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:Security12bTitle" id="Tc_WGewaTB4_0WB7Q0HqNElPQ_1_0"><span style="font-size:8pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:TradingSymbol" id="Tc_jfUZdayyTEiuj8LtH_yA0w_1_2"><span style="font-size:8pt;">CAPR</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:SecurityExchangeName" id="Narr_-fkmpkMOXUa3QZGQnVqYvw"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_bR0uctebnEWpHxcSJGhvug"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityVoluntaryFilers" id="Narr_XiRN_NVg5UqTNjSo6Bf52g"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityCurrentReportingStatus" id="Narr_Qgihjnh3gU6zNh0bU7hn6Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityInteractiveDataCurrent" id="Narr_aHYU80TZlUOvztjITlhzcw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_de60562c_2849_4185_8488_76f31a820b5e"></a><a id="Tc_8A7r9Lcey0-rlxWTTbAKCQ_1_0"></a><a id="Tc_6OzBofWtSUK_0QOZjFyGSg_1_1"></a><a id="Tc_YR85j2vPtkmgK6CyWo6hIw_1_3"></a><a id="Tc_M9b7tCJimEqVpQapBAhDCA_1_4"></a><a id="Tc_V-jKlKmxykCnb9aWM9EWUA_2_1"></a><a id="Tc_GuxwtpSYGEyJXcv5oRMhhg_2_3"></a><a id="Tc_bIs3PHqmrEueTqKCk-Ruag_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"/><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityFilerCategory" id="Tc_Dai4pGm7QE-92-v6Qnr7hQ_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Wingdings';">&#254;</span></p></td><td style="vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntitySmallBusiness" id="Tc_3aQ96nU-_UCGG95aVsFsKA_2_4"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityEmergingGrowthCompany" id="Tc_9cENdOTauE6hHLhRdfBzcA_3_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:IcfrAuditorAttestationFlag" id="Narr_1psJ4wYq5UWqBzMmp1S2Ww"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_e9-P2gW50UCHLuRqNmjV6Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</span><span style="font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:EntityShellCompany" id="Narr_NAfFbNcb8kOeAbUcrxWUYg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> Yes </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of June&#160;30, 2023 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_381IvcRiHkGNroOTc9xh6Q" decimals="0" name="dei:EntityPublicFloat" id="Narr_1Z4bFuRjYU6fdtsH3qQdfA">119,715,277</ix:nonFraction>, based on the last reported sale of the registrant&#8217;s common stock on The Nasdaq Capital Market on June&#160;30, 2023 of $4.78 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">As of March 7, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_7_2024_locdSCvZGUSg9uuiWZPwEg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_-rL2AJCaNUifdyn3jCD3_Q">31,399,667</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:36pt;margin:0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Part III of this Annual Report on Form 10-K incorporates information by reference from the definitive proxy statement for the registrant&#8217;s 2024 Annual Meeting of Stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1fce1ca_114a_4e81_84b3_f7f67183e4f8"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"/><td style="vertical-align:bottom;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTI_672344"><b style="font-style:normal;font-weight:bold;">Part&#160;I</b></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUSINESS_934608"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUSINESS_934608"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_519944"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_519944"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_587459"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_587459"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1CCYBERSECURITY_749782"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1CCYBERSECURITY_749782"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM2PROPERTIES_686301"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM2PROPERTIES_686301"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_177465"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_177465"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_831629"><span style="font-style:normal;font-weight:normal;">Item 4</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_831629"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:middle;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTII_650295"><b style="font-style:normal;font-weight:bold;">Part&#160;II</b></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_208778"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_208778"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_15000"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_15000"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#item9B"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#item9B"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTIII_949158"><b style="font-style:normal;font-weight:bold;">Part&#160;III</b></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_737825"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_737825"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTIV_304221"><b style="font-style:normal;font-weight:bold;">Part&#160;IV</b></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:10.56%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_363246"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_363246"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">121</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#SIGNATURES_842538"><b style="font-style:normal;font-weight:bold;">SIGNATURES</b></a></p></td><td style="vertical-align:bottom;width:6.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">122</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.41%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><b style="font-weight:bold;">INDEX OF EXHIBITS FILED WITH THIS REPORT</b></p></td><td style="vertical-align:bottom;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">References to &#8220;the Company,&#8221; &#8220;Capricor Therapeutics,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Annual Report on Form&#160;10-K refer to Capricor Therapeutics,&#160;Inc., a Delaware corporation, and its subsidiaries, unless the context indicates otherwise. References to &#8220;Capricor&#8221; in this Annual Report on Form&#160;10-K refer to our wholly owned subsidiary, Capricor,&#160;Inc., unless the context indicates otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act. The forward-looking statements are only predictions and provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;&#160;&#8220;potential,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will&#8221; or &#8220;should&#8221; or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts and include, without limitation, statements about the development of our product candidates, including when we expect to undertake, initiate and complete clinical trials of our product candidates; expectation of or dates for commencement of clinical trials; timing of study or trial results; manufacturing capabilities, investigational new drug filings, similar plans or projections; the regulatory approval of our drug candidates and dates for regulatory meetings; our ability to achieve product milestones and to receive milestone payments from commercial partners; our use of clinical research centers, third-party manufacturers and other contractors; our ability to find collaborative partners for research, development and commercialization of potential products; our or a designated third-party&#8217;s ability to manufacture products for clinical and commercial use; our ability to protect our patents and other intellectual property; our ability to market any of our products; our projected operating losses and ability to operate as a going concern; the impact of taxes on our business, including our ability to utilize net operating losses; our ability to compete against other companies and research institutions; the effect of potential strategic transactions on our business; acceptance of our products by doctors, patients or payors and the availability of reimbursement for our product candidates; our ability to attract and retain key personnel; the volatility of our stock price; our ability to continue as a going concern; and other risks and uncertainties detailed in the section of this Annual Report on Form&#160;10-K entitled &#8220;Risk Factors&#8221;. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Annual Report on Form&#160;10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Pharmaceutical and biotechnology companies have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results and preclinical studies. Data obtained from such clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Readers are expressly advised to review and consider certain risk factors, which include risks associated with (1)&#160;our ability to successfully conduct clinical trials and preclinical studies for our product candidates, (2)&#160;our ability to obtain required regulatory approvals to develop, manufacture and market our product candidates, either on an accelerated basis or at all, (3)&#160;our ability to raise additional capital or to license our products on favorable terms, (4)&#160;our ability to execute our development plan on time and on budget, (5)&#160;our ability to identify and obtain additional product candidates, (6)&#160;our ability to raise enough capital to fund our operations, (7)&#160;our ability to protect our intellectual property rights, and (8)&#160;our compliance with legal and regulatory requirements as a public company. Although we believe that the assumptions underlying the forward-looking statements contained in this Annual Report on Form&#160;10-K are reasonable, any of the assumptions could be inaccurate, and therefore there can be no assurance that such statements will be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be achieved. Furthermore, past performance in operations and share price is not necessarily indicative of future performance. Except to the extent required by applicable laws or rules, we do not undertake to update any forward-looking statements or to announce publicly revisions to any of our forward-looking statements, whether resulting from new information, future events or otherwise.</i></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">The following discussion should be read together with our consolidated financial statements and related consolidated notes contained in this Annual Report on Form&#160;10-K. Results for the year ended December&#160;31, 2023 are not necessarily indicative of results that may be attained in the future.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_39d59163_5139_48c0_8409_fdeb5f319bae"></a><a id="PARTI_672344"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART&#160;I</b></p><a id="ITEM1BUSINESS_934608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Capricor Therapeutics,&#160;Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#8220;DMD&#8221;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Technology and Platforms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cell Therapy Platform </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our core program is focused on the development and commercialization of a cell therapy (referred to herein as CAP-1002) comprised of cardiosphere-derived cells (&#8220;CDCs&#8221;), which are a population of stromal cells isolated from donated cells of healthy human hearts currently being developed for the treatment of DMD. DMD is a rare, monogenic, X-linked muscle disease driven by the impaired production of functional dystrophin, which normally functions as a structural protein in muscle. The reduction of functional dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of CDCs, which are mediated by secreted exosomes laden with bioactive cargo. Among the cargo elements known to be bioactive in CDC-exosomes are microRNAs. Collectively, these non-coding RNA species alter gene expression in macrophages and other target cells, dialing down generalized inflammation and stimulating tissue regeneration in DMD (and in a variety of other inflammatory diseases). This mechanism of action, consistent with the changes observed in clinical studies to date in circulating inflammatory biomarkers, contrasts with that of exon-skipping oligonucleotides and gene therapy approaches that aim to restore dystrophin expression. Our CAP-1002 cell therapy program for the treatment of DMD is currently in Phase 3 clinical development in the United States, for which we expect to have top-line data available in the fourth quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Exosomes Platform</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Extracellular vesicles, including exosomes and microvesicles, are nano-scale, membrane-enclosed vesicles secreted by most cells and contain characteristic lipids, proteins and nucleic acids such as mRNA and microRNAs. They can signal through the binding and activation of membrane receptors or the delivery of their cargo into the cytosol of target cells. Exosomes act as messengers to regulate the functions of neighboring or distant cells and have been shown to regulate functions such as cell survival, proliferation, inflammation and tissue regeneration. Their size, low or null immunogenicity and ability to communicate in native cellular language potentially make them an exciting new class of therapeutic agents with the potential to expand our ability to address complex biological responses. Because exosomes are cell-free substances, they can be stored, handled, reconstituted and administered in similar fashion to common biopharmaceutical products such as antibodies. Aspects of our exosome pipeline have been supported through collaborations and alliances. Our collaborations and research around exosomes include the National Institutes of Health (&#8220;NIH&#8221;), the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), Johns Hopkins University (&#8220;JHU&#8221;), the Department of Defense (&#8220;DoD&#8221;), the U.S. Army Institute of Surgical Research (&#8220;USAISR&#8221;), and Cedars-Sinai Medical Center (&#8220;CSMC&#8221;). Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. Currently, we are developing exosome-based vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our current strategy is focused on securing partners who will provide capital and additional resources to enable us to bring this program into the clinic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Objectives and Business Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe that our cell therapy and exosome-based platforms can be used to develop novel therapeutics to treat a broad range of diseases. We intend to leverage our technology, collaborations and resources to develop therapeutics for diseases with high unmet needs. In pursuit of this objective, we intend to focus on the following activities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing the development of our CAP-1002 program for the treatment of DMD in preparation for potential commercialization, which includes streamlining our manufacturing capabilities, furthering our commercial capabilities and securing additional partners in other markets around the world for the potential launch in the U.S., Japan and in other select territories;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advancing our exosome technology for therapeutic development, focused on internal research, strategic partnerships and collaborations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">opportunistically evaluating strategic collaborations to accelerate development and commercialization timelines as well as potentially expand our pipeline within our core therapeutic areas.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Our History</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor, Inc., a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#225;n, M.D., Ph.D. Our core cell therapy technology was first identified in the academic laboratory of Dr. Eduardo Marb&#225;n while he was Chief of Cardiology at Johns Hopkins. Since its initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. We began to explore the therapeutic potential of exosomes as we learned that CDCs mediate most of their therapeutic activities through the secretion of exosomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have assembled a scientific advisory board with cardiology and neurology experts, including DMD specialists. Our advisors include clinicians and researchers who are experts on DMD&#8217;s skeletal and cardiac aspects. Moreover, some of our advisors lead clinical units at some of the leading DMD centers in the United States and are actively involved in our drug development process and programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor became public after the completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (&#8220;Nile&#8221;), in 2013, where Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics was listed on the Nasdaq Capital Market shortly thereafter and currently trades under the symbol &#8220;CAPR&#8221;. Capricor Therapeutics and Capricor have together raised approximately $145.0 million in equity capital (both privately and publicly) as well as approximately $90.0 million in non-dilutive funding from our partners including Nippon Shinyaku Co. Ltd., a Japanese corporation (&#8220;Nippon Shinyaku&#8221;), as well as government sources such as the NIH and the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Core Therapeutic Areas</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Duchenne muscular dystrophy (DMD): </i>DMD is a rare, monogenic, X-linked muscle disease with mortality at a median age of approximately 30 years. There is no cure for DMD, and for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. It is estimated that DMD occurs in approximately one in every 3,500 to 5,000 live male births and that the patient population is estimated to be approximately 15,000-20,000 in the United States. DMD pathophysiology is driven by the impaired production of functional dystrophin, which normally functions as a structural protein in muscle. The reduction of functional dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. Due to reduced functional dystrophin protein, affected individuals generally experience the following symptoms, although disease severity and life expectancy vary: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">muscle damage characterized by inflammation and fibrosis beginning at an early age; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">muscle weakness and progressive loss of muscle function beginning in the first few years of life;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decline of ambulation and respiratory function after the age of seven;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">total loss of ambulation in the pre-teenage or early teenage years;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">progressive loss of upper extremity function during mid- to late-teens; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respiratory and/or cardiac failure, resulting in death before the age of 30; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cardiomyopathy eventually leads to heart failure, which is currently the leading cause of death among those with DMD.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Glucocorticoid treatment, the current standard of care, has been shown to improve muscle strength temporarily, prolong the period of ambulation and slow the progression of DMD. However, glucocorticoid use is associated with well-known adverse side effects, including: severe weight gain, stunted growth, weakening of bone structure (osteoporosis) and metabolic dysfunctions, among others. Despite recent therapeutic advances, DMD represents a significant societal and economic burden. The annual cost of care for patients with DMD is very high and increases with disease progression. &#160;The economic burden includes costs associated with hospital admissions, medications, frequent doctor visits, assistive devices, as well as indirect costs related to productivity losses for caregivers and costs due to pain, anxiety, social handicap as well as end-of-life care expenses. While there are many clinical initiatives in DMD, Capricor&#8217;s program is one of the very few to focus on predominantly non-ambulant patients. These boys and young men are looking to maintain their function in their arms and hands and slow the progression of cardiomyopathy. We therefore believe that DMD represents a significant market opportunity for our product candidate, CAP-1002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">SARS-CoV-2</i>: Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans, several known coronaviruses cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (&#8220;SARS&#8221;), Middle East respiratory syndrome (&#8220;MERS&#8221;) and COVID-19. SARS-CoV-2 is the novel coronavirus first identified in humans in 2019 and is the cause of COVID-19. The risk of mortality increases with age and the risk of severe disease and mortality increases for persons with certain pre-existing diseases or comorbid conditions (e.g. cardiovascular disease, diabetes, chronic lung disease, obesity). Since late 2021, infections have been dominated by subvariants of the Omicron strain which continue to displace previous circulating strains by evading immunity and spreading more efficiently resulting in an increased risk of breakthrough infection among the vaccinated. As the world pivots from the kinds of responses needed during the pandemic, vulnerable populations need a vaccine strategy to provide protective durable immunity against current and emerging variants of SARS-CoV-2 to reduce the infection and disease burden for both the public and the health care systems globally. We therefore believe that SARS-CoV-2 represents a potential market opportunity for our exosome-based vaccine program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Our Pipeline &#8211; Key Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAP-1002: Duchenne Muscular Dystrophy Program:</span> CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of CDCs, with the goal of improving skeletal and cardiac muscle function in patients with DMD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 3 (HOPE-3) Clinical Trial</i><i style="font-style:italic;">:</i> HOPE-3 is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial comprised of two cohorts evaluating the safety and efficacy of CAP-1002 in participants with DMD and impaired skeletal muscle function who are on a stable regimen of systemic glucocorticoids. Non-ambulatory and ambulatory boys who meet eligibility criteria are randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during the first 12-months of the study. Approximately 102 eligible study subjects will participate in this dual-cohort study. Enrollment has been completed for Cohort A where 61 subjects were randomized to either CAP-1002 or placebo in a 1:1 ratio and is intended to support a Biologics License Application (&#8220;BLA&#8221;) submission. In December 2023, we announced a positive outcome of the interim futility analysis for Cohort A of HOPE-3, which was reviewed by the Data Safety Monitoring Board (&#8220;DSMB&#8221;). This resulted in a favorable recommendation to continue the HOPE-3 trial as planned. At this time, we expect to have topline data available from Cohort A in the fourth quarter of 2024. Cohort A uses product manufactured at our Los Angeles facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:129.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Performance of the Upper Limb (PUL entry items)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">(CAP-1002 current DMD target population)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="capr-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:129.6pt;width:315.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:11.66pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Image from HOPE-2 </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lancet </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Publication (March 2022)</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Enrollment is underway for Cohort B, which is designed to enroll approximately 44 participants randomized to either CAP-1002 or placebo in a 1:1 ratio. A primary efficacy and safety analysis will be performed for each individual cohort at month 12, following 4 administrations of CAP-1002 or placebo. We plan to complete enrollment for Cohort B in the second quarter of 2024. Cohort B uses product manufactured at our San Diego facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The primary outcome measure of the HOPE-3 study will be the Performance of the Upper Limb (&#8220;PUL&#8221;) v2.0, a validated tool specifically designed for assessing high (shoulder), mid (elbow) and distal (wrist and hand) functions, with a conceptual framework reflecting weakness progression in upper limb function. HOPE-3 will also measure various secondary endpoints including cardiac function assessments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under our RMAT designation, in the third quarter of 2023, we met with the FDA in a Type-B meeting where we discussed our manufacturing plans in anticipation of potentially submitting a BLA application. In this meeting, we affirmed alignment with respect to our Phase 3, HOPE-3 program. Additionally, we discussed our plans with respect to commercial manufacturing activities, including our potency assay and other product release criteria to support commercialization. We plan to meet with FDA in the first quarter of 2024 to continue discussing our pathway to BLA. In the upcoming Type-B meeting, we intend to discuss our further CMC plans for commercial launch, if approved, with the aim of expediting our BLA submission pathway. Our ultimate goal is to file a BLA allowing for the use of CAP-1002 commercial product manufactured at our San Diego facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2 HOPE-2 Clinical Trial:</i><i style="font-style:italic;"> </i>HOPE-2 was a randomized, double-blind, placebo-controlled clinical trial conducted at multiple sites in the United States and was completed in 2021. The clinical trial was designed to evaluate the safety and efficacy of repeated, intravenous doses of CAP-1002, in boys and young men with evidence of skeletal muscle impairment regardless of ambulatory status. Approximately 90% of the patients in the study were non-ambulant and all patients were on a stable regimen of steroids. Demographic and baseline characteristics were similar between the two treatment groups. The final one-year results from HOPE-2 were published in <i style="font-style:italic;">The Lancet</i> in March 2022, showing that the trial met its primary efficacy endpoint of the mid-level dimension of the PUL v1.2 (p=0.01) and additional positive endpoints of full PUL v2.0 (p=0.04). Although the PUL v1.2 for the mid-level was the primary endpoint established for the trial, we also conducted an analysis using the PUL v2.0 as the FDA suggested the use of the updated PUL v2.0 as the primary efficacy endpoint in support of a BLA. Left ventricular ejection fraction (LVEF), a global measure of cardiac pump function, decreased in the placebo group over time, but improved in the CAP-1002 group, showing a 107% slowing of the progression of cardiac disease (p=0.002). Additionally, the data suggested global improvements in cardiac function as measured by indexed volumes (LVESV, LVEDV). These are surrogate measures of cardiac function and are considered significant in relevance to long-term outcomes. Furthermore, the data showed a reduction in the biomarker CK-MB, an enzyme that is only released when there is cardiac muscle cell damage. In normal human subjects, there is typically no CK-MB measurable in the blood. It is well accepted that continuous muscle cell damage in DMD leads to pathologically high enzyme levels associated with cardiac muscle cell loss. To our knowledge, this is the first clinical study in DMD that correlates cardiac functional stabilization with a reduction of a biomarker of cell damage. &#160;With the exception of steroids, preservation of function in DMD is uncommon. The results of the placebo patients were consistent with natural history, but in the treated group, most patients were stable or improved on these endpoints throughout the one-year treatment period. CAP-1002 was generally safe and well tolerated throughout the study. With the exception of hypersensitivity </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:139.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reactions early in the clinical trial, which were mitigated with a common pre-medication regimen, there were no serious safety signals identified by the HOPE-2 DSMB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">HOPE-2 Study Results - 12-Month Efficacy Data</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12-Month Difference in Change from Baseline&#8224;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#916;, CAP-1002 vs. Placebo  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(n=8, n=12)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">p-value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Skeletal-Muscle (Upper Limb Function)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Mid-level PUL (v1.2)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.01</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Shoulder + Mid + Distal PUL (v1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.02</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Shoulder + Mid + Distal PUL (v2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.04</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cardiac Function</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">LV Ejection Fraction %*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.002</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">LV End-Diastolic Volume,&#160;Indexed mL/m<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-12.4&#8225;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.03</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">LV End-Systolic Volume,&#160;Indexed mL/m<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-4.2&#8225;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.01</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Creatine Kinase-MB (% of total CK)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-2.2&#8225;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.02</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ITT (intent to treat) population shown</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;Non-parametric mixed model repeated measures analysis with percentile ranked baseline, treatment, visit, visit-by-treatment interaction, PUL entry-item score at stratification, and site as model effects. Percentile ranked change from baseline converted back to original scale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8225;Negative value favors CAP-1002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*Graphed figures below</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PUL v1.2 mid-level dimension</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="capr-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:139.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:209.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Left ventricular ejection fraction % (LVEF)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="capr-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:138.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:209.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Images from HOPE-2 </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lancet </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Publication (March 2022)</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2 HOPE-2-Open Label Extension (&#8220;OLE&#8221;) Clinical Trial</i><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">:</span><span style="font-weight:normal;"> We are currently conducting an OLE clinical trial available to all patients who participated in the HOPE-2 study which includes those patients who received placebo. </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">12 patients elected to continue treatment. We announced positive one-year and two-year results from this ongoing OLE study. Data from the study suggests disease modification with statistically significant differences in the PUL v2.0 scale in the CAP-1002 original treatment group when compared to the original placebo group from HOPE-2. The HOPE-2-OLE study previously met its primary endpoint at the one-year timepoint on the PUL v2.0 scale (p=0.02). At the two-year timepoint, data showed statistically significant differences in the PUL v2.0 in the OLE treatment group when compared to the original rate of decline of the placebo group from HOPE-2 after one-year (p=0.021). LVEF was measured using cardiac magnetic resonance imaging (cMRI) and six of nine patients showed improvements in heart function with CAP-1002 treatment compared to their final assessment at the end of the HOPE-2 study. CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study. At this time, we expect to have three-year data available from this OLE study in the second quarter of 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1/2 HOPE-Duchenne Clinical Trial</i><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">:</span><span style="font-weight:normal;"> HOPE-Duchenne was a randomized, controlled, multi-center Phase 1/2 clinical trial which was designed to evaluate the safety and exploratory efficacy of CAP-1002 in patients with cardiomyopathy associated with DMD. Twenty-five patients were randomized in a 1:1 ratio to receive either CAP-1002 on top of usual care or usual care only. In patients receiving CAP-1002, 25 million cells were infused into each of their three main coronary arteries for a total dose of 75 million cells. It was a one-time treatment, and the last patient was infused in September 2016. Patients were observed over the course of 12 months. Efficacy was evaluated according to several exploratory outcome measures. This study was funded in part through a grant award from the CIRM. In 2019, this study was published in Neurology, the medical journal of the American Academy of Neurology. As shoulder function had already been lost in most of the HOPE-Duchenne participants, investigators used the combined mid-distal PUL subscales to assess changes in skeletal muscle function and found significant improvement in those treated with CAP-1002 in a defined post-hoc analysis. Among the lower-functioning patients, defined as patients with a baseline mid-distal PUL score &lt; 55 out of 58, investigators reported sustained or improved motor function at 12 months in 8 of 9 (89%) patients treated with CAP-1002 as compared to none (0%) of the usual care participants (p=0.007). Additionally, we reported improvements in systolic thickening of the left ventricular wall as well as reduction in scarring of the heart muscle among those treated with CAP-1002 relative to the control group. CAP-1002 was generally safe and well-tolerated in the HOPE-Duchenne trial. There was no significant difference in the incidences of treatment-emergent adverse events in either group. There were no early study discontinuations due to adverse events.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAP-1002 - Investigator Sponsored Clinical Trials</span><span style="font-weight:normal;">: Capricor provided CAP-1002 for investigational purposes in two clinical trials sponsored by CSMC. These cells were developed as part of the Company&#8217;s past research and development efforts. The first trial is known as &#8220;Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFpEF Patients Treated with Allogeneic CDCs (the &#8220;REGRESS trial&#8221;). Dr. Eduardo Marb&#225;n is the named principal investigator under the study. The second trial is known as &#8220;Pulmonary Arterial Hypertension treated with Cardiosphere-derived Allogeneic Stem Cells (the &#8220;ALPHA trial&#8221;). Enrollment of the REGRESS and ALPHA trials have been completed. In December 2023, the results from the ALPHA study were published in the peer-reviewed journal, </span><i style="font-style:italic;font-weight:normal;">eBioMedicine</i><span style="font-weight:normal;">, a </span><i style="font-style:italic;font-weight:normal;">Lancet</i><span style="font-weight:normal;"> journal. The Phase 1 results were shown to be safe, with no short-term clinical safety adverse events related to the investigational product, which was the primary outcome measure of the study. Although this study was only designed to assess the safety of the CAP-1002 infusions, investigators observed encouraging changes that might indicate the 16 patients who received CAP-1002 infusions had improved cardiopulmonary health.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exosome Platform</span><span style="font-weight:normal;">: Our exosome platform program consists of engineered exosomes and exosomes derived from CDCs (CAP-2003), both of which are in preclinical development. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;font-weight:normal;">Exosome Platform: Engineered Exosome-Based Vaccines</i><span style="font-weight:normal;">: The StealthX&#8482; vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface. Preclinical results from murine and rabbit models published in the peer-reviewed journal, </span><i style="font-style:italic;font-weight:normal;">Microbiology Spectrum</i><span style="font-weight:normal;">, showed the StealthX&#8482; vaccine, resulted in robust antibody production, potent neutralizing antibodies, a strong T-cell response and a favorable safety profile. These effects were obtained with administration of only nanogram amounts of protein and without adjuvant or synthetic lipid nanoparticles. Exosomes offer a new antigen delivery system that could potentially be utilized to rapidly generate multivalent protein-based vaccines. Recently, we were selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with our StealthX&#8482; vaccine, subject to regulatory approval. At this time, we have submitted an Investigational New Drug Application (&#8220;IND&#8221;) to the FDA for our StealthX&#8482; vaccine, which is currently under review and we anticipate that if the IND is approved, that NIAID plans to initiate this trial in late 2024. NIAID's Division of </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Microbiology and Infectious Diseases (DMID) would oversee the study. If NIAID finds that our StealthX&#8482; vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Exosome Platform: Engineered Exosome-Based Therapeutics</i><span style="font-weight:normal;">: We are focused on developing a precision-engineered exosome platform technology that has the potential to deliver defined sets of effector molecules that exert their effects through defined mechanisms of action. At this time, we are exploring the use of our proprietary StealthX&#8482; exosome platform for a broad range of therapeutic applications including targeted RNA, protein and small molecule therapeutics to treat or prevent a variety of diseases.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Exosome Platform: CDC-Derived Exosomes (CAP-2003)</i><span style="font-weight:normal;">: CAP-2003 is the name of our exosomes product candidate which are derived from CDCs. We have promising preclinical data in several indications from studies done utilizing CAP-2003 in our labs as well as in collaboration with other academic institutions. In 2020, we filed an IND with the FDA to investigate the use of CAP-2003 in patients with DMD. The FDA has requested more information related to manufacturing for this product candidate and we are evaluating the next steps for this program as we continue to further develop our exosome platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">These programs represent our core technology and products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">The following table summarizes our active product development programs:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.83%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.77%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:18.65%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.77%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product Candidate</b></p></td><td style="vertical-align:bottom;width:2.08%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:18.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Indication</b></p></td><td style="vertical-align:bottom;width:2.08%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:26.43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development Stage</b></p></td><td style="vertical-align:top;width:0.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Distributor/Partner/Collaborator</b></p></td></tr><tr><td style="vertical-align:top;width:20.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CAP-1002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(allogeneic CDCs)</p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Duchenne muscular dystrophy*</p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Phase 3 (HOPE-3)<br/>Cohort A: enrollment complete</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cohort B: enrolling</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Phase 2 (HOPE-2) completed**</p></td><td style="vertical-align:top;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Nippon Shinyaku Co., Ltd. (U.S. and Japan rights)</p></td></tr><tr><td style="vertical-align:top;width:20.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exosome protein-based vaccine (multivalent design)</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SARS-CoV-2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">IND submitted</p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Collaboration with National Institute of Allergy and Infectious Diseases</p></td></tr><tr><td style="vertical-align:top;width:20.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Engineered Exosomes (RNA, protein and small molecule delivery)</p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Evaluating</p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CAP-2003 (CDC-exosomes)</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Duchenne muscular dystrophy</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">IND submitted</p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">*</b>&#160;The FDA has granted orphan drug, Regenerative Medicine Advanced Therapy, and Rare Pediatric Disease designations to CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">**We are currently conducting an OLE study of the HOPE-2 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Manufacturing, Supply and Distribution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We have developed proprietary Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) and manufacturing capabilities that allow manufacturing and testing of our product candidates to support both clinical development as well as potential commercialization. Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. We continue to enhance, refine and optimize our manufacturing processes. We currently maintain two manufacturing facilities for the production of CAP-1002. In 2022, we completed construction of our San Diego Research and Development Facility (GMP pilot manufacturing facility) as we prepare for potential commercial launch, subject to FDA approval. This facility was designed to be compliant with U.S. and European Medicines Agency (&#8220;EMA&#8221;) standards. This facility is currently producing CAP-1002 product for clinical use in Cohort B of our HOPE-3 trial and supporting our OLE trials. We are preparing for a potential commercial launch, subject to FDA approval, from the San Diego facility. It is to be determined whether the FDA will ultimately approve commercial manufacturing at this facility. Our second manufacturing facility is located within our laboratory, research and manufacturing facilities at CSMC in Los Angeles pursuant to a Facilities Lease. In that portion of the leased premises where we manufacture CAP-1002 and may manufacture our exosome products for potential clinical use, we believe that we follow, current good manufacturing practices to the extent that they are applicable to the stage of our clinical programs although our facility at CSMC is not current Good Manufacturing Practices (&#8220;cGMP&#8221;) qualified for commercial at this time. Capricor manufactured CAP-1002 </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">in this facility for our current and previous studies including Cohort A of the HOPE-3 trial. Our Facilities Lease at CSMC has an expiration date of July 31, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In the third quarter of 2023, we met with the FDA, where we affirmed alignment with respect to our Phase 3, HOPE-3 program where the FDA agreed to allow us to submit a BLA supported by results using product manufactured at our Los Angeles manufacturing site. At this time, we are planning on utilizing such data for the submission of a BLA, but it is to be determined whether the FDA will ultimately approve commercial manufacturing at this facility. The sale of commercial product produced in our Los Angeles facility may require the consent of CSMC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We are required to obtain and maintain certain other licenses in connection with our manufacturing facilities and activities. At this time, we have a Drug Manufacturing License issued from the State of California for both our San Diego and CSMC facilities. We are currently applying for a Tissue Bank License from the State of California for both of our facilities. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Additionally, in February 2024, we entered into a License and Services Agreement with Azzur Cleanrooms-on-Demand &#8211; San Diego, LLC (the &#8220;Azzur License Agreement&#8221;) pursuant to which we have been granted an exclusive license to use certain space and the non-exclusive right to use certain equipment and property for our early phase clinical and/or pre-clinical manufacturing purposes. We are planning to use this facility to manufacture our exosome-based vaccine for potential clinical use to support our collaboration with NIAID.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Manufacturing Process for CAP-1002</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The manufacturing process for CAP-1002 begins with material from an entire heart from a donor that was collected from an organ procurement organization (&#8220;OPO&#8221;). This tissue is then taken to the lab where the cells are isolated, expanded, and processed through a series of proprietary unit operations. After expanding, processing, release testing and quality review, the CAP-1002 product becomes available for administration to patients participating in clinical trials. CAP-1002 is cryo-preserved, enabling us to produce large lots that can be frozen and then administered to patients as needed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Manufacturing Process for Engineered-Exosome Technologies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have also made significant progress planning the next steps for the manufacturing process for our exosome product candidates. We believe these developments will enable us to scale up our manufacturing capabilities and allow us to manufacture enough material for early-stage clinical development, subject to FDA approval. We have explored the use of various cell sources to generate our exosomes for preclinical and potential clinical use.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Manufacturing Process for CDC-Exosomes (CAP-2003)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The process for manufacturing CAP-2003 starts with the proprietary process of creating a cell bank from donor heart tissue through the expansion of CDCs. Afterwards, exosomes are isolated from the expanded CDCs. After these exosomes are prepared, formulated, filled, tested, and validated, the exosomes product may become available for clinical investigation, subject to regulatory approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Material Agreements, License Agreements &amp; Collaborations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To accelerate the advancement of our technologies, we have entered into, and intend to seek other opportunities to form collaborations with a diverse group of strategic partners. We have forged productive collaborations with pharmaceutical and biotechnology companies, government agencies, academic laboratories, and research institutes with diverse area expertise and resources in as effort to advance our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 24, 2022, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;U.S. Distribution Agreement&#8221;) with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S Distribution Agreement, Capricor received an upfront payment of $30.0 million in the first quarter of 2022. The first milestone payment of $10.0 million was paid upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, there are potential milestones totaling up to $90.0 million leading up to and including the BLA approval. Further, there are various potential sales-based milestones, if commercialized, tied to the achievement of certain sales thresholds for annual net sales of CAP-1002 of up to $605.0 million. Further, pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and Capricor will have the right to receive a meaningful mid-range double-digit share of product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On February 10, 2023, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;Japan Distribution Agreement&#8221;) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023 and in addition, Capricor may potentially receive additional development and sales-based milestone payments of up to approximately $89.0 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Subject to regulatory approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Collaboration Agreement with NIH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2023, we were notified by the NIH that we had been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with our StealthX&#8482; vaccine, subject to regulatory approval. NIAID's Division of Microbiology and Infectious Diseases (DMID) will oversee the study. Under the terms of the collaboration, Capricor will be responsible for supplying investigational product for the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2018, we entered into a Cooperative Research and Development Agreement with the USAISR, pursuant to which we agreed to cooperate in research and development on the evaluation of our CAP-2003 for the treatment of trauma related injuries and conditions. In 2021, in collaboration with the USAISR, we published a manuscript demonstrating CAP-2003 as a potential antishock therapeutic, if delivered early.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Intellectual Property Rights for Capricor&#8217;s Technology - CAP-1002 and Exosomes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Universit&#224; Degli Studi Di Roma La Sapienza (the &#8220;University of Rome&#8221;), JHU and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">University of Rome License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and the University of Rome entered into a License Agreement, dated June&#160;21, 2006 (the &#8220;Rome License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per&#160;year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third-party to Capricor. The minimum annual royalties are creditable against future royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party&#8217;s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days&#8217; written notice to the University of Rome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Johns Hopkins University License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License Agreement for CDCs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement, effective June&#160;22, 2006 (the &#8220;JHU License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit&#160;percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the FDA. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase 3 study for which a payment of $500,000 will be due. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days&#8217; written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">License Agreement for Exosome-based Vaccines and Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement (the &#8220;JHU Exosome License Agreement&#8221;), effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provided for the grant of an exclusive, worldwide, royalty-bearing license of JHU&#8217;s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. The JHU Exosome License Agreement was terminated by Capricor on December 15, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cedars-Sinai Medical Center License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License Agreement for CDCs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Original CSMC License Agreement&#8221;), for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December&#160;30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the &#8220;Amended CSMC License Agreement&#8221;), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty-bearing product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days&#8217; notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents and extend the timing of certain development milestones, among other things. Capricor reimbursed CSMC for certain attorneys&#8217; fees and filing fees incurred in connection with the additional patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recently received a letter from CSMC alleging that pursuant to the Amended CSMC License Agreement between CSMC and Capricor, Capricor has certain overdue payment obligations to CSMC arising out of a milestone payment received by Capricor pursuant to the U.S. Distribution Agreement entered into between Capricor and Nippon Shinyaku. The notice letter requests that Capricor cure the alleged breaches of the Amended CSMC License Agreement, and reserves CMSC&#8217;s purported right to terminate the Amended CSMC License Agreement if such alleged breaches are not cured. We dispute the allegations in the letter from CSMC and intend to vigorously defend our position and pursue all available remedies, but there is no guarantee that any disputes that we have with CSMC will be resolved or if resolved, will not result in our incurring certain payment and other obligations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License Agreement for Exosomes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Exosomes License Agreement&#8221;), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, added certain performance milestones&#160;with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights, and converted certain exclusive rights to co-exclusive rights. These amendments also obligated Capricor to reimburse CSMC for certain attorneys&#8217; fees and filing fees in connection with the additional patent applications and patent families.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;text-decoration-color:#000000;text-decoration-line:none;">Cell Line License Agreement with Life Technologies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in 2022 and additional milestone fees may become due based on the progress of our development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patents and Proprietary Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our goal is to obtain, maintain and enforce patent rights for our products, formulations, manufacturing processes, methods of use and other proprietary technologies, preserve our trade secrets, and operate without knowingly infringing on the valid and enforceable proprietary rights of other parties, both in the United States and abroad. Our policy is to actively seek to obtain, where appropriate, the broadest and focused intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the United States and abroad. Even patent protection, however, may not always afford us with complete protection against competitors who seek to circumvent our patents. If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish. To this end, we require all of our employees, consultants, advisors and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other contractors to enter into confidentiality agreements that prohibit the disclosure and use of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions relevant to our technologies and important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of complex biotechnology products such as ours typically includes the early discovery of a technology platform &#8211; often in an academic institution &#8211; followed by increasingly focused development around a product opportunity, including identification and definition of a specific product candidate and development of manufacturing processes, formulations, patient selection and treatment regimes, and delivery and dosage regimens. As a result, biotechnology products are often protected by several families of patent filings that are made at different times in the development cycle and cover different aspects of the product. Earlier filed broad patent applications directed to the discovery of the platform technology thus usually expire ahead of patents covering later developments such as manufacturing processes, specific formulations, additional indications and dosing regimens. Patent expirations on products may therefore span several years and vary from country to country based on the scope of available coverage. Our patents, or patent applications, if issued and upon payment of patent maintenance fees, would expire as early as 2024 and as late as 2044 or beyond depending on any patent term adjustment or patent term extension. There are also limited opportunities to obtain extensions of patent terms in certain countries. The earlier expiring patents are generally directed to precursor cell populations or early non-DMD indications and administration methods. We have patents directed to CAP-1002 for the treatment of DMD that expire in 2038 unless otherwise extended under Hatch-Waxman. We continue to file patents on processes, indications, dosage forms and formulations directed to extend the patent portfolio related to CAP-1002 and our exosome technologies as our technology progresses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and our technologies are primarily protected by composition of matter and process (methods of use and methods of making) patents and patent applications as well as trade secrets. As of the date of this filing, we have 46 granted patents and 15 pending patent applications covering processes and compositions of matter related to our CDC (CAP-1002) technology and 37 granted patents and 43 pending patent applications covering processes and compositions of matter related to our exosome technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Designations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulatory Designations for CAP-1002 for the treatment of DMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2015, the FDA granted orphan drug designation to CAP-1002 for the treatment of DMD. Orphan drug designation is granted by the FDA&#8217;s Office of Orphan Drug Products to drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the United States or a disease or condition that affects more than 200,000 people in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. This designation confers special incentives to the drug developer, including tax credits on the clinical development costs and prescription drug user fee waivers and may allow for a seven-year period of market exclusivity in the United States upon FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2017, the FDA granted Rare Pediatric Disease Designation to CAP-1002 for the treatment of DMD. The FDA defines a &#8220;rare pediatric disease&#8221; as a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and that affects fewer than 200,000 individuals in the United States, or a disease or condition that affects more than 200,000 people in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Under the FDA's Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying New Drug Application (&#8220;NDA&#8221;) or BLA for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a Rare Pediatric Disease Priority Review Voucher that can be used to obtain priority review for a subsequent NDA or BLA. The Priority Review Voucher may be sold or transferred an unlimited number of times. If Capricor were to receive market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher based on its designation as a rare pediatric disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2018, we were granted the Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation for CAP-1002 for the treatment of DMD. The FDA grants the RMAT designation to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates a potential to address unmet medical needs for that condition. The RMAT designation makes therapies eligible </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for the same actions to expedite the development and review of a marketing application that are available to drugs that receive fast track or breakthrough therapy designation &#8211; including increased meeting opportunities, early interactions to discuss any potential surrogate or intermediate endpoints and the potential to support accelerated approval. CAP-1002 is one of the few therapies currently in development to help late-stage patients with DMD. To receive the RMAT designation, we submitted data from the HOPE-Duchenne Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trademarks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our trademarks are generally filed to protect our corporate brand, our products and our platform technologies. We typically file trademark applications and pursue their registration in the U.S., Europe and other markets in which we anticipate using such trademarks. We are the owner of several common law, and federal trademark registrations or applications in the U.S. including, but not limited to, Capricor&#174;, Capricor Therapeutics, STEALTHX&#8482; and the Capricor logo. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor&#8217;s research and development program has been advanced in part through federal and state grants and loan awards totaling approximately $28.0 million to date. Our ongoing research and development activities primarily concern CDCs and exosomes and are focused on the characterization of their composition and actions, the evaluation of their therapeutic potential in selected disease settings, the development of next generation product candidates, and the identification of new technologies and indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:normal;">We are engaged in fields that are characterized by extensive worldwide research and competition by pharmaceutical companies, medical device companies, specialized biotechnology companies, hospitals, physicians, academic institutions, government agencies and research organizations both in the United States and abroad. There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations that compete with us in developing various approaches to the treatment of DMD, which includes competitors both in the United States and internationally. With CAP-1002, we expect to face competition from existing products and products in development. &#160;In addition, at this time, there are four FDA conditionally approved exon skipping drugs: EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), which are phosphorodiamidate Morpholino oligomers (PMOs) approved for the treatment of DMD patients amenable to Exon 51, Exon 45 and Exon 53 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., and VILTEPSO (vitolarsen), a PMO approved for the treatment of DMD patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku (U.S. subsidiary: NS Pharma, Inc.). In June 2023, the FDA approved Sarepta&#8217;s BLA application seeking accelerated approval of Elevidys (delandistrogene moxeparvovec), its microdystrophin gene therapy, for the treatment of ambulant individuals with Duchenne. There are multiple other companies focused on developing genetic based therapies that target dystrophin mechanisms and non-dystrophin mechanisms for the treatment of DMD. Additionally, competition is particularly intense for products involving the treatment or prevention of diseases associated with COVID-19. The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many smaller companies being involved. Many of the organizations competing with us have substantially greater financial resources, larger research and development staffs and facilities, longer drug development history in obtaining regulatory approvals, and greater manufacturing and marketing capabilities than we do. We expect any future products and product candidates we develop to compete on the basis of, among other things, product efficacy and safety, time to market, price, extent of adverse side effects, and convenience of treatment procedures. The biotechnology and pharmaceutical industries are subject to rapid and significant technological change. The drugs that we are attempting to develop will have to compete with existing and future therapies. Our future success will depend in part on our ability to maintain a competitive position with respect to evolving cell therapy and exosome technologies. There can be no assurance that existing or future therapies developed by others will not render our potential products obsolete or noncompetitive. In addition, companies pursuing </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">different but related fields represent substantial competition. These organizations also compete with us to attract patients for clinical trials, qualified personnel and parties for acquisitions, joint ventures, or other collaborations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, serialization and tracking, promotion, advertising, distribution and marketing, post-approval monitoring and reporting, and export and import, among other things, of our product candidates are extensively regulated by governmental authorities in the United States and other countries. In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending NDA or a pending BLA, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution. We would also be facing additional regulations and requirements from regulatory authorities in other countries outside the U.S. if we seek approval of our product candidates for sale or distribution within such countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Approval Process for Drugs and Biologics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical products, including biological products such as ours, may not be commercially marketed without prior approval from the FDA and comparable regulatory agencies in other countries. In the United States, the process for receiving such approval is long, expensive and risky, and includes the following steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical laboratory tests, animal studies, and formulation studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an IRB at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA, for a drug, or BLA, for a biological product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential FDA audit of the pre-clinical and clinical trial sites that generated the data in support of the NDA or BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain clearance or approval of companion diagnostic tests, if required, on a timely basis, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA or BLA prior to any commercial marketing or sale of the drug in the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sponsors submit NDAs in order to obtain marketing approval for drugs. Sponsors submit BLAs in order to obtain marketing approval for biologics, which include, among other product classes, vaccines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regulation by U.S. and foreign governmental authorities is a significant factor affecting our ability to commercialize any of our products, as well as the timing of such commercialization and our ongoing research and development activities. The commercialization of drug products requires regulatory approval by governmental agencies prior to commercialization. Various laws and regulations govern or influence the research and development, non-clinical and clinical testing, manufacturing, processing, packaging, validation, safety, labeling, storage, record keeping, registration, listing, distribution, advertising, sale, marketing and post-marketing commitments of our products. The lengthy process of seeking these approvals, and compliance with applicable laws and regulations, require expending substantial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The results of preclinical testing, which include laboratory evaluation of product chemistry, formulation, toxicity and carcinogenicity animal studies to assess the potential safety and efficacy of the product and its formulations, details </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">concerning the drug manufacturing process and its controls, and a proposed clinical trial protocol and other information must be submitted to the FDA as part of an IND that must be reviewed and become effective before clinical testing can begin. The study protocol and informed consent information for patients in clinical trials must also be submitted to an independent Institutional Review Board (&#8220;IRB&#8221;) for approval covering each institution at which the clinical trial will be conducted. Once a sponsor submits an IND, the sponsor must wait 30 calendar days before initiating any clinical trials. If the FDA has comments or questions within this 30-day period, the issue(s)&#160;must be resolved to the satisfaction of the FDA before a clinical trial can begin. In addition, the FDA or IRB may impose a clinical hold on ongoing clinical trials if, among other things, it believes that a clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable and significant risk to clinical trial patients. If the FDA imposes a clinical hold, clinical trials can only proceed under terms authorized by the FDA. If applicable, our preclinical and clinical studies must conform to the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;), and Good Clinical Practice (&#8220;GCP&#8221;) requirements, respectively, which are designed to ensure the quality and integrity of submitted data and protect the rights and well-being of study patients. Information for certain clinical trials also must be publicly disclosed within certain time limits on the clinical trial registry and results databank maintained by the NIH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, clinical testing involves a three-phase process; however, the phases may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trials typically are conducted in a small number of volunteers or patients to assess the early tolerability and safety profile, the pattern of drug absorption, distribution and metabolism, the mechanism of action in humans, and may include studies where investigational drugs are used as research to explore biological phenomena or disease processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 clinical trials typically are conducted in a limited patient population with a specific disease in order to assess appropriate dosages and dose regimens, expand evidence of the safety profile and evaluate preliminary efficacy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3 clinical trials typically are larger scale, multicenter, well-controlled trials conducted on patients with a specific disease to generate enough data to statistically evaluate the efficacy and safety of the product, to establish the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A therapeutic product candidate being studied in clinical trials may be made available for treatment of individual patients, intermediate-size patient populations, or for widespread treatment use under an expanded access protocol, under certain circumstances. Pursuant to the 21st Century Cures Act (the &#8220;Cures Act&#8221;), which was signed into law in December&#160;2016, the manufacturer of one or more investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The results of the preclinical and clinical testing, chemistry, manufacturing and control information, proposed labeling and other information are then submitted to the FDA in the form of either an NDA or BLA for review and potential approval to begin commercial sales. Within 60 days following submission of the application, the FDA reviews an application submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any application that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the application must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. In responding to an NDA or BLA, the FDA may grant marketing approval, or issue a Complete Response Letter (&#8220;CRL&#8221;). A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of an NDA or BLA and may require substantial additional testing or information. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter, which authorizes commercial marketing of the product with specific prescribing information for specific indications, and sometimes with specified post-marketing commitments and/or distribution and use restrictions imposed </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">under a Risk Evaluation and Mitigation Strategy program. Any approval required from the FDA might not be obtained on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Disclosure of Clinical Trial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Orphan Drugs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic candidate for that particular disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the other benefits of orphan drug designation are tax credits for certain research and an exemption from the NDA or BLA application fee. The FDA may revoke orphan drug designation, and if it does, it will publicize that the drug is no longer designated as an orphan drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a therapeutic candidate with orphan drug designation subsequently receives the first FDA approval for such drug for the disease for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, for seven years, unless the sponsor of the subsequent application demonstrates clinical superiority, in the form of a greater efficacy, greater safety, or a major contribution to patient care. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains orphan drug designation and FDA approval of the same therapeutic candidate for the same condition or disease as our orphan-designated drug. For macromolecules, FDA considers a drug to be the same drug as an orphan-designated macromolecule if it contains the same principal molecular structural features, but not necessarily all of the same structural features.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as the FDA has interpreted the Orphan Drug Act, even if a previously approved same drug does not have unexpired orphan exclusivity, a demonstration of clinical superiority is required for a subsequent marketing application for the same orphan-designated drug for the same disease or condition to be awarded a 7-year period of orphan exclusivity upon marketing approval. In recent years, there have been multiple legal challenges to this FDA interpretation, and in August&#160;2017, Congress amended the orphan drug provisions of the FDCA through enactment of the FDA Reauthorization Act of 2017 to codify FDA&#8217;s longstanding interpretation. Section&#160;527 of the FDCA now expressly provides that if a sponsor of an orphan-designated drug that is otherwise the same as an already approved drug for the same rare disease or condition is seeking orphan exclusivity, FDA shall require such sponsor to demonstrate that such drug is clinically superior to any already approved or licensed drug that is the same drug in order to obtain orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees. Upon submission of the first section of the application FDA may revoke the Fast Track designation if it believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Products may also be eligible for other types of FDA programs intended to expedite development and review, such as Breakthrough Therapy designation, priority review and accelerated approval. Under the Breakthrough Therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for the benefits of the Fast Track program when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product is eligible for priority review if it is intended to treat a serious condition and, if approved, it would provide a significant improvement in safety or effectiveness. FDA intends to take action on a priority review marketing application within 6 months of filing, compared to 10 months of filing for regular review submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, a product may be eligible for accelerated approval if it is intended to treat a serious or life-threatening disease or condition and would provide meaningful therapeutic benefit over existing treatments. Eligible products may receive accelerated approval on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality and is reasonably likely to predict an effect on irreversible morbidity, mortality, or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval diligently perform adequate and well-controlled post-marketing clinical studies demonstrating clinical benefit. In addition, the FDA requires as a condition for accelerated approval the submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for full approval but may expedite the development or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Regenerative Medicine Advanced Therapies (RMAT) Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has established a RMAT designation as part of its implementation of the Cures Act. The RMAT designation program is intended to fulfill the Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1)&#160;it qualifies as an RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Rare Pediatric Disease Priority Review Voucher</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA generally defines a &#8220;rare pediatric disease&#8221; as a serious or life-threatening disease that affects fewer than 200,000 individuals in the U.S. primarily under the age of 18 years old. Under the FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program, upon the approval of an application for a product for the treatment of a rare pediatric disease, the sponsor of such application is eligible for a Rare Pediatric Disease Priority Review Voucher. Currently, the Priority Review Voucher can be used to obtain priority review for any subsequent application and may be sold or transferred an unlimited number of times. Congress has only authorized the rare pediatric disease priority review voucher program until September 30, 2024. However, if a drug candidate receives Rare Pediatric Disease designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Oftentimes, even after a drug has been approved by the FDA for sale, the FDA may require that certain post-approval requirements be satisfied, including the conduct of additional clinical studies. If such post-approval requirements are not satisfied, the FDA may withdraw its approval of the drug. In addition, holders of an approved NDA or BLA are required to report certain adverse reactions to the FDA, comply with certain requirements concerning advertising and promotional labeling for their products, and continue to have quality control and manufacturing procedures conform to cGMP after approval. In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Among the conditions for an NDA or BLA approval is the requirement that the manufacturing operations conform on an ongoing basis with cGMP. In complying with cGMP, we must expend time, money and effort in the areas of training, production and quality control within our own organization and at our contract manufacturing facilities. A successful inspection of the manufacturing facility by the FDA is usually a prerequisite for final approval of a pharmaceutical product. Following approval of the NDA or BLA, we and our manufacturers will remain subject to periodic inspections by the FDA to assess compliance with cGMP requirements and the conditions of approval. We will also face similar inspections coordinated by foreign regulatory authorities if we are selling or manufacturing in foreign countries. The FDA periodically inspects the sponsor&#8217;s records related to safety reporting and/or manufacturing facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under an REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription drug products is subject to the Prescription Drug Marketing Act (the &#8220;PDMA&#8221;) which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product samples and impose requirements to ensure accountability in distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pricing, Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any of our products, if and when approved. Sales of pharmaceutical products depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs, such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as commercial insurance, and managed healthcare organizations. Prices at which we or our customers seek reimbursement for our therapeutic product candidates may be subject to challenge, reduction, or denial by payors. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all of the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Third-party payors are increasingly challenging the prices charged for medical products and services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A payor&#8217;s decision to provide coverage for a product does not imply reimbursement will be available at a rate that covers our costs, including research, development, manufacture, and sales and distribution costs. Additionally, in the United States there is no uniform policy among payors for determining coverage or reimbursement. Many third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will likely be a time-consuming process. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or payor negotiations may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products once approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. Decreases in third-party reimbursement for our products once approved or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have an adverse effect on our sales, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additionally, efforts to contain healthcare costs (including drug prices) have become a priority of federal and state governments. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution by generic products. There has also been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Several federal healthcare reform efforts have been adopted in recent years which aim to restrict drug product pricing and limit reimbursement. For further details, See Part I, Item 1- Healthcare Reform. We anticipate additional state and federal healthcare reform measures will be adopted in the future. These may include price controls and cost-containment measures, or more restrictive policies in jurisdictions with existing controls and measures, any of which could limit the amounts that federal and state governments will pay for healthcare products </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and services, and potentially could reduce demand for our products once approved, create additional pricing pressures, or ultimately limit our net revenue and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the EU do not follow price structures of the U.S. and generally tend to have price structures that are significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In Japan, almost all medical-use drugs that have been approved (i.e., whose efficacy and safety have been confirmed) under the Pharmaceuticals and Medical Devices Act may be covered by the National Health Insurance (&#8220;NHI&#8221;). In order to be covered by the NHI, a drug must be listed on the NHI drug price standard within 60 or 90 days after approval for marketing. After the NHI drug price is listed, the NHI price, which is the official price of drugs, will be reviewed and updated on a regular basis. In principle, NHI price revisions are conducted once every two years in conjunction with the April revision of medical fees. When NHI drug prices are revised, most drugs will be priced lower than before the revision. The reason for this is that between pharmaceutical wholesalers and medical institutions and pharmacies, drugs are sold at prices lower than the NHI price, and the basic principle of NHI price revision is to reduce the NHI price in line with the prevailing market price. Accordingly, the NHI drug price revisions every two years may lead to the cut of the drug price in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other Healthcare Fraud and Abuse Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we currently do not have any products on the market and do not make patient referrals or bill Medicare, Medicaid, or other government or commercial third-party payors, our activities, including current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may be subject to additional healthcare laws, regulations and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting, and physician sunshine laws. Some of our pre-commercial activities also may be subject to some of these laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity, including a prescription drug manufacturer or a party acting on its behalf, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service that may be reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers, among others, on the other, including, for example, arrangements relating to consulting/speaking arrangements, discount and rebate offers, grants, charitable contributions, and patient support offerings. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common business activities from prosecution under the Anti-Kickback Statute. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;Affordable Care Act&#8221; or the &#8220;ACA&#8221;), to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. A violation of the federal Anti-Kickback Statue includes per violation civil monetary penalties and significant criminal fines under the statute, additional civil penalties and treble damages under the False Claims Act, as discussed in more detail below, possible imprisonment, and mandatory exclusion from participation in the federal healthcare programs, meaning that federal healthcare programs would no longer reimburse (directly or indirectly) for products or services furnished by the excluded entity or individuals. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal civil False Claims Act, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. Persons and entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, certain of our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information, and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. Penalties for federal civil False Claims Act violations may include up to three times the actual damages sustained by the government, plus mandatory civil penalties of between $13,946 and $27,894 per false claim or statement for penalties assessed after January 15, 2024 with respect to violations occurring after November 2, 2015. Other penalties include the potential for exclusion from participation in federal healthcare programs. Additionally, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate various federal criminal statutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is also the U.S. federal criminal False Claims Act, which is similar to the federal civil False Claims Act and imposes criminal liability on those that make or present a false, fictitious or fraudulent claim to the federal government. The Federal Criminal Statute on False Statements Relating to Health Care Matters makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Federal Civil Monetary Penalties Law (the &#8220;CMPL") authorizes the imposition of substantial monetary penalties against an entity, such as a pharmaceutical manufacturer, that engaged in activities including, among others (1) &#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors, or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. Regulatory guidance and obligations continue to evolve. For example, on December 10, 2020, the Office for Civil Rights (&#8220;OCR&#8221;) issued a proposed rule aimed at reducing regulatory burdens that may exist in discouraging coordination of care, among other changes. Finally, pursuant to legislation passed in 2021, OCR recently issued guidance on recognized security practices for covered entities and business associates. &#160;OCR indicated that recognized security practices will not be an aggravating factor in OCR investigations, but that implementation of recognized security practices strengthen an organization&#8217;s cybersecurity and regulatory posture, as well as possibly lessening enforcement penalties in a potential regulatory enforcement. As HIPAA and HITECH requirements evolve, we may be required to update our compliance strategies or modify our business processes to comply.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Federal Trade Commission (&#8220;FTC&#8221;) and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. Privacy laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating individuals&#8217; privacy rights, publishing false or misleading information about security practices, or failing to take appropriate steps to keep individuals&#8217; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. Additionally, the FTC recently published an advance notice of proposed rule making on &#8220;commercial surveillance&#8221; and data security, and is seeking comment on whether it should implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (1) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive. Federal regulators, state attorneys general and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. For instance, the California Consumer Privacy Act (&#8220;CCPA&#8221;) became effective on January 1, 2020, giving California residents expanded privacy rights, and requiring businesses to provide detailed information about their data practices. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for PHI and certain clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices may increase our compliance costs and legal risks. Additionally, the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020 and amended the CCPA beginning in 2023. The CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Similar laws have been adopted in other states or proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. Additional compliance investment and potential business process changes may be required to respond to this rapidly changing privacy law landscape. If we fail to comply with existing or new privacy laws and regulations, we could face legal liability from regulatory actions or litigation, as well as reputational damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. federal Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;), created under the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists, and licensed chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, certified nurse-midwives and U.S. teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 (adjusted annually for inflation) per year and up to an aggregate of $1,000,000 (adjusted annually for inflation) per year for &#8220;knowing failures.&#8221; Covered manufacturers are required to submit reports on aggregate payment data to the Secretary of the U.S. Department of Health and Human Services on an annual basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states have similar statutes or regulations to the above federal laws that may be broader in scope and may apply regardless of payor. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing or marketing expenditures. These laws may differ from each other in significant ways and may not have the same effect, further complicating compliance efforts. Additionally, to the extent that we have business operations in foreign countries or sell any of our products in foreign countries and jurisdictions, including Japan or the European Union, we may be subject to additional regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Although we do not currently have any products on the market, once our product candidates or clinical trials are covered by federal health care programs, we will be subject to additional healthcare statutory and regulatory requirements </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Because we intend to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we intend to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the rules and program requirements to which we will or may become subject. Although the development and implementation of compliance programs can mitigate the risk of violating these laws, and the subsequent investigation, prosecution, and penalties assessed for violations of these laws, the risks cannot be entirely eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject, without limitation, to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from participation in federal and state healthcare programs, reputational harm, diminished profits and future earnings, additional oversight and reporting obligations pursuant to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with applicable laws and regulations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we expect our products, if and when approved, may be eligible for coverage under Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to treat a beneficiary&#8217;s health condition. In addition, our products may be covered and reimbursed under other government programs, such as Medicaid and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to statutorily defined covered entities that participate in the program. As part of the requirements to participate in certain government programs, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average manufacturer price (&#8220;AMP&#8221;) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to healthcare systems that could affect our future results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the pharmaceutical industry has been a particular focus of healthcare reform efforts and has been significantly affected by major legislative and regulatory initiatives, including the ACA, which has had, and is expected to continue to have, a significant impact on the healthcare industry. This law was designed to expand access to health insurance coverage for uninsured and underinsured individuals while at the same time containing overall healthcare costs. With regard to pharmaceutical products, among other things, the ACA contains provisions that may potentially affect the profitability of our products, including, for example, subjecting biologics potential competition by lower-cost biosimilars, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain products under Medicare Part D, expansion of entities eligible for discounts under the Public Health Service&#8217;s pharmaceutical pricing program, and a significant annual fee on companies that manufacture or import certain branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare providers and entities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additionally, there have been executive, judicial, and legislative challenges to certain aspects of the ACA. For example, while Congress has not passed legislation to comprehensively repeal the ACA, the Tax Cuts and Jobs Act included a provision that, effective January 1, 2019, changed to $0 the tax-based shared responsibility payment imposed by ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, in March 2021, Congress enacted the American Rescue Plan Act of 2021, which included among its provisions a temporary increase in premium tax credit assistance for individuals eligible to receive qualified health plan premium subsidies for 2021 and 2022 and temporarily removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium such tax credits. The Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) extended this increased tax credit assistance and removal of the 400% federal poverty limit through 2025. &#160;Moreover, on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden had issued an executive order that instructed certain governmental agencies to review and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict what effect the healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal, amend or replace the ACA would have on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 included reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislation, will stay in effect into through the first six months of the fiscal year 2032 sequestration order (with the exception of a temporary suspension due to the COVID-19 pandemic from May 1, 2020 through March 31, 2022 and a subsequent reduction to 1% from April 1, 2022 until June 30, 2022). Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In the future, there may be additional challenges and/or amendments to the ACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it may have on the availability and cost of healthcare items and services, including drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in recent years the pricing and costs of prescription pharmaceuticals has been the subject of considerable discussion in the United States. A number of federal reports and inquiries have focused on these issues, and various legislative and regulatory provisions have been proposed and enacted at the federal and state level that seek to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. Additionally, on December 21, 2020, Congress passed a $900 billion U.S. coronavirus relief and government appropriations legislation, the Consolidated Appropriations Act of 2021, which contains several important new drug price reporting and transparency measures that could result in additional transparency with respect to manufacturers&#8217; prescription drug prices. Among other things, the Act includes provisions requiring Medicare Part D prescription drug plan (the &#8220;PDP&#8221;) sponsors and Medicare Advantage organizations (&#8220;MAOs&#8221;) to implement tools to display Medicare Part D prescription drug benefit information in real time and provisions requiring group and health insurance issuers offering health insurance coverage to report information on certain pharmacy benefit and drug costs to the Secretaries of HHS, Labor, and the Treasury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the Biden Administration and Congress have each indicated that it will continue to pursue new legislative and administrative measures to control drug costs. For example, the American Rescue Plan Act of 2021 included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. However, effective January 1, 2024, manufacturers&#8217; Medicaid Drug Rebate Program rebate liability is no longer be capped, potentially resulting in a manufacturer paying more in Medicaid Drug Rebate Program rebates than it receives on the sale of certain covered outpatient drugs. Further, in August 2022, President Biden signed into law IRA, which implements substantial changes to the Medicare program, including drug pricing reforms and the creation of new Medicare inflation rebates. &#160;Namely, the IRA imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap &#160;beneficiary annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of high expenditure pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the CMS. Since its enactment, CMS has taken steps to implement various drug pricing provisions of the IRA. This includes, without limitation, issuing guidance on June 30, 2023 detailing the requirements and parameters of the first round of price negotiations, to take place during 2023 and 2024, for products subject to the &#8220;maximum fair price&#8221; provision that would become effective in 2026; on August 29, 2023, releasing the initial list of 10 drugs subject to price negotiations; and on December 14, 2023 releasing a list of 48 Medicare Part B products that had adjusted coinsurance rates based on the inflationary rebate provisions of the IRA for the time period of January 1, 2024 to March 31, 2024. Several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the Department of Health and Human Services, the Secretary of the Department of Health and Human Services, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA&#8217;s drug price negotiation provisions. We cannot predict whether the IRA, or any of its component parts, will be overturned, repealed, replaced, or amended nor can we predict the likelihood, nature, or extent of other health reform initiatives that may arise from future legislation, administrative, or other action. However, we expect these initiatives to increase pressure on drug pricing.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the Biden administration continues to direct the Department of Health and Human Services to consider new healthcare payment and delivery models that would lower drug costs and promote access to innovative therapies for beneficiaries enrolled in the Medicare and Medicaid programs. For example, on October 14, 2022 President Biden issued an Executive Order on Lowering Prescription Drug Costs for Americans, which instructed the Secretary of the Department of Health and Human Services to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. On February 14, 2023, the Department of Health and Human Services issued a report in response to the October 14, 2022 Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center. Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum co-payment amount for certain common generic drugs at $2; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements for certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments. We cannot predict how, or to what extent, the Biden administration&#8217;s drug pricing policies will affect our products. We cannot predict what other healthcare reforms will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation. Accordingly, we face uncertainties that might result from additional reforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control biopharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any product that is ultimately approved, if approved. In addition, several recently passed state laws require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes. Another emerging trend at the state level is the establishment of prescription drug affordability boards, some of which will prospectively permit certain states to establish upper payment limits for drugs that the state has determined to be &#8220;high-cost.&#8221; Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our future reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our corporate and research headquarters are located at 10865 Road to the Cure, Suite 150, San Diego, California 92121. Our telephone number is (858) 727-1755 and our internet address is&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.capricor.com</i>. The information on, or accessible through, our website is not incorporated into this Annual Report on Form&#160;10-K or any other filings we make with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). We have included our website address in this Annual Report on Form&#160;10-K solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had 102 employees, of whom 101 are full-time employees with 34 holding advanced degrees. None of our employees are covered by a collective bargaining agreement. We believe that our relations with our employees are satisfactory. We have also retained several consultants to perform various operational and administrative functions. Certain officers of Capricor are also serving as officers of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f908bac_bbdf_41b0_98c2_1624088bbe58"></a><a id="ITEM1ARISKFACTORS_519944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investment in our common stock involves significant risk. You should carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this Annual Report on Form&#160;10-K, before making an investment decision regarding our common stock. If any of the events or circumstances described in these risks actually occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or a part of your investment in our common stock. Moreover, the risks described below are not the only ones that we face.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Summary Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, clinical and commercialization activities, the manufacturing of our product candidates, intellectual property, third-party relationships, competition factors, product and environmental liability, and common stock. These risks are discussed more fully below and include, but are not limited to, risks related to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial additional funding is needed to complete the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has incurred significant losses and may never be profitable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of security breaches, improper access to or disclosure of our data or user data, and other cyber incidents or undesirable cyber activity related to our, or our third-party vendor&#8217;s systems and data; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not have adequate personnel and may not be able to attract or retain personnel needed to develop our products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Clinical and Commercialization Activities</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our success depends upon the viability of our product candidates, all of which require regulatory approval to commercialize and we cannot be certain any of them will receive regulatory approval to be commercialized;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in commencement, enrollment, and completion of clinical testing could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our exosome technologies are unproven in their ability to achieve sufficient biological activity or scale in development to date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates can fail to meet their efficacy endpoints at any time during the clinical development process, which would likely make them ineligible for becoming commercial products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to use our facilities to manufacture CAP-1002 product for commercial purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to obtain consent from CSMC in order to sell commercial product from our Los Angeles facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to satisfy clinical and/or regulatory requirements necessary for the approval of our product in the U.S. or Japan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to reach the milestones set forth in our distribution agreements therefore preventing us from receiving the financial benefits of those agreements; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our partners may not perform as expected and therefore deny us the financial benefits of those agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to the Manufacturing of our Product Candidates</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing of our product candidates is heavily reliant on supply chain requirements including the availability of donor hearts and other raw materials that are critical for the manufacturing of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may need to rely upon third-party manufacturers for the expansion of our manufacturing capabilities for later-stage clinical trials and for ultimate commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not have adequate manufacturing facilities required for any scale-up of manufacturing which may be required in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to replicate our manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to comply with cGMP regulations;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to identify or retain necessary manufacturing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may not accept the viability or comparability of our manufacturing processes; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may not approve our manufacturing facilities for the manufacture of commercial products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain, maintain, protect, and enforce our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face potential challenges to the validity, enforceability, or scope of our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience claims from third parties that we are infringing their patents or other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to satisfy our obligations under our licensing agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Relationships with Third Parties</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we depend on our relationships with our licensors, collaborators, and other third parties and there is no guarantee that such relationships will continue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will depend on the ability of Nippon Shinyaku to perform according to the terms of the U.S. Distribution and Japan Distribution Agreements and all applicable laws, and to successfully commercialize our lead product CAP-1002 in DMD.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Competitive Factors</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our products will likely face intense competition; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of our product candidates for which we receive regulatory approval may not achieve broad market acceptance, which could limit the revenue that we will generate from their sales, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Product and Environmental Liability</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our products may expose us to potential product liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we expect that our stock price will continue to fluctuate significantly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have never paid dividends and we do not anticipate paying dividends in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We need substantial additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital, we will be forced to delay, reduce or eliminate our product development and clinical programs and may not have the capital required to otherwise operate our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials and establishing manufacturing capabilities, is expensive. As of December&#160;31,&#160;2023, we had cash, cash equivalents, and marketable securities totaling approximately $39.5 million. Additionally, we received a milestone payment of $10.0 million in the first quarter of 2024 under the terms of our U.S. Distribution Agreement with Nippon Shinyaku and we may potentially receive other additional development and sales-based milestones. We have not generated any revenues from the commercial sale of products. We will not be able to generate any product revenues until, and only if, we receive approval to sell our drug candidates from the FDA or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From inception, we have financed our operations through private and public sales of our equity securities, government grants and payments from distribution agreements and collaboration partners. As we have not generated any revenue from the commercial sale of our products to date, and we do not expect to generate revenue for several years, if ever, we will need to raise substantial additional capital in order to fund our general corporate activities and to fund our research and development, including our long-term plans for clinical trials and new product development.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek to raise additional funds through various potential sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure such additional sources of funds to support our operations or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. Moreover, to the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates, or grant licenses on terms that may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to raise sufficient funds to support our current and planned operations, we may elect to discontinue certain of our ongoing activities or programs. The inability to raise additional funds could also prevent us from taking advantage of opportunities to pursue promising new or existing programs in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our forecasts regarding our beliefs in the sufficiency of our financial resources to support our current and planned operations are forward-looking statements and involve significant risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, cost and results of our research and development activities, especially our CAP-1002 and exosomes programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the next steps in the development of our DMD program, which includes our HOPE-3 clinical trial for our CAP-1002 product candidate for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of funding from government programs including the NIH, DoD, and CIRM, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of developing adequate manufacturing processes and facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with and timing of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and risks involved in conducting clinical trials and manufacturing operations in the U.S. and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaboration, licensing or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture commercial-scale GMP CAP-1002 product at our San Diego manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of technology transfer for, and completion of, clinical and commercial-scale outsourced manufacturing activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of establishing sales, marketing and distribution capabilities, as applicable, for any product candidates for which we may receive regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our business plans are not successful, we may not be able to continue operations as a going concern and our stockholders may lose their entire investment in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:normal;font-weight:normal;">Our audited financial statements include a statement that there is substantial doubt about our ability to continue as a going concern. We have historically incurred substantial losses to fund our business operations including our research and development activities and more recently manufacturing scale-up activities. We will, in all likelihood, sustain operating expenses without corresponding revenues for the foreseeable future. This may result in our incurring net operating losses that will increase continuously until we are able to obtain regulatory approval for, and commercialize, our product candidates, the occurrence of which cannot be assured. While we have historically been able to adjust the timing associated with our R&amp;D efforts, as well as reducing headcount and implementing certain budget restrictions, to alleviate </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">uncertainties surrounding our ability to continue as a going concern, if ultimately we cannot continue as a going concern, our stockholders may lose their entire investment in us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have a history of net losses, and we expect losses to continue for the foreseeable future. In addition, a number of factors may cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a history of net losses, expect to continue to incur substantial net losses for the foreseeable future, and may never achieve or maintain profitability. Our operations to date have been primarily limited to organizing and staffing our company, developing our technology, and undertaking preclinical studies and clinical trials of our product candidates. We have not yet obtained regulatory approval for any of our product candidates. Specifically, our financial condition and operating results have varied significantly in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our need for substantial additional capital to fund our trials and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the commencement, enrollment, and timing of clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the viability of CAP-1002 as a potential product candidate and its development through all stages of clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the viability of our exosome technologies as potential product candidates and the advancement of our exosome technologies through all stages of its preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays in regulatory review and approval of our product candidates in clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to receive regulatory approval or commercialize our product candidates, within and outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential side effects of our current or future products and product candidates that could delay or prevent commercialization or cause an approved treatment to be taken off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish an effective sales and marketing infrastructure once our products are commercialized, as necessary or to establish partnerships with other companies who have greater sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our distribution partner, Nippon Shinyaku, to successfully market and sell our CAP-1002 product if and to the extent it is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish or maintain collaborations, licensing or other arrangements, including strategic partnerships for CAP-1002 outside of DMD and our exosomes technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability and third parties&#8217; abilities to obtain and protect intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing products or new products that may emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">guidelines and recommendations of therapies published by various organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of patients to obtain coverage of, or sufficient reimbursement for, our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain adequate insurance policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully manufacture our product candidates in sufficient quantities and on a timely basis to meet clinical trial and potential commercial demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our dependency on third parties to formulate and manufacture our product candidates, as necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain and staff our current manufacturing facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to build or secure new manufacturing facilities, if necessary, and achieve and maintain cGMP and obtain required certifications as required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to and outcomes of potential intellectual property litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with obligations under intellectual property licenses with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to implement additional internal systems and infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to adequately support future growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if our products are approved for commercial sale, the ability to secure adequate reimbursement levels for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key personnel to manage our business effectively; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of members of our senior management to manage our business and operations.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s technology is not yet proven and each of our product candidates is still in clinical or preclinical <span style="letter-spacing:0pt;">development</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s product candidates, CAP-1002 and our exosome technologies, are in development and each requires further and, in some cases, extensive clinical testing before it may be approved by the FDA, or another regulatory authority in a jurisdiction outside the United States, which could take several years to complete, if ever. The Company&#8217;s failure to establish the efficacy of its technologies would have a material adverse effect on the Company. We cannot predict with any certainty the results of such clinical testing, including the results of our ongoing Phase 3 trial of our CAP-1002 product candidate for DMD. Additionally, we cannot predict with any certainty if, or when, we might commence any additional clinical trials of our product candidates, whether we will be able to secure additional strategic partners, or whether our current trials will yield sufficient data to permit us to proceed with additional clinical development and ultimately submit an application for regulatory approval of our product candidates in the United States or abroad, or whether such applications will be accepted by the appropriate regulatory agencies. We are also unable to predict whether our preclinical studies of our exosomes products will result in a viable clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business depends entirely on the successful development and commercialization of our product candidates. We currently have no products approved for sale and generate no revenues from sales of any products, and we may never be able to develop a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The success of our product candidates will&#160;depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful and timely completion of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation and successful patient enrollment and completion of additional clinical trials on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of COVID-19 or some other infectious disease outbreak on our operations, ability to conduct clinical trials and on the ability of our regulators to review and approve or authorize our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate our products&#8217; safety, tolerability and efficacy to the FDA or any comparable foreign regulatory authority for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely receipt of marketing approval for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avoiding and successfully defending against any claims that we have infringed, misappropriated or otherwise violated any intellectual property of any third-party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of our current and future distributors or collaborators, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of, and our ability to timely complete, any required post-marketing approval commitments imposed by FDA or other applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully developing a companion diagnostic test on a timely and cost effective basis, if required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-parties for raw materials and product supplies and potential manufacturers who are able to manufacture clinical trial and commercial quantities of drug substance and drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with cGMP at a scale sufficient to meet anticipated demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with potential manufacturers who are able to develop, validate and maintain a commercially viable manufacturing process that is compliant with cGMP at a scale sufficient to meet anticipated demand and over time enable us to reduce our cost of manufacturing, if necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of scaled production arrangements with third-party manufacturers to obtain finished products that are compliant with cGMP and appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to conduct post-marketing surveillance and comply with requirements of FDA and other comparable regulatory authorities after product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of our products. If we are not successful in marketing or commercializing our products, or are significantly delayed in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Business <span style="letter-spacing:0pt;">disruptions</span> such as natural disasters, widespread infectious diseases, or pandemics or geopolitical conflicts could seriously harm our future revenues and financial condition and increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters and our manufacturing and research facilities are located in San Diego and in the greater Los Angeles, California area, a region known for seismic activity, as well as being susceptible to drought and fires. A significant natural disaster, such as an earthquake, flood or fire, occurring at our headquarters or manufacturing facilities, or at the facilities of any third-party manufacturer or vendor, could have a material adverse effect on our business, financial condition and results of operations. In addition, outbreaks of viruses, infectious diseases or pandemics (including, for example, the outbreak of the novel coronavirus (COVID-19), terrorist acts or acts of war targeted at the United States, and specifically in the California region, or geopolitical conflicts, such as the Russia-Ukraine conflict and the conflicts in the Middle East, could cause damage or disruption to us, our employees, facilities, contractors and collaborators, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A <span style="letter-spacing:0pt;">breakdown, corruption</span> or breach of our information technology systems or computer systems, or those used or hosted by our CROs, contractors, consultants or third-party vendors could subject us to liability or interrupt the operation of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are increasingly dependent upon information technology systems, computer systems and data, as well as the information technology systems, computer systems and data of our current and future clinical research organizations (&#8220;CROs&#8221;), contractors, consultants and third-party vendors, especially if we expand our clinical trials and therefore our databases of patient information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our information technology systems, computer systems and data (and those of our current and future CROs, contractors, consultants and third-party vendors) are potentially vulnerable to breakdown, corruption, deliberate attacks, malicious intrusion or software, as well as unintentional cybersecurity incidents, such as system misconfigurations, misuses or human error. Likewise, data privacy or security breaches by individuals authorized to access our information technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We utilize and rely on services of third parties in connection with our clinical trials, which services involve the collection, use, storage and analysis of personal health information. While we receive assurances from these third parties that their systems and services are compliant with HIPAA and other applicable privacy and cybersecurity laws, there can be no assurance that such third parties will comply with applicable laws or regulations. Non-compliance by such third parties or weaknesses in their cybersecurity programs may result in liability for us which would have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Despite the implementation of security measures, our information technology systems and computer systems, and those of our current and future CROs, contractors, consultants and other third parties are potentially vulnerable to breakdown, corruption, disruption or cybersecurity incidents. Cyber-attacks are increasing in their frequency, sophistication and intensity and are becoming increasingly difficult to detect. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be significantly delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We continue to build and improve our information systems and infrastructure and believe we have taken appropriate security measures to minimize these risks to our data, information technology systems and computer systems, and we intend to defend against and respond to data security incidents. There can be no assurance that our efforts will prevent breakdowns or breaches in our systems, or adequately contain and mitigate risks from a data security incident, which could result in a material disruption of our development programs and business operations, and our business, financial condition, results of operations and prospects could be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we <span style="letter-spacing:0pt;">achieve</span> our near-term product development milestones, we may not be able to manage any subsequent growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should we achieve our near-term product development milestones, of which no assurance can be given, our long-term viability will depend upon the expansion of our operations and the effective management of our growth, which will place a significant strain on our management and on our administrative, operational and financial resources, especially if we expand our business and operations internationally. To manage this growth, we may need to expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel. If we are unable to manage our growth effectively, our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Clinical and Commercialization Activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends upon the viability of our product candidates and we cannot be certain any of them will receive regulatory <span style="letter-spacing:0pt;">approval</span> to be commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need FDA approval to market and sell any of our product candidates in the United States and approvals from FDA-equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any of our product candidates, we must submit to the FDA an NDA or BLA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal testing, which are referred to as preclinical studies, as well as human testing, which are referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, testing and manufacturing. We cannot predict whether our research and clinical approaches will result in drugs that the FDA considers safe for humans and effective for indicated uses. The FDA and other foreign regulatory agencies have substantial discretion in the approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation, administrative action or changes in FDA policy that occur prior to or during our regulatory review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs or BLAs, as applicable. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of any of our product candidates will reduce our number of potentially salable products, if any, and, therefore, corresponding product revenues, and will have a material and adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited experience in conducting late-stage clinical trials, which are complex and subject to strict regulatory oversight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited late-stage clinical trial experience with respect to its product candidates. The clinical testing process is governed by stringent regulations and is highly complex, costly, time-consuming, and uncertain as to outcome, and pharmaceutical products and products used in the regeneration of tissue may invite particularly close scrutiny and requirements from the FDA and other regulatory bodies. Our failure or the failure of our collaborators to conduct clinical trials successfully or our failure to capitalize on the results of clinical trials for our product candidates would have a material adverse effect on the Company. If our clinical trials of our product candidates or future product candidates do not sufficiently enroll or produce results necessary to support regulatory approval in the United States or elsewhere, or if they show undesirable side effects, we will be unable to commercialize these product candidates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To receive regulatory approval for the commercial sale of our product candidates, we must conduct adequate and well-controlled clinical trials to demonstrate efficacy and safety in humans. Clinical failure can occur at any stage of testing. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing. In addition, the results of our clinical trials may show that our product candidates are ineffective or may cause undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in the denial of regulatory approval by the FDA and other regulatory authorities. Furthermore, negative, delayed or inconclusive results may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the termination of clinical trial sites or entire trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costly litigation arising out of the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement that additional trials be conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenues; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">As the results of earlier preclinical studies or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;font-style:normal;font-weight:normal;">Even if our preclinical studies and clinical trials are completed as planned, we cannot be certain that their results will support the claims of our product candidates. Positive results in preclinical testing and early clinical trials do not ensure that results from later clinical trials will also be positive, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;font-style:normal;font-weight:normal;">Our clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay or cause us to refrain from the filing of our NDAs and/or BLAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues. In addition, our clinical trials to date involve small patient populations. Because of the small sample size, the results of these clinical trials may not be indicative of future results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;font-style:normal;font-weight:normal;">Despite the results reported in earlier clinical trials for our product candidates, we do not know whether any Phase 2, Phase 3 or other clinical trial which we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidates. A number of companies in the pharmaceutical industry, including those with greater resources and experience, have suffered significant setbacks in Phase 2 or Phase 3 clinical trials, even after seeing promising results in earlier clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Our&#160;</span>exosome technologies are based on a novel therapeutic approach which makes it difficult to predict the time and cost of <span style="letter-spacing:0pt;">development</span> and the probability of subsequently obtaining regulatory approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our exosome technologies involve a relatively new therapeutic approach which will face both clinical and regulatory challenges. To date<span style="color:#333333;">, and to the best of our knowledge, no products based on exosomes have been approved in the United States for therapeutic use. It is therefore difficult to accurately predict the developmental challenges we may face for our exosome technologies as they proceed through preclinical studies and clinical trials. In addition, because we have only conducted preclinical studies with our exosome technologies, we have not yet been able to assess their safety in humans, and there may be short-term or long-term effects from treatment with our exosomes that we cannot predict at this time. Also, animal models for the indications we may explore may not exist or may be difficult to obtain for our preclinical studies. As a result of these factors, we are unable to predict the time and cost of development of our exosome technologies and we cannot predict whether the application of our exosome technologies, or any similar or competitive exosome technologies, will result in regulatory approval of any products. There can be no assurance that any development problems we experience in the future related to our exosomes or any of our research programs will not cause significant delays or&#160;</span>unanticipated costs, or that such development problems can be solved. We may also decide to discontinue exosome development programs if we believe that there is excessive competition in a disease target. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy&#160;<span style="color:#333333;">of a product candidate vary substantially according to the type, complexity and intended use and market of the product candidate. As a result, the regulatory approval process for our exosomes is uncertain and may be more expensive and take longer than the approval process for other product candidates. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our exosomes in either the United States or the European Union or other regions of the world or how long it will take to commercialize our product candidates, if at all. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects may be adversely impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0pt;">Negative</span> developments in the field of exosomes could damage public perception of any product candidates that we develop, which could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Exosome-based therapeutics and vaccines are novel and unproven therapies which may not gain the acceptance of the public, patients or the medical community. To date, efforts by others to leverage natural exosomes have generally demonstrated an inability to generate exosomes with predictable biologically active properties or to manufacture exosomes at suitable scale to treat more than a small number of patients. Our success will depend on our ability to demonstrate that our exosome technologies can overcome these challenges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, our success will depend upon physicians who specialize in the treatment of diseases targeted by our exosomes prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of our exosomes or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of exosome therapeutics, could result in a decrease in demand for any products that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of, or modification to, our clinical trials. Any future negative developments in the field of exosomes and their use as therapies could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our exosomes or other potential future product candidates. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our exosomes or any other product candidates which we may develop in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advancing product candidates based on our exosome platform as novel products creates significant challenges for us, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to our knowledge, obtaining marketing approval from the FDA or comparable foreign regulatory authorities has never been done before;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing the sales and marketing capabilities to gain market acceptance, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able<span style="font-style:normal;font-weight:normal;"> </span><span style="letter-spacing:0pt;">to</span> do so, the FDA may not permit us to proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We hope to file additional INDs over the next several years, including with respect to our exosome technologies in one or more indications. However, the timing of our filing of these INDs is primarily dependent on receiving further data from our preclinical studies, having sufficient processes in place in connection with the manufacturing of the exosomes and the availability of necessary funding for any potential clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Any IND we submit could be denied by the FDA or the FDA could place any future investigation of ours on clinical hold until we provide additional information, either before or after clinical trials are initiated. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trial set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. The FDA may also impose clinical holds at any time before or during clinical trials due to unacceptable and significant risks to clinical trial subjects or non-compliance with FDA requirements. Unfavorable future trial results or other factors, such as insufficient capital to continue development of a product candidate or program, could also cause us to voluntarily withdraw an effective IND.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Delays in the commencement, enrollment, and completion of clinical testing could result in increased costs to us and <span style="letter-spacing:0pt;">delay</span> or <span style="letter-spacing:0pt;">limit</span> our ability to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays in the commencement, enrollment or completion of clinical testing could significantly affect our product development costs. Additionally, a clinical trial may be suspended or terminated by the Company, the FDA, or other regulatory authorities due to a number of factors. The commencement and completion of clinical trials require us to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clinical trial as a result of changing standards of care, or we may become ineligible to participate in clinical studies. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. The commencement, enrollment and completion of clinical trials can be delayed for a number of reasons, including, but not limited to, delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">findings in preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreements on acceptable terms with prospective CROs, vendors and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, vendors and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory clearance to commence a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complying with conditions imposed by a regulatory authority regarding the scope or term of a clinical trial, or being required to conduct additional trials before moving on to the next phase of trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining IRB approval to conduct a clinical trial at numerous prospective sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including the size of the patient population, nature of trial protocol, meeting the enrollment criteria for our studies, screening failures, the inability of the sites to conduct trial procedures properly, the inability of the sites to devote their resources to the trial, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of COVID-19 on site personnel availability, patient screening and patient enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from other companies operating in the same disease setting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any conflicts with new or existing laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to add new clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retaining patients who have initiated their participation in a clinical trial but may withdraw due to the treatment protocol, lack of efficacy, personal issues, or side effects from the therapy, or who are lost to further follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining advice from regulatory authorities regarding the statistical analysis plan to be used to evaluate the clinical trial data or other trial design issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrating the bioequivalence of products we manufacture to prior products manufactured by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complying with design protocols of any applicable special protocol assessment we receive from the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severe or unexpected drug-related side effects experienced by patients in a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collecting, analyzing and reporting final data from the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">breaches in quality of manufacturing runs that compromise all or some of the doses made; positive results in FDA-required viral testing; karyotypic abnormalities in our cell product; or contamination in our manufacturing facilities, all of which events would necessitate disposal of all cells made from that source;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of materials provided by third parties necessary to manufacture our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of adequate amounts of acceptable tissue for preparation of master cell banks for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct additional trials and studies, and increased expenses associated with the services of the Company&#8217;s CROs and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting logistical requirements for the delivery of investigational product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, we or our development partners, if any, may be delayed in obtaining, or may not be able to obtain or maintain, clinical or marketing approval for these product candidates. We may not be able to obtain approval for </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">indications that are as broad as intended, or we may be able to obtain approval only for indications that are entirely different from those indications for which we sought approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in regulatory requirements and guidance may occur, and we may need to amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. In August 2023, the FDA published a guidance document, Informed Consent, Guidance for IRBs, Clinical Investigators, and Sponsors, which supersedes past guidance and finalizes draft guidance on informed consent. The FDA&#8217;s new guidance presents evolving requirements for informed consent which may affect recruitment and retention of patients in clinical trials. Further, in December 2023, the FDA published a final rule, Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations, which allows exceptions from informed consent requirements when a clinical investigation poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of human subjects. Modifications to informed consent or other clinical trial requirements may affect enrollment or retention of patients, require modifications to trial documents and may cause delays to the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination which may impact the costs, timing, or successful completion of a clinical trial. If we experience delays in the completion of, or if we terminate, our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenues will be delayed or will not be realized. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Even if we are able to ultimately commercialize our product candidates, other therapies for the same or similar indications may have been introduced to the market and already established a competitive advantage. Any delays in obtaining regulatory approvals may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay commercialization of, and our ability to derive product revenues from, our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose costly procedures on us; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diminish any competitive advantages that we may otherwise enjoy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors, including our CROs, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, our investigators, or any of the overseeing IRBs or ethics committees might decide to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are insufficiently positive to support marketing approval, or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are narrower or more limited in scope than intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval subject to significant use or distribution restrictions or with labeling that includes significant safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the drug removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Furthermore, we rely on third-party CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring drugs to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, <span style="letter-spacing:0pt;">interim</span> results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable drugs. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate with substantial evidence through adequate and well-controlled clinical trials that our product candidates are safe and effective for use in treating specific conditions in order to obtain marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Product candidates that have shown promising results in preclinical studies and early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish or report interim or preliminary data from our clinical trials, once initiated. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the design of a clinical trial can determine whether its results will support approval of a drug and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing late-stage clinical trials and may be unable to design and conduct a clinical trial to support marketing approval. Further, if our product candidates are found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in preclinical studies and earlier clinical trials.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that an adverse safety issue, clinical hold or other adverse finding occurs in one or more of our clinical trials, once initiated, such event could adversely affect our other clinical trials using the same product candidate. Moreover, there is a relatively limited safety data set for product candidates using an exosome platform. An adverse safety issue or other adverse finding in a clinical trial conducted by a third-party with a product candidate similar to ours could adversely affect our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase&#160;3 clinical trials or registration trials. The FDA or comparable foreign regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or comparable foreign regulatory authorities. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. In addition, the FDA or other comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining marketing approval for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA and elsewhere to the satisfaction of other comparable foreign regulatory authorities, that the product candidate is safe and effective for use for that target indication. There is no assurance that the FDA or other comparable foreign regulatory authorities will consider our future clinical trials to be sufficient to serve as the basis for approval of one of our product candidates for any indication. The FDA and other comparable foreign regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that a product candidate is safe and effective. If we are required to conduct additional clinical trials of a product candidate than we expect prior to its approval, we will need substantial additional funds and there is no assurance that the results of any such additional clinical trials will be sufficient for approval in our target markets, including the United States and Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory pathway for COVID-19 or other infectious disease vaccines is continually evolving and may result in unexpected or unforeseen challenges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The speed at which select parties have acted to create and test many therapeutics and vaccines for COVID-19 or other infection diseases is atypical. Further, changing plans or priorities within the FDA or the regulatory authorities in other jurisdictions, including changes based on new knowledge of COVID-19 or other infectious diseases, and new variants of the virus, may significantly affect the regulatory timeline for further authorizations or approvals. We cannot anticipate or predict with certainty the timelines or regulatory processes that may be required for the development of our potential COVID-19 vaccine that may be developed to fight against variants of the SARS-CoV-2 virus. We may also decide to discontinue exosome development programs if we believe that there is excessive competition in a disease target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may <span style="letter-spacing:0pt;">not</span> be successful in our efforts to identify or discover additional potential product candidates or additional indications for our existing product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research programs may initially show promise in identifying potential product candidates or potential additional indications for existing product candidates, yet fail to lead to successful clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be safe or effective in treating their targeted diseases.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less <span style="letter-spacing:0pt;">effective</span> than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of <span style="letter-spacing:0pt;">any</span> future distributors or collaborators, to market the drug could be compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval and we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the drug or seize the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug may become less competitive in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market <span style="letter-spacing:0pt;">acceptance</span> by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient revenues from sales of drugs to cover our costs and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential advantages of the product compared to alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the product is designated under physician and other provider treatment guidelines as a first-, second- or third-line therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product&#8217;s convenience and ease of administration for patients and healthcare practitioners compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions and safety information contained in the product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of sales, marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of third-party distributors, such as our exclusive distributor for our lead product candidate, CAP-1002;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for the product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage by, and the amount of reimbursement from, government payors, managed care plans and other third-party payors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or <span style="letter-spacing:0pt;">more</span> successfully than we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries are highly competitive and characterized by rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary drugs. We face competition with respect to any product candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies. Potential competitors also include academic institutions and governmental agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of the companies that we compete or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations that compete with us in developing various approaches to the treatment of DMD which includes competitors both in the United States and internationally. We have competitors both in the United States and internationally. With CAP-1002, we expect to face competition from existing products and products in development. In addition, at this time, there are four FDA conditionally approved exon skipping drugs: EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), which are PMOs approved for the treatment of DMD patients amenable to Exon 51, Exon 45 and Exon 53 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., and VILTEPSO (vitolarsen), a PMO approved for the treatment of DMD patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku (U.S. subsidiary: NS Pharma, Inc.). In June 2023, the FDA approved Sarepta&#8217;s BLA application seeking accelerated approval of Elevidys (delandistrogene moxeparvovec), its microdystrophin gene therapy, for the treatment of ambulant individuals with Duchenne. There are multiple other companies focused on developing genetic based therapies that target dystrophin mechanisms and non-dystrophin mechanisms for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other comparable foreign regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has granted orphan drug status and an RMAT designation to CAP-1002 for the treatment of DMD, but we may be unable to maintain or receive the benefits associated with orphan drug <span style="letter-spacing:0pt;">status</span>, including market exclusivity, or an RMAT designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for a disease or condition will be recovered from sales in the United States for that drug or biologic. If a biological product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received orphan drug status for CAP-1002 for the treatment of DMD. Even though we have received orphan drug designation (ODD) as described above, we may not be the first to obtain marketing approval for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. For any product candidate for which we have been or will be granted ODD in a particular indication, it is possible that another company also holding ODD for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#8217;s period of exclusivity expires. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our exclusive marketing rights in the United States, if obtained, may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure the availability of sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Even though we have obtained orphan drug designation for CAP-1002 for a select indication, we may be unable to seek or obtain orphan drug designation for our future product candidates and we may not be the first to obtain marketing approval for any particular orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, Congress is considering updates to the orphan drug provisions of the FDCA in response to a recent 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have also obtained an RMAT designation for CAP-1002 for the treatment of DMD. The RMAT designation program is intended to fulfill the Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1)&#160;it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or may be able to rely upon data obtained from a meaningful number of sites, including through expansion to additional sites. RMAT designation does not change the standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we were to obtain approval for CAP-1002 for the treatment of DMD with the rare pediatric disease designation, the <span style="letter-spacing:0pt;">Rare</span> Pediatric Disease Priority Review Voucher Program may no longer be in effect at the time of such approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CAP-1002 has received rare pediatric disease designation from the FDA for the treatment of DMD. The FDA generally define a "rare pediatric disease" as a serious or life-threatening disease that affects fewer than 200,000 individuals in the U.S. primarily under the age of 18 years old. Under the FDA's Rare Pediatric Disease Priority Review Voucher program, upon the approval of a NDA or BLA for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a Rare Pediatric Disease Priority Review Voucher that can be used to obtain priority review for a subsequent NDA or BLA. The Priority Review Voucher may be sold or transferred an unlimited number of times, as long as the sponsor making the transfer has not yet submitted the application. Also, although Priority Review Vouchers may be sold or transferred to third parties, there is no guaranty that we will be able to realize any value if we were to sell a Priority Review Voucher. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Congress has only authorized the rare pediatric disease priority review voucher program until September 30, 2024. However, if a drug candidate receives Rare Pediatric Disease designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026. This program has been subject to criticism, including by the FDA, and it is possible that even if we obtain approval for CAP-1002 and qualify for such a Priority Review Voucher, the program may no longer be in effect at the time of approval.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0pt;">Providing</span> product for use in third-party trials or for compassionate use poses risks to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to manufacturing CAP-1002 for its own clinical trials, Capricor provided CAP-1002 for investigational purposes in two clinical trials sponsored by CSMC. Additionally, we recently were selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with our StealthX&#8482; vaccine, subject to regulatory approval. NIAID's Division of Microbiology and Infectious Diseases (DMID) would oversee the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Providing product for clinical trials sponsored by third parties poses significant risks for the Company as we will not have control over the conduct of the trial even though we have used our commercially reasonable efforts to ensure that the investigative sites are contractually bound to follow the protocol and other procedures established by Capricor. Similarly, providing product for compassionate use can pose risks for the Company as its use will not be subject to the same protocol and procedures established in our clinical trials. Additionally, even though the investigative sites have experience in conducting clinical trials, any adverse event that may occur during the trial may have a negative impact on our efforts to obtain regulatory approval for our product. There are no assurances that the clinical trial sites will perform the studies in accordance with the protocol, the manuals provided by Capricor or the sponsor&#8217;s instructions, or otherwise act in accordance with applicable law. There is no assurance that if research injuries are sustained, any insurance carrier will compensate Capricor for any liabilities or other losses sustained by Capricor arising out of these injuries.&#160;We have been informed by CSMC that both of the CAP-1002 (REGRESS and ALPHA) trials have ceased enrollment and that the trials have been concluded. Notwithstanding their cessation, there is a risk that injuries could result from the use of the product or other claims may arise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0pt;">products</span> face a risk of failure due to adverse immunological reactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A potential risk of an allogeneic therapy such as that being tested by the Company with CAP-1002 is that patients might develop an immune response to the cells being infused. Such an immune response may induce adverse clinical effects which would impact the safety and efficacy of the Company&#8217;s products and the success of our trials. Additionally, if research subjects have pre-existing antibodies or other immune sensitization to our cells, our cells and the therapy could potentially be rendered ineffective which could have a negative impact on the regulatory pathway for our product as well as the viability for other potential indications. After a patient in the HOPE-2 trial had a serious adverse event in the form of anaphylaxis, we put a voluntary hold on dosing in December&#160;2018 to develop a plan to manage potential allergic reactions. The investigation suggests that the patient may have been allergic to something contained in the investigational product, including possibly an excipient, or inactive ingredient, in the formulation. To reduce the risk of future events, we initiated a pre-medication strategy commonly used by physicians to prevent and treat allergic reactions. We cannot provide any assurances that this will not happen again in our current trials or in any future studies. If these or other reactions continue to occur, it could have a material adverse impact on the effectiveness of the product, our ability to receive approval of our product candidates, and could result in substantial delays, increased costs and potentially termination of the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0pt;">business</span> faces significant government regulation, and there is no guarantee that our product candidates will receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our research and development activities, preclinical studies, clinical trials, and manufacturing and marketing of our potential products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, as well as by regulatory authorities in other countries. In the United States, our product candidates are subject to regulation as biological products or as combination biological products/medical devices under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act and other statutes, and as further provided in the Code of Federal Regulations. Different regulatory requirements may apply to our products depending on how they are categorized by the FDA under these laws. These regulations can be subject to substantial and significant interpretation, addition, amendment or revision by the FDA and by the legislative process. The FDA may determine that we will need to undertake clinical trials beyond those currently planned. Furthermore, the FDA may determine that results of clinical trials do not support approval for the product. Similar determinations may be encountered in foreign countries including determinations that our manufacturing processes being utilized in the United States are not compliant with the regulations adopted in those foreign countries. The FDA will continue to monitor products in the market after approval, if any, and may determine to withdraw its approval or otherwise seriously affect the marketing efforts for any such product. The same possibilities exist for trials to be conducted outside of the United States that are subject to regulations established by local authorities and local law. Any such determinations </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">would delay or deny the introduction of our product candidates to the market and have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Agency, other federal agencies and corresponding state agencies to ensure strict compliance with good manufacturing practices, and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards, nor can we guarantee that we will maintain compliance with such regulations in regards to our own manufacturing processes. Other risks include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the IND or the product or require us to take our approved products off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way the product is manufactured or administered, and we may be required to conduct additional clinical trials or change the labeling of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will be required to manufacture on our own behalf or retain the services of a commercial manufacturer to develop product suitable for commercial sale in compliance with cGMP requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have limitations on how we or our distributor promote our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the products we manufacture may experience failures in the manufacturing process.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0pt;">There</span> are additional risks involved in conducting clinical trials internationally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we decide to expand or conduct one or more of our clinical trials to investigative sites in Europe, Japan, or other countries outside of the United States, we will have additional regulatory requirements that we will have to meet in connection with our manufacturing, distribution, use of data and other matters. For example, if we decide to conduct our trials in Europe, we may have to move our manufacturing facility to a facility located in Europe, enter into an agreement with a European manufacturer to manufacture our product candidates for us, enter into an agreement with a domestic manufacturer who maintains an acceptable cGMP facility or ensure that our facility meets Japanese, European or other foreign specifications. Any of those options would involve a significant monetary investment, time delays, and increased risk and may impact the progress of our clinical trials and regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we have entered into the Japanese Distribution Agreement with Nippon Shinyaku for the distribution of CAP-1002 in Japan. &#160;In order for us to be able to sell CAP-1002 in Japan, we will be required to satisfy the requirements of and get approval from the PMDA. &#160;At this time, we are uncertain as to the type or types of trials that may be required, whether the PMDA in Japan will accept product manufactured at our facilities, if approved, the price at which our product may be sold and market acceptance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent we conduct business in the European Union (&#8220;EU&#8221;), or receive information about EU residents, we will also have to comply with the EU General Data Protection Regulation (the &#8220;GDPR&#8221;), which was officially adopted in April&#160;2016 and went into effect in May&#160;2018. The GDPR introduces new data protection requirements in the EU, as well as substantial fines for breaches of data protections rules. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements and onerous new obligations on services providers. Non-compliance with the GDPR may result in monetary penalties of up to &#8364;20 million or 4% of worldwide revenue, whichever is higher. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations. As we expand our business outside of the United States, ensuring compliance with the FCPA and the laws of other countries will involve additional monetary and time commitments on behalf of the Company.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our <span style="letter-spacing:0pt;">product</span> candidates receive regulatory approval, we may still face future development and FDA regulatory difficulties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies. If any of our products were granted accelerated approval, the FDA could require post-marketing confirmatory trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. FDA may withdraw approval of a drug or indication approved under the accelerated approval pathway if any of the following were to occur: a trial required to verify the predicted clinical benefit of the product fails to verify such benefit; other evidence demonstrates that the product is not shown to be safe or effective under the conditions of use; the applicant fails to conduct any required post-approval trial of the drug with due diligence; or the applicant disseminates false or misleading promotional materials relating to the product. In addition, the FDA currently requires as a condition for accelerated approval the pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the number of recent high-profile adverse safety events with certain drug products, the FDA may require, as a condition of approval, costly risk management programs, which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, and restrictions on direct-to-consumer advertising. Furthermore, heightened Congressional scrutiny on the adequacy of the FDA&#8217;s drug approval process and the FDA&#8217;s efforts to assure the safety of marketed drugs have resulted in the proposal of new legislation addressing drug safety issues. If enacted, any new legislation could result in delays or increased costs during the period of product development, clinical trials, and regulatory review and approval, as well as increased costs to assure compliance with any new post-approval regulatory requirements. Any of these restrictions or requirements could force us to conduct costly studies or increase the time for us to become profitable. For example, any labeling approved for any of our product candidates may include a restriction on the term of its use, or it may not include one or more of our intended indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping, and submission of safety and other post-market information on the drug. New issues may arise during a product lifecycle that did not exist, or were unknown, at the time of product approval, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured. Since approved products, manufacturers, and manufacturers&#8217; facilities are subject to continuous review and periodic inspections, these new issues post-approval may result in voluntary actions by Capricor or may result in a regulatory agency imposing restrictions on that product or us, including requiring withdrawal of the product from the market or for use in a clinical trial. If our product candidates fail to comply with applicable regulatory requirements, such as good manufacturing practices, a regulatory agency may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, and penalties for noncompliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose other civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications filed by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a product recall.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In order to market and commercialize any product candidate outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding manufacturing, safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. Failure to obtain regulatory approval in other countries, or any delay or setback in obtaining such approval, could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on product sales and potential royalties, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and that such approval may be subject to limitations on the indicated uses for which the product may be marketed or require costly, post-marketing follow-up studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we or current or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, <span style="letter-spacing:0pt;">we</span> or they could be subject to enforcement actions and substantial penalties, which could affect our ability to <span style="letter-spacing:0pt;">develop</span>, market and sell our products and may harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we do not currently have any products on the market, if our therapeutic candidates or clinical trials become covered by federal health care programs, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse, transparency, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Some of our pre-commercial activities also may be subject to some of these laws. For more information on potentially applicable healthcare laws and regulations, See Part I, Item 1 &#8211; Other Healthcare Fraud and Abuse Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any of these or any other healthcare regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or similar programs in other countries or jurisdictions, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement and curtailment or restructuring of our operations, any of which could adversely impact our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation, even the mere issuance of a subpoena or the fact of an investigation alone, regardless of the merit, could result in negative publicity, a drop in our share price, or other harm to our business, financial condition and results of operations. Defending against any such actions could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any drugs we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or <span style="letter-spacing:0pt;">healthcare</span> reform initiatives, thereby harming our future business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for newly-approved drugs. Moreover, eligibility for coverage does not necessarily signify that a drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new drugs, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. In addition, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for pharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently expect that certain drugs we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part&#160;B. Specifically, Medicare Part&#160;B coverage may be available for eligible beneficiaries when the following, among other requirements have been satisfied:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product is typically furnished incident to a physician's services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product has been approved by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Reimbursement rates under Medicare Part&#160;B would depend in part on whether the newly approved product would be eligible for a unique billing code. Self-administered, outpatient drugs are typically reimbursed under Medicare Part&#160;D, and drugs that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part&#160;A under a bundled payment. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality of care and/or expanding access to care and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. See Part I, Item 1 &#8211; Healthcare Reform for additional detail on recent legislative and regulatory changes that could affect our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our risk mitigation measures cannot guarantee that we effectively manage all operational risks and that we are in compliance with all potentially applicable U.S. federal and state regulations and all potentially applicable foreign regulations and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development, manufacturing, distribution, pricing, sale, marketing and reimbursement of our product candidates, together with our general operations, are subject to extensive federal and state regulation in the United States and may be subject to extensive regulation in foreign countries. In addition, our business is complex, involves significant operational risks and includes the use of third parties to conduct business. While we intend to implement numerous risk mitigation measures to comply with such regulations in this complex operating environment, we cannot guarantee that we will be able to effectively mitigate all operational risks. We cannot guarantee that we, our employees, our consultants, our contractors or other third parties are or will be in compliance with all potentially applicable U.S. federal and state regulations and/or laws, and all potentially applicable foreign regulations and/or laws. If we fail to adequately mitigate our operational risks or if we or our agents fail to comply with any of those regulations or laws, a range of actions could result, including, but not limited to, the termination of clinical trials, the failure to approve a product candidate, restrictions on our products or manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation. Any of these occurrences could have a material and adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee or consultant fraud or other misconduct. Misconduct by our employees or consultants could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct could involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to obtain reimbursement or funding for our programs from the federal government may be impacted by possible reductions in federal spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">U.S. federal government agencies currently face potentially significant spending reductions. For example, as a result of the Budge Control Act of 2011, the Bipartisan Budget Act (&#8220;BBA&#8221;), and the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), an annual 2% reduction to Medicare payments took effect on April 1, 2013, and has been extended into through the first six months of the fiscal year 2032 sequestration order (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a subsequent reduction to 1% from April 1, 2022 until June 30, 2022). &#160;The U.S. federal budget remains in flux, which could, among other things, result in additional cuts to Medicare payments to providers and otherwise affect federal spending on clinical and preclinical research and development. The Medicare program is frequently mentioned as a target for spending cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. In addition, we cannot predict any impact which the actions of President Biden&#8217;s administration and the U.S. Congress may have on the federal budget. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vaccines carry unique risks and uncertainties, which could have a negative impact on future results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are planning to potentially develop vaccine candidates using our exosome technologies.&#160; The successful development, testing, manufacturing and commercialization of vaccines is a long, complex, expensive and uncertain process.&#160; There are unique risks and uncertainties associated with vaccines, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, media pathogens, bacteria, viral strains, synthesized nucleic acids, including mRNA and other biological materials. In addition, government regulations in multiple jurisdictions, such as the United States, Japan and the EU, could result in restricted access to, or the transport or use of, such materials. If the Company in unable to access sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research or product development activities as planned and may incur additional costs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The development, manufacturing and marketing of vaccines are subject to regulation by the FDA, the EMA, PMDA and other regulatory bodies that are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the United States, a BLA, including both preclinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial lot.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vaccines are frequently costly to manufacture because production ingredients are inactive biological materials derived from virus, animals, or plants and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Manufacturing of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited manufacturing capability and may not be able to maintain our manufacturing licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2022, we completed construction of our new primary manufacturing facility located within our Research and Development Facility in San Diego, California as we prepare for potential commercial launch. This facility is designed to produce commercial-scale GMP CAP-1002 product for clinical and potential commercial use, subject to FDA approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we also maintain a portion of our laboratories, research and manufacturing facilities in leased premises at CSMC in Los Angeles, California. Currently, in the area of our leased premises at CSMC where we manufacture CAP-1002 and may potentially manufacture our exosome technologies, we believe that we follow good manufacturing practices sufficient for an investigational stage product. Capricor has been manufacturing CAP-1002 in this facility for our current and previous studies including Cohort A of the HOPE-3 trial. We are using product manufactured from our San Diego facility to support Cohort B of the ongoing HOPE-3 trial and supporting our OLE trials. Furthermore, it is to be determined whether the FDA will ultimately approve commercial manufacturing at this facility. Our plans to use the CSMC facility for future trials could change if we fail to meet the specifications necessary to produce our product in a qualified manner. Currently, our CSMC Facilities Lease is scheduled to expire on July 31, 2026. There can be no assurance that the Facilities Lease for the manufacturing space will be continued beyond July 31, 2026 or whether the facility will be approved by the FDA for commercial manufacturing following approval of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the third quarter of 2023, we met with the FDA, where we affirmed alignment with respect to our Phase 3, HOPE-3 program where the FDA agreed to allow us to submit a BLA supported by results using product manufactured at our Los Angeles manufacturing site. At this time, we can provide no assurance that the FDA will ultimately approve this facility for commercial use, or that CMSC will allow us to market commercial product from this facility. Should this facility ultimately not be approved to manufacture commercial product, this may result in delays and significant expenses which would materially impact our business and product development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, FDA may consider the data we provide are insufficient to prove that the drug used in Cohort B of our HOPE-3 study is comparable to the drug produced in our Los Angeles facility and used in our prior clinical studies. This could result in us being required to conduct further comparability testing and may result in us being required to conduct </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">additional clinical and/or nonclinical studies before we are able to submit a BLA for approval. Additional testing or clinical trial requirements could lead us not to pursue an application for approval. Conducting a clinical trial may prove too difficult or too expensive, and the process of designing a clinical trial, enrolling enough patients, and completing treatment and data collection under the protocol could take a significant amount of time, effort, and resources. Even if we do complete the clinical trial, the study may not meet its prespecified endpoints, and even if it does, the FDA may still disagree with our determination that the trial is sufficient to support the submission and approval of a BLA application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We obtain the donor hearts from which our CDCs are manufactured from organ procurement organizations (&#8220;OPOs&#8221;). &#160;There is no guarantee that the OPOs which currently provide donor hearts to us will be able to continue to supply us with donor hearts in the future or, in that case, that an alternative OPO will be available to us. If those OPOs or an alternative OPO is not able or willing to supply us with donor hearts, we would be unable to produce our CDCs or CDC-exosomes and the development of our lead product candidate would be significantly impaired and possibly terminated. Additionally, OPOs are subject to regulations of various government agencies. There is no guarantee that laws and regulations pursuant to which our OPOs provide donor hearts will not change, making it more difficult or even impossible for the OPOs to continue to supply us with the hearts we need to produce our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are required to obtain and maintain certain licenses in connection with our manufacturing facilities and activities. For example, we have recently entered into Azzur License Agreement with Azzur Cleanrooms-on-Demand &#8211; San Diego, LLC pursuant to which we have been granted an exclusive license to use certain space and the non-exclusive right to use certain equipment and property for our early phase clinical and/or pre-clinical manufacturing purposes. We are planning to use this facility to manufacture our exosome-based vaccine for potential clinical use. There is no guarantee that any licenses issued to us will not expire, be revoked, forfeited by operation of law or otherwise. If we were denied any required license or if any of our licenses were to be revoked or forfeited, we would suffer significant harm. Additionally, if a serious adverse event in any of our clinical trials were to occur during the period in which any required license was not in place, we could be exposed to additional liability if it were determined that the event was due to our fault and we had not secured the required license. Other states may impose additional licensing requirements upon us which, until obtained, would limit our ability to conduct our trials in such states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The process of manufacturing our products is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities.</span><span style="display:inline-block;width:11.94pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently producing doses of CAP-1002 in order to conduct our ongoing clinical trials at both of our facilities. The process of manufacturing our products is complex, highly regulated and subject to multiple risks. The complex processes associated with the manufacture of our product candidates expose us to various manufacturing challenges and risks, which may include delays in manufacturing adequate supply of our product candidates, limits on our ability to increase manufacturing capacity, and the potential for product failure and product variation that may interfere with preclinical and clinical trials, along with additional costs. We also may make changes to our manufacturing process at various points during development, and even after commercialization, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of current or future clinical trials, or the performance of the product, once commercialized. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical trials or at earlier portions of a trial to the product used in later clinical trials or later portions of the trial. We may also make further changes to our manufacturing process before or after commercialization, and such changes may require us to show the comparability of the resulting product to the product used in the clinical trials using earlier processes. We may be required to collect additional clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If clinical data are not ultimately comparable to that seen in the earlier trials in terms of safety or efficacy, we may be required to make further changes to our process and/or undertake additional clinical and/or nonclinical testing, which could significantly delay the clinical development or commercialization of the associated product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Although we continue to build on our experience in manufacturing our product candidates, we have no experience, as a company, manufacturing product candidates for commercial supply. We may never be successful in manufacturing product candidates in sufficient quantities or with sufficient quality for commercial use. Our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, operator error, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">natural disasters, unavailability of qualified personnel, difficulties with logistics and shipping, problems regarding yields or stability of product, contamination or other quality control issues, power failures, and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, compliance with cGMP requirements and other quality issues may arise during our internal efforts to scale-up manufacturing, and with our current suppliers, or any future CMOs. If contaminants are discovered in our supply of our product candidates or in our manufacturing facilities or those of our CMOs, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, we may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If we were to encounter any of these difficulties, our ability to provide our product candidate to patients in clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to a number of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of manufacturing our product candidates is complex, highly regulated, and subject to several risks. For example, the process of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our product candidates are made could be adversely affected by supply chain issues, equipment failures, labor shortages, natural disasters, power failures and numerous other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may need to rely exclusively on third parties to formulate and manufacture our product candidates and provide us with the devices and other products necessary to administer such a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our resources and expertise to formulate or manufacture our product candidates on a large or commercial scale basis are still very limited. If we need to secure an additional manufacturer of our product candidates, demand for third-party manufacturing or testing facilities may grow at a faster rate than their existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of such raw materials, components, parts, and consumables required to manufacture our products. If CAP-1002 or any of our exosome technologies receives FDA approval, we may need to ultimately rely on one or more third-party contractors to manufacture supplies of these products which may cause delays in our ability to sell commercially. Our current and anticipated future reliance on a limited number of third-party manufacturers exposes us to the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to identify manufacturers needed to manufacture our product candidates on acceptable terms or at all because the number of potential manufacturers is limited, and subsequent to approval of an NDA or BLA, the FDA must approve any replacement contractor. This approval would require new testing and compliance inspections. In addition, a new manufacturer may have to be educated in, or develop substantially equivalent processes for, production of our products or the devices after receipt of FDA approval, if any. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our third-party manufacturers may not be able to formulate and manufacture our drugs in the volume and of the quality required to meet our clinical and commercial needs, if any.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our third-party manufacturers may not be able to manufacture or supply us with sufficient quantities of acceptable materials necessary for the development or use of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products or the materials needed to manufacture or utilize our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our contract manufacturers may elect to terminate our agreements with them.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Agency, and corresponding state agencies to ensure strict compliance with good manufacturing practices and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA, or the commercialization of our product candidates, or result in higher costs or deprive us of potential product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates, if approved, will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. In addition, approved products, manufacturers and manufacturers&#8217; facilities are subject to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If our product candidates fail to comply with applicable regulatory requirements, such as cGMPs, a regulatory agency may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for non-compliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose other civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications filed by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a product recall.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third parties we use in the manufacturing process for our product candidates may fail to comply with cGMP regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we decide to transfer the manufacturing of our product candidates for future clinical trials or for commercial supply, our contract manufacturers will be required to produce our products in compliance with cGMP. These contract manufacturers are subject to periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign requirements. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and requirements. In addition, changes in cGMP could negatively impact the ability of our contract manufacturers to complete the manufacturing process of our product candidates in a compliant manner on the schedule we require for clinical trials or for potential commercial use. The failure to achieve and maintain high quality compliance, including failure to detect or control anticipated or unanticipated manufacturing errors, could result in patient injury or death or product recalls. Any difficulties or delays in our contractors&#8217; manufacturing and supply of product candidates, or any failure of our contractors to maintain compliance with the applicable regulations and requirements could increase our costs, make us postpone or cancel clinical trials, prevent or delay regulatory approvals by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our products, cause us to lose revenue, result in the termination of the development of a product candidate, or have our product candidates recalled or withdrawn from use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may face uncertainty and difficulty in obtaining and enforcing our patents and other proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our success will depend in large part on our ability to obtain, maintain, and defend patents on our product candidates, obtain licenses to use third-party technologies, protect our trade secrets and operate without infringing the valid and enforceable proprietary rights of others. Legal standards regarding the scope of claims and validity of biotechnology patents are uncertain and evolving. There can be no assurance that our pending, in-licensed or Company-owned patent applications will be approved, or that challenges will not be instituted against the validity or enforceability of any patent licensed-in or owned by us. Additionally, we have entered into various confidentiality agreements with employees and third parties. There is no assurance that such agreements will be honored by such parties or enforced in whole or part by the courts. The cost of litigation to uphold the validity and enforce against infringement of a patent is substantial. Furthermore, there can be no assurance that others will not independently develop substantially equivalent technologies not covered by patents to which we have rights or obtain access to our know-how. In addition, the laws of certain countries </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">may not adequately protect our intellectual property. Our competitors may possess or obtain patents on products or processes that are necessary or useful to the development, use, or manufacture of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can also be no assurance that our proposed technology will not infringe upon valid and enforceable patents or proprietary rights owned by others, with the result that others may bring infringement claims against us and require us to license such proprietary rights, which may not be available on commercially reasonable terms, if at all. Any such litigation, if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management resources, and injunction against continued manufacture, use, or sale of certain products or processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our technology has resulted and/or will result from research funded by agencies of the U.S. government and the State of California. As a result of such funding, the U.S. government and the State of California have certain rights in the technology developed with the funding. These rights may include a non-exclusive, non-transferable, irrevocable, paid-up, worldwide license to practice or have practiced for or on behalf of the government(s)&#160;such inventions. In addition, the government(s)&#160;has the right to &#8220;march in&#8221; and require us to grant third parties licenses to such technology, in certain circumstances, such as if we fail to take effective steps to achieve practical application of such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The licenses by which we have obtained some of our intellectual property are subject to the rights of the funding agencies. We also rely upon non-patented proprietary know-how and trade secrets. There can be no assurance that we can adequately protect our rights in such non-patented proprietary know-how and trade secrets, or that others will not independently develop substantially equivalent proprietary information or techniques or gain access to our proprietary know-how and trade secrets. Any of the foregoing events could have a material adverse effect on us. In addition, if any of our trade secrets, know-how or other proprietary information were to be disclosed, or misappropriated, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March&#160;2013 to a &#8220;first to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), and may become involved in derivation, post-grant review, or&#160;<i style="font-style:italic;">inter partes</i>&#160;review, proceedings challenging our patent rights or the patent rights of our licensors. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our or our licensors&#8217; patent rights, which could adversely affect our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If we fail to protect or enforce our intellectual property rights adequately or secure rights to patents of others, the value of our intellectual property rights and product candidates would diminish.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial viability will depend, in part, on obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have licensed certain patent and other intellectual property rights that cover cardiospheres (CSps), and cardiosphere-derived cells (CDCs), (including our CAP-1002 product candidate) from the University of Rome, JHU, and CSMC. We have also licensed certain patent and other intellectual property rights from CSMC that cover extracellular vesicles, such as exosomes and microvesicles. Under the license agreements with the University of Rome and JHU, those institutions prosecute and maintain their patents and patent applications in collaboration with us. We rely on these institutions to file, prosecute, and maintain patent applications, and otherwise protect the intellectual property to which we have a license, and we have not had and do not have primary control over these activities for certain of these patents or patent applications and other intellectual property rights. We cannot be certain that such activities by these institutions have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. Under our Amended and Restated Exclusive License Agreement with CSMC and our Exclusive License Agreement with CSMC, as the same have been amended, we have assumed, in coordination with CSMC, financial responsibility for the prosecution and maintenance of certain patents and patent applications </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">thereunder. Our enforcement of certain of these licensed patents or defense of any claims asserting the invalidity and/or unenforceability of these patents would also be subject to the cooperation of the University of Rome, JHU, and/or CSMC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent laws regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States. The biopharmaceutical patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in the patents we own or that are in-licensed. Further, if any of our owned or in-licensed patents are determined by legal authority to be invalid or unenforceable, it could impact our ability to commercialize or license our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of any of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by any issued patents or patent applications we may have (or third parties from whom we license intellectual property may have);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that any pending patent applications we may have will not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any issued patents may not provide us with any competitive advantage, or may be held invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable or protectable under trade secrets law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our trade secrets, know-how or other proprietary information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our viability also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors, as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality agreements. To this end, we require all of our employees, consultants, advisors and contractors to enter into agreements which prohibit unauthorized disclosure and use of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements are often limited in duration and may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information. In addition, enforcing a claim that a third-party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. If any of our trade secrets, know-how or other proprietary information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may incur substantial costs as a result of litigation or other adversarial proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If we choose to go to court to stop a third-party from using the inventions covered by our patents, that individual or company has the right to ask the court to rule&#160;that such patents are invalid and/or should not be enforced against that third-party. These lawsuits are expensive and would consume time and other resources, even if we were successful in </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">discontinuing the infringement of our patents. In addition, there is a risk that the court will determine that these patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe our rights to these patents. In addition, the U.S. Supreme Court has modified certain legal tests so as to make it harder to obtain patents from the USPTO, and to defend issued patents against invalidity challenges. As a consequence, issued patents may be found to contain invalid claims according to the revised legal standards. Some of our own or in-licensed patents may be subject to challenge and subsequent invalidation in a variety of post-grant proceedings, before the Patent Trial and Appeal Board (the PTAB) of the USPTO or in litigation under the revised legal standards, which make it more difficult to defend the validity of claims in already issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, a third-party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third-party&#8217;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. These lawsuits are costly and could affect the results of our operations and divert the attention of managerial and technical personnel. There is a risk that a court could determine that we or our commercialization partners are infringing the third-party&#8217;s patents and order us or our partners to stop the activities covered by the patents. In addition, there is a risk that a court could order us or our partners to pay the other party damages for having violated the other party&#8217;s patents. We have agreed to indemnify certain of our commercial partners against certain patent infringement claims brought by third parties. The biotechnology industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products, manufacturing processes or methods of use. The coverage of patents is subject to claim construction by the courts, which is not always predictable or reasonable. If we are sued for patent infringement, we would need to demonstrate that our products, manufacturing processes or methods of use either do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires a proof by clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent applications may have priority over our patent applications or patents, which could further require us to obtain licenses to these issued patents covering such technologies. For patent applications filed before the Leahy-Smith Act, if another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation or&#160;<i style="font-style:italic;">inter partes&#160;</i>review proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some jurisdictions in which we operate have enacted legislation which allows members of the public to access information under statutes similar to the U.S. Freedom of Information Act. Even though we believe our information would be excluded from the scope of such statutes, there are no assurances that we can protect our confidential information from being disclosed under the provisions of such laws. If any confidential or proprietary information is released to the public, such disclosures may negatively impact our ability to protect our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that we or our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used, misappropriated or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are dependent on patents, trade secrets, know-how and proprietary technology, both our own and that licensed from others. We have several license agreements, including with the University of Rome, JHU and CSMC. These licenses may be terminated upon certain conditions, including in some cases, if we fail to meet certain minimum funding or spending requirements, fail to take certain developmental actions, fail to pay certain minimum royalties, or fail to maintain the licensed intellectual property. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other contract interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patent and other rights to third parties under collaborative development relationships; our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Relationships with Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will depend on our exclusive distributor, Nippon Shinyaku, for the commercial sale of our lead product CAP-1002 in DMD in the United States and Japan, if we receive regulatory approval in those territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that a substantial portion of our revenue for the foreseeable future will depend on milestones and other payments received from our distributor, Nippon Shinyaku. Nippon Shinyaku has exclusive distribution rights for CAP-1002 in the United States and Japan for a significant period of time, with only limited rights of either party to terminate these agreements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are dependent on our relationships with our licensors and collaborators and there is no guarantee that such relationships will be maintained or continued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into certain license agreements for certain intellectual property rights which are essential to enable us to develop and commercialize our products. Agreements have been entered into with the University of Rome, JHU and CSMC. Each of those agreements provides for an exclusive license to certain patents and other intellectual property and requires the payment of fees, milestone payments and/or royalties to the institutions that will reduce our net revenues, if and to the extent that we have future revenues. Each of those agreements also contains additional obligations that we are required to satisfy. There is no guarantee that we will be able to satisfy all of our obligations under our license agreements to each of the institutions and that such license agreements will not be terminated. By way of example, we recently received a letter from CSMC alleging that pursuant to the Amended CSMC License Agreement between CSMC and Capricor, Capricor has certain overdue payment obligations to CSMC arising out of a milestone payment received by Capricor pursuant to the U.S. Distribution Agreement entered into between Capricor and Nippon Shinyaku. The notice letter requests that Capricor cure the alleged breaches of the Amended CSMC License Agreement, and reserves CMSC&#8217;s purported right to terminate the Amended CSMC License Agreement if such alleged breaches are not cured. We dispute the allegations in the letter from CSMC and intend to vigorously defend our position and pursue all available remedies, but there is no guarantee that any disputes that we have with CSMC will be resolved or if resolved, will not result in our incurring certain payment and other obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Each of the institutions receives funding from independent sources such as the NIH and other private or not-for-profit sources and are investigating scientific and clinical questions of interest to their own principal investigators as well as the scientific and clinical communities at large. These investigators (including Capricor,&#160;Inc.&#8217;s founder, Dr.&#160;Eduardo </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marb&#225;n, who is the Director of the Smidt Heart Institute at CSMC) are under no obligation to conduct, continue, or conclude either current or future studies utilizing our cell therapy or exosomes technology, and they are not compelled to license any further technologies or intellectual property rights to us except as may be stated in the applicable licensing agreements or research agreements between those institutions and us. Further, the failure of any third-party licensor to comply with its licensing obligations under its respective agreement with us would have a material adverse effect on us. We are substantially dependent on our relationships with these institutions from which we license the rights to our technologies and know-how. If requirements under our license agreements are not met, including meeting defined milestones, we could suffer significant harm, including losing rights to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to the proprietary technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finally, we may be required to obtain licenses to patents or other proprietary rights of third parties (including and other than the University of Rome, JHU and CSMC) in connection with the development and use of our product candidates and technologies. Licenses required under any such patents or proprietary rights might not be made available on terms acceptable to us, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have received government grants and a loan award which impose certain conditions on our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Commencing in 2009, we received several grants from the NIH and DoD to fund various projects. Some of these awards remain subject to annual and quarterly reporting requirements and require us to allocate expenses to the applicable project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, the HOPE-Duchenne trial. Pursuant to terms of the CIRM Award, disbursements were tied to the achievement of specified operational milestones. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we enter into strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to terms unfavorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are actively looking into potential additional strategic partnerships for our product candidates, particularly for CAP-1002 in additional territories outside the United States and Japan and our exosomes product candidates. If we do not establish strategic partnerships, we potentially will have to undertake development and commercialization efforts with respect to our product candidates on our own, which would be costly and adversely impact our ability to commercialize any future products or product candidates. If we enter into any strategic partnerships with pharmaceutical, biotechnology or other life science companies, we will be subject to a number of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners may experience financial difficulties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business combinations or significant changes in a strategic partner&#8217;s business strategy may also adversely affect a strategic partner&#8217;s willingness or ability to complete its obligations under any arrangement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely and will rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend and will depend upon independent investigators and collaborators, such as universities, medical institutions, CROs, vendors and strategic partners to conduct our preclinical and clinical trials under agreements with us. We negotiate budgets and contracts with CROs, vendors and trial sites which may result in delays to our development timelines and increased costs. We rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with current good clinical practices (&#8220;cGCPs&#8221;), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the cGCP regulations. Further, GCP requirements may evolve. In June 2023, the FDA published a draft guidance, E6(R3) Good Clinical Practice (GCP), which seeks to unify standards for clinical trial data for ICH member countries and regions. Changes to data requirements may cause the FDA or comparable foreign regulatory authorities to disagree with data from preclinical studies or clinical trials, and may require further studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biologic products for commercial purposes must also be produced under cGMP. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, which in some instances may be limited, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third-party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Competitive Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our products will likely face intense competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is engaged in fields that are characterized by extensive worldwide research and competition by pharmaceutical companies, medical device companies, specialized biotechnology companies, hospitals, physicians and academic institutions, both in the United States and abroad. We will experience intense competition with respect to our existing and future product candidates. The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many smaller companies. Many of these organizations competing with us have substantially greater financial resources, larger research and development staffs and facilities, greater clinical trial experience, longer drug development history in obtaining regulatory approvals, and greater manufacturing, distribution, sales and marketing capabilities than we do. There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies, and research organizations actively engaged in research and development of products which may target the same indications as our product candidates. We expect any future products and product candidates that we develop to compete on the basis of, among other things, product efficacy and safety, time to market, price, extent of adverse side effects, and convenience of treatment procedures. One or more of our competitors may develop products based upon the principles underlying our proprietary technologies earlier than we do, obtain approvals for such products from the FDA more rapidly than we do, or develop alternative products or therapies that are safer, more effective and/or more cost effective than any product developed by us. Our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, useful, and less costly than ours, and may also be more successful than us in manufacturing and marketing their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future success will depend in part on our ability to maintain a competitive position with respect to evolving therapies as well as other novel technologies. Existing or future therapies developed by others may render our potential products obsolete or noncompetitive. The drugs that we are attempting to develop will have to compete with existing therapies. In addition, companies pursuing different but related fields represent substantial competition. These organizations also compete with us to attract qualified personnel and parties for acquisitions, joint ventures, or other collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to retain and recruit qualified scientists and advisors, or if any of our key executives, key employees or key consultants discontinues his or her employment or consulting relationship with us, it may delay our development efforts or otherwise harm our business. In addition, several of our consultants render services on a part-time basis to other entities which may result in the creation of intellectual property rights in favor of those entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the specialized nature of our technology, we are dependent upon existing key personnel and on our ability to attract and retain qualified executive officers and scientific personnel for research, clinical studies, and development activities conducted or sponsored by us. There is intense competition for qualified personnel in our fields of research and development, and there can be no assurance that we will be able to continue to attract additional qualified personnel necessary for the development and commercialization of our product candidates or retain our current personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have experienced employee turnover from time to time, including involving some of our key employees. The loss of any of our current key employees or key consultants could impede the achievement of our research and development objectives. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future is critical to the Company&#8217;s success, both to enable the Company to grow, and to allow the Company to replace any employees or consultants whose relationships with the Company have been terminated. The market for employees with experience in the cell therapy and exosome industries is especially competitive, and we may not be able to recruit employees needed to develop and manufacture our products or be able to retain the employees whom we do recruit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There has been a close working relationship between the academic lab at CSMC and our research and development team where employees and consultants of both entities from time to time have contributed time and services to the research being performed by the other. As a result, it can sometimes be unclear whether intellectual property developed out of these services for CSMC would be owned by CSMC or by the Company, although if owned by CSMC, the Company may have rights to that intellectual property under the terms of its license agreements with CSMC.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, biopharmaceutical, and health care companies, universities, and non-profit research institutions for experienced scientists. Certain of the Company&#8217;s officers, directors, scientific advisors, and/or consultants or certain of the officers, directors, scientific advisors, and/or consultants hereafter appointed may from time to time serve as officers, directors, scientific advisors, and/or consultants of other biopharmaceutical or biotechnology companies. The Company currently does not maintain &#8220;key man&#8221; insurance policies on any of its officers or employees. All of the Company&#8217;s employees will be employed &#8220;at will&#8221; and, therefore, each employee may leave the employment of the Company at any time. If we are unable to retain our existing employees, including qualified scientific and manufacturing personnel, and attract additional qualified candidates, the Company&#8217;s business and results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not establish strategic partnerships, we will have to undertake development and commercialization efforts on our own, which would be costly and delay our ability to commercialize any future products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An element of our business strategy includes potentially partnering with pharmaceutical, biotechnology and other companies to obtain assistance for the development and potential commercialization of our product candidates, including having access to the cash and other resources we need for such development and potential commercialization. We may not be able to negotiate strategic partnerships on acceptable terms, or at all. If we are unable to negotiate strategic partnerships for our product candidates, we may be forced to curtail the development of a particular candidate, reduce, delay, or terminate its development program, delay its potential commercialization, reduce the scope of our sales or marketing activities or undertake development or commercialization activities at our own expense. In addition, we will bear all risk related to the development of that product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we will need to obtain substantial additional capital, which may not be available to us on acceptable terms, or at all. If we do not secure sufficient funds, we will not be able to complete our trials or bring our product candidates to market and generate product revenue. We have entered into the U.S. Distribution Agreement and the Japan Distribution Agreement with Nippon Shinyaku for the exclusive commercialization and distribution rights in the United States and Japan of CAP-1002 for DMD. We continue to evaluate additional potential partners for this program in other territories outside of these territories, subject to any rights of Nippon Shinyaku. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no experience selling, marketing, or distributing products and no current internal capability to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company currently has no sales, marketing, or distribution capabilities. We do not anticipate having resources in the foreseeable future to allocate to the sales and marketing of our proposed products. Our future success depends, in part, on our ability to enter into and maintain sales and marketing collaborative relationships, or on our ability to build sales and marketing capabilities internally. As we entered into the U.S. Distribution Agreement and the Japan Distribution Agreement with Nippon Shinyaku, we will depend upon Nippon Shinyaku&#8217;s strategic interest in our CAP-1002 product candidate and Nippon Shinyaku&#8217;s ability to successfully market and sell any such products, if and when approved. If any of our other product candidates are cleared for commercialization, we intend to pursue collaborative arrangements regarding the sales and marketing of such products, however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that such collaborators will have effective sales forces. To the extent that we decide not to, or are unable to, enter into collaborative arrangements with respect to the sales and marketing of our proposed products, significant capital expenditures, management resources, and time will be required to establish and develop an in-house marketing and sales force with sufficient technical expertise. There can also be no assurance that we will be able to establish or maintain relationships with third-party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution, such as our partnership with Nippon Shinyaku, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales, if any, will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercial viability of our product candidates for which we may obtain marketing approval from the FDA or other regulatory authorities will depend upon their acceptance among physicians, the medical community, patients, and coverage and reimbursement of them by third-party payors, including government payors. The degree of market acceptance of any of our approved products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in a product&#8217;s FDA-approved labeling;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for any of our product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations inherent in the approved indication for any of our product candidates compared to more commonly understood or addressed conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower demonstrated clinical safety and efficacy compared to other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence and severity of adverse effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffective marketing and distribution efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of availability of reimbursement from managed care plans and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of cost-effectiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market introduction and perceived effectiveness of competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of alternative therapies at similar costs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to effectively promote and sell our product candidates in the marketplace will also depend on pricing, including our ability to manufacture a product at a competitive price. We will also need to demonstrate acceptable evidence of safety and efficacy and may need to demonstrate relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and severity of any expected or unexpected adverse side effects associated with our product candidates. If our product candidates are approved but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. If our approved drugs fail to achieve market acceptance, we will not be able to generate significant revenue, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our development of a potential vaccine for COVID-19 or other indications is at an early stage and is subject to significant risks. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our development of a vaccine is in early stages and we may be unable to produce a vaccine that successfully treats a particular virus in a timely manner, if at all. Even if we were able to successfully develop and obtain regulatory approval for a vaccine, if the outbreak is effectively contained or the risk of coronavirus infection is diminished or eliminated before we can successfully develop and manufacture our vaccine, we may not be able to generate product revenues from the vaccine. Additionally, a number of pharmaceutical companies have already obtained regulatory approval for COVID-19 vaccines, and other companies with significantly more resources and visibility than us are developing COVID-19 vaccines. Even if we were able to successfully develop and obtain regulatory approval for a COVID-19 vaccine, vaccines produced by these other companies may be superior to our vaccine. Even if a vaccine that we develop is not inferior to other available vaccines, it could be difficult to obtain market acceptance. We are committing financial resources and personnel to the development of a COVID-19 vaccine which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of coronavirus as a global health concern. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which our vaccine, if developed, may not be partially or fully effective, or for which better vaccine options may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our product candidates are approved, our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our or our collaborators&#8217; ability to generate significant sales of our products, if approved, depends on the availability of adequate coverage and reimbursement from third-party payors. Healthcare providers that purchase medicine or medical products for treatment of their patients generally rely on third-party payors to reimburse all or part of the costs and fees associated with the products. Adequate coverage and reimbursement from governmental payors, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely to use our products if they do not receive reimbursement adequate to cover the cost of our products. Orphan drugs in particular have received negative publicity for the perceived high prices charged for them by their manufacturers, and as a result, other orphan drug developers such as us may be negatively impacted by such publicity and any U.S. or other government regulatory response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Many third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes to decide which drugs they </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will pay for and establish reimbursement levels. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. If any of our product candidates fail to demonstrate attractive efficacy profiles, they may not qualify for coverage and reimbursement. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop through approval will be made on a plan-by-plan basis. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and adequate reimbursement for the product. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will likely be a time-consuming process. Each plan determines whether or not it will provide coverage for a drug, what amount it will pay for the drug, the applicable formulary tier, and whether to require step therapy or other utilization management controls. Such decisions can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and treating healthcare providers generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients may be unlikely to use and prescribers unlikely to prescribe our products unless adequate coverage is provided and reimbursement is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, a third-party payor&#8217;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors, such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices charged for, drug products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices charged for products. We may also be required to conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage or reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, there have been a number of legislative and regulatory proposals to change the healthcare system that could affect our ability to sell any future drugs profitably. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution by generic products. We anticipate additional state and federal healthcare reform measures will be adopted in the future. These may include price controls and cost-containment measures, or more restrictive policies in jurisdictions with existing controls and measures, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and potentially could reduce demand for our products once approved, create additional pricing pressures, or ultimately limit our net revenue and results. There can be no assurance that any of our product candidates, if approved, will be considered medically reasonable and necessary, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that reimbursement policies and practices in the United States and in foreign countries where our products are sold will not harm our ability to sell our product candidates profitably, if they are approved for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Product and Environmental Liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our products may expose us to potential product liability, and there is no guarantee that we will be able to obtain and maintain adequate insurance to cover these liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The testing, marketing, and sale of human cell therapeutics, pharmaceuticals, biologics, and services entail an inherent risk of adverse effects or medical complications to patients and, as a result, product liability claims may be asserted against us. A future product liability claim or product recall could have a material adverse effect on the Company. There can be no assurance that product liability insurance will be available to us in the future on acceptable terms, if at all, or that coverage will be adequate to protect us against product liability claims. In the event of a successful claim against the Company, insufficient or lack of insurance or indemnification rights could result in liability to us, which could have a material adverse effect on the Company and its future viability. The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval, if at all, expose the Company to the risk of product liability claims. Product liability claims might be brought against the Company by consumers, health care providers or others using, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of clinical trial sites or entire trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenues; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has obtained clinical trial insurance coverage for its clinical trials. However, such insurance coverage may not reimburse the Company or the levels of coverage may not be sufficient to reimburse it for expenses or losses it may suffer or for its indemnification obligations. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect the Company against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against the Company could have a material adverse effect on us and, if judgments exceed our insurance coverage, could significantly decrease our cash position and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trial agreements and most agreements with third-party vendors contain provisions requiring us to maintain certain levels of insurance extending for multiple years beyond the termination or expiration of the agreement as well as indemnification obligations requiring us to indemnify them from any losses and claims that may be brought in connection with their provision of services, testing, manufacture or other activities in connection with the use of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business involves risk associated with handling hazardous and other dangerous materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities involve the controlled use of hazardous materials, chemicals, human blood and tissue, animal blood and blood products, animal tissue, biological waste, and various radioactive compounds. The risk of accidental contamination or injury from these materials cannot be completely eliminated. The failure to comply with current or future regulations could result in the imposition of substantial fines against the Company, suspension of production, alteration of our manufacturing processes, or cessation of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business depends on compliance with ever-changing environmental and human health and safety laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot accurately predict the outcome or timing of future expenditures that may be required to comply with comprehensive federal, state and local environmental laws and regulations, as well as laws and regulations designed to protect employees and others who handle hazardous materials. We must comply with environmental laws that govern, among other things, all emissions, waste water discharge and solid and hazardous waste disposal, and the remediation of contamination associated with generation, handling and disposal activities. To date, the Company has not incurred significant costs and is not aware of any significant liabilities associated with its compliance with federal, state and local environmental laws and regulations. However, both federal and state environmental laws have changed in recent years and the Company may become subject to stricter environmental standards in the future and may face large capital expenditures to comply with environmental laws. We have limited capital and we are uncertain whether we will be able to pay for significantly large capital expenditures that may be required to comply with new laws. Also, future developments, administrative actions or liabilities relating to environmental matters may have a material adverse effect on our financial condition or results of operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that our stock price will continue to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock market, particularly in recent years, has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. Our operating results may fluctuate from period to period for a number of reasons, and as a result our stock price may be subject to significant fluctuations. Factors that could cause volatility in the market price of our common stock include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial condition, including our need for additional capital, as well as the impact of any terms imposed on our business and operations by the providers of additional capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results from, delays in, or discontinuation of, any of the clinical trials for our drug candidates, including delays resulting from slower than expected or suspended patient enrollment or discontinuations resulting from a failure to meet pre-defined clinical endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning clinical trials and regulatory developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or delays in entering drug candidates into clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or discontinuation of any of our research or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in establishing and maintaining new strategic alliances or with existing alliances or collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet milestone requirements under distribution agreements, including the U.S. Distribution Agreement and Japan Distribution Agreement with Nippon Shinyaku;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to satisfy licensing obligations, including our ability to meet milestone requirements under our license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical, biotechnology and other healthcare related sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our quarterly financial and operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning our intellectual property or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of technological innovations or new commercial products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issues in manufacturing our drug candidates or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issues with the supply or manufacturing of any devices or materials needed to manufacture or utilize our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA or other U.S. or foreign regulatory actions affecting us or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risks and costs of increased operations, including clinical and manufacturing operations, on an international basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our drugs when they enter the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party healthcare coverage and reimbursement policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation or public concern about the safety of our drug candidates or drugs or the operations of the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of new or revised securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential delisting of our stock from the Nasdaq Stock Market; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility in the stock prices of other companies in our industry.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid dividends and we do not anticipate paying dividends in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never paid dividends on our capital stock and do not anticipate paying any dividends for the foreseeable future. We anticipate that the Company will retain its earnings, if any, for future growth. Investors seeking cash dividends should not invest in the Company&#8217;s common stock for that purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may issue shares of blank check preferred stock without stockholder approval in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation authorizes the issuance of up to 5,000,000 shares of preferred stock, none of which are currently issued or currently outstanding. If issued, our Board of Directors will have the authority to fix and determine the relative rights and preferences of preferred shares, as well as the authority to issue such shares, without further stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that is senior to our common stock that would grant to holders preferred rights to our assets upon liquidation, the right to receive dividends, additional registration rights, anti-dilution protection, and the right to the redemption of such shares, together with other rights, none of which will be afforded holders of our common stock.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Market and economic conditions may adversely affect our industry, business and ability to obtain financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Recent global market and economic conditions have been unpredictable and challenging. These conditions and any adverse impact on the financial markets may adversely affect our liquidity and financial condition, including our ability to access the capital markets to meet our liquidity needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts maintain coverage of us, the trading price of our stock could decrease. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could also decline. If one or more of these analysts cease to cover our stock altogether, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">The operational and other projections and forecasts that we may make from time to time are subject to inherent risks, many of which are beyond our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The projections and forecasts that our management may provide from time to time (including, but not limited to, those relating to timing, progress and anticipated results of clinical development, regulatory processes, clinical trial timelines and any anticipated benefits of our product candidates) reflect numerous assumptions made by management, including assumptions with respect to our specific as well as general business, economic, market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond our control. Accordingly, there is a risk that the assumptions made in preparing the projections, or the projections themselves, will prove inaccurate. There will be differences between actual and projected results, and actual results may be materially different from those contained in the projections. The inclusion of the projections in (or incorporated by reference in) this prospectus should not be regarded as an indication that we or our management or representatives considered or consider the projections to be a reliable prediction of future events, and the projections should not be relied upon as such. Additionally, final data may differ significantly from preliminary reported data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our certificate of incorporation and by-laws contain provisions that may discourage, delay or prevent a change in our management team that stockholders may consider favorable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Our certificate of incorporation, our bylaws and Delaware law contain provisions that may have the effect of preserving our current management, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorizing the issuance of &#8220;blank check&#8221; preferred stock without any need for action by stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">These provisions could make it more difficult for our stockholders to affect our corporate policies or make changes in our Board of Directors and for a third-party to acquire us, even if doing so would benefit our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">A significant number of shares of our common stock are issuable pursuant to outstanding stock awards and warrants, and we expect to issue additional stock awards and shares of common stock in the future. Exercise of these awards and warrants, and sales of shares will dilute the interests of existing security holders and may depress the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, there were approximately 31.1 million shares of common stock outstanding and approximately 5.0 million common warrants outstanding, as well as outstanding awards to purchase approximately 8.2 million shares of common stock under various incentive stock plans of the Company. Additionally, as of December&#160;31, 2023, there were approximately 1.2 million shares of common stock available for future issuance under our incentive plans. This number of shares available for future issuance under those plans was subsequently increased by 1,557,416 shares in accordance with the terms of our 2021 equity incentive plan which include an automatic increase previously approved by our Board and stockholders. We may issue additional common stock, warrants and other convertible securities from time to time to finance our operations. We may also issue additional shares to fund potential acquisitions or in connection with additional stock options or other equity awards granted to our employees, officers, directors and consultants under our various incentive plans. The issuance of additional shares of common stock, warrants or other convertible securities and the perception that such issuances may occur or exercise of outstanding warrants or options may have a dilutive impact on other stockholders and could have a material negative effect on the market price of our common stock.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s ability to utilize Nile&#8217;s net operating loss and tax credit carryforwards in the future is subject to substantial limitations and may further be limited as a result of the merger with Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Federal and state income tax laws impose restrictions on the utilization of net operating loss (&#8220;NOL&#8221;), and tax credit carryforwards in the event that an &#8220;ownership change&#8221; occurs for tax purposes, as defined by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In general, an ownership change occurs when stockholders owning 5% or more of a &#8220;loss corporation&#8221; (a corporation entitled to use NOL or other loss carryforwards) have increased their aggregate ownership of stock in such corporation by more than 50 percentage points during any three-year period. If an &#8220;ownership change&#8221; occurs, Section&#160;382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income that may be offset with pre-ownership change NOLs of the loss corporation experiencing the ownership change. The annual limitation is calculated by multiplying the loss corporation&#8217;s value immediately before the ownership change by the greater of the long-term tax-exempt rate determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) in the month of the ownership change or the two preceding months. This annual limitation may be adjusted to reflect any unused annual limitation for prior years and certain recognized built-in gains and losses for the year. Section&#160;383 of the Code also imposes a limitation on the amount of tax liability in any post-ownership change year that can be reduced by the loss corporation&#8217;s pre-ownership change tax credit carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The merger between Nile and Capricor resulted in an &#8220;ownership change&#8221; of Nile. In addition, previous or current changes in the Company&#8217;s stock ownership may have triggered or, in the future, may trigger an &#8220;ownership change,&#8221; some of which may be outside of our control. Accordingly, the Company&#8217;s ability to utilize Nile&#8217;s NOL and tax credit carryforwards may be substantially limited. These limitations could, in turn, result in increased future tax payments for the Company, which could have a material adverse effect on the business, financial condition, or results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The requirements of being a public company may strain our resources and divert management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and other applicable securities rules&#160;and regulations, and are subject to the listing requirements of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). Compliance with these rules&#160;and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results and maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight is required. In addition, these rules&#160;and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance. As a result, management&#8217;s attention may be diverted from other business concerns, which could harm our business and operating results. Although we have hired employees in order to comply with these requirements, we may need to hire more employees in the future, which will increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Failure to achieve and maintain effective internal controls in accordance with Section&#160;404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Sarbanes-Oxley Act of 2002, as amended (&#8220;Sarbanes-Oxley&#8221;), as well as rules&#160;implemented by the SEC, Nasdaq and any market on which the Company&#8217;s shares may be listed in the future, impose various requirements on public companies, including those related to corporate governance practices. The Company&#8217;s management and other personnel will need to devote a substantial amount of time to these requirements. Moreover, these rules&#160;and regulations will increase the Company&#8217;s legal and financial compliance costs and will make some activities more time consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Section&#160;404 of Sarbanes-Oxley (&#8220;Section&#160;404&#8221;) requires that we establish and maintain an adequate internal control structure and procedures for financial reporting. Our annual reports on Form&#160;10-K must contain an assessment by management of the effectiveness of our internal control over financial reporting and must include disclosure of any material weaknesses in internal control over financial reporting that we have identified. The requirements of Section&#160;404 are ongoing and also apply to future years. We expect that our internal control over financial reporting will continue to evolve as our business develops. Although we are committed to continue to improve our internal control processes and we will continue to diligently and vigorously review our internal control over financial reporting in order to ensure compliance with Section&#160;404 requirements, any control system, regardless of how well designed, operated and evaluated, can provide only reasonable, not absolute, assurance that its objectives will be met. Therefore, we cannot be certain that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. If material weaknesses or other </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">significant deficiencies occur, these weaknesses or deficiencies could result in misstatements of our results of operations, restatements of our consolidated financial statements, a decline in our stock price, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">You may experience future dilution as a result of future equity offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share paid by any investor. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investor, and investors purchasing shares or other securities in the future could have rights superior to you. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by any investor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If our business plans are not successful, our stockholders may lose their entire investment in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We have historically incurred substantial losses to fund our business operations including our research and development activities. We will, in all likelihood, sustain operating expenses without corresponding revenues for the foreseeable future. This may result in our incurring net operating losses that will increase continuously until we are able to obtain regulatory approval for, and commercialize, our product candidates, the occurrence of which cannot be assured. If our business plans are not successful, our stockholders may lose their entire investment in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">We may be at risk of securities class action litigation or litigation initiated by individual stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We may subject to securities class action litigation or litigation initiated by individual stockholders. This risk is especially relevant due to our dependence on positive clinical trial outcomes and regulatory approvals. In the past, biotechnology and pharmaceutical companies have experienced significant stock price volatility, particularly when associated with binary events such as clinical trials and product approvals. Additionally, we may be subject to litigation and business challenges in the operation of our company due to actions instituted by activist stockholders. Perceived uncertainties as to our future direction as a result of stockholder activism may lead to the perception of a change in the direction of the business or other instability and may affect our relationships with vendors, distributors, collaborators, prospective and current employees and others. Responding to legal and/or business challenges related to securities class action litigation, or litigation initiated by individual stockholders, including activist stockholders, could be costly and time-consuming, may not align with our business strategies, and could divert management&#8217;s attention and resources from the pursuit of our business strategies, any of which could harm our business and result in a decline in the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the event we fail to satisfy any of the listing requirements of The Nasdaq Capital Market, our common stock may be delisted, which could affect our market price and liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our common stock is listed on The Nasdaq Capital Market. For continued listing on The Nasdaq Capital Market, we will be required to comply with the continued listing requirements, including the minimum market capitalization standard, the minimum stockholders&#8217; equity requirement, the corporate governance requirements and the minimum closing bid price requirement, maintaining board diversity among other requirements. In the event that we fail to satisfy any of the listing requirements of The Nasdaq Capital Market, our common stock may be delisted. If our securities are delisted from trading on The Nasdaq Stock Market, however, and we are not able to list our securities on another exchange or to have them quoted on The Nasdaq Stock Market, our securities could be quoted on the OTC Markets or on the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that our common stock is a &#8220;penny stock,&#8221; which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news and analyst coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5fbeee68_0101_4472_9296_2c92a9a190a6"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_587459"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1B. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0f301981_e385_409a_ae0c_6a0bd9e90e6f"></a><a id="ITEM1CCYBERSECURITY_749782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 1C. CYBERSECURITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft&#894; fraud&#894; extortion&#894; harm to employees&#894; violation of privacy laws and other litigation and legal risk&#894; and reputational risk. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use various tools and methodologies to manage cybersecurity risk that are tested on a regular cadence to the best of our ability. We also monitor and evaluate our cybersecurity posture and performance on an ongoing basis through regular vulnerability scans and penetration tests. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our business depends on the availability, reliability, and security of our information systems, networks, data, and intellectual property. Any disruption, compromise, or breach of our systems or data due to a cybersecurity threat or incident could adversely affect our operations, research, product development, and competitive position. They may also result in a breach of our contractual obligations or legal duties to protect the privacy and confidentiality of our stakeholders. Such a breach could expose us to business interruption, future lost revenue, ransom payments, remediation costs, liabilities to affected parties, cybersecurity protection costs, lost assets, litigation, regulatory scrutiny and actions, reputational harm, and harm to our vendor relationships.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The company is currently in the process of implementing a more formalized cybersecurity program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b8f43625_fc8e_477b_b085_49786bdbc833"></a><a id="ITEM2PROPERTIES_686301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We do not own any real property. Our primary operations are conducted at the leased facilities summarized in the below table. We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future, if necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Location of Property</b></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Lease Expiration Date </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Purpose</b></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Square Footage (approximate)</b></p></td></tr><tr><td style="vertical-align:top;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">10865 Road to the Cure, Suite 150, San Diego, California</p></td><td style="vertical-align:top;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">September 30, 2026</p></td><td style="vertical-align:top;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Corporate Headquarters: Laboratory, manufacturing and office space</p></td><td style="vertical-align:top;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">12,161</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">10865 Road to the Cure, Room 7, San Diego, California</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">October 31, 2024</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Laboratory space</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">234</p></td></tr><tr><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">8840 Wilshire Blvd., 2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> Floor, Beverly Hills, California</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Month-to-Month, terminable on 90-day notice</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Office space</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">1,627</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">8700 Beverly Blvd., Davis Building, Los Angeles, California</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">July 31, 2026</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Laboratory, manufacturing and office space</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">1,892</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain leases have specific options for potential renewal or extensions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_58d42e5e_258d_4a1d_80c1_763043a0274e"></a><a id="ITEM3LEGALPROCEEDINGS_177465"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 3. LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are not involved in any material pending legal proceedings and are not aware of any material threatened legal proceedings against us by any governmental authority. We draw your attention to the disclosure in Item 1A. above under &#8220;Risk Factors -- Risks Related to Our Relationships with Third Parties -- We are dependent on our relationships with our licensors and collaborators and there is no guarantee that such relationships will be maintained or continued.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_000a2f48_2f62_4c98_898d_2b022648cc26"></a><a id="ITEM4MINESAFETYDISCLOSURES_831629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4.&#160;MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59bd8b78_9457_4b7b_80d9_ffd7f99c9fc9"></a><a id="PARTII_650295"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART&#160;II</b></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 5.&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Market for Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;CAPR&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">According to the records of our transfer agent, Equiniti Trust Company LLC, as of March 7, 2024, we had 126 holders of record of common stock, which does not include holders who held in &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We have never declared or paid a dividend on our common stock and do not anticipate paying any cash dividends in the foreseeable future. The ability of our Board of Directors to declare a dividend is subject to limits imposed by Delaware corporate law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The information required by this item is set forth in the section entitled &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; in&#160;our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance Graph</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company, as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide a performance graph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Sales of Unregistered Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_122b1834_fd66_481f_af8b_2126db70019d"></a><a id="ITEM6SELECTEDFINANCIALDATA_208778"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">ITEM 6.&#160;RESERVED</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cb0f93c4_26d4_4827_aefb_636a0d536317"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 7.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with the audited consolidated financial statements and the related audited consolidated notes to those statements included elsewhere in this Annual Report on Form&#160;10-K. This discussion includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those set forth under Item 1A., &#8220;Risk Factors&#8221; or elsewhere in this annual report, our actual results may differ materially from those anticipated in these forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#8220;DMD&#8221;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have devoted substantial resources to developing CAP-1002 and our other product candidates including our exosomes platform, developing our manufacturing processes, staffing our company and providing general and administrative support for these operations. We do not have any products approved for sale. Our ability to eventually generate any product revenue sufficient to achieve profitability will depend on the successful development, approval and eventual commercialization of CAP-1002 for the treatment of DMD and our other product candidates. If successfully developed and approved, we intend to commercialize CAP-1002 in the United States and Japan with our partner, Nippon Shinyaku Co., Ltd., a Japanese corporation (&#8220;Nippon Shinyaku&#8221;), and may enter into licensing agreements or strategic collaborations in other markets. If we generate product sales or enter into licensing agreements or strategic collaborations, or further distribution relationships, we expect that any revenue we generate will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of any product sales, license fees, milestone payments and other payments. If we fail to complete the development of our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A summary description of our key product candidates, is as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CAP-1002 for the treatment of DMD (Phase 3): </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our core program is focused on the development and commercialization of a cell therapy technology (referred herein as CAP-1002) comprised of CDCs, which are a population of stromal cells isolated from donated cells of healthy human hearts, for the treatment of DMD. CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of CDCs, which are mediated by secreted exosomes laden with bioactive cargo. Among the cargo elements known to be bioactive in CDC exosomes are microRNAs. Collectively, these non-coding RNA species alter gene expression in macrophages and other target cells, dialing down generalized inflammation and stimulating tissue regeneration in DMD (and in a variety of other inflammatory diseases). This mechanism of action, consistent with the changes observed in clinical studies to date in circulating inflammatory biomarkers, contrasts with that of exon-skipping oligonucleotides and gene therapy approaches, which aim to restore dystrophin expression. DMD is a rare form of muscular dystrophy which results in muscle degeneration and premature death. DMD pathophysiology is driven by the impaired production of functional dystrophin which normally functions as a structural protein in muscle. The reduction of functional dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. The annual cost of care for patients with DMD is very high and increases with disease progression. We therefore believe that DMD represents a significant market opportunity for our product candidate, CAP-1002. Our CAP-1002 cell therapy program for the treatment of DMD is currently in Phase 3 clinical development in the United States, for which we expect to have top-line data available in the fourth quarter of 2024. </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">To date, we have completed two promising clinical trials investigating CAP-1002 for DMD. Data from the first trial, a Phase I/II trial named HOPE-Duchenne, suggested improvements in skeletal and cardiac endpoints. In HOPE-2, a Phase II clinical trial conducted in the United States, CAP-1002 was used to treat patients with late-stage DMD. In March 2022, we announced that the final one-year results from HOPE-2 were published in <i style="font-style:italic;">The Lancet</i> showing that the trial met its primary efficacy endpoint of the mid-level dimension of the Performance of the Upper Limb (&#8220;PUL&#8221;) v1.2 (p=0.01) and additional positive endpoints </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 54pt;">of full PUL v2.0 (p=0.04) and a cardiac endpoint of left ventricular ejection fraction (p=0.002). CAP-1002 was generally safe and well-tolerated throughout the studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Additionally, we are currently conducting an open label extension (&#8220;OLE&#8221;) study of the HOPE-2 trial in which 12 patients have elected to continue treatment of CAP-1002. We announced positive one-year and two-year results from this ongoing OLE study. The HOPE-2-OLE study previously met its primary endpoint at the one-year timepoint on the PUL v2.0 scale (p=0.02). At the two-year timepoint, data showed statistically significant differences in the PUL v2.0 in the OLE treatment group when compared to the original rate of decline of the placebo group from HOPE-2 after one-year (p=0.021). CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study. At this time, we expect to have three-year data available from this OLE study in the second quarter of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 3 (HOPE-3) Clinical Trial:</i> HOPE-3 is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial comprised of two cohorts evaluating the safety and efficacy of CAP-1002 in participants with DMD and impaired skeletal muscle function who are on a stable regimen of systemic glucocorticoids. Non-ambulatory and ambulatory boys who meet eligibility criteria are randomly assigned to receive either CAP-1002 or placebo every 3 months for 4 doses during the first 12-months of the study. Approximately 102 eligible study subjects will participate in this dual-cohort study. Enrollment has been completed for Cohort A where 61 subjects were randomized to either CAP-1002 or placebo in a 1:1 ratio and is intended to support a Biologics License Application (&#8220;BLA&#8221;) submission. In December 2023, we announced a positive outcome of the interim futility analysis for Cohort A of HOPE-3, which was reviewed by the Data Safety Monitoring Board (&#8220;DSMB&#8221;). This resulted in a favorable recommendation to continue the HOPE-3 trial as planned. At this time, we expect to have topline data available from Cohort A in the fourth quarter of 2024. &#160;Cohort A uses product manufactured at our Los Angeles facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Enrollment is underway for Cohort B which is designed to enroll approximately 44 participants randomized to either CAP-1002 or placebo in a 1:1 ratio. A primary efficacy and safety analysis will be performed for each individual cohort at month 12, following 4 administrations of CAP-1002 or placebo. We plan to complete enrollment for Cohort B in the second quarter of 2024. Cohort B uses product manufactured at our San Diego facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The primary outcome measure of the HOPE-3 study will be the Performance of the Upper Limb (&#8220;PUL&#8221;) v2.0, a validated tool specifically designed for assessing high (shoulder), mid (elbow) and distal (wrist and hand) functions, with a conceptual framework reflecting weakness progression in upper limb function. HOPE-3 will also measure various secondary endpoints including cardiac function assessments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Under our RMAT designation, in the third quarter of 2023, we met with the FDA in a Type-B meeting where we discussed our manufacturing plans in anticipation of potentially submitting a BLA application. In this meeting, we affirmed alignment with respect to our Phase 3, HOPE-3 program. Additionally, we discussed our plans with respect to commercial manufacturing activities, including our potency assay and other product release criteria to support commercialization. We plan to meet with FDA in the first quarter of 2024 to continue discussing our pathway to BLA. In the upcoming Type-B meeting, we intend to discuss our further CMC plans for commercial launch, if approved, with the aim of expediting our BLA submission pathway. Our ultimate goal is to file a BLA allowing for the use of CAP-1002 commercial product manufactured at our San Diego facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The regulatory pathway for CAP-1002 is supported by RMAT designation as well as orphan drug designation. In addition, if Capricor were to receive FDA marketing approval for CAP-1002 for the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (&#8220;PRV&#8221;) based on its previous receipt of a rare pediatric disease designation. Capricor retains full rights to the PRV, if received. Further, Capricor has entered into two Commercialization and Distribution Agreements with Nippon Shinyaku appointing Nippon Shinyaku as its exclusive distributor of CAP-1002 in the United States and Japan.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Exosome-Based Platform (Preclinical):</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Extracellular vesicles, including exosomes and microvesicles, are nano-scale, membrane-enclosed vesicles which are secreted by most cells and contain characteristic lipids, proteins and nucleic acids such as mRNA and microRNAs. They can signal through the binding and activation of membrane receptors or the delivery of their cargo into the cytosol of target cells. Exosomes act </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as messengers to regulate the functions of neighboring or distant cells and have been shown to regulate functions such as cell survival, proliferation, inflammation and tissue regeneration. Their size, low or null immunogenicity and ability to communicate in native cellular language potentially make them an exciting new class of therapeutic agents with the potential to expand our ability to address complex biological responses. Because exosomes are cell-free substances, they can be stored, handled, reconstituted and administered in similar fashion to common biopharmaceutical products such as antibodies. </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules that exert their effects through defined mechanisms of action. Aspects of our exosome pipeline have been supported through collaborations and alliances. Our collaborations and research around exosomes include the National Institutes of Health (&#8220;NIH&#8221;), the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), Johns Hopkins University (&#8220;JHU&#8221;), the Department of Defense (&#8220;DoD&#8221;), the U.S. Army Institute of Surgical Research (&#8220;USAISR&#8221;), and Cedars-Sinai Medical Center (&#8220;CSMC&#8221;). We have published preclinical data on our StealthX&#8482; platform showing the rapid development of a recombinant protein-based vaccine for immunization and prevention against SARS-CoV-2, the virus causing COVID-19. Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. &#160;Recently, we were selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with our StealthX&#8482; vaccine, subject to regulatory approval. At this time, we have submitted an Investigational New Drug Application (&#8220;IND&#8221;) to the FDA for our StealthX&#8482; vaccine, which is currently under review and we anticipate that once the IND is approved, that NIAID plans to initiate this trial in late 2024. Furthermore, If NIAID finds that our StealthX&#8482; vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2. At this time, we are developing exosome-based vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our current strategy is focused on securing partners who will provide capital and additional resources to enable us to bring this program into the clinic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities totaling approximately $39.5 million. In the fourth quarter of 2023, we announced a positive outcome of the interim futility analysis for HOPE-3, which was reviewed by the Data Safety Monitoring Board. This resulted in a favorable recommendation to continue the HOPE-3 trial as planned, and in accordance with our </span>U.S. Distribution Agreement with Nippon Shinyaku<span style="background:#ffffff;">, triggered a milestone payment of $10.0 million which was received in January 2024. We estimate this will fund our operating expenses and capital expenditure requirements into the first quarter of 2025. This expectation includes the $10.0 million milestone payment but excludes any additional potential milestone payments under our Commercialization and Distribution agreements with Nippon Shinyaku. We have not generated any revenues from the commercial sale of products. We will not be able to generate any product revenues until, and only if, we receive approval to sell our drug candidates from the FDA or other regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Due to our significant research and development expenditures, and general administrative costs associated with our operations, we have generated substantial operating losses in each period since our inception. Our net losses were $22.3 million and $29.0 million, for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $159.4 million. We expect to incur significant expenses and operating losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2023, we sold 877,821 shares of common stock at an average price of approximately $4.78 per share pursuant to a sales agreement by and between us and H.C. Wainwright &amp; Co. LLC (&#8220;Wainwright&#8221;) under our at-the-market offering, resulting in net proceeds of $4.1 million. Additionally, in October 2023, we completed a registered direct offering for gross proceeds of approximately $23.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Operational Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAP-1002 DMD Program Updates</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment has been completed for Cohort A in our Phase 3 trial which enrolled 61 subjects randomized to either CAP-1002 or placebo in a 1:1 ratio.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reported a positive outcome from the interim futility analysis for Cohort A which triggered the first milestone payment of $10.0 million under our U.S. Commercialization Agreement with Nippon Shinyaku. There is an additional $90.0 million in potential milestone payments up to the time of approval which are triggered upon certain regulatory-based achievements. Following potential approval, there is an additional $605.0 million in potential milestones payments which may be payable to Capricor based on various sales-based targets being met. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Next steps for Cohort A: plan to readout top-line data in the fourth quarter of 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment is underway for Cohort B designed to enroll approximately 44 subjects randomized to either CAP-1002 or placebo in a 1:1 ratio. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Next steps for Cohort B: expect to complete enrollment in the second quarter of 2024. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced the scale-up to expand the manufacturing capacity of CAP-1002 to our new San Diego facility, intended for commercial use, subject to regulatory approval. This facility was designed to be a versatile and cost-effective way to bring CAP-1002 to market efficiently and it is expected that our enhanced manufacturing capacity will increase our supply capabilities and improve our margins on ultimate product sales, if any. We are currently producing CAP-1002 doses at our San Diego facility for use in Cohort B.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced a positive outcome from a Type-B meeting held with FDA in the third quarter of 2023. In the meeting, the FDA affirmed alignment on the current HOPE-3 clinical trial design comprised of two cohorts and our plan to submit a BLA supported by results from Cohort A which uses product manufactured from our Los Angeles manufacturing facility. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to meet with FDA in the first quarter of 2024 to continue discussing our pathway to BLA. &#160;In the upcoming Type-B meeting, we intend to discuss our further CMC plans for commercial launch, if approved, with an aim to expedite the approval pathway to our BLA filing. Our ultimate goal is to transition to our San Diego manufacturing facility for commercial manufacturing as quickly as possible. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Hosted a webinar in conjunction with Parent Project Muscular Dystrophy (PPMD) where key updates on our DMD program were outlined.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Presented a late-breaking poster at the 28</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> International Annual Congress of the World Muscle Society (WMS). Highlights from the poster included data from the HOPE-2 OLE trial measured by the Performance of the Upper Limb (PUL 2.0) showing a delta change=4.9 points, p=0.021 after 24-months of treatment, compared with the placebo patient group.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exosome Program </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced that our proprietary StealthX&#8482; exosome-based multivalent vaccine (StealthX&#8482; vaccine) for the prevention of SARS-CoV-2 was selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, NIAID, part of the National Institutes of Health, will conduct and fund a Phase 1 clinical trial with our StealthX&#8482; vaccine, subject to regulatory approval. Under the terms of the collaboration, Capricor will supply the investigational product and NIAID's Division of Microbiology and Infectious Diseases (DMID) will oversee the trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Next steps for this project: NIAID plans to initiate the Phase 1 clinical trial in late 2024, subject to regulatory approval. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Currently, in collaboration with an undisclosed pharmaceutical company, we are also investigating the therapeutic application of our StealthX&#8482; exosome platform.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Presented a late-breaking poster at the WMS on the application of our StealthX&#8482; exosome platform for the delivery of antisense oligonucleotides (ASO). Highlights from the poster included data showing the presence of exosomes loaded with a labeled ASO in the lower limbs of mice 24 hours post-intravenous (IV) injection. Notably, the exosomes carrying the muscle-targeting moiety were not detected in any other tissues except for the expected clearance pathways (kidney and liver) with a single dose.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Updates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced receipt of our first milestone payment of $10.0 million under our U.S. Exclusive Distribution and Commercialization Agreement with Nippon Shinyaku. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced completion of a registered direct offering with participation from Nippon Shinyaku for gross proceeds of approximately $23.0 million. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As we seek to develop and commercialize CAP-1002 or any other product candidates including those related to our exosomes program, we anticipate that our expenses will increase significantly and that we will need substantial additional funding to support our continuing operations. Until such time when we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity financings, debt financings or other sources, which may include licensing agreements or strategic collaborations or other distribution agreements. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, if at all. If we fail to raise capital or other potential funding or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of CAP-1002 or our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have no commercial product sales to date and will not have the ability to generate any commercial product revenue until after we have received approval from the FDA or equivalent foreign regulatory bodies to begin selling our product candidates. Developing biological products is a lengthy and very expensive process. Even if we obtain the capital necessary to continue the development of our product candidates, whether through a strategic transaction or otherwise, we do not expect to complete the development of a product candidate for several years, if ever. To date, most of our development expenses have related to our product candidates, consisting of CAP-1002 and our exosome technologies. As we proceed with the clinical development of CAP-1002, and as we further develop our exosome technologies, our expenses will further increase. Accordingly, our success depends not only on the safety and efficacy of our product candidates, but also on our ability to finance the development of our products and our clinical programs. Our recent major sources of working capital have been primarily proceeds from public equity sales of securities and upfront payments pursuant to our U.S. and Japan Distribution Agreements with Nippon Shinyaku. While we pursue our preclinical and clinical programs, we continue to explore potential partnerships for the development of one or more of our product candidates in the US and in other territories across the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results have included non-cash compensation expense due to the issuance of stock options and warrants, as applicable. We expense the fair value of stock options and warrants over their vesting period as applicable. When more precise pricing data is unavailable, we determine the fair value of stock options using the Black-Scholes option-pricing model. The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. Generally, the awards vest based upon time-based conditions. Stock-based compensation expense is included in the consolidated statements of operations under general and administrative (&#8220;G&amp;A&#8221;) or research and development (&#8220;R&amp;D&#8221;) expenses, as applicable. We expect to record additional non-cash compensation expense in the future, which may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations for the fiscal years ended December&#160;31, 2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development Income. </i>Clinical development income for the years ended December&#160;31,&#160;2023 and 2022 was approximately $25.2 million and $2.6 million, respectively. The Company began to recognize the $30.0 million upfront payment received from Nippon Shinyaku related to an Exclusive Commercialization and Distribution Agreement (the &#8220;U.S. Distribution Agreement&#8221;) with Nippon Shinyaku in the third quarter of 2022. The Company began to recognize the $10.0 million milestone payment in connection with the U.S. Distribution Agreement in the fourth quarter of 2023. Revenue is ratably recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical trial (Cohort A).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i>. R&amp;D expenses consist primarily of compensation and other related personnel costs, supplies, clinical trial costs, patient treatment costs, rent for laboratories and manufacturing facilities, consulting fees, costs of personnel and supplies for manufacturing, costs of service providers for preclinical, clinical and manufacturing, certain legal expenses resulting from intellectual property prosecution, stock-based compensation expense and other expenses relating to the design, development, testing and enhancement of our product candidates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our R&amp;D expenses by category for each of the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Compensation and other personnel expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,272,356</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,450,879</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,821,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Duchenne muscular dystrophy (CAP-1002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,667,993</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,470,558</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,197,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exosomes platform research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,090,999</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,600,916</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,509,917)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,457,097</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,070,598</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 386,499</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,916,245</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 805,089</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,111,156</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 138</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 626,514</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 420,581</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 205,933</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 416,835</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 998,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (581,493)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (58)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,448,039</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,816,949</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,631,090</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses for 2023 increased by approximately $14.6 million, or 67%, compared to 2022. The increase was primarily driven by the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.8 million increase in compensation and other personnel expenses primarily due to increases in headcount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$11.2 million increase in DMD (CAP-1002) program primarily due to the enrollment of our HOPE-3 clinical program, our HOPE-2 OLE clinical trial and our expanded manufacturing production efforts for CAP-1002;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4 million increase in facility expenses primarily related to increased lease expenses due to our expansion efforts of our research and manufacturing facility in San Diego;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.1 million increase in stock-based compensation expense primarily due to increases in headcount and risk-free rate, which resulted in an increase in fair value of option issued; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2 million increase in depreciation expense primarily related to increased equipment purchases and capital improvements related to expansion efforts of our research and manufacturing facility in San Diego.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This increase was partially offset by a $1.5 million decrease in exosomes research primarily due to reduced expenses related to completion of certain research projects and a $0.6 million decrease in research and other primarily due to the completion of activities related to our INSPIRE clinical program in 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i>. G&amp;A expenses consist primarily of compensation and other related personnel expenses for executive, finance and other administrative personnel, stock-based compensation expense, accounting, legal and other professional fees, consulting expenses, rent for corporate offices, business insurance and other corporate expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our G&amp;A expenses by category for each of the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,476,151</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,653,489</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,822,662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Compensation and other personnel expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,702,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,283,964</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 418,505</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,700,852</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,958,666</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (257,814)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 294,841</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 355,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (60,477)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 442,368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 112,550</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 329,818</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other corporate expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,191,205</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,067,916</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 123,289</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,807,886</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,431,903</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,375,983</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses for 2023 increased by approximately $2.4 million, or 23%, compared to 2022. The increase was primarily driven by the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.8 million increase in stock-based compensation expense primarily due to increases in headcount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4 million increase in compensation and other personnel expenses primarily due to increases in headcount and recruiting costs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.3 million increase in depreciation related to leasehold improvements to our San Diego corporate headquarters; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million increase in other corporate expenses primarily related to increased travel and payroll processing costs due to increased headcount.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This increase was partially offset by a $0.3 million decrease in professional service expenses primarily due to a decrease in business development related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Other Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Income</i>. Other income for the years ended December&#160;31, 2023 and 2022 was approximately $0.1 million and $0.2 million, respectively. Other income in 2022 was related to the Employer Retention Credit under the CARES Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investment Income</i>. Investment income for the years ended December&#160;31, 2023 and 2022 was approximately $1.7 million and $0.5 million, respectively. The increase in investment income in 2023 as compared to 2022 is due to increased interest rates and the higher principal balance in our marketable securities, savings and money market fund accounts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Products Under Active Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CAP-1002&#160;for the treatment of DMD </i>&#8211; We are currently conducting our HOPE-3, Phase 3 study for DMD and our ongoing OLE study of the HOPE-2 trial for which we expect to spend approximately $25.0 million to $35.0 million in 2024. The expenses for our DMD program will include costs for personnel, clinical, regulatory and manufacturing-related expenses, including expenses related to the scale-up for potential commercial scale manufacturing if our CAP-1002 product is approved. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exosome-Based Therapeutics and Vaccines</i>&#160;&#8211; Our exosome platform is in early-stage preclinical development. We expect to spend approximately $3.0 million to $5.0 million during 2024 on development expenses related to our exosomes program, which includes personnel, preclinical studies and manufacturing related expenses for these technologies. Our expenses for this program are primarily focused on the expansion of our engineered exosomes platform including the manufacturing of our StealthX&#8482; vaccine to be used in connection with our collaboration with NIAID. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our expenditures on current and future clinical development programs, particularly our CAP-1002 and exosomes programs, cannot be predicted with any significant degree of certainty as they are dependent on the results of our current trials and our ability to secure additional funding and a strategic partner. Further, we cannot predict with any significant degree of certainty the amount of time which will be required to complete our clinical trials, the costs of completing research and development projects or whether, when and to what extent we will generate revenues from the commercialization and sale of any of our product candidates. The duration and cost of clinical trials may vary significantly over the life of a project as a result of unanticipated events arising during manufacturing and clinical development and as a result of a variety of other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of trials and studies in a clinical program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients who participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rates of patient recruitment and enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient treatment and follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of necessary materials required to make our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, requirements and timing of, and the ability to secure, regulatory approvals. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources for the fiscal years ended December&#160;31, 2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our liquidity and capital resources as of and for each of our last two fiscal years, and our net increase (decrease) in cash, cash equivalents, and marketable securities as of and for each of our last two fiscal years and is intended to supplement the more detailed discussion that follows. The amounts stated in the tables below are expressed in thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liquidity and capital resources</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,818</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,586</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,601</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Cash flow data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,596)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,917</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35,073)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,580</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,874</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:72.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,092</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,282)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our total cash, cash equivalents, and marketable securities as of December&#160;31, 2023 were approximately $39.5 million compared to approximately $41.4 million as of December&#160;31, 2022. The decrease in cash, cash equivalents and marketable securities from December&#160;31, 2023 as compared to December&#160;31, 2022 is due to a net loss of approximately $22.3 million for the year ended December 31, 2023, receipt of $12.0 million upfront from Nippon Shinyaku related to the Japan Distribution Agreement in the first quarter of 2023, and approximately $23.0 million raised in October 2023 through a registered direct offering. The net loss of approximately $22.3 million for the year ended December 31, 2023 was driven by the increased R&amp;D expenses in connection with our clinical program in DMD. As of December&#160;31, 2023, we had approximately $36.1 million in total liabilities, of which approximately $24.3 million relates to deferred revenue and approximately $2.2 million related to lease liabilities in connection with our operating lease right-of-use assets. As of December&#160;31, 2023, we had approximately $19.6 million in net working capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities was approximately $25.6 million for the year ended December 31, 2023 and cash provided by operating activities was approximately $4.9 million for the year ended December 31, 2022. The net change of approximately $30.5 million in cash from operating activities is due to the milestone payment of $10.0 million from Nippon Shinyaku and deferred revenue. Furthermore, there was an increase of approximately $2.9 million in stock-based compensation and a decrease in net loss of approximately $6.7 million for the year ended December&#160;31, 2023 as compared to the same period in 2022. Furthermore, there was a net change of approximately $0.1 million in accounts payable and accrued expenses, which includes related party accounts payable and accrued expenses. To the extent we obtain sufficient capital and/or long-term debt funding and are able to continue developing our product candidates, including if we expand our platform technology portfolio, engage in further research and development activities, and, in particular, conduct preclinical studies and clinical trials, we expect to continue incurring substantial losses, which will generate negative net cash flows from operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had cash flow provided by investing activity of approximately $5.1 million for the year ended December 31, 2023 and cash flow used in investing activities of approximately $35.1 million for the year ended December 31, 2022. The change in cash flow by investing activities for the year ended December&#160;31, 2023 as compared to the same period of 2022 is due to the net effect from purchases, sales, and maturities of marketable securities as well as purchases of property and equipment and leasehold improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had cash flow provided by financing activities of approximately $25.6 million and $4.9 million for the years ended December&#160;31, 2023 and 2022, respectively. The increase in cash provided by financing activities for the year ended December&#160;31, 2023 as compared to the same period of 2022 is primarily due to the net proceeds from the sale of common stock. During 2023 we received net proceeds from the sale of stock of approximately $25.5 million compared to approximately $4.8 million over the same period of 2022.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From inception through December&#160;31, 2023, we financed our operations primarily through private and public sales of our equity securities, government grants, and payments from distribution agreements and collaboration partners. As we have not generated any revenue from the commercial sale of our products to date, and we do not expect to generate revenue for several years, if ever, we will need to raise substantial additional capital to fund our research and development, including our long-term plans for clinical trials and new product development. We may seek to raise additional funds through various potential sources, such as equity and debt financings, government grants, or through strategic collaborations and license agreements or other distribution agreements.&#160;We can give no assurances that we will be able to secure such additional sources of funds to support our operations, complete our clinical trials or if such funds become available to us, that such additional financing will be sufficient to meet our needs. Moreover, to the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our estimates regarding the sufficiency of our financial resources are based on assumptions that may prove to be wrong. We may need to obtain additional funds sooner than planned or in greater amounts than we currently anticipate. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of our clinical and research activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our clinical and research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our preclinical and clinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of the development efforts of parties with whom we have entered into research and development agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully manufacture product for our clinical trials and potential commercial use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of materials necessary to manufacture our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing our product candidates, and the progress of efforts with parties with whom we may enter into commercial manufacturing agreements, if necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain current research and development programs and to establish new research and development and licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional costs associated with maintaining licenses and insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Collaborations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 24, 2022, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;U.S. Distribution Agreement&#8221;) with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S Distribution Agreement, Capricor received an upfront payment of $30.0 million in the first quarter of 2022. The first milestone payment of $10.0 million was paid upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Capricor received this milestone payment from Nippon Shinyaku in January 2024. Additionally, there are potential milestones totaling up to $90.0 million leading up to and including the BLA approval. Further, there are various potential sales-based milestones, if commercialized, tied to the achievement of certain sales thresholds for annual net sales of CAP-1002 of up to $605.0 million. Further, pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and Capricor will have the right to receive a meaningful mid-range double-digit share of product revenue. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2023, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;Japan Distribution Agreement&#8221;) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023 and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89.0 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Subject to regulatory approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financing Activities by the Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">October 2023 Financing </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On October 3, 2023, the Company entered into Securities Purchase Agreements with its commercial partner, Nippon Shinyaku and funds associated with Highbridge Capital Management, LLC (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), an aggregate of 4,935,621 shares of its common stock, par value $0.001 per share, at a price per share of $4.66 for an aggregate purchase price of approximately $23.0 million. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. As part of the Registered Direct Offering, the Company agreed not to issue or sell shares (subject to customary exceptions for employee stock option issuances and other customary exceptions) for a period of 30 days following the date of the prospectus supplement that was used in the Registered Direct Offering. &#160;That prospectus was dated September 29, 2023, and the Company &#8220;lock-up&#8221; expired on October 29, 2023. &#160;The Company&#8217;s directors and executive officers also entered into &#8220;lock-up&#8221; agreements with the placement agent in the Registered Direct Offering, which agreements expired on the 60<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day following the date of the Securities Purchase Agreements, or December 2, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 21, 2021, the Company initiated an at-the-market offering under a prospectus supplement for aggregate sales proceeds of up to $75.0 million (the &#8220;ATM Program&#8221;), with the common stock to be distributed at the market prices prevailing at the time of sale. The ATM Program was established under a Common Stock Sales Agreement (the &#8220;Sales Agreement,&#8221;), with Wainwright, under which we may, from time to time, issue and sell shares of our common stock through Wainwright as sales agent. The Sales Agreement provides that Wainwright will be entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold. All shares issued pursuant to the ATM Program were issued pursuant to our shelf registration statement on Form S-3 (File No. 333-254363), which was initially filed with the SEC on March 16, 2021, amended on June 15, 2021 and declared effective by the SEC on June 16, 2021. From June 21, 2021 through March 7, 2024, the Company sold an aggregate of 3,227,501 shares of common stock under the ATM Program at an average price of approximately $5.50 per share for gross proceeds of approximately $17.8 million. Approximately $57.2 million of common stock may still be sold pursuant to the ATM Program. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CIRM Grant Award</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June&#160;16, 2016, Capricor&#160;entered into an award (the &#8220;CIRM Award&#8221;) with the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) in the amount of approximately $3.4 million to fund, in part, Capricor&#8217;s Phase 1/2 HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section&#160;100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June&#160;20, 2016, Capricor&#160;entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in the CIRM Loan Policy and CIRM Grants Administration Policy for Clinical Stage Projects (the &#8220;New Loan Balance&#8221;), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. Depending on the timing of our election, additional funds may be owed. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. If we elect to do so, Capricor would be required to repay the amounts awarded by CIRM, therefore the Company accounts for this award as a liability rather than income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In&#160;2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of December&#160;31, 2023, Capricor&#8217;s liability balance for the CIRM Award was approximately $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements are prepared in accordance with generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis, including research and development and clinical trial accruals, and stock-based compensation estimates. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates. We believe the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of our financial statements and accompanying notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">ASC Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use (&#8220;ROU&#8221;) asset. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases office and laboratory space, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company applies ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its distribution agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and shared revenue payments, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#8217;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the respective clinical program. Milestones or shared revenue payments achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The determination as to when income is earned is dependent on the language in each specific grant. Generally, we recognize grant income in the period in which the expense is incurred for those expenses that are deemed reimbursable under the terms of the grant. Grant income is due upon submission of reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CIRM Grant Award</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor accounts for the disbursements under its CIRM Award as long-term liabilities. Capricor recognizes the CIRM grant disbursements as a liability as the principal is disbursed rather than recognizing the full amount of the grant award. After completing the CIRM funded research project and after the award period end date, Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and the stage of development at the time the election is made.&#160;In June, 2016, Capricor&#160;entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Since Capricor may be required to repay some or all of the amounts awarded by CIRM, the Company accounts for this award as a liability rather than income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses consist primarily of salaries and related personnel costs, supplies, clinical trial costs, patient treatment costs, rent for laboratories and manufacturing facilities, consulting fees, costs of personnel and supplies for manufacturing, costs of service providers for preclinical, clinical and manufacturing, and certain legal expenses resulting from intellectual property prosecution, stock compensation expense and other expenses relating to the design, development, testing and enhancement of our product candidates. Except for certain capitalized intangible assets, R&amp;D costs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our cost accruals for clinical trials and other R&amp;D activities are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical trial centers and contract research organizations (&#8220;CROs&#8221;), clinical study sites, laboratories, consultants or other clinical trial vendors that perform activities in connection with a trial. Related contracts vary significantly in length and may be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of fixed, variable and capped amounts. Activity levels are monitored through close communication with the CROs and other clinical trial vendors, including detailed invoice and task completion review, analysis of expenses against budgeted amounts, analysis of work performed against approved contract budgets and payment schedules, and recognition of any changes in scope of the services to be performed. Certain CRO and significant clinical trial vendors provide an estimate of costs incurred but not invoiced at the end of each quarter </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for each individual trial. These estimates are reviewed and discussed with the CRO or vendor as necessary, and are included in R&amp;D expenses for the related period. For clinical study sites which are paid periodically on a per-subject basis to the institutions performing the clinical study, we accrue an estimated amount based on subject screening and enrollment in each quarter. All estimates may differ significantly from the actual amount subsequently invoiced, which may occur several months after the related services were performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the normal course of business, we contract with third parties to perform various R&amp;D activities in the on-going development of our product candidates. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the accrual policy is to match the recording of expenses in the financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical trials and other R&amp;D activities are recognized based on our estimates of the degree of completion of the event or events specified in the applicable contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No adjustments for material changes in estimates have been recognized in any period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results include non-cash compensation expense as a result of the issuance of stock, stock options and warrants, as applicable. We have issued stock options to employees, directors and consultants under our five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the &#8220;2012 Plan&#8221;), (iii) the 2012 Non-Employee Director Stock Option Plan (the &#8220;2012 Non-Employee Director Plan&#8221;), (iv) the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), and (v) the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan and no longer issues options under the 2006 Stock Option Plan, the 2012 Plan, or the 2012 Non-Employee Director Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense the fair value of stock-based compensation over the vesting period. When more precise pricing data is unavailable, we determine the fair value of stock options using the Black-Scholes option-pricing model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation. These variables and assumptions include the weighted-average period of time that the options granted are expected to be outstanding, the volatility of our common stock, and the risk-free interest rate. We account for forfeitures upon occurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options or other equity instruments to non-employees (including consultants) issued as consideration for goods or services received by us are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. Generally, the awards vest based upon time-based conditions. Stock-based compensation expense is included in general and administrative expense or research and development expense, as applicable, in the Statements of Operations and Comprehensive Income (Loss). We expect to record additional non-cash compensation expense in the future, which may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical Trial Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, CROs and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial.&#160;We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">Recently Issued or Newly Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This standard was issued in response to the SEC&#8217;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the Financial Accounting Standards Board, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_865a6505_f7a0_446e_bc53_99b32f8f17fc"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 7A.</b></span>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest Rate Sensitivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our exposure to market risk for changes in interest rates relates primarily to our marketable securities and cash and cash equivalents. As of December&#160;31, 2023, the fair value of our cash, cash equivalents, and marketable securities was approximately $39.5 million. Additionally, as of December&#160;31, 2023, Capricor&#8217;s investment portfolio was classified as cash, cash equivalents and marketable securities which consisted primarily of money market funds and bank money market accounts, which included short term U.S. treasuries, bank savings and checking accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The goal of our investment policy is to place our investments with highly rated credit issuers and limit the amount of credit exposure. We seek to improve the safety and likelihood of preservation of our invested funds by limiting default risk and market risk. Our investments may be exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments, if any. We will manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying value has always approximated their fair value. Our policy is to mitigate default risk by investing in high credit quality securities, and we currently do not hedge interest rate exposure. Due to our policy of making investments in U.S. treasury securities with primarily short-term maturities, we believe that the fair value of our investment portfolio would not be materially impacted by a hypothetical 100 basis point increase or decrease in interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_61b20851_7c8b_4576_ac4a_a1c132a2edd2"></a><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><a id="FSTABLE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 8.</b></span>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPRICOR THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">INDEX TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#REPORTOFACCOUNTINGFIRM"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> <b style="font-weight:bold;">(PCAOB ID </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:AuditorFirmId" id="Narr_o-fhKlqRKkanypQsTiXCAg"><b style="font-weight:bold;">468</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:middle;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEET"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:middle;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTOFOPERATIONS"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:middle;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTOFEQUITY"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:middle;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 13.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:13.7pt;text-indent:-13.7pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTOFCASHFLOWS"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">94</p></td></tr><tr><td style="vertical-align:middle;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:0pt 0pt 0pt 12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">95</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fff6bdcf_cd9d_4e18_97dc_d1cc4e6d1e76"></a><a id="REPORTOFACCOUNTINGFIRM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">To the Board of Directors and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Stockholders of Capricor Therapeutics,&#160;Inc. and Subsidiary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Opinion on the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have audited the accompanying consolidated balance sheets of Capricor Therapeutics, Inc. and Subsidiary (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Explanatory Paragraph &#8211; Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has continued to incur significant operating losses and negative cash flows from operations, during the year ended December 31, 2023. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical Audit Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition &#8211; Revenue Recognized Over Time</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of the Matter</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed in Note 1 and Note 7 to the Consolidated Financial Statements, the Company earns its revenue through an exclusive commercialization and distribution agreement. For performance obligations related to services that are required to be recognized over time, the Company generally measures its progress to completion using an input measure of total costs for patient visits incurred divided by total costs expected to be incurred for all patient visits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Auditing revenue recognition is complex and highly judgmental due to the variability and uncertainty associated with the Company&#8217;s assessment of measure of progress. Changes in these estimates would have a significant effect on the amount of revenue recognized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">How We Addressed the Matter in Our Audit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To test the measures of progress used for performance obligations related to services that are required to be recognized over time, our audit procedures included, among others, evaluating the appropriateness of the Company&#8217;s accounting policy for each type of arrangement, testing the identified measure of performance by reading contracts with customers, including all amendments, and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently. We also tested the completeness and accuracy of the underlying data used for the measure of progress by testing and or analyzing the underlying data and conducting interviews of project personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:AuditorName" id="Narr_urTguipqV02jpZ-yscJCGw"><span style="font-size:10pt;">Rose, Snyder&#160;&amp; Jacobs LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rose, Snyder&#160;&amp; Jacobs LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="dei:AuditorLocation" id="Narr_bYJhIn77-Eq_3q3GOXkbhg">Encino, California</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_107846c9_e624_4861_aff4_049e02edba26"></a><a id="CONSOLIDATEDBALANCESHEET"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPRICOR THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">DECEMBER&#160;31, 2023 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fb39b450_f4cb_4f13_9c7b_9ae0c0ac1c92"></a><a id="Tc_DHyk7sDFUUaC9_OpIpR-iQ_2_0"></a><a id="Tc_CYh1Vx5QtkyoUVZ60ZwTcQ_5_2"></a><a id="Tc_rSaUR4Iqbkmp_nPkbqu6iA_5_5"></a><a id="Tc_wOYmuafdtEuc6o_xO_Ab7g_7_0"></a><a id="Tc_PJ1y0senQkWfz4gxwrDDdQ_8_0"></a><a id="Tc_edvv0TqLH06bYORT9OpYAg_8_2"></a><a id="Tc_T-JMis_-OkShtlY_AysipQ_8_5"></a><a id="Tc_FyHqYGVb1U-mPnpUSGmkcg_9_0"></a><a id="Tc_wgt16w9c9kW616uzrtImXg_10_0"></a><a id="Tc_3dmsTt0umE-X7uR5vWsCIA_11_0"></a><a id="Tc_safGJkgzmk22ppO0voq_LA_13_0"></a><a id="Tc_3RIohjqrpE2VG6iKWAREew_15_0"></a><a id="Tc_JurkQYGz_kuGPk5mbMFAWQ_17_0"></a><a id="Tc_DP-HeLU90Ea3SwIh1-G0lg_18_0"></a><a id="Tc_-WY8zrOIFEaYoBEuyH9d2g_19_0"></a><a id="Tc_Abn8F7TH6E-id0gzWPV_TQ_21_0"></a><a id="Tc_6WqO8-8wCEGgCJz_94W6bA_21_2"></a><a id="Tc_XDMFfq4VTk2jTjFecdpcRw_21_5"></a><a id="Tc_NfE0d217mUaIMGCVrgSh0w_23_0"></a><a id="Tc_Kme4AQ08tEOSC0yuiQFWfg_25_0"></a><a id="Tc_-l70p7qwo0uhE8VhfXLZCQ_26_0"></a><a id="Tc_djo5XmjaJkq2MADVZVyvGg_26_2"></a><a id="Tc_n_DfpI1y-UK-dpWWaIUkdw_26_5"></a><a id="Tc_1iwc9kF3Ck2ZuCrkbbuDfg_27_0"></a><a id="Tc_bRFaoeA-C06lKX6_ZUziXw_28_0"></a><a id="Tc_zHb318ANQEuXAUCvDHW74w_29_0"></a><a id="Tc_1_cLNefHRUiHBUubhl9t9A_31_0"></a><a id="Tc_YgTbNNZ3mUaiJBBu4PTdMA_33_0"></a><a id="Tc_RdWouvcac0O8Nv-V7npVOA_34_0"></a><a id="Tc_0ZxyfO_TzEW7oH07ksHOqQ_35_0"></a><a id="Tc_ONckx7occ0Cr-beb06kWRg_36_0"></a><a id="Tc_cijncDrd2EqwroR3HP1uIA_38_0"></a><a id="Tc_8k29goGY3Eio8TBuzJHWrQ_40_0"></a><a id="Tc_H0OoPvEFt0Gy8mSh8U-7ZQ_42_0"></a><a id="Tc_LUgmUUnK80mf6Jasun6K6g_44_0"></a><a id="Tc_SH4XahJDKkabUwCyqlj92A_45_0"></a><a id="_649cd7d0_92df_47f8_b7a3_09a88bdf7d4a"></a><a id="_649cd7d0_92df_47f8_b7a3_09a88bdf7d4a_2"></a><a id="_649cd7d0_92df_47f8_b7a3_09a88bdf7d4a_3"></a><a id="_8107f94a_7829_4198_8c21_6c284e17c5e0"></a><a id="_8107f94a_7829_4198_8c21_6c284e17c5e0_2"></a><a id="_8107f94a_7829_4198_8c21_6c284e17c5e0_3"></a><a id="Tc_zV1E01D-vUugkE0IfLsYMg_46_0"></a><a id="Tc_TCSZb1VQKEq5QdGtPQP48w_47_0"></a><a id="Tc_d2ZZiU6zuUOmWnQIEUcN8g_48_0"></a><a id="Tc_tVe3NoRMFECy0Qy2DN4NsQ_49_0"></a><a id="Tc_d7MtkO0kmEqJKFyIkkJPpQ_51_0"></a><a id="Tc_YdBWvFkCu0uz2uSTCbX1_Q_53_0"></a><a id="Tc_EFC4Vg_FiEi1bbGBFTH_Hg_53_2"></a><a id="Tc_SCcb0sIkikq2rD3pVUq41w_53_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">ASSETS</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">CURRENT ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc__aYH-cUUvUqvipbRNVFS_A_8_3">14,694,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_jU6q2Inq0kGTq-tPBclD2g_8_6">9,603,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_6d4A_hDWmk2AX_l_pmpOaA_9_3">24,792,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_tECOkVAnXE-XTuXbtC7gwA_9_6">31,818,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_kRTViZeFS0Ws-BsUB4KbcA_10_3">10,371,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_0SYh7-14Dk2671qNXvFZtg_10_6">547,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_6QRfGswzyk6elZlIDubZQA_11_3">995,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_UdXOEqRF5kaZOpYWmoficg_11_6">919,892</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL CURRENT ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_nycmO8PINUmx8by9ZLsimA_13_3">50,855,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_B65bCY_xy0y5NbrI0_p9RA_13_6">42,888,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PROPERTY AND EQUIPMENT, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_N9teVFxKvkWNR4UY0U83YQ_15_3">5,560,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_q_mwCGSSwkWNad3X7xOPgw_15_6">4,588,030</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">OTHER ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Lease right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_2dXwRSFYo0mH_c4_zZlNXQ_18_3">2,050,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_slfxkD2jZ06KE7iblO-fRA_18_6">2,349,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="0" id="Tc_0NhhpHOIn0qluTvoifkeUw_19_3">268,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="0" id="Tc_Tk9PdIpte0aheOLBRkG0aQ_19_6">268,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_Hf9qZWJ6b0WRDapouufVeg_21_3">58,734,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_F8g3mQQCNUKxXcAYjzpOzw_21_6">50,094,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">CURRENT LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_NexLYihGlU2XjEbNivQQTQ_26_3">6,222,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_NfhLkFcJjk-wSwqXH654-w_26_6">4,834,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued expenses, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_XPCegLiUXUyF9i5uqf-7sg_27_3">27,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_kjEG9yfOvkeTYjSfapki5A_27_6">89,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_6uqExRzwl0mHLmPa3dmsCQ_28_3">749,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_UipC6pjhN0i3_SV3aXGM_A_28_6">682,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_vb8eBVrWXk-5WTZiHzNnMA_29_3">24,270,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_TtwFdzwsqkmqRce8GPrW0w_29_6">17,980,599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL CURRENT LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_s2WmNoRSKEWiRHYHo1hjFQ_31_3">31,269,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_BKJa5SjSjk-VI_d3Sp2lkA_31_6">23,586,555</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">LONG-TERM LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">CIRM liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermDebtNoncurrent" scale="0" id="Tc_tWiZmKfB2kqq6hT8kMsAbg_34_3">3,376,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermDebtNoncurrent" scale="0" id="Tc_ya7GzjIL_0ukBFHsx3UviA_34_6">3,376,259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_w7Jp_K1tlkmFLTWu3Dn9bQ_35_3">1,486,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_r4xmYxL3Fk-wR6S3CafK6Q_35_6">1,878,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="Tc_IU1RPTcpCU2oDqQGI4GyWw_36_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="Tc_XHCzHvd2OkC0SJAm7wQWLg_36_6">9,467,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL LONG-TERM LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_EwWiN44Q60aS0etg1iw4rg_38_3">4,863,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_ASUbCVQH50i7IDqdXOcMCw_38_6">14,722,261</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_6-hUv2o0cE-pPwb1gMlE5w_40_3">36,132,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_Sf87AJmS10aEFdtR20TvcQ_40_6">38,308,816</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">COMMITMENTS AND CONTINGENCIES (NOTE 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">STOCKHOLDERS&#8217; EQUITY </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_YgW2REiaBkCIecaFOmoXNw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_NBfrYatKJEuTioWxSO2Fng">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_nrhJM12ILkqrscgLbOT0FQ"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_DqSBzDO_yEa_89sWsiF6Sw">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, none issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_csn4ML-U40qMKF0mNA918w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_gJAaLp8guEGZnxuR63MXJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common stock, </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Np4yb0C580G6NN7nrP62FA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_PfEggW4QmkaTN8XCp_56Uw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tOto2lt0-0yclpUy0F7Dvg"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Y2q8On1QQUqjADW3KsJU3g">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Cj9xxxWNmUmmhqwO5k16mg">31,148,320</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_UDjVkEWrbU2juirRqnsMxA">25,241,402</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_hQRFCNamYUa9BA896rhzWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_sJHoZlsetECWy9vfmM5zoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;">, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_N6E2DVaKu0i-gvJqMOdEOQ_46_3">31,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_PBebyo_3fUCO7G9RYH7jxw_46_6">25,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc_eTukbG4V102CTVU_2oaMxg_47_3">181,701,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc__v0TPiCJw0K1X799QKpzrw_47_6">148,735,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="Tc_-n3QGr9KEEWbY8eucjvP4Q_48_3">235,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="Tc_pDEvSYx9b0uc8rSlmppwJw_48_6">105,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_L8Ikdi1T50Wlmh0-IAhFfg_49_3">159,367,353</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_4wJHkJ4e60qTwWW-1jok1A_49_6">137,079,811</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL STOCKHOLDERS&#8217; EQUITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_SVuS1qYR10O2FCakYolY4g_51_3">22,601,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_0i422w2waE2yODiTFehPLw_51_6">11,786,094</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_Ho3-X1xkCEWWoMNfAmXXaQ_53_3">58,734,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_TlWJA1TxlUq3CUq5qxhBiQ_53_6">50,094,910</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See accompanying notes to the audited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e19bbd36_6208_43ba_b425_9dace6f7c5a9"></a><a id="CONSOLIDATEDSTATEMENTOFOPERATIONS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPRICOR THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5960bb57_f2a5_40a6_9b96_ba3c42523524"></a><a id="Tc_Pk_dNpAaakC-CC6udtDNNQ_1_2"></a><a id="Tc_cMr73vv4KUWoOgGbytnq1Q_2_2"></a><a id="Tc_ttxqPvqXlEOSmX5sSW0pFw_2_5"></a><a id="Tc_K8CKecaX606IoCjrL0eO8A_4_0"></a><a id="Tc_eW4I9ILBzkWkJeZ44PPFoQ_5_0"></a><a id="Tc_W_BGJGYUR0aigu-lL8K1gg_5_2"></a><a id="Tc_YAnB83K68EatoR_LqRByEw_5_5"></a><a id="Tc_oIY9eKg9f0eWOd-oC5p9NQ_7_0"></a><a id="Tc_XBwdXZyleE-BMj4Bj9AsCQ_9_0"></a><a id="Tc_Q9hh3lmwK02jj8JesgMo3w_10_0"></a><a id="Tc_GPHGk0B_DUqIm6YdVTlmPQ_11_0"></a><a id="Tc_URuP3q9D10yDDQdxBqJXVQ_13_0"></a><a id="Tc_cngeYdBqL0ursI8SciRS8w_15_0"></a><a id="Tc_G6x8O9E92UyXV54fyNF1Ew_17_0"></a><a id="Tc_6AzmqFpaCkGZ0n_1v2xh7A_18_0"></a><a id="Tc_eTTkduELYkKsv1seg6Nw7g_19_0"></a><a id="Tc_7KeoFtmrmEOp_6deCwq0HA_20_0"></a><a id="Tc_8dxXj26E7ESMza7OJU_8gw_22_0"></a><a id="Tc_DvF4Q9YkL0-Raqrx4wPK3Q_24_0"></a><a id="Tc_0zbGQDIHAkmlqkb6nRHb6g_26_0"></a><a id="Tc_adsl6XdGzkOej4jbPjUGKQ_27_0"></a><a id="Tc_gEcujwcHdk2EaYzqd3ekFw_29_0"></a><a id="Tc_wrUM0RiIkUeK7YjJlHrpDA_29_2"></a><a id="Tc_q8z8pQQRdk6J7msHNW8PVQ_29_5"></a><a id="Tc_pkf7UGGb502ubwiGJSixlQ_31_0"></a><a id="Tc_KqiJexuCt0K3eRKeRWWonw_32_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">REVENUE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_2gUdH9Zl9EOELfb0xbGz1A_5_3">25,178,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Lo4ffeLCYUS4OKjENgc14g_5_6">2,551,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL REVENUE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_lLjtmsUoIUmjNn5mOUt6jQ_7_3">25,178,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_NSlNicEG00yZw2xkmC_c6w_7_6">2,551,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">OPERATING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_5nrf5o3uIEebueQDSosR3g_10_3">36,448,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_s53YAb4X1UqUqcKVqE6thQ_10_6">21,816,949</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_ZIvK_6Bqg063FdknrE2q6w_11_3">12,807,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_tu2o-uQ5v0ejoxKUnezIgw_11_6">10,431,903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL OPERATING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_u-Ssx78-DUiV6DBDPnrQeA_13_3">49,255,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_MX3xYwqAsESdK22xRN0bHg_13_6">32,248,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">LOSS FROM OPERATIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_c3cHrRDrp020ZHgZx7eTYg_15_3">24,077,859</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_XIFh699IxkublXr6WH8VtA_15_6">29,697,383</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">OTHER INCOME (EXPENSE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="Tc_RJCL6grHW0qkVJdZHYCFoA_18_3">67,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="Tc_CQ1p-kwO8kaYOmysi2H7GQ_18_6">190,582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Investment income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" id="Tc_bkHjF1fLz0iyE58lUMgAQQ_19_3">1,728,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" id="Tc_AWvX2FjdKkKTDtBLG18rVw_19_6">521,535</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="0" id="Tc_tq0UXcn2-0GkaezL0uclnQ_20_3">6,041</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="0" id="Tc_iG3SvY6QOkGO_ube0OpIuw_20_6">34,266</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">TOTAL OTHER INCOME (EXPENSE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_b_LDL1EtWEOkDZjpF_XBbg_22_3">1,790,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_MLURwOCaYkiTiXf09z9PIQ_22_6">677,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">NET LOSS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VhFcEjPib0qG6mrODrv5Jw_24_3">22,287,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_meE62dYuoEGKOzymPpP8Hw_24_6">29,019,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">OTHER COMPREHENSIVE INCOME (LOSS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_i9Ie-0vgukeFF8pNYr2xKQ_27_3">130,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_JAM-K4r0SU2UzZLHY-S8Sg_27_6">105,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">COMPREHENSIVE LOSS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_eiyqmm2MpU2NAA1xUtXQug_29_3">22,156,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_nfwishHQEkytnuWdTNZOTA_29_6">28,914,288</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_3fnBnzAAkUyQ2u5GgMTsEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_viDl_66iLEyViCo5q-xD0Q_31_3">0.83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Fem3QWtdUEWo4L6QdPIeUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_kZtHLlGuSUWFLUY5pZ9lXA_31_6">1.18</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Weighted average number of shares, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_y0gffCcoH02TuLJUiETk9w_32_3">26,778,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_fr2Xy1I3xEqAM1HgppuGsg_32_6">24,552,688</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See accompanying notes to the audited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_31e4e427_7b2c_4eba_88b5_4e0d96bb7fe5"></a><a id="CONSOLIDATEDSTATEMENTOFEQUITY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPRICOR THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FOR THE PERIOD FROM DECEMBER&#160;31, 2021 THROUGH DECEMBER&#160;31, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c097c631_e2bd_40a2_b399_347333a2988e"></a><a id="Tc_SqiFdVyNy0ucdP3gxC6jCA_1_10"></a><a id="Tc_wfjvgmnLdkqMbWnC3tj5-g_1_16"></a><a id="Tc_DUKj5O20gEWxtCBkShFXhA_2_2"></a><a id="Tc_b6pG-n4uWEKCoNY_8Hb8UQ_2_7"></a><a id="Tc_n5IQ6WvQhEGI1WuqSu3-9A_2_10"></a><a id="Tc_2ClIb10NOECM7vrxBaW13g_2_13"></a><a id="Tc_lv9IiUCoxUKFu_P74zHJ7w_2_16"></a><a id="Tc_5cC4thlMXE6u5PaNdA2D1w_3_2"></a><a id="Tc_npvEUz79n0qV4whVJLFong_3_4"></a><a id="Tc_OGuH6Los-UKwj79hlNwjug_3_7"></a><a id="Tc_LMi9L-8evUyCm_maZKdCFw_3_10"></a><a id="Tc_RwY269xEM0eyw-3O2SrZSA_3_13"></a><a id="Tc_G-2ni3Ht5ki3sx_rbTNCZw_3_16"></a><a id="Tc_Td2UMCSwHkChtKcUy3j-dw_6_0"></a><a id="Tc_v_9uwtbqHUaunblSP7336w_6_4"></a><a id="Tc_k79gZ-pAkkuAb9mk8GfPng_6_7"></a><a id="Tc_ZiRYKLAssESkf1AfvNpY1Q_6_10"></a><a id="Tc_wdQLm4KC7EGSn6BV3NvPfQ_6_11"></a><a id="Tc_5kqtj4W8gUWGcTz5vE7OMg_6_13"></a><a id="Tc_8MDU6IwlVEG4pZw91YMlfA_6_16"></a><a id="Tc_AzLdQ70EBU6rI8ao45YhWw_8_0"></a><a id="Tc_55JT-dDEXUWS4bKusilRRw_8_11"></a><a id="Tc_w_1NBGbva0az4IplkQpptg_8_14"></a><a id="Tc_Nw7qZBx4uUGszYCyIJEnBg_10_0"></a><a id="Tc_ZbWvWguM-0q9MJAFASx4Gw_10_2"></a><a id="Tc_vno-Jdulq0aikpiHZ0VLfQ_10_5"></a><a id="Tc_4XzImmPlI0OkmpqMjY8Zqg_10_11"></a><a id="Tc_kEVLRNR-2Eu6yQOhy9QYbA_10_14"></a><a id="Tc_bGGBPnI2NEax6KxwOWhFzQ_12_0"></a><a id="Tc_TT8CG3To7EGca6zKaktwow_12_11"></a><a id="Tc_8u7jnP1Q_kS8tg8cdGJasw_12_14"></a><a id="Tc_FTcgslpq3E6Jq8s3h9KIWg_14_0"></a><a id="Tc_2NPerAy_20GtPoVt2FHZ1Q_14_2"></a><a id="Tc_6MHhObsbPk2ltqU3qAqqPA_14_5"></a><a id="Tc_G1AB5untF0-ga9j-l6971A_14_8"></a><a id="Tc_X8ijPjv7FEiILEUfos1Ycg_14_14"></a><a id="Tc_HI3XiPUI5UG9aQ4mkc_abA_16_0"></a><a id="Tc_N5utjM7W00yMjbOyd9AYtw_16_2"></a><a id="Tc_o3dOddhCp0OlgZBOLfKRpg_16_5"></a><a id="Tc_WHsEtVfa90-PPM7CVGlPjA_16_8"></a><a id="Tc_hvL5pY_cj0aTHIhGFSdbhQ_16_11"></a><a id="Tc_p-JUhX-E70mjjQEFK_kYEQ_18_0"></a><a id="Tc_qYXm0_OMIEWR-JT3a49VFg_18_4"></a><a id="Tc_XEVwL3MQd0-E533HFsm4VQ_18_7"></a><a id="Tc_YRC9QMPAFU-jCD1-Z0xF9w_18_10"></a><a id="Tc_RhXpPChDEk2vxk71ZhQgqw_18_13"></a><a id="Tc_fG_ArGeIeUeUUe_7dkkipA_18_16"></a><a id="Tc_U1jEXqt4oEOtudxeILInlg_20_0"></a><a id="Tc_woCW7ruAmEKmUe0YDmjfnQ_20_11"></a><a id="Tc_d40Z_s_QQkaNoxjUAT37jg_20_14"></a><a id="Tc_Gx7c8OZqrEec-VrFFdOkaw_22_0"></a><a id="Tc_78x8qODQaEe92mOYp0NOFQ_22_2"></a><a id="Tc_tc44Yf4NuEiGH9GSC-h56A_22_5"></a><a id="Tc_LZuYua4XaEaU3z_0_FixMQ_22_11"></a><a id="Tc_VbwIXsUAH0GR6HSMV5cSJA_22_14"></a><a id="Tc_qvELSxBPok2_6cbbkvRxGw_24_0"></a><a id="Tc_dHmSa5VxyUanRbDlYLdP7w_24_11"></a><a id="Tc_TgZ-587xoUWokJhaDUoisA_24_14"></a><a id="Tc_jjrqLAuqtUaOnNUpBG2kWA_26_0"></a><a id="Tc_27bW1hDpgkC7g4O8B6S7sw_26_2"></a><a id="Tc_hDYjdyMNA0OjYcqm1W7Ijg_26_5"></a><a id="Tc_mcrQdIli4EibtziTlhtMEQ_26_8"></a><a id="Tc_XpGTpnnBUEO09zAgYrehvQ_26_14"></a><a id="Tc_sc-2pp9ZYUiAMefQGkIkrQ_28_0"></a><a id="Tc_h-2-LqFCpkq5GTQE96Hvyg_28_2"></a><a id="Tc__ke2T4o4J0COprLKBvnofg_28_5"></a><a id="Tc_I5sCuo_6PUq280vo31UrVQ_28_8"></a><a id="Tc_8hv0rVpYuE65a2t7qoRCgQ_28_11"></a><a id="Tc_B8HObNCyEEiyTokJH6E35g_28_16"></a><a id="Tc_amxgnUk3z0azWW4Fr9B6rg_30_0"></a><a id="Tc_a4VPYk0a80uqFU8nTmXM_A_30_4"></a><a id="Tc_l-v5Rsk3uk6hjKYkNtZs_A_30_7"></a><a id="Tc_Vm30iF_uEkC12QVh_Q2PxQ_30_10"></a><a id="Tc_7Yi4Gdr5aUS44qpP4g0oig_30_13"></a><a id="Tc_kkEFtN--xke7NR_l44-fOA_30_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OTHER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TOTAL</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMMON&#160;STOCK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADDITIONAL&#160;PAID-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPREHENSIVE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACCUMULATED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDERS'</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMOUNT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IN&#160;CAPITAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EQUITY&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_c-Oa1RYfkEmKM6S6fWZ6og_6_2">24,185,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_E_CQ8mtmeEqxNP5oUsn7Dw_6_5">24,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ec85mF__lkWbIVrr9-VJSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YpMEX54IME2SRjs_NQ4JFw_6_8">139,404,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HU_mvTo810KMf88JbAhomA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_TZBNtyBkaUek2X901uoHVg_6_14">108,060,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_1gryOBlozki7EfC078TYhA_6_17">31,367,966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance of common stock, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_NpBsnnqDiE67hvX51ZP_sg_8_2">830,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_HvHLpM0FXEG72wdjAxlYMA_8_5">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_R_9Yz8A4LUOrxH8btgh0QA_8_8">4,802,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_DcDqaj100ECxmgbSKYa2ZA_8_17">4,803,534</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_Z__9Ovr3bkCtHBG1fKRqEA_10_8">4,458,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_aQ_jfzEvlUaAaqxinFUUzw_10_17">4,458,578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_sZiBhc_i3UKr7sgUdSQEsA_12_2">225,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Z_J05oW-RUaao-rd4vIuuQ_12_5">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_JZKvoNphgUSC9ARPalvQVw_12_8">70,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_fdDKkc1Bd0qhkSAnxTrZuQ_12_17">70,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_zfDRweqJO0KyY-n8-mOXUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_CwzqCmIK2kKoAhsDHzRpdA_14_11">105,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_3v2KWsN78E6UGX4uikC8_w_14_17">105,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BT9Hpe-z3EmOCGA9Ohlt9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_5OEtLAHoK0Oo5kcINMGBKw_16_14">29,019,532</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_9AMah4Tgyka7WoqhGvoTSQ_16_17">29,019,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gZeFjl2g70it8yotqx1Svw_18_2">25,241,402</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-Z1IHQopsEiEV5_UMoY18g_18_5">25,241</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J8eFa0zA6kGN_euvLuaNqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_pwW6PZ9Xd0yfF5nV1FGNIA_18_8">148,735,420</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_E2rfLuwSdkG6a9ykiY4nqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YIwHbesaxUuGitaaU2U8PQ_18_11">105,244</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tf5OikZQFUONNK7Iknfs5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_73FfyBy8uEWvpqUib1FxRg_18_14">137,079,811</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_42qlUv4vv0ej67K4tzZIoQ_18_17">11,786,094</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance of common stock, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_uE_gna0t2EqqZORdUoKzHg_20_2">5,813,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_uDQJK3h980ODA0r45zdmvQ_20_5">5,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_662H9QKM2UerxtbjFSNwig_20_8">25,509,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_6h7S4HCPLkCzbAgvjQs9iA_20_17">25,515,349</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_m8PWxAJiaE-3xZV_FXUpWA_22_8">7,392,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_3gKQ58MSjEu-B64MBRavzQ_22_17">7,392,396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_td5j9_5F90qZTLuaUubSUg_24_2">93,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_07AixAZjFUS-8s0QEuokZw_24_5">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_cINZi7lvIESD_0ezwqojBQ_24_8">64,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_rBtpBfZjkUOoegtkSq5_1w_24_17">64,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_0FeZ1sWYakOU07ed4P8ELw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_8575fEpWlkm9XT37-SaIwA_26_11">130,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Tc_0nB9jbvG-02j99lTEaaj_Q_26_17">130,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5BsNuYaQz02q8UT51aO1_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_rM2_sPMQ0kiqMQMiEFgt1g_28_14">22,287,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_rxuErLjTO061OWBWorE3mA_28_17">22,287,542</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:31.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Nsu3rWZPjkqZxVN3Y5mTqA_30_2">31,148,320</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_uFWcMNNSJ0C6R1JK1wfOLg_30_5">31,148</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6T-zyWrrmkSBVCPBt8HidA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_C2leL5fmykevNX0dlVszdQ_30_8">181,701,859</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_QonEck6FD0KdgFPM0l4WBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tG7fc3QB7Uq49nyJqmsqtg_30_11">235,813</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4X-qf24Pnkim2ijfGAzOrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_JP7NkmINLkCkaK87P54VWA_30_14">159,367,353</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_llqdDfNtGEqIHSn6uRX1Sw_30_17">22,601,467</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See accompanying notes to the audited consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fe3c779b_3149_48c9_90c1_823cf55a4b57"></a><a id="CONSOLIDATEDSTATEMENTOFCASHFLOWS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPRICOR THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3dd41bbd_f1ca_4adc_91ac_5bcbd999bad8"></a><a id="Tc_jz47trLj6keuG6zJ2zISIA_1_2"></a><a id="Tc_aa0iKogQ5UyNi97J8VNiSw_2_2"></a><a id="Tc_6j6qWXtVwEuUq9UauS6JKA_2_5"></a><a id="Tc_MoFQ-rEo0kujTBk3t72XKg_3_0"></a><a id="Tc_4Z4yhaFyPkWsadVOZ4FaPQ_4_0"></a><a id="Tc_PhpPKK-_aUqyjepjONZQ9g_4_2"></a><a id="Tc_NCmrVK1p_UeFz_-QqjRpBw_4_5"></a><a id="Tc_8RbL1YKvikWr-9S2iLAG3Q_5_0"></a><a id="Tc_YA0c-qFh-EifeyrB6JxEew_6_0"></a><a id="Tc_olOoMytKaU62_D4i5uKQaQ_7_0"></a><a id="Tc_v-Wjji3F7UK_zMG9rovWVA_8_0"></a><a id="Tc_L7RMtXXMWk63R6RWLp4sIg_9_0"></a><a id="Tc_bAZ2vNJx5kuTJHZwdxUDeQ_10_0"></a><a id="Tc_1dTTj1EJ9UCqSh15VuWNlA_11_0"></a><a id="Tc_TuhZLVpb1EGfCUeiTpt2Og_12_0"></a><a id="Tc_77jpgym5rEmnPGzrmkVUGg_13_0"></a><a id="Tc_sxU3BZs6tE-Txn27yMr1QA_14_0"></a><a id="Tc_Al0QuUfNjEWH_F8UcGwuZg_15_0"></a><a id="Tc_sA9zISQNtEmCnnUKEzuFSQ_16_0"></a><a id="Tc__0FeknF8iEWsRLJXoXraqA_17_0"></a><a id="Tc_gjXjXQU360KF0bjrI7N96Q_19_0"></a><a id="Tc_1fzvAf-9bUCFbGYkpG-3wQ_20_0"></a><a id="Tc___OLTGWhxECjTK4KKZE7EA_21_0"></a><a id="Tc_nLLtACZj1kaGeA3L4PsYiA_22_0"></a><a id="Tc_BUSFaXp5OkKRxVT46ACRnQ_23_0"></a><a id="Tc_S59xuTzjGkeYxztlczlkvw_24_0"></a><a id="Tc_w0E8KYnlAU2ACGn6ZZfhMA_26_0"></a><a id="Tc__WyTvZHCFkarrSmxy2Aaog_27_0"></a><a id="Tc_6epSe9RGRkSap8t7LD8N6g_28_0"></a><a id="Tc_VfAXjXOmZEGEveWTvG7flg_29_0"></a><a id="Tc_qLqJBEzWj06c8IOAw9HRIw_31_0"></a><a id="Tc_1Vcp0tLwQUeJA_Smgj3w_w_33_0"></a><a id="Tc_l194_8QNM062jwexQ9KYQg_35_0"></a><a id="Tc_DMlp1cCYuUuhAR6vjwo7wA_35_2"></a><a id="Tc_ez6vVrpjx0KXklxp4UvehA_35_5"></a><a id="Tc_ySH-LN1nvkS-y6iRUnpxjg_37_0"></a><a id="Tc_D449luscok-BaVgmAmu3GA_38_0"></a><a id="Tc_DqYB3VXDFE-P35QV4HLsAQ_38_2"></a><a id="Tc_4JbEuKUXrkquZEnlhpP8Ag_38_5"></a><a id="Tc_tXXs0fEvU0CiT1oGnIDfoQ_39_0"></a><a id="Tc_6lNyv7CWxk2Z7lHrYitFJw_39_2"></a><a id="Tc_qVT6J7_XsECCRzM3dlkiNg_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.23181534%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_hswMM86hJk227C6E6Iw6fQ_4_3">22,287,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_b5wVIWUOake-8zcSc3YA9Q_4_6">29,019,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="0" id="Tc_f2sdkdBTnkWzNGIbvUe2sg_6_3">6,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="0" id="Tc_xP4yDYRr70GX-jMZcRaqww_6_6">34,266</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_DZyIJI43_UuSO7YFmZ8Xbw_7_3">1,068,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_IDJZzX5EYEqL8giUr3BY9Q_7_6">533,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_i_9GfW7RjUeJlnS3vZ3Mpg_8_3">7,392,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_a1kCMLHdL0Go-8fMVfySMQ_8_6">4,458,578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Changes in lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:NoncashLeaseExpenses" sign="-" scale="0" id="Tc_jzUUXANuxECz2n8oRUBvFQ_9_3">24,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="capr:NoncashLeaseExpenses" scale="0" id="Tc_0FSeTaDJ8kuIZYoY1VrNhw_9_6">161,740</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:IncreaseDecreaseFromGrantsReceivable" scale="0" id="Tc_2BfhQf8TAUKyd8a5iXl8NA_11_3">9,824,413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="capr:IncreaseDecreaseFromGrantsReceivable" scale="0" id="Tc_NwZu8y_KNkqyR8ZyRYGK1g_11_6">155,830</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_nuyxDdV0iEKcKjNMBYhbAw_12_3">75,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_nPosAIpn_k6ElDNea1BgEg_12_6">240,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDepositsOutstanding" scale="0" id="Tc_I3RcjdOgwUeiETgrI2FnVQ_13_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDepositsOutstanding" sign="-" scale="0" id="Tc_rntWpPZvRUCqj1qN90h3lw_13_6">7,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_j4oQUTFkiE6vav3IpiPzFQ_14_3">1,388,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_1omlNl-zrUe-ujiHS4ZKBQ_14_6">1,718,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued expenses, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_UEc8CDQLZkqVaYoqM7HOiw_15_3">61,755</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_2slTEW_G4kC5f20EalyuuQ_15_6">510,154</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="0" id="Tc_8foqdMOnH0uPGyYO1JNV1Q_16_3">3,178,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_xnBeZ2nWe0m3mwCNKXSqZA_16_6">27,448,531</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_DavmIG5uKkGKX1ahOMMzww_17_3">25,596,545</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="Tc_HpTeix-s70uYENvFS-FOlw_17_6">4,916,637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Purchase of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="Tc_bVLx4LTlE0OrA_f6U4r-vw_20_3">97,441,506</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="Tc_P9tGeAu5G0ypZUgctt0JLw_20_6">114,218,737</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from sales and maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="Tc_Y2klva5jSE6p8l7ig2e5_w_21_3">104,597,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="Tc_9aSCO9-XEEOzl5-oJm8sbQ_21_6">82,505,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_L8BLz2bGc0K4XdFhWIDVdA_22_3">1,311,660</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_coyauhbokECfUVTH1T12Pg_22_6">2,000,243</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments for leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:PaymentsToAcquireLeaseholdImprovements" scale="0" id="Tc_E4hP3ecX1Ee4z2FvHjfUqQ_23_3">735,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="capr:PaymentsToAcquireLeaseholdImprovements" scale="0" id="Tc_BdAAzfz8QEuEtCyy0e8EWw_23_6">1,359,488</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_EF5EGnK21kGDHs-HqzXw3w_24_3">5,108,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc__LWLQ79uh0m4wpP1A1Zp7g_24_6">35,072,507</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net proceeds from sale of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_59eL1jGYjkmf90W3IhhJlg_27_3">25,515,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_-rqDKA1G3kCCUxBWdfArYg_27_6">4,803,534</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_aosefrpERUaxrzdxqDqMJA_28_3">64,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_zS06UpLm00CJEmsukx4UNA_28_6">70,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_VLC5RQ0v9k2oB0ohVBXakw_29_3">25,579,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_SSOyQLxRNkS99-K_q_DZjA_29_6">4,873,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 30pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_sygenxwA1kKA6p8rRUJ_oQ_31_3">5,091,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_FwyUBFTZSE-c6clb0UTjfQ_31_6">25,282,032</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_nBH_BuEykUaGKDMUtq6ZoA_33_3">9,603,242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_DzY8eMwuA0GZKW_FYonEAA_33_6">34,885,274</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_z2rNtUEnDk6zLmCBnegk3Q_35_3">14,694,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_KMX-TW5RukmGlx9ej6pZPA_35_6">9,603,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Interest paid in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="0" id="Tc_gAOQSb3g906GoxtyfbzTWw_38_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="0" id="Tc_2pJN88_Dck21dJkzF6uEgw_38_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Income taxes paid in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_9Kr9PklzFk6znXA73qHz8w_39_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_KKVXG5zvfESO5tCQkQIunA_39_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See accompanying notes to the audited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTESTOFINANCIALSTATEMENTS"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ZBkP9g6ghUasSwotoaHqbg" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="Tb_RBGMpCB2vk2InAmefcx8YA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor Therapeutics,&#160;Inc., a Delaware corporation (referred to herein as &#8220;Capricor Therapeutics&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#8220;DMD&#8221;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (&#8220;Capricor&#8221;), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#225;n, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics,&#160;Inc., a Delaware corporation (&#8220;Nile&#8221;), on November&#160;20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics,&#160;Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple therapeutic drug candidates in various stages of development.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_-ZthW11RPUe6POQc59Oblg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basis of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="Tb_eDfi3uF-3EuIKy82QUdBzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:LiquidityPolicyTextBlock" id="Tb_BDPVq4aCckesjkdEp3PWKw" continuedAt="Tb_BDPVq4aCckesjkdEp3PWKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities as of December 31, 2023 were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_IY_x5zcEB0-8h8n8Dn4Klw">39.5</ix:nonFraction> million, compared to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_E3yDNKib4UuDPNYagEtAlA">41.4</ix:nonFraction> million as of December&#160;31, 2022. In the first quarter of 2023, the Company received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_3_31_2023_1YjBI06wLU-zMo3y3uhc5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="Narr_paHgITablkOLx5rZDQwi7g">12.0</ix:nonFraction> million from Nippon Shinyaku Co., Ltd., a Japanese corporation, (&#8220;Nippon Shinyaku&#8221;), in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). In October 2023, the Company completed a registered direct offering for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GkllSxdfAUuGq58nSnX8Jw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_CxLjQYUiA0mGUMsPa0Ds-w">23.0</ix:nonFraction> million (see Note 2 &#8211; &#8220;Stockholder&#8217;s Equity&#8221;). We received our first milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_QldM9U_12EOep7ZCnuvYiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="Narr_DCC7whZZpUiIoyRjlUZ11w">10.0</ix:nonFraction> million in the first quarter of 2024, which was triggered upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with our research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase 3 clinical trial of CAP-1002 in DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with potential commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our research programs, including the expansion of our exosomes program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont1" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont2"><ix:continuation id="Tb_BDPVq4aCckesjkdEp3PWKw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. The Company has incurred significant operating losses and negative cash flows from operations. Based on the Company&#8217;s available cash resources and based upon the Company&#8217;s projections for its operations, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Therefore, there is a substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s plan to address its financial position may include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and from government grants. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company&#8217;s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial and research and development programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" id="Tb_TBmhOzVykkqQ1RVVn0UqsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Uncertainty Related to the Coronavirus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In light of past uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company submitted for the Employee Retention Credit (&#8220;ERC&#8221;), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2020_HyvjpaP4ukelUP5RqqGhUg" decimals="0" format="ixt:numdotdecimal" name="capr:EmployeeRetentionCreditCaresActReceivable" scale="0" id="Narr_aYZbf6Pl_026qfe_wmiyIg"><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew" decimals="0" format="ixt:numdotdecimal" name="capr:EmployeeRetentionCreditCaresActReceivable" scale="0" id="Narr_4pgbxjzJJku3xnZjNM1uhw">738,778</ix:nonFraction></ix:nonFraction> in ERC for applicable 2020 and 2021 periods, receiving $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2021_To_12_31_2021_t8_RP8tgw0mTuYIP9tOUPg" decimals="0" format="ixt:numdotdecimal" name="capr:EmployeeRetentionCreditCaresActRevenue" scale="0" id="Narr_8LPsvY52KU6yKENarZh7fw">191,199</ix:nonFraction> in 2021 and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:EmployeeRetentionCreditCaresActRevenue" scale="0" id="Narr_6aqVQD_gSUuAIW9FudQcqg">191,463</ix:nonFraction> in 2023. As of December 31, 2023, the Company has recorded a receivable for $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="capr:EmployeeRetentionCreditCaresActReceivable" scale="0" id="Narr_3-JIkFJOQE-SXk2I62i4Xw">366,551</ix:nonFraction> for the remainder of funds expected to be received. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:UseOfEstimates" id="Tb_t06zVnV6CEC65J2oYfEQqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_tTbs6-ckxUi-6fpOGwwwhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_9LqHkIGJv0yJP_7IMWqjlw" continuedAt="Tb_9LqHkIGJv0yJP_7IMWqjlw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Marketable Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company&#8217;s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_0tP15ogplUejTNO7E4qG6g_1_2"></a><a id="Tc_ZYpGsdzz30SXagL-v6wS5Q_1_5"></a><a id="Tc_3zeLjFX9rUuoeNc48UEl7A_2_2"></a><a id="Tc_CGIQ9yglhEKp1kE1r1boeA_2_5"></a><a id="Tc_zVuo7qhnT0y_5zT-lEhO8w_3_0"></a><a id="Tc_C9uO5iI390e4IT_3D0brmQ_3_2"></a><a id="Tc_wYZsUz7kwEqV9-6gACRaTA_3_5"></a><a id="Tc_1a_HmxKY1Uqdko4SFWliTg_4_0"></a><a id="Tc_oX13Lpq9J0G45AXEbqifeA_5_0"></a><a id="Tc_gBXR8Bu7F0-N3RkI-p7lPg_7_0"></a><a id="Tc_aK-XGb48O02EVmox7f6Rxg_8_0"></a><a id="Tc_BkN9j9wa6UiL6xEmkZ58UQ_8_2"></a><a id="Tc_ideHcJxbqES-qYKKC9aHyg_8_5"></a><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont2" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont3"><ix:continuation id="Tb_9LqHkIGJv0yJP_7IMWqjlw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented as accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. As of December 31, 2023, marketable securities consist primarily of short-term United States treasuries. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_fcTBfA4p5k2Xo2olMuR80w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from <span style="-sec-ix-hidden:Hidden_4p8iOFeSNEmdNJAChajhxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_bqLzk-PKtkyrIwepnUrEfw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_WZyV80Ha8UGXLp5lhMKxqA">seven years</ix:nonNumeric>. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_kxSGunqXLEOQm8c-i3XKbg">1,068,882</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_3cHtnfmZ40mHky6EHGFJzw">533,131</ix:nonFraction> for the&#160;years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_bYcNBBlbEEurmWaALEdRsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5ZNv_wjOyUmsCoYiegAY_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Jlok-6FiYUyLYhBqeaGEXQ_3_3">187,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_9P99ospyIU6YpKdhtGl_Tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_egnzxZB4aEOfUxtmcF_JUg_3_6">139,336</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pKISfRGyWUC5dXwS0_Kalw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_rFg4bvwVn0Cg5xn7mx1X2A_4_3">5,449,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_H_E_Lr6_YUepovFiKb6S1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_b9_zIxA51kGHAc4TC9f1Cg_4_6">4,237,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_xpiwJvCFFEONVOfrrGbCGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Wl-fk2UOTEGOVNQZrLlGFQ_5_3">2,129,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RmDL9OhBUESyNzJ0kgQcWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_eUb8dFnkzkGeamwWfYng9w_5_6">1,393,230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_fB34ju0ySUSI3ipilrThmg_6_3">7,766,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_fCw-VqPu50qcbqnmETjXMQ_6_6">5,769,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_We5j-yjWkEej8uOR20yeyA_7_3">2,206,055</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_PfB4gnKQUUi1hYvJ_E8n4A_7_6">1,181,625</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_zzNdCO0EM0iGPxUkMjyv2g_8_3">5,560,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_oqe2KPqXWkSoDoiuWrGcrg_8_6">4,588,030</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_OMO4CbYsqU25DJn3vF_lHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_L9wkcYdhmkG_GRaGYIwmNg"><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_g-Z5x58SOUKFOnR-vc7cVw">No</ix:nonFraction></ix:nonFraction> impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;</p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_mX1sCN377kSk3eMVB3D60Q" continuedAt="Tb_mX1sCN377kSk3eMVB3D60Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">ASC Topic 842, <i style="font-style:italic;">Leases</i>&#160;(&#8220;ASC 842&#8221;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (&#8220;ROU asset&#8221;). ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases office and laboratory space, all of which are operating leases (see Note 6 - &#8220;Commitments and Contingencies&#8221;). Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont3" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont4"><ix:continuation id="Tb_mX1sCN377kSk3eMVB3D60Q_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_zTgxSmAA6UCbH8iKNKG_SA" continuedAt="Tb_zTgxSmAA6UCbH8iKNKG_SA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company adopted ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i> (&#8220;ASU 606&#8221;), which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#8217;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments were achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont4" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont5"><ix:continuation id="Tb_zTgxSmAA6UCbH8iKNKG_SA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the U.S. Commercialization and Distribution Agreement (the &#8220;US Distribution Agreement&#8221;) with Nippon Shinyaku, the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the estimated duration of the HOPE-3 clinical trial, Cohort A arm. Therefore, upon receipt of the upfront payment and achievement of milestones, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the &#8220;CIRM Award&#8221;) from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - &#8220;Government Grant Awards&#8221;). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt-sec:numwordsen" name="capr:GrantIncome" scale="0" id="Narr_LGLxXNBos0qtF_Pp1voLaw"><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt-sec:numwordsen" name="capr:GrantIncome" scale="0" id="Narr_mpH61npuKUimdDaXQP16DQ">No</ix:nonFraction></ix:nonFraction> grant income was recognized during the years ended December 31, 2023 and 2022.  </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_iFyQP7JtOUWR3l-I0VXrgg" continuedAt="Tb_iFyQP7JtOUWR3l-I0VXrgg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are recognized for the amount of taxes payable or refundable for the current&#160;year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company&#8217;s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion or the entire deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_kDjWtwP9-EO-I7Xo4Yt-xA">106.9</ix:nonFraction> million, available to reduce future taxable income, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_lebBwGVUJ0GYE1xtWwny7w">50.7</ix:nonFraction> million will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA" name="capr:OperatingLossCarryForwardsExpirationYear" id="Narr_Y0lRSyQzWkWM8O7jHY09Ew">2027</ix:nonNumeric>. <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="Narr_I4xQ-SJxmUSDuqG3sOighQ">The post December 31, 2017 net operating losses generated of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g" decimals="-5" format="ixt:numdotdecimal" name="capr:OperatingLossCarryForwardsIndefinitely" scale="6" id="Narr_ppo0BYUaY0-PEJkjYt0cUg">56.2</ix:nonFraction> million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization.</ix:nonNumeric> As of December&#160;31, 2023, the Company had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_KTrLvd7n_kW3fJkJoMqk2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_0YJdvrR6n0GRbWKmjdB5Rw">147.3</ix:nonFraction> million, available to reduce future taxable income, which will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ZlaNNG4xJUeX586mgmAzAw" name="capr:OperatingLossCarryForwardsExpirationYear" id="Narr_vAn-cgGwnU6JuCqMuoDIAg">2028</ix:nonNumeric>. Utilization of these net operating losses could be limited under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state laws based on ownership changes and the value of the Company&#8217;s stock. Additionally, currently, the Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_hIIPvdfnnkWCVs4dZrEouA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_12PkZiVn90G13JTR8FK4Sg">6.2</ix:nonFraction> million of federal research and development credits and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_666ZzRUp-EqzLeKGKVR3Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_T-UFM-PvlEWIWyxvfPK4aA">3.7</ix:nonFraction> million of federal orphan drug credits, available to offset future taxable income. These federal research and development and orphan drug credits begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2RTneoE4LUiql_wj_gb_WA" name="capr:TaxCreditCarryForwardsExpirationYear" id="Narr__BpVAiR9KUqsrb5MyF9xog">2027</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_W4VghYTqKU60Dmy4MPpb1A" name="capr:OperatingLossCarryForwardsExpirationYear" id="Narr_pfSyy0cxvkibEXxKsMrVng">2035</ix:nonNumeric>, respectively. Additionally, the Company currently has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_CaliforniaFranchiseTaxBoardMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_t5-jJPzGkk-S3fnBbEiOcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_8xXqjon9mkenYaW5ykJZgQ">2.2</ix:nonFraction> million of California research and development credits available to offset future taxable income which will carryforward indefinitely. Utilization of these credits could be limited under Section 383 of the Code and similar state laws based on ownership changes and the value of the Company&#8217;s stock. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont5" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont6"><ix:continuation id="Tb_iFyQP7JtOUWR3l-I0VXrgg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;382 of the Code, the Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as federal tax credits, in any taxable&#160;year may be limited if the Company has experienced an &#8220;ownership change.&#8221; Generally, a Section&#160;382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of&#160;a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. Similar rules&#160;may apply under state tax laws. We have experienced an ownership change that we believe under Section&#160;382 of the Code will result in limitation in our ability to utilize net operating losses and credits. In addition, the Company may experience future ownership changes as a result of future offerings or other changes in ownership of its stock. As a result, the amount of the NOLs and tax credit carryforward presented in the financial statement could be limited and may expire unutilized. The Company&#8217;s net operating loss carryforwards are subject to Internal Revenue Service (&#8220;IRS&#8221;) examination until they are fully utilized and such tax&#160;years are closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company incurred <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_NtEvH80GjEyBwJkCUVbAmg"><ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_8-u2cWkrJE2AYCYyeBvZgg">no</ix:nonFraction></ix:nonFraction> interest or penalties for the&#160;years ended December 31, 2023 and 2022. The Company files income tax returns with the IRS and the California Franchise Tax Board.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_FduhOyAWG0muyMs4Y-7LnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, <i style="font-style:italic;">Research and Development</i>. Research and development costs amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_O3Smk0j0PUahpKmPucVKnw">36.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_ZTP1mGYsxkueEiy90dmQ4A">21.8</ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_FTKvPoIQJU6leFkQ82bK6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Comprehensive Income (Loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) generally represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders. The Company&#8217;s comprehensive loss was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="6" id="Narr_oTIEZlJijUmlWHWWu38_ow">22.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="6" id="Narr_08YAfLskREidQX6g_wviow">28.9</ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, respectively. The Company&#8217;s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the&#160;years ended December 31, 2023 and 2022, the Company&#8217;s other comprehensive income was $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Narr_LcCNkfGMXEGHWajF_GH84g">130,569</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="Narr_0kSMwI-Hj0WoHK7-wcWR8Q">105,244</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:ClinicalTrialExpensePolicyPolicyTextBlock" id="Tb_oeDK_ROQ1k2qzGhA7270Wg" continuedAt="Tb_oeDK_ROQ1k2qzGhA7270Wg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Trial Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (&#8220;CROs&#8221;), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4a33e1ce_2346_40eb_ad8c_2b63181bffaa"></a><a id="Tc_94UcLGXhCEiz9bEpolnjIQ_1_2"></a><a id="Tc_enIBcbPJaEeOs2SG69L7Vw_2_2"></a><a id="Tc_ZUMojj2NekGQUL66rIypng_2_5"></a><a id="Tc_w4PK_tU1s0qUy0zPiHFe5A_2_8"></a><a id="Tc_6NJ0uN9w-EqRDV1gGs4h-A_2_11"></a><a id="Tc_vMgw80xVMkWajxB60ls5zw_3_0"></a><a id="Tc_MCN1s2R-nEWqeF5QFJs1Ag_3_2"></a><a id="Tc_ZvuZDD3e50yo-tWjzTa3JA_3_5"></a><a id="Tc_fitL2pDkP0KbejmnKwguRQ_3_6"></a><a id="Tc_zIfXQHJExEWSWZ0i13K1LA_3_8"></a><a id="Tc_R4ZrgoDFvUyK4KzqYr2IfQ_3_9"></a><a id="Tc_2A5_Cgfonked5psKf6IgWQ_3_11"></a><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont6" continuedAt="Tb_ZBkP9g6ghUasSwotoaHqbg_cont7"><ix:continuation id="Tb_oeDK_ROQ1k2qzGhA7270Wg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_HyhPf0ehL06RIfufaGdTXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No.&#160;110,&#160;Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company&#8217;s estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_lOI7jQ6GNEqGoOxqdpc6Vg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basic and Diluted Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reports earnings per share in accordance with FASB ASC 260-10, <i style="font-style:italic;">Earnings per Share. </i>Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, warrants and options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_tFPWFycdZECXb76Hmik08Q">13,268,807</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_b4udqpao7UWs4Wn0sMDiOA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_YPga0z2vj02zqEC8IJPaSA">5,882,621</ix:nonFraction> shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive shares of common stock, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the years ended December 31, 2023 and 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_6qlNxKxlsUK82Yls2MCGsQ" continuedAt="Tb_6qlNxKxlsUK82Yls2MCGsQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:14.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level Input:</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:83.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Input Definition:</p></td></tr><tr><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level I</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level II</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level III</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unobservable inputs that reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the fair value measurements by level at December 31, 2023 and 2022 for assets and liabilities measured at fair value on a recurring basis:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_Sva46UZiakmmH3PIUyidUA" continuedAt="Tb_Sva46UZiakmmH3PIUyidUA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lcBRc0KVsUmNSWtqubCDrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_VnwzL1RHEU-bCZbkvoeXiQ_3_3">24,792,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_R8DkG6IMVECOSpiB9MgiwA_3_12">24,792,846</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c05590ef_b297_46cb_af98_95a17c7fc244"></a><a id="Tc_9fOdRoA6t060SY7nTgl-Og_1_2"></a><a id="Tc_xw28Yd_wKUqLmXLH8fMrPw_2_2"></a><a id="Tc_Cx-TobtWxkyqK8Ap9gjHuw_2_5"></a><a id="Tc_SK3PzLw_xU-A_kdd9YSykw_2_8"></a><a id="Tc_TBC_i6i74U6lsqusGD7oJw_2_11"></a><a id="Tc_9IxjNaxB5UCJ0WBJnXP6SA_3_0"></a><a id="Tc_JGxbl1azWkCCi4w1JmHIqg_3_2"></a><a id="Tc_9gQYOK9UyE6R_t19RxSjww_3_5"></a><a id="Tc_e2q-jn1phkapV8muaK5uZg_3_6"></a><a id="Tc_hMMb5XzVz0ybEPIKY6j-eQ_3_8"></a><a id="Tc_DAFtUl553UKop9raNW2uMA_3_9"></a><a id="Tc_bkkVmXZsV0WYpKQIAldglA_3_11"></a><ix:continuation id="Tb_ZBkP9g6ghUasSwotoaHqbg_cont7"><ix:continuation id="Tb_6qlNxKxlsUK82Yls2MCGsQ_cont1"><ix:continuation id="Tb_Sva46UZiakmmH3PIUyidUA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4jUtqUF9xUW3YXYFwchNdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_aB-EgJglx0CxxosdPm7g5Q_3_3">31,818,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_b5u34GlNrU6qAr1zibPqjg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_gdRQbF6XpUaBsxPU_Hh0VQ_3_12">31,818,020</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company&#8217;s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_IIrOsD0LMUOucEdAwUzsPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This standard was issued in response to the SEC&#8217;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_laMGFaendkabXKiVzBA-IA" continuedAt="Tb_laMGFaendkabXKiVzBA-IA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATM Program </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company established an &#8220;at-the-market&#8221; program (the &#8220;ATM Program&#8221;) on June 21, 2021, with an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_6_22_2021_To_6_22_2021_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_uDaog7QSQEmqbstoEX4SJQ" decimals="-5" format="ixt:numdotdecimal" name="capr:CommonStockSharesAuthorizedValue" scale="6" id="Narr_aZgtXZLDM0yI40KHyr0yeg">75.0</ix:nonFraction> million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="3" format="ixt:numdotdecimal" name="capr:CommissionRateOnSalePricePerShare" scale="-2" id="Narr_1bFvh26vh0y6An8azW2P5Q">3.0</ix:nonFraction>% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">From June 21, 2021 through December 31, 2023, the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_6_21_2021_To_3_15_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_UJ-PEwE3u0eQNWZSzusEPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_XtlouaXjakukmzDFi_yW8A"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_6_21_2021_To_12_31_2023_fcukxm__uEiN61L1wZ0xDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_riao4cgMX0eas__OLw410g">2,976,154</ix:nonFraction></ix:nonFraction> shares of common stock under the ATM Program at an average price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_qp1o0pSjSEynST8Sz742XQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_ePOpRHhhcEiw-rTEMLzqwQ">5.59</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_uB1tlaoQkku1zzf8hUoNNg">16.6</ix:nonFraction> million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_T54zdKLbn0-uoUvyB-UkBw">0.6</ix:nonFraction> million. As of the date of this filing, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_3_7_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_ZkaD9BdX-Ue4UjbW-P8o9Q" decimals="-5" format="ixt:numdotdecimal" name="capr:CommonStockOfferingRemainingAmountIssuable" scale="6" id="Narr_oYors-pi90yABgZiNpxVHw">57.2</ix:nonFraction> million of common stock may still be sold pursuant to the ATM Program. Additionally, subsequent to December 31, 2023, the Company sold shares under the ATM Program (see Note 9 &#8211; &#8220;Subsequent Events&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">October 2023 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On October 3, 2023, the Company entered into Securities Purchase Agreements with its commercial partner, Nippon Shinyaku and funds associated with Highbridge Capital Management, LLC (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), an aggregate of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_S8BTiEiFf0qv5JQC98Ql2Q">4,935,621</ix:nonFraction></span><span style="background:#ffffff;">&#160;shares of its common stock, par value </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_K9I1wbRHnEC80fPLn4IbAw">0.001</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share, at a price per share of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_eXzufi48v0OMuYwhFWN8Wg">4.66</ix:nonFraction></span><span style="background:#ffffff;">&#160;for an aggregate purchase price of approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_iQOm4WOdBE6cg-mSI8pJXQ">23.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million. Each share of common stock offered was sold with a warrant to purchase&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_lDcHrXTB6EqSZyPhWeeT5w">one</ix:nonFraction></span><span style="background:#ffffff;">&#160;share of common stock at an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vfUUQMdpbUS-mZIo5Z2QIQ">5.70</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share. Each warrant will be exercisable beginning&#160;</span><ix:nonNumeric contextRef="As_Of_10_3_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_-rsa000sD0a8m5UVTffp1Q" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_LaMZYKtQ6EWXvO84m1C3-w"><span style="background:#ffffff;">six months</span></ix:nonNumeric><span style="background:#ffffff;">&#160;after issuance and will expire&#160;</span><ix:nonNumeric contextRef="As_Of_10_3_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_bQCWtMxE70i-06Cl52c_Sg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_kxr39E8WDE-zY7vVEmNvJQ"><span style="background:#ffffff;">seven years</span></ix:nonNumeric><span style="background:#ffffff;">&#160;from the date of issuance. As part of the Registered Direct Offering, the Company agreed not to issue or sell shares (subject to customary exceptions for employee stock option issuances and other customary exceptions) for a period of&#160;</span><ix:nonNumeric contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g" format="ixt-sec:durwordsen" name="capr:LockUpPeriodNotToIssueOrSellShares" id="Narr_lNWXmcf8rEy6UgYtEdQQjQ"><span style="background:#ffffff;">30 days</span></ix:nonNumeric><span style="background:#ffffff;">&#160;following the date of the prospectus supplement that</span> <span style="background:#ffffff;">was used in the Registered Direct Offering. &#160;That prospectus was dated September 29, 2023, and the Company &#8220;lock-up&#8221; expired on October 29, 2023. The Company&#8217;s directors and executive officers also entered into &#8220;lock-up&#8221; agreements with the </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_laMGFaendkabXKiVzBA-IA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">placement agent in the Registered Direct Offering, which agreements expired on the </span><ix:nonNumeric contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g" format="ixt-sec:durday" name="capr:AgreementExpiryTerm" id="Narr_I4xihScmrUy8RAnOWCcN3g"><span style="background:#ffffff;">60</span></ix:nonNumeric><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">th</sup><span style="background:#ffffff;"> day following the date of the Securities Purchase Agreements, or December 2, 2023.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outstanding Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At December&#160;31, 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_OzDbAMCr5kSajzKzyZLOfA">31,148,320</ix:nonFraction> shares of common stock issued and <span style="-sec-ix-hidden:Hidden_aR2fiAmS1k-ZXTjTa9frtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_drxiTDBvwUitTxk3rMCPxQ_1_4"></a><a id="Tc_I6xVTYlR_UiuBSXi-LxqVw_2_2"></a><a id="Tc_cxpyTxeF3kyH8XtI2nFKPA_2_4"></a><a id="Tc_hZMB1D9pN0ipgFJgTISEBQ_3_0"></a><a id="Tc_2ICq4MZC-0CWmF5mRPSKJg_3_4"></a><a id="Tc_0sHW45X2Rk-MbjGW21lrug_4_0"></a><a id="Tc_OOfn-sdSV0yFdosEulcZ4g_5_0"></a><a id="Tc_OJtVOxVB-kmuusExyWF68g_6_0"></a><a id="Tc_OhT4tzHKZkOTOyExedzaaQ_6_4"></a><a id="Tc_MzFoRN5aFUGzMDkANGbohA_7_0"></a><a id="Tc_lFu-gdnEYUSC-EGRuh9wnQ_8_0"></a><a id="Tc_Fsdil5W_wkGfIDPUIquHEQ_9_0"></a><a id="Tc_XQ124FLhjEej4ZWMqT6o_A_9_4"></a><a id="Tc_8QFlqiBlKEiUUjzi10BGwQ_1_4"></a><a id="Tc_9V_7bPUVbEuRA1FVurWe5w_2_4"></a><a id="Tc_ruCJy4J7x0-qZzmTMrQFFA_2_6"></a><a id="Tc_JqzsvXtX8k6gbfXoY2D9rQ_2_8"></a><a id="Tc_3G_LFRcqD0i3A1kDLJgPng_2_11"></a><a id="Tc_FyrlR6OkLUyh-S1tfLzcSg_3_0"></a><a id="Tc_uDtaB3BupkuGt184K4QdIA_3_2"></a><a id="Tc_Mkm8N4dIVEWC-UIdQHJ0YA_3_4"></a><a id="Tc_D0L_v7cfCUKpya6pLqQUCA_3_6"></a><a id="Tc_HnF9MdJdCkeUbRXTnDx6mA_3_8"></a><a id="Tc_UvKrotZn8kCqnOgsb97bkQ_3_11"></a><a id="Tc_qLt_f2anP0WPuO5PK0-4WA_5_0"></a><a id="Tc_Fc8PD_UkgEWIILD-s4h1oQ_5_8"></a><a id="Tc_GSwvTsmZ_kWOPpiTWNpy2g_6_0"></a><a id="Tc_y8QGFTK3-k-NMlIGn33jGg_6_8"></a><a id="Tc_V57faRyssUSMtjYYlPiTxQ_7_0"></a><a id="Tc_qZUqqrE9cEO8mCL0r8hGEQ_7_6"></a><a id="Tc_ChbeNWHMMkifY380f5mKfA_7_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_rpPQJ0lsWkKDKn1PFo6RRg" continuedAt="Tb_rpPQJ0lsWkKDKn1PFo6RRg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCK AWARDS, WARRANTS AND OPTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all warrant activity for the&#160;years ended December 31, 2023 and 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA" name="capr:ScheduleOfWarrantActivityTableTextBlock" id="Tb_nDYHbcz-jkGunSgMUFbB_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_snqpG5v5IUq24CMq59ZRDw_3_2">105,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew" decimals="2" format="ixt:numdotdecimal" name="capr:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="Tc_O2QKfG7IDEO7kEIKsMVJVg_3_5">1.37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:zerodash" name="capr:ClassOfWarrantOrRightGranted" scale="0" id="Tc_eVU3fUvD_UGCFctrJpkLHw_4_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:zerodash" name="capr:WeightedAverageExercisePriceGranted" scale="0" id="Tc_UElfHaHl6EePjan3i0fDog_4_5">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:zerodash" name="capr:ClassOfWarrantOrRightExercised" scale="0" id="Tc_BwGMXfzwrUei5Wbn5Ecrag_5_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:zerodash" name="capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" scale="0" id="Tc_8R9AxcLQO0-5cMNiy0xwIw_5_5">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_2gcp-P2agEO0fE83PQvVOA_6_2">105,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="2" format="ixt:numdotdecimal" name="capr:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="Tc_dBV5bQB4Mk-zuiuqhMFhQw_6_5">1.37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:ClassOfWarrantOrRightGranted" scale="0" id="Tc_Qj4a9OgzVEeD7XSWUb1N3w_7_2">4,935,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="capr:WeightedAverageExercisePriceGranted" scale="0" id="Tc_BYRySpwklEO_fZhixRfzNg_7_5">5.70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:zerodash" name="capr:ClassOfWarrantOrRightExercised" scale="0" id="Tc_0MCpZuOY80mQDUx9GFADdQ_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_inwFgsXzk0-bGk5MAURUnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_NNeaILGtYEejk4PpTCm2_Q_9_2">5,041,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="2" format="ixt:numdotdecimal" name="capr:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="Tc_x7q9DoQh-USEthAejdyKYA_9_5">5.61</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all outstanding warrants to purchase shares of the Company&#8217;s common stock:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_bV_ekvDHlUa_qnJng1067w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q" format="ixt:datemonthdayyear" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Tc_tcp_Pe0fIkmxKpFxo_p6ng_5_2">12/19/2019</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_p7Z0RCI_KEemqhTQ3qFsLg_5_4">40,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_xrETY022i06_Ku6R6SeboQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_m9kmr2cynUivC4DgI5Wcvg_5_6">40,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_hyEDWuwm70mbv2-sSzrXRw_5_9">1.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q" format="ixt:datemonthdayyear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="Tc_DLcGfGo3y0K_5gXX7-HOHQ_5_11">12/19/2024</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q" format="ixt:datemonthdayyear" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Tc_KASz8Wm7B0C6GvV0NR0Q8w_6_2">3/27/2020</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_oNWtjqNAWkCDnKOxrXqJaQ_6_4">65,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_d-yKIQOYmUyiV6A4kVWmVQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_KUaOtC4MEECLkFJzCMWl1A_6_6">65,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_fQI7GCntZUi0IuU4kULH1A_6_9">1.5313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q" format="ixt:datemonthdayyear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="Tc_dyfM-C-5iESD7AwqXuWXrg_6_11">3/27/2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A" format="ixt:datemonthdayyear" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Tc_TgTtNE3S4kGOx3cvKNGmoA_7_2">10/3/2023</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_yJnxIlgEP0ifLmT_5uQb0w_7_4">4,935,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_MiX133jzOUukevYqeQVc9Q_7_9">5.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A" format="ixt:datemonthdayyear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="Tc_8_URxPzHbUWP6j4qCBtU3g_7_11">10/3/2030</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_aW6aFISXRkqDMiGzcJa2cw_9_4">5,041,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_UvXZJlHgMUmzvXabGgxwZA_9_6">105,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has approved <ix:nonFraction unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="INF" format="ixt-sec:numwordsen" name="capr:ShareBasedCompensationNumberOfPlans" scale="0" id="Narr_kVV1sUZu8UWYZZbkrDlv6Q">five</ix:nonFraction> stock option plans: (i)&#160;the 2006 Stock Option Plan, (ii)&#160;the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the &#8220;2012 Plan&#8221;), (iii)&#160;the 2012 Non-Employee Director Stock Option Plan (the &#8220;2012 Non-Employee Director Plan&#8221;), (iv) the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), and (v) the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan and no longer issues options under the 2006 Stock Option Plan, the 2012 Plan, or the 2012 Non-Employee Director Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company&#8217;s stockholders approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), which authorized <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_6_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_eiRHIQU2P0-iE89u76MZug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_qcm1ZJKeWkGOyqXwIFJsgg">2,500,000</ix:nonFraction> shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.&#160; Pursuant to the &#8220;evergreen&#8221; provision, on January 1, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_DBWOt4gfCES-rIx3f5YORA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_PjddboNwQECGJm4pchdAlQ">823,084</ix:nonFraction> shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_6_11_2021_To_6_11_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member__c5YnH6Py0aKqf8BOj9xog" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_gCygGB81jkS3IJW2tZKUDw">no</ix:nonFraction> new shares were added to the share reserve under the 2020 Plan pursuant to its &#8220;evergreen&#8221; provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company&#8217;s stockholders approved the 2021 Plan, which authorized <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_6_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_60dARrLHYEG7PVahuY09wQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_wnpWcXobZ0y215Eion_HLg">3,500,000</ix:nonFraction> shares of common stock reserved under the 2021 Plan for the issuance of stock awards.&#160; The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_A6Z0lu9se0qlyMMZv3i5ag_1_2"></a><a id="Tc_7DR2LgfUnU6PCE-GFZvKAw_2_2"></a><a id="Tc_Ca6DyhTkQ06-BQ7Tf_vIrA_2_4"></a><a id="Tc_wIlKh5JV-EyPIt9vsEzSNQ_3_0"></a><a id="Tc_QadgCpm9CE-XMXIdgHQLLw_3_2"></a><a id="Tc_kB4Fgu6_cEWMOUYItnRLSg_3_3"></a><a id="Tc_vOyJIN-Dp02tmGo5NTT16Q_3_4"></a><a id="Tc_5N2xlpAJQ0mTBCfq_6aXWA_3_5"></a><a id="Tc_j7XruHsikk-Y6CelyKGaCg_4_0"></a><a id="Tc_NCEzjhUVzkqy46LrzvIuHw_4_2"></a><a id="Tc_OF9SU2GVZk2fgwx2Nl3ePQ_4_4"></a><a id="Tc_QnjgbP2NJEKwGo5BQ7Q1zA_5_0"></a><a id="Tc_mLNxcRPNr0uAzU2_Qi4F_g_5_3"></a><a id="Tc_VO7YrhNVKkWiSjG4QC6gPw_5_5"></a><a id="Tc_Hxg6qkVqqEyVXR1uObBGQg_6_0"></a><a id="Tc_2RXd3sZkE0-X8lPboHJPPw_6_2"></a><a id="Tc_pAEzuvIlsUC3l_pjaXBT1Q_6_3"></a><a id="Tc_G-nd5GgFYkaPvrtfxZZ4Eg_6_4"></a><a id="Tc_16OwIgZSOEunpCZqcdDrHg_6_5"></a><a id="Tc_Git1y2EuE0OibAl22DqSVA_1_2"></a><a id="Tc_3bSWW7AK-UWNeMpD0PuPwg_2_2"></a><a id="Tc_qPk9PnMaREKPnPk_8b3FBA_2_5"></a><a id="Tc_7rdQVaAje0-_d5AKSjY1ng_4_0"></a><a id="Tc_djZ8KinCtUaE39z8SZBPVA_4_2"></a><a id="Tc_HfzPV5sZN0eQDpCzu9AosA_4_5"></a><a id="Tc_vu_GI02A3kquwEaInQFxDg_5_0"></a><a id="Tc_TYA_uknlsEqNwAw_UHiFCA_6_0"></a><a id="Tc_ra_chegs402wMbzCJFFwyw_6_2"></a><a id="Tc_I8pWGIjCgEOM6Jxj1Qs4nA_6_5"></a><ix:continuation id="Tb_rpPQJ0lsWkKDKn1PFo6RRg_cont1" continuedAt="Tb_rpPQJ0lsWkKDKn1PFo6RRg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2024 and 2023, <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_FGAMc8suqEKYI1VbJay2BQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_gtGKVbi960iC4THhsg1SBA">1,557,416</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_cQDaPBIGKkWSfcAzIJL2Zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_5kbPTkdn4UGJZLChNqdaBQ">1,262,070</ix:nonFraction> shares were added under the 2021 Plan, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="capr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" scale="0" id="Narr_me9wV-1twk2xxLhb5w5cvQ">1,232,318</ix:nonFraction> options remain available for issuance under the respective stock option plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock option plans are administered by the Board, in conjunction with the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar&#160;year (under all plans of the Company and any parent or subsidiary) exceeds $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="capr:MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" scale="0" id="Narr_VaGe9wh9iEq9cyymPHL1mw">100,000</ix:nonFraction>, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price not less than equal to the closing price of the Company&#8217;s common stock on the date of grant, and generally vest over a period of <span style="-sec-ix-hidden:Hidden_ncn7a3kMgkO12NbLrZBVLA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_qwWcvHvp5UyQHCdO_ERssg">four years</ix:nonNumeric>. The term of stock options granted under each of the plans cannot exceed <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_TX6YDKKvkkmYDJJJS7NP7Q">ten years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated weighted average fair value of the options granted during 2023 and 2022 were approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_a09mvnVAXUGD6tOGkdwu5g">3.85</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_XbCCzxErAESs5cODW33eyA">3.04</ix:nonFraction> per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The company used the following assumptions to estimate the fair value of stock options issued during the year ended December 31, 2023 and 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_i50liQD6NEmqnRTFmJQ98Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_mu67czyg6EqB5CHExUn_5g">111</ix:nonFraction></span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_q1-yOdHUekGw7sIl54CoSQ">121</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_T-Ith9QZbESGKe5E8qOLiw">123</ix:nonFraction></span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_msLcE_6RXEeOkG4iu1dXAg">124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_BlHLyak64Eyji3NPcPBsrQ">5</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_4DifOeWn1E-pl80I3ioMeQ">7 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_B-Y637VwK06PJ8NRgj159g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_wtbKwOg8MkW1RS7xUoIY-Q">6</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_3hggLcl2wEOMWMDA2p08QQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_T0jgNundbECtuY8Cq5C8Jw">7 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_CeieMi8ltECW--p8UMNgTA_5_2">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_xBb7vWjcEEi1TdmB5HSWYg_5_4">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Risk-free interest rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_SOXNGOSLiEG4sRNjSCWbng">3.5</ix:nonFraction></span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_0hBP9bxtB0G0o2VLpm7jlA">4.5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_DMfoy07zqUipSgaN_MSMNg">1.5</ix:nonFraction></span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_2hUnWXfsnUWII5C3Tl148A">3.9</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Employee and non-employee stock-based compensation expense was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" id="Tb_8342MTHlJkebpWiPk9LlLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tpwrEaOXFkyl_lEK9GeKjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Lf8bcIX7f0-MUyZ9jpKwyA_4_3">5,476,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rSWNvsGxUkyv-s30zMi0YA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_NQbv-BdjZU2sApO21t5YxQ_4_6">3,653,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P0GvjWMIp0OgB3_UoJ_50A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_ZNvY3DtiGUiJeyU8it17UQ_5_3">1,916,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ur1NlChm70CaqH2aI7vchQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Za2KKdy-ZESg37Ok0nT15g_5_6">805,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_aj1ooEJwnEufRmvo9nYK7w_6_3">7,392,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_dK9gh6rREUa1hxQYVWuH0w_6_6">4,458,578</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59dbcc00_78e2_4e3a_b2f6_9a1830b39a42"></a><a id="Tc_lTkHojTY-UqjPdqayJjYgw_1_0"></a><a id="Tc_kOU82pRw5E-8RhlMKzQeHw_2_4"></a><a id="Tc_bCSmuX3LP0OA_0g5ao-HOA_2_6"></a><a id="Tc_eCxXCu_WdE6yePUO7MXo7w_3_0"></a><a id="Tc_EnCfQFrySEqKj5Rcyd6rdg_3_2"></a><a id="Tc_ojG8iB93NUCe6N1kRct-5Q_3_4"></a><a id="Tc_5RB8v67KzUahPSCa3Zx0-Q_3_6"></a><a id="Tc_NKqhC5i-v0WQB-as7GBnYg_4_0"></a><a id="Tc_QBwVjkxBt0yN7iH1HVycDg_4_6"></a><a id="Tc_wS82nzWYn0-iuZGHUYCeaA_5_0"></a><a id="Tc_9CGF1lQzk0qCYQVgd9qamA_6_0"></a><a id="Tc_LVzer22EW064u4HYspB1Dw_7_0"></a><a id="Tc_Maxc9ghCsESkyu2_mb_UZw_8_6"></a><a id="_e72b72ef_fd43_4018_9be7_fd4809c2546c"></a><a id="Tc_GAPIkk7aP0Sd6e63sI4oHg_1_0"></a><a id="Tc_s4GY8W5ydEeSVGVz-zHBQg_2_4"></a><a id="Tc_-Ru-3CQZT0-Edhy6yjlhCQ_2_6"></a><a id="Tc_l30STgi800yiRdOcAZG7NQ_3_0"></a><a id="Tc_Zm9h4A4J-0mE5BANngZ1nw_3_2"></a><a id="Tc_JQgvVI4vFE6AP5C6JrA8gw_3_4"></a><a id="Tc_XM1ADUV0ukWpKIKka---9A_3_6"></a><a id="Tc_bFD7ikvZb0uLaguc3vbLJg_4_0"></a><a id="Tc_KXZE40RFNEeZAqdEKQnmQg_4_6"></a><a id="Tc_ieK6vWA-I0qBsvdm_DtLDg_5_0"></a><a id="Tc_GsfSioXIwEy4QcrJcNt4bA_6_0"></a><a id="Tc_5e4eQuWMCUqT8MeLOaAmyQ_7_0"></a><a id="Tc_eQ-8RGEHwUGXDOl461AFUg_8_6"></a><a id="Tc_rlCZJdoal0a2UIHlxZS4Hg_1_2"></a><a id="Tc_DHh3olAQfU6hteLD9IqoWQ_1_4"></a><a id="Tc_1cr0TfzLXkS-aAiM1kq-GQ_1_7"></a><a id="Tc_MatlGv3TJ0u6SQG_VqSh1w_2_2"></a><a id="Tc_H4sbZ3X5Q0uaxUPKI6iyGg_2_4"></a><a id="Tc_M_o16GldlEiJPSsUQbTB3g_2_7"></a><a id="Tc_3nJ1n8caf0anYX3Ucpfucg_3_0"></a><a id="Tc_X0k3zkM_KkuUIrs8jbWNZA_3_4"></a><a id="Tc_yvB2WJDweUyGcddtdaSTjw_4_0"></a><a id="Tc_TuhnzooFLUe22IoDcizxSA_5_0"></a><a id="Tc_fV1-Xn1vSU2lZuewDT7SVA_5_7"></a><a id="Tc_0EgUZS2490GIHHGT8kNstQ_6_0"></a><a id="Tc_rLG2XshxQUazSxMvnMSQjQ_7_0"></a><a id="Tc_8ySE3P4Qq0eUkvmlu0NAKA_7_4"></a><a id="Tc_-vFsomZW7E-ztLuFCfzjZg_8_0"></a><a id="Tc_Um6l_2QUeEOB9kQk-4yGYg_9_0"></a><a id="Tc_GMOnOQtiVUKnE2jW1PWiCQ_9_7"></a><a id="Tc_WMN0lceNIk6BPW5ghIYBQg_10_0"></a><a id="Tc_Gx6CLNmOp0GJpHmKmS1z5w_11_0"></a><a id="Tc_2THMPQvwdEq6SVHx1H6CEw_11_4"></a><a id="Tc_lq5uHqDOjEyzEdqM93oSQA_11_7"></a><a id="Tc_c-yhq2b0ZEyAgdEAHIaPTw_12_0"></a><a id="Tc_ecFsps44Z02r-XQGItbXgQ_12_4"></a><a id="Tc_nxsOZw1AVUO9pjg_kTN5jA_12_7"></a><ix:continuation id="Tb_rpPQJ0lsWkKDKn1PFo6RRg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes information about stock options outstanding and exercisable at December&#160;31, 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb__qY2t1WpQUygk7_cE1mzZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_PPgEeGX3REWy87f2IpfWwA">1.39</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_U1ysn92SS0asjdA3pr4KsQ_4_2">1,600,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_xO_m3XPrmUSk-ub9kz-Yew_4_4"> 5.71</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_uvyscWqoyky6OGWRd1bxtA_4_7">1.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_rjTkkNOJ7ka9ipewD0Nyjg">2.54</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_XOJEHSo-Mkmwl-QdNP-aEQ">3.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_y_7z6LeGbEKkPF960bjclQ_5_2">1,889,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_2qywSJVSUESCPl_JW40rKg_5_4"> 8.14</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_Ngynyb_iYE2698b-K2LCeA_5_7">3.19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_NZ4DCBvPtkOE3r14jBkGxw">3.61</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_R5Sps_Topkq86PMnfH1x9g">3.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_qaDiWbocP02-usGR9qU6Dw_6_2">3,004,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_1jrUbMxQGUOB0HkPuZdc1g_6_4"> 8.17</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_9DQeUu5pqEKJGqCtJMhnVw_6_7">3.80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_iWjW_8mrz0in03j2ck53PQ">4.11</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_sZ4U3zNjK0iZbnwlxSWv_A">7.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc__j8fTI1OXEu-6ixYUYYVTg_7_2">1,733,167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_MdbhcSkVdka_OBn5efMgNQ_7_4"> 9.02</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_yK7EYKVKY0itlf76TuYo_w_7_7">5.08</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_T2koH3ZWM0KuwmHaLWanHQ_8_2">8,227,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_9kvGgFb6TkawmruelFexWQ_8_7">3.46</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_rg8Y7WBjk0GBsbDv_Og_WQ">1.39</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_3JNmHe2b20--MPTm-Nf3_g_4_2">1,544,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_4wCEr69D40qCEfkWJnOhbA_4_4"> 5.69</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_dT5XT6ASo0an3UVq69d70Q_4_7">1.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_jIn3g53FmkW1H3YMiYIPQg">2.54</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr__140NcHRF0exm5k39qqZ3A">3.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_C88cjSL-E0OKxxPYRHF_CQ_5_2">845,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_YjEWK_H9pk6J3Zkar0ZZzA_5_4"> 8.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_0TvjRRO0f0KyET69-h0WQw_5_7">3.18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_s3fnrFg-I0-RGPyPP5W1kw">3.61</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_yqNerzxeUUyZf50Vp76sPg">3.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_42xGA2IwykG0-IvdsB1dFQ_6_2">1,601,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_gTkjtaGu0keJuT9cmykm5Q_6_4"> 7.85</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_Q7SfXRR1fECYiIBz0pJ4pw_6_7">3.79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_xVKxWRI0EUmOPZwBf7RG1g">4.11</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_3jwJBkc-kkaJTxx8UO3l-g">7.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_kmUVLvYickeXzuMEKkgTxg_7_2">255,561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_2oOL9OJIEU2HApEECmUe3Q_7_4"> 7.49</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_9WmSyeJHp0-W6vNBMX00tA_7_7">5.16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_ZVsCHXZXIkqmmSK7XmYUOg_8_2">4,248,136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_T_45hAVp40O9lsDcPmPxzg_8_7">2.88</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_YBj8rq7uRU2W1skq31SAjw">13.5</ix:nonFraction> million, which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_DOC7d5sJSki-O3N2aMJwUA">1.5</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a schedule summarizing employee and non-employee stock option activity for the&#160;years ended December 31, 2023 and 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_gpfUJGmwjkWDF7V84fj_QA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_6FGEryBLvEeRolX5zAGMvQ_3_2">3,793,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Tj3XrqU_IkSepPPNCM3CgA_3_5">2.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc__ysKZB5ISEuk4a7uGVu2Hw_4_2">2,817,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_5MhovxDI4EmyAjKdox5Nrg_4_5">3.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_2RXYh_OKlEO7iy2u7FPT0w_5_2">325,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_cnzx4L2jtEqBFSEYcgZFJQ_5_5">1.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Tc_ZX4gc-R2mEeYXHfEHBn7qw_5_8">867,854</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_NHHUX2OXI0ShE_Ku4JZTnw_6_2">508,688</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vcX_L2AGbkyM0YRxaNzc3w_6_5">4.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_0cjv2B39UUS0YwDRC5mLNQ_7_2">5,776,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_4sZFFKMbyky5CcQGLFHORA_7_5">2.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_rLOcVbwneEuZZlXOlqJM0w_8_2">3,420,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Zt7DW2tYzEyJGeQfACEmsw_8_5">4.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_FJxbJ20FyUOYpG_bHgQhUg_9_2">182,405</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_kn7-Ei9KW0mfchPTJCZJhg_9_5">2.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Tc_Amzme-7ldUCd_W27HkeQiQ_9_8">367,422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_5UML-2ksIUGUDb0s2OpJmg_10_2">788,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_lpFej_khN0muKSYzfrfdEg_10_5">3.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fCs36ID9PE6HG5jX5pgg1g_11_2">8,227,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_OkbbVzqAa0-OnI4UPUrJ4w_11_5">3.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_QSziLLvRFU67e4XdjMf-hQ_11_8">12,493,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_r3rDdlWwfEa81JH5FxPNag_12_2">4,248,136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_657vEGgatkm_JXoanRzYCA_12_5">2.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_uG0_5t9lxkWaHQS0PWq8YQ_12_8">8,636,326</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock for each of the respective periods. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Tb_kbpkcSPOYk-pP3RXsus5EA" continuedAt="Tb_kbpkcSPOYk-pP3RXsus5EA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">CONCENTRATIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company maintains accounts at <ix:nonFraction unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt-sec:numwordsen" name="capr:NumberOfFinancialInstitutions" scale="0" id="Narr_D21bKRI0S0WvnZPEXm4Dhw">three</ix:nonFraction> financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) for up to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_3ugJCAg170uTSGKQf4uQJg">250,000</ix:nonFraction> and/or the Securities Investor Protection Corporation, as applicable. The Company&#8217;s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of December&#160;31,&#160;2023, were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="Narr_ASEf9Ffq7ku0XOp1HyBcyw">39.2</ix:nonFraction> million. The Company monitors the financial stability of the financial institutions with which it maintains accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. Historically, the Company has not experienced any significant losses </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kbpkcSPOYk-pP3RXsus5EA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:GovernmentGrantAwardsDisclosureTextBlock" id="Tb_xbwIOVf4YU6KxrIzn31DTg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">GOVERNMENT GRANT AWARDS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CIRM Grant Award (HOPE)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_8kCOk0e360iW2gA4XW8iYA" decimals="-5" format="ixt:numdotdecimal" name="capr:GrantAwardLiability" scale="6" id="Narr_gz4MPvjpr0uEjPOv77AYig">3.4</ix:nonFraction> million to fund, in part, Capricor&#8217;s Phase 1/2 HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_6_1_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_X7Uz7GC3XUmBUEPTyo0nPg" decimals="-5" format="ixt:numdotdecimal" name="capr:MinimumExpectedContribution" scale="6" id="Narr_2dg8VPSuDE-b4hnHtRnQyg">2.3</ix:nonFraction> million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section&#160;100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to <ix:nonFraction unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug" contextRef="Duration_6_16_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_2oh6xrIk3U6oGA7dPrVBkg" decimals="0" format="ixt-sec:numwordsen" name="capr:NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" scale="0" id="Narr_2Df72oGTO0KQZUk0et9j_A">nine</ix:nonFraction> times the total amount awarded and paid to Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After completing the CIRM funded research project and at any time after the award period end date (but no later than the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ" format="ixt-sec:durwordsen" name="capr:TermOfAward" id="Narr_0C3sSP_SrkWnfPJNF8XXeA">ten-year</ix:nonNumeric> anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_nWnKT-hasUuR6O47M1z0nQ">five years</ix:nonNumeric> from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ" format="ixt-sec:durwordsen" name="capr:TermOfAward" id="Narr_paYLhYRWJE6CLcZP5EyoTA">ten-year</ix:nonNumeric> anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in the CIRM Loan Policy and CIRM Grants Administration Policy for Clinical Stage Projects (the &#8220;New Loan Balance&#8221;), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_us-gaap_VariableRateAxis_capr_LiborMember_bGOtzNXAZUys8V9CVS72yA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="Narr_yuGz0hHmB0WG-kDaQelLzA">one</ix:nonFraction> percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. Depending on the timing of our election, additional funds may be owed. If we elect to do so, Capricor would be required to repay the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of December 31, 2023, Capricor&#8217;s liability balance for the CIRM Award was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_RVq8CNEcHEiNiTlY9gUr_A" decimals="-5" format="ixt:numdotdecimal" name="capr:GrantAwardLiability" scale="6" id="Narr_1sVmuYfGg066SJwmCfhs1w">3.4</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_OYWVyI7AnkS-3NHUrw6Qqw" continuedAt="Tb_OYWVyI7AnkS-3NHUrw6Qqw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Short-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_kA0mAYf3qUO9WDdma2Dkmg">90 days</ix:nonNumeric>&#8217; written notice to the other party. Commencing in July 2022, the monthly lease payment was $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_7_1_2022_To_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_bD2EIdyBUUuS0qgSmQHcbg" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_fYWBUB03yEGmZ_7A9vxWOw">7,869</ix:nonFraction> per month. Effective July 1, 2023, the monthly lease payment was reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_7_1_2023_To_7_1_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_1IeDcw5S-Emny3Ah0glf7Q" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_hi6n5v7hBkGMmPT-6zcLMg">7,619</ix:nonFraction> per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred under short-term operating leases for the years ended December 31, 2023 and 2022 were $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr__yJPwyQsXk-fmWr2StmEFA">92,928</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_ztBgOe6LO0utYsvlcIn3LQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_inIHpLJQRUiDrqJaCRtijg">81,735</ix:nonFraction>, respectively. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_767317c9_5b51_491d_901d_6cf583e8e23d"></a><a id="Tc_MEWttfpwiUq-pQtJMq4pqw_1_0"></a><a id="Tc_spL9aw3r_ku5-ujg0WnD1A_1_2"></a><a id="Tc_0VDEhq0zwkSjhQ-T1gyc5g_2_0"></a><a id="Tc_A5udhcs3y0iUrAXdwhpqTQ_3_0"></a><a id="Tc_BnTX9WqZTEChUtVctZfXYA_4_0"></a><a id="Tc_C53FeXv41Eqf3j24pyMENw_4_3"></a><a id="Tc__SOARR1Y9UeZaXh_jQj9zQ_5_0"></a><a id="Tc_88t8rIkRJ0O2xRa7Q_zAoA_5_3"></a><a id="Tc_iXNu4W99nEWpUQWuYaHo2Q_6_0"></a><a id="Tc_FwE0NtZyK0mfbfYcpAUjdA_7_0"></a><a id="Tc_8HhdU_m0dE-WhYK-kcoIGA_8_0"></a><a id="Tc_4aVTRVf8sEKztwhOhtSgyg_8_2"></a><a id="Tc_ogaN_kZnkkOYAzcVuLioeA_9_0"></a><a id="Tc_vHvxs4tVekyPB2icpwPWKQ_10_0"></a><a id="Tc_PqEN-5uOpEKF7yfBiFbjTw_10_2"></a><a id="Tc_R0o22VU_ekO3nubaip90XQ_11_0"></a><a id="Tc_76UdZsEDEkGEMXTKZTQ_Hw_12_0"></a><a id="Tc_OQAeVqN8PUeCGdepTqE2Mw_12_2"></a><a id="Tc_-HRuOHdzPEiz23HgCIhWsg_14_0"></a><a id="Tc_eZUYm2kNJUKCiUtphsm-ag_15_0"></a><a id="Tc_GwCWwEhuG0aUQXYarhYcuQ_15_3"></a><a id="Tc_uM5MzvtGq0iHbjxUmmQozA_16_0"></a><ix:continuation id="Tb_OYWVyI7AnkS-3NHUrw6Qqw_cont1" continuedAt="Tb_OYWVyI7AnkS-3NHUrw6Qqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (&#8220;CSMC&#8221;), a related party (see Note 8 &#8211; &#8220;Related Party Transactions&#8221;), pursuant to a lease (the &#8220;Facilities Lease&#8221;) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional <ix:nonNumeric contextRef="As_Of_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_FacilitiesLeaseMember_X5iGALpimEK3OkzCpCCfPA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_JR5_y2fHMUe2ym7VK0DXtA">24-month</ix:nonNumeric> period extending the term through July 31, 2024 with a monthly lease payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_gpq9drB0NkmE4zplTZT6kg" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_QX6LPsJaFUqOVH5KTIeuoQ">10,707</ix:nonFraction>. Additionally, in September 2023, we entered into an amendment pursuant to which Capricor was granted an option to extend the lease for an additional <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_5EcEBXyvWkCaPP71aV_17g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_8gCXYowXP0GJBtdw3Xc7KA">24-month</ix:nonNumeric> period extending the term through July 31, 2026 with a monthly lease payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_S7NB6S2w7UatfWnNM-rVaw" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_udbI5QVVoEmXuhIZtvp2Dg">11,028</ix:nonFraction> commencing on August 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (&#8220;Altman&#8221;) for <ix:nonFraction unitRef="Unit_Standard_sqft_rMuzb-X9s06FnUhxCkVIgQ" contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="Narr_miYag-FlKUCvI1b1ovsN1Q">9,396</ix:nonFraction> square feet of office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the &#8220;San Diego Lease&#8221;). The rent is subject to a <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_10_1_2021_To_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_MLcvLvWUPEyWrlR72udH3w" decimals="4" format="ixt:numdotdecimal" name="capr:OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" scale="-2" id="Narr_up9kSQ46XUK4sG_pFSQd9g">3.0</ix:nonFraction>% annual rent increase during the initial lease term of <ix:nonNumeric contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="Narr_X44LYl6Vz069l3RrBsqlFg">five years</ix:nonNumeric>, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of <ix:nonNumeric contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_ZdUhGaHYB0mM8ZXcT4Zc_g">five years</ix:nonNumeric>. The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022, the monthly lease payment was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_7_1_2022_To_7_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_e9bkzfMXvE6M55FAWBdCdA" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseLeaseRentPerMonth" scale="0" id="Narr_6E3y6fMoeU2cDG9Zt9vtzA">49,322</ix:nonFraction> per month. Effective December 1, 2022, the monthly lease payment was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_12_1_2022_To_12_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_gQ0jiQuHOkO7EnvSiVT1AQ" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_BVSZPXUo3EOGNHPV3SIz9A">51,444</ix:nonFraction> per month. Effective October 1, 2023, the monthly lease payment was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_k8CGgnMufEuiNCH_zmsw3A">58,409</ix:nonFraction> per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (&#8220;Explora&#8221;), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_Ey_uQgi4H0m25WTuLxrgcg">4,021</ix:nonFraction> per month for an exclusive large vivarium room located in San Diego, California. The lease term is for <ix:nonNumeric contextRef="As_Of_11_1_2021_srt_RangeAxis_srt_MinimumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_khGZ9fyPC02WUrVz7NyC4g" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="Narr_0i2sugYiu0W9JAIn8_HUeQ">one-year</ix:nonNumeric> and will automatically renew for additional successive <ix:nonNumeric contextRef="As_Of_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_gO-91n0nUE2kR2Y9RTTwLQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_CD5rtAN7gEqWfR6jrKaxvQ">one-year</ix:nonNumeric> renewal terms unless either party provides the other party with <ix:nonNumeric contextRef="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_xlcA5DMpxU2oOhc2GG3QSA">60-day</ix:nonNumeric> written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w" decimals="3" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseMonthlyRentEscalationPercent" scale="-2" id="Narr_QZ3ANG47zku7ou3prV094g">4.5</ix:nonFraction>% bringing the base rent to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w" decimals="0" format="ixt:numdotdecimal" name="capr:LesseeOperatingLeaseBaseLeaseRentPerMonth" scale="0" id="Narr_7bCMl1lP3kmHtL3MwV8g6w">4,202</ix:nonFraction> per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of <ix:nonNumeric contextRef="As_Of_11_30_2021_srt_RangeAxis_srt_MaximumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_pZgkKv4xj0G4O10XC-Wx9g" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="Narr_x_QbhSuPcUKv6m2CCvqhyQ">five years</ix:nonNumeric>. &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The long-term real estate operating leases are included in &#8220;lease right-of-use assets, net&#8221; on the Company&#8217;s Consolidated Balance Sheet and represent the Company&#8217;s right-to-use the underlying assets for the lease term. The Company&#8217;s obligation to make lease payments are included in &#8220;lease liabilities, current&#8221; and &#8220;lease liabilities, net of current&#8221; on the Company&#8217;s Consolidated Balance Sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_2eMvp0UhakmmtFwMlefbqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_RI4aIXvz0U6rPR6k0-h-qQ_1_3">886,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_MD0BCi7lMkepCzg8jhGNQQ_2_3">910,106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_cFQ3X90npEWv9BZiwjVYzw_3_3">676,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_wTuyZ2vEyk2J00U5qheKhg_6_3">2,473,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_ojXHMBKcVEWBPzUQ0FAFCA_7_3">237,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_sVGZr-fehEa-3mRDEGnA6Q_8_3">2,235,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in the consolidated balance sheet:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_pgR_mS1EBUKJPLZFrdK0OQ_10_3">749,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_WAkuxyrGc0621vmz1GDe-w_11_3">1,486,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_UF6DW1cp5EiTJUgcWtI-UA_12_3">2,235,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_WeWsuKRP50KOeTo8iac5VA">2.73</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_ciGkvDpgXkKhIiJY-jeiFQ_16_3">7.24</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1de5c430_2675_4c9a_8ca5_714a449b7233"></a><a id="Tc_xYvQm2I9Hk-dUKPwXf6u6Q_1_1"></a><a id="Tc_cQ5c2LIg9UG7YyH6cIdIYA_2_1"></a><a id="Tc_JA9lp8g6Lkmv4gXxmKY2hA_2_4"></a><a id="Tc_Fd3hLdw-jk-M8AQ4mgqcfQ_4_0"></a><a id="Tc_61ZRSly3wUaKzeAVRomrxA_4_1"></a><a id="Tc_4cxATHPyTk-8hSdxvsBe-g_4_4"></a><a id="Tc_pNoIIxhjOkO_hRhu1EAptw_5_0"></a><a id="Tc_lb3R1gTXLUqHzGSaPGRGCw_6_0"></a><a id="Tc_UXi6OZIhRkuUJn3E876uaw_7_0"></a><ix:continuation id="Tb_OYWVyI7AnkS-3NHUrw6Qqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>As of December 31, 2023, ROU assets for operating leases were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_7U1Sj0uMfUudqcooKvzHOg">2.1</ix:nonFraction> million and operating lease liabilities were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_lxfsvKXKrkG3LIACnJUO4A">2.2</ix:nonFraction> million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company&#8217;s operating leases under ASC 842 for the period indicated: &#160; </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_jGdSeUl750KJ6zzVMFkZfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_aIA4P6o5vkuOyBGZFvS8Nw_4_2">663,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_Dx-dumJH40C0GZZlIbhH4Q_4_5">632,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_PvFl9UXsdUCNL088yLisXQ_5_2">129,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Tc_GuFqBn1wEk23S4Td4Gt7Jg_5_5">128,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_R5SDevrZSky_JuXTOAclpg_6_2">684,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_t9djnZcOWkOYEkjQaVawyg_6_5">470,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_UcBmkLGn7ECloBYK5Df07Q_7_2">117,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_b6k2qyelc02t6gw8ak0Xhg_7_5">128,478</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company has not recorded any material accruals for loss contingencies as of December 31, 2023. The Company has received a letter from CSMC alleging certain overdue payment obligations and alleged breaches (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Funding Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 - "License and Distribution Agreements").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Severances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt-sec:durwordsen" name="capr:SeverancePackageToBePaidForPeriodOfBaseSalary" id="Narr_aiksnjBU-0ik1k2sl3mlIg">six months</ix:nonNumeric> of their base salaries, in the event of termination of their employment, subject to certain conditions. <ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RestructuringReserve" scale="0" id="Narr_TkvE6l79UEeo71squ8xNGQ">No</ix:nonFraction> liability under these severance packages has been recorded as of December 31, 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="capr:LicenseAgreementsTextBlock" id="Tb_SKsyafYZsU-kgsiIWME4JQ" continuedAt="Tb_SKsyafYZsU-kgsiIWME4JQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">LICENSE AND DISTRIBUTION AGREEMENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights for Capricor&#8217;s Technology&#160;- CAP-1002 and Exosomes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Universit&#224; Degli Studi Di Roma La Sapienza (the &#8220;University of Rome&#8221;), JHU and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">University of Rome License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the &#8220;Rome License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SKsyafYZsU-kgsiIWME4JQ_cont1" continuedAt="Tb_SKsyafYZsU-kgsiIWME4JQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of <ix:nonFraction unitRef="Unit_Standard_EUR_1WG7i0WyeU6pv6Zueih0aw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_nwrh_aVVjkGtRzSmUAp6Pw" decimals="0" format="ixt:numdotdecimal" name="capr:AnnualPaymentsForRoyalties" scale="0" id="Narr_OTTcwDg3Xki2z7yEiStsmQ">20,000</ix:nonFraction> Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third-party to Capricor. The minimum annual royalties are creditable against future royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party&#8217;s material breach, provided that the breaching party will have up to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_o_rOiVFmBkOpdldl9LffKw">90 days</ix:nonNumeric> to cure its material breach. Capricor may also terminate for any reason upon <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_9A4q-gNVVkShjX6yzy8vyA">90 days</ix:nonNumeric>&#8217; written notice to the University of Rome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Johns Hopkins University License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">License Agreement for CDCs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the &#8220;JHU License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the FDA. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_oHpjOTKGoUykLnbV-fTRSQ" decimals="0" format="ixt:numdotdecimal" name="capr:PotentialMilestonePayments" scale="0" id="Narr_gImTE3OF2ke2kCAPjD0hQw">1,850,000</ix:nonFraction>. In March 2022, Capricor paid the $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_3_1_2022_To_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_jFLITrcimUyqsFvsZebRCA" decimals="0" format="ixt:numdotdecimal" name="capr:MilestonePayments" scale="0" id="Narr_nxpDMlJtkUuMxsGr5HVC1A">250,000</ix:nonFraction> development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase 3 study for which a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_CwHLfODuHEWscaDC4mM3SQ" decimals="0" format="ixt:numdotdecimal" name="capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" scale="0" id="Narr_ivkKhHgZZk2FwM6edcLiRw">500,000</ix:nonFraction> will be due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_raj702HzaEWCiJY45rn1UA" format="ixt-sec:durwordsen" name="capr:PeriodOfAgreementWillBeInEffective" id="Narr_CzDnAe-tBEOo8D3y5PG5qA">twenty years</ix:nonNumeric> from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy or fail to cure a material breach within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw" format="ixt-sec:durwordsen" name="capr:ThresholdPeriodToCureBreach" id="Narr_Zh6mj-FibECj0b8A0fcFBg">30 days</ix:nonNumeric> after notice. In addition, Capricor may terminate for any reason upon <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_Jv28LHdLIEWD7DJvjVSH3w">60 days</ix:nonNumeric>&#8217; written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">License Agreement for Exosome-based Vaccines and Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement (the &#8220;JHU Exosome License Agreement&#8221;), effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provided for the grant of an exclusive, world-wide, royalty-bearing license of JHU&#8217;s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. The JHU Exosome License Agreement was terminated by Capricor on December 15, 2023.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SKsyafYZsU-kgsiIWME4JQ_cont2" continuedAt="Tb_SKsyafYZsU-kgsiIWME4JQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cedars-Sinai Medical Center License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 36pt;">License Agreement for CDCs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Original CSMC License Agreement&#8221;), for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the&#160;percentage of sublicense fees which would have been payable to CSMC. Effective December&#160;30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the &#8220;Amended CSMC License Agreement&#8221;), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty-bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_bybMKDXxsEWCLX8wsTPgbw" format="ixt-sec:durwordsen" name="capr:AgreementTerminationPeriod" id="Narr_uzNodOvAhUa1orvpSNKu5w">30 days</ix:nonNumeric> for non-payment of royalties; (v)&#160;after <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_vjuMg_ZNqkuHDVxlRGx3Dg" format="ixt-sec:durwordsen" name="capr:AgreementTerminationPeriod" id="Narr_bW78lFyixUmvvnzQIVjEhw">90 days</ix:nonNumeric>&#8217; notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_kNOGvDAtg0KsQmmw19rGSg" format="ixt-sec:durwordsen" name="capr:AgreementTerminationPeriod" id="Narr_FXQ-XZe5jUC6OMN2cH030w">90 days</ix:nonNumeric>; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_2-wubRxozEmpbQcL1C0TJg" format="ixt-sec:durwordsen" name="capr:AgreementTerminationPeriod" id="Narr_T7NuhrIOrE6HEpukpwlK3A">90 days</ix:nonNumeric>&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_hcCGu4aCq0aWdI1ic9gMFg" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_rA80p8gjLkG1xZSb_exhRw">90 days</ix:nonNumeric> after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents and extend the timing of certain development milestones, among other things. Capricor reimbursed CSMC for certain attorneys&#8217; fees and filing fees incurred in connection with the additional patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We recently received a letter from CSMC alleging that pursuant to the Amended CSMC License Agreement between CSMC and Capricor, Capricor has certain overdue payment obligations to CSMC arising out of a milestone payment received by Capricor pursuant to the U.S. Distribution Agreement entered into between Capricor and Nippon Shinyaku. Capricor has received a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__dhbnCoFj0mFXSecYuidNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_aDvGvbX_LEK6elyutWwxRw">10.0</ix:nonFraction> million under its U.S. Distribution Agreement with Nippon Shinyaku, which CSMC is claiming <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_-d6RYF7mlUWi4_x3ZsGV7g" decimals="2" format="ixt:numdotdecimal" name="capr:MilestonePaymentsPercentageOwedToThirdParty" scale="-2" id="Narr_wnXWioLYQ0Gksscb5rZ7IA">10</ix:nonFraction>% of this milestone payment is owed to them. The notice letter requests that Capricor cure the alleged breaches of the Amended CSMC License Agreement, and reserves CMSC&#8217;s purported right to terminate the Amended CSMC License Agreement if such alleged breaches are not cured. We dispute the allegations in </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SKsyafYZsU-kgsiIWME4JQ_cont3" continuedAt="Tb_SKsyafYZsU-kgsiIWME4JQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the letter from CSMC and intend to vigorously defend our position and pursue all available remedies, but there is no guarantee that any disputes that we have with CSMC will be resolved or if resolved, will not result in our incurring certain payment and other obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 0pt 36pt;">License Agreement for Exosomes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Exosomes License Agreement&#8221;), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit&#160;percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_p6GoxGGgcE2JSpPe0-Rv6Q" format="ixt-sec:durwordsen" name="capr:ThresholdPeriodToCureBreach" id="Narr_o_HpZg_Y4UuAVtLv0LLvWw">30 days</ix:nonNumeric> for non-payment of royalties; (v)&#160;after <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_fHaPByLkFEWmMCmmItdYUA" format="ixt-sec:durwordsen" name="capr:ThresholdPeriodToCureBreach" id="Narr_AFSRstBg_EiP2AD6OkqsKA">90 days</ix:nonNumeric> if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_G6HBLmII80uwt4M0Xn301w" format="ixt-sec:durwordsen" name="capr:ThresholdPeriodToCureBreach" id="Narr_v8lAuhocW0aveNuulD97iQ">90 days</ix:nonNumeric>; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_Xt587NoPDES43nwHwu-1Rg" format="ixt-sec:durwordsen" name="capr:ThresholdPeriodToCureBreach" id="Narr_fDqhlUn6eUCWPRvDWg0z4A">90 days</ix:nonNumeric>&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_JVh39f55SEWCSfGr2sFfwQ" format="ixt-sec:durwordsen" name="capr:WrittenNoticePeriod" id="Narr_PcINGFEjF0qY9m9e5hkWfw">90 days</ix:nonNumeric> after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights, and converted certain exclusive rights to co-exclusive rights. These amendments also obligated Capricor to reimburse CSMC for certain attorneys&#8217; fees and filing fees in connection with the additional patent applications and patent families.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cell Line License Agreement with Life Technologies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in 2022 and additional milestone fees may become due based on the progress of our development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On January 24, 2022, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;U.S. Distribution Agreement&#8221;) with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SKsyafYZsU-kgsiIWME4JQ_cont4" continuedAt="Tb_SKsyafYZsU-kgsiIWME4JQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S Distribution Agreement, Capricor received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_hUhoFzMYxU2y08SvRW_3Vg" decimals="-5" format="ixt:numdotdecimal" name="capr:UpfrontPayment" scale="6" id="Narr_40-nuVEA7ke5qOJ5DNPOGw">30.0</ix:nonFraction> million in the first quarter of 2022. The first milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="-5" format="ixt:numdotdecimal" name="capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" scale="6" id="Narr_G5P_SCg-O0azBsstZAfCaQ">10.0</ix:nonFraction> million was paid upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, there are potential milestones totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA" decimals="-5" format="ixt:numdotdecimal" name="capr:PotentialMilestonePayments" scale="6" id="Narr_YIiuivSHA0qcNLlbWk9grQ">90.0</ix:nonFraction> million leading up to and including the BLA approval. Further, there are various potential sales-based milestones, if commercialized, tied to the achievement of certain sales thresholds for annual net sales of CAP-1002 of up to $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_1_24_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_f49c96jOM0qAScvbNEBu5w" decimals="-5" format="ixt:numdotdecimal" name="capr:PotentialMilestonePayments" scale="6" id="Narr_BgcDu9kJ7kWp5HvCp9jPfw">605.0</ix:nonFraction> million. Further, pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and Capricor will have the right to receive a meaningful mid-range double-digit share of product revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase 3 clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined the transaction price totaled $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_oeC63qvRMkKBhVSqouykUg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_8ANsKAcTFEyBZKMExUVjoA">40.0</ix:nonFraction> million, which was the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_l8hYv85mhkiSnt-G1Lj7Iw" decimals="-5" format="ixt:numdotdecimal" name="capr:UpfrontPayment" scale="6" id="Narr_0Wj0JQ-xnkSUmS2nSng3OA">30.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA" decimals="-5" format="ixt:numdotdecimal" name="capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" scale="6" id="Narr_gka0krZgeEqkAujeaExOZw">10.0</ix:nonFraction> million milestone payment. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_qQnWowdCk0ycTDEN3vYiFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_l9xfH18FJ0yPzEygoSrpRA">40.0</ix:nonFraction> million transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study, Cohort A arm, to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract&#8217;s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the Company recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_YSrt3eyVpUyrEiyR3LkflQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_8Kx3ziDJd0mu9jWQqxk6VQ">25.2</ix:nonFraction> million as revenue compared to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_7DiFd0JLoUiEm79PuGWQEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_tXcOCKGLEEyaE6aeTWZ5fA">2.6</ix:nonFraction> million for the year ended December 31, 2022. In relation to the U.S. Distribution Agreement, as of December 31, 2023, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_0ffc869l0UKbwuwbKNvYEQ">12.3</ix:nonFraction> million as current deferred revenue on the Company&#8217;s consolidated balance sheets. As of December 31, 2023, the Company recorded a receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA" decimals="-5" format="ixt:numdotdecimal" name="capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" scale="6" id="Narr_SJ54WGQeHUy05IwyNsGKJQ">10.0</ix:nonFraction> million in connection with the interim futility milestone, which payment was received in January 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had no opening or closing contract asset balances recognized. &#160;The difference between the opening and closing balances of the Company&#8217;s contract liability results from the Company performance of services in connection to its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of December 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_7HH-j-xILEK0z1TW4fsz_w">12.3</ix:nonFraction> million. At this time, we estimate <ix:nonFraction unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ" contextRef="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="Narr_G9LHAQQHSkKeCAqip2t7Hg">100</ix:nonFraction>% of the remaining performance obligations are expected to be recognized over the next <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg" format="ixt-sec:durwordsen" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Narr_8svmEyqyAUejNPbWkGsDYA">12 months</ix:nonNumeric>. Remaining performance obligations estimates are subject to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2023, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;Japan Distribution Agreement&#8221;) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_r9pBOG-cqUSu0_0p-X_SUA" decimals="-5" format="ixt:numdotdecimal" name="capr:UpfrontPayment" scale="6" id="Narr_b97JJriaW06fuVRTUn2rtg">12.0</ix:nonFraction> million in the first quarter of 2023 and in addition, Capricor may potentially receive additional development and sales-based milestone payments of up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_GyIsPMRQwEid4EesUv_0_A" decimals="-5" format="ixt:numdotdecimal" name="capr:PotentialMilestonePayments" scale="6" id="Narr_6t-PYZOwTUaHyp0_S1yDKg">89.0</ix:nonFraction> million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Subject to regulatory approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SKsyafYZsU-kgsiIWME4JQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_nh_OEK25AkW9IIAVReouWg">12.0</ix:nonFraction> million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_xpoNYL9T7kShk1Mvy3yhfg">12.0</ix:nonFraction> million as current deferred revenue on the Company&#8217;s consolidated balance sheets as of December&#160;31,&#160;2023. &#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_VQYJVtbj0U2i92zRO713Pg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lease and Sub-Lease Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, Capricor is a party to lease agreements with CSMC (see Note&#160;6&#160;&#8211; &#8220;Commitments and Contingencies&#8221;), and CSMC has served as an investigative site in Capricor&#8217;s clinical trials. Additionally, Dr.&#160;Eduardo Marb&#225;n, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company&#8217;s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consulting Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company&#8217;s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q" decimals="0" format="ixt:numdotdecimal" name="capr:MonthlyConsultingFeesToRelatedParty" scale="0" id="Narr_3YUDnbXHNUO9SGMoOJBjxg">10,000</ix:nonFraction> per month for consulting services. The agreement is terminable upon <ix:nonNumeric contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q" format="ixt-sec:durwordsen" name="capr:TerminableNoticePeriod" id="Narr_MJqRSLgv80a-QmMWvr24vg">30 days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marb&#225;n whereby he was granted an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_R17I3foYh02N_TLWyWcP4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_eCIKoQWKnkqYhxfGUh8h_g">50,000</ix:nonFraction> shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marb&#225;n was granted an additional option grant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_m81pZxvbV0ifPEk3pIVFTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Da-R3S7PB0KFW-ccX7i3cQ">50,000</ix:nonFraction> shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, Capricor entered into a Consulting Agreement with Michael Kelliher, a member of its Board of Directors, related to business development services whereby he was granted an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_MichaelKelliherMember_What73q3UE2-6pZFUmISsA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ZKSUGhPz1EGihom-6rWcew">30,000</ix:nonFraction> shares of the Company's common stock. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payables to Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2023 and 2022, the Company had accounts payable and accrued expenses to related parties totaling $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_7oVyEjhT4E-aZsnM78WtUQ">27,479</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_TQCWQuA0wkScX36vohL-UA">89,234</ix:nonFraction>, respectively. CSMC accounts for $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_aYVKDRCxe0SMDBzgeTcNdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_-UE61y9HLkS2rfolpXT9Vw">17,479</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__Feo3dGKN0Sy2w8lAyM8Cg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_7GGjcpbHOEKIA1XazGuhng">79,234</ix:nonFraction> of the total accounts payable and accrued expenses to related parties as of December 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the&#160;years ended December 31, 2023 and 2022, the Company paid CSMC approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_I1LoZTPxAU2_UBJz6muQiQ" decimals="0" format="ixt:numdotdecimal" name="capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" scale="0" id="Narr_ghxgSsxiHEi9sWC3ZesVHQ">226,400</ix:nonFraction> and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_qFit8CulBkqXDIzMZnp4pg" decimals="0" format="ixt:numdotdecimal" name="capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" scale="0" id="Narr_OH82nulXJkW_HTqofQOkyg">794,000</ix:nonFraction>, respectively, for such costs.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_UmF8g0V2SESDatZD5cHFtg" continuedAt="Tb_UmF8g0V2SESDatZD5cHFtg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SUBSEQUENT EVENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Sales under ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2023 and through March 7, 2024, the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_HGjV5w_FAkWPtN9C0kobHQ">251,347</ix:nonFraction> shares of common stock under the ATM Program at an average price of approximate $<ix:nonFraction unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA" contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i1t2nRzziUyi6BVPUlI6Pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_xwVIqL5QZUmjEFwre27aaQ">4.50</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_fzH2s-4p0USdfZj0SBzddA">1.1</ix:nonFraction> million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to the placement agent in the aggregate amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_a2RhIM3K8EKahzsXYSTZkQ">35,900</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw" contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9vSuYHyy80Soi04pDnBeCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_L5U4-2P6KEykFIKHf3jnEg">2,203,726</ix:nonFraction> stock options to its employees, certain non-employee consultants, and directors.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2023 AND 2022</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UmF8g0V2SESDatZD5cHFtg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License and Service Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2024, we entered into a License and Services Agreement with Azzur Cleanrooms-on-Demand &#8211; San Diego, LLC (the &#8220;Azzur License Agreement&#8221;) pursuant to which we have been granted an exclusive license to use certain space and the non-exclusive right to use certain equipment and property for our early phase clinical and/or pre-clinical manufacturing purposes. Our estimated license fee is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA" contextRef="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ" decimals="0" format="ixt:numdotdecimal" name="capr:LicenseFee" scale="0" id="Narr_0nN7IEIMyU2i8On29nHwRQ">120,500</ix:nonFraction> per month for a term of approximately <ix:nonNumeric contextRef="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ" format="ixt-sec:durwordsen" name="capr:TermOfLicense" id="Narr_9yTcX-uTUkCtzFKesUjsig">6 months</ix:nonNumeric>.</p></ix:continuation><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">114</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aa545e26_aeb1_4140_9cb4_7159494d876f"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9.</b></span>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_70d406df_4896_40a2_82b0_1688da5cc78e"></a><a id="ITEM9ACONTROLSANDPROCEDURES_15000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9A.</b></span>CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have adopted and maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that controls and procedures, no matter how well designed and operated, cannot provide absolute assurance of achieving the desired control objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As required by Rule&#160;13a-15(b), under the Securities Exchange Act of 1934, as amended, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that as of December&#160;31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule&#160;13a-15(f)&#160;and 15d-15(f)&#160;of the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed to provide reasonable assurance to our management and Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes policies and procedures that: (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements, errors or fraud. Also, projections of any evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023 based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commissions in Internal Control-Integrated Framework. Based on that assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules&#160;of the SEC that permit smaller reporting companies to provide only management&#8217;s report in this Annual Report on Form&#160;10-K.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">115</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Controls over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Securities Exchange Act of 1934, as amended) during the fiscal year ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_db644d38_51a1_4c5a_8344_b2bf8306c624"></a><a id="item9B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9B.</b></span><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_1N3UwuJe0kiA2IsKnwJL8A">N</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_-iYJK5fbo0Ca2XMaJx_mTg">o</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_-ClHLAKz7EWxFANqWfpR6A">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_Oq8TxgBkW0-JUwAgk-Lk5g">e</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_40210e3e_0632_4c17_84e0_3ca90e2a76d5"></a><a id="PARTIII_949158"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART&#160;III</b></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this item will be set forth in the sections entitled &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; &#8220;Information Regarding Executive Officers&#8221; and &#8220;Delinquent Section&#160;16(a)&#160;Reports&#8221; in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders (our &#8220;2024 Proxy Statement&#8221;), to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_816aea79_cebe_4aa7_a76f_1663c47c891b"></a><a id="ITEM11EXECUTIVECOMPENSATION_737825"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ITEM 11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">EXECUTIVE COMPENSATION.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this item will be set forth in the section entitled &#8220;2023 Executive Compensation&#8221; and &#8220;Compensation of Directors&#8221; in our 2024 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_24b335c8_9493_4641_bb8e_23f2981d01e2"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ITEM 12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this item will be set forth in the sections entitled &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our 2024 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_da4e9642_11a8_475c_88a6_fbb499245a49"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this item will be set forth in the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our 2024 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e2be2084_c5b2_4ce2_952c_71df7770105a"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ITEM 14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">PRINCIPAL ACCOUNTING FEES AND SERVICES.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this item will be set forth in the section entitled &#8220;Principal Accountant Fees and Services&#8221; in our 2023 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d39d9b3a_33d4_4a10_a1ce_500fc4d42414"></a><a id="PARTIV_304221"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART&#160;IV</b></p><a id="ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 15.</b></span>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(1)&#160;Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The financial statements required by this item are included in a separate section of this Annual Report on Form&#160;10-K beginning on page 88.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">116</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(2)&#160;Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial Statement Schedules have been omitted because they are either not applicable or the required information is included in the consolidated financial statements or notes thereto listed in (a)(1)&#160;above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(3)&#160;Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following exhibits are filed herewith or incorporated herein by reference:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420407006159/v065143_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 9, 2007).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420413064127/v361510_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 26, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420419029669/tv522974_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 4, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420407006159/v065143_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 9, 2007).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465920098381/tm2029227d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on August 25, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Company&#8217;s Common Stock, par value $0.001 per share.*</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465919072396/tm1925140d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Warrant (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Amendment No. 1 to Registration Statement on Form S-1/A, filed with the Commission on December 13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465920062698/tm2014566d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant #2 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement between Capricor, Inc. and Frank Litvack, dated March 24, 2014 (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014).</span></a> &#8224;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014).</span></a>&#160;&#8224;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414013306/v370320_ex4-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Capricor, Inc. 2012 Restated Equity Incentive Plan (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on March 4, 2014).</span></a> &#8224;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414013306/v370320_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Capricor, Inc. 2012 Restated Equity Incentive Plan (incorporated by reference to Exhibit 4.12 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on March 4, 2014). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414013306/v370320_ex4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement for the Capricor, Inc. 2012 Restated Equity Incentive Plan (incorporated by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on March 4, 2014). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement, dated June 21, 2006, between Capricor, Inc. and the Universita Degli Studi Di Roma &#8220;La Sapienza&#8221; (incorporated by reference to Exhibit 10.31 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement, dated June 22, 2006, between Capricor, Inc. and the Johns Hopkins University (incorporated by reference to Exhibit 10.32 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Exclusive License Agreement, dated May 13, 2009, between Capricor, Inc. and the Johns Hopkins University (incorporated by reference to Exhibit 10.33 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">117</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Exclusive License Agreement, dated December 20, 2013, between Capricor, Inc. and the Johns Hopkins University (incorporated by reference to Exhibit 10.34 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-36.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License Agreement, dated December 30, 2013, between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.36 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan Agreement, dated February 1, 2013, between Capricor, Inc. and the California Institute for Regenerative Medicine (incorporated by reference to Exhibit 10.38 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414019617/v372462_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Notice of Loan Award, dated February 1, 2013, between Capricor, Inc. and the California Institute for Regenerative Medicine (incorporated by reference to Exhibit 10.39 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 31, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415049296/v417053_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated March 29, 2012, between Capricor, Inc. and The Bubble Real Estate Company, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 14, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415049296/v417053_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Lease Agreement, dated June 13, 2013, between Capricor, Inc. and The Bubble Real Estate Company, LLC (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 14, 2015). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414033348/v379534_ex10-46.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement, dated May 5, 2014 between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.46 to the Company&#8217;s Amendment No. 1 to Registration Statement on Form S-1, filed with the Commission on May 23, 2014). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420414031429/v377873_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Facilities Lease, dated June 1, 2014, between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2014).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415014616/v403843_ex10-54.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Exclusive License Agreement, dated as of February 27, 2015, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.54 to the Company&#8217;s Registration Statement on Form S-1, filed with the Commission on March 6, 2015). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415014616/v403843_ex10-55.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease Agreement, dated March 3, 2015, by and between Capricor, Inc. and The Bubble Real Estate Company, LLC (incorporated by reference to Exhibit 10.55 to the Company&#8217;s Registration Statement on Form S-1, filed with the Commission on March 6, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415049296/v417053_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Exclusive License Agreement, dated as of June 10, 2015, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 14, 2015). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420415065364/v423417_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Joinder Agreement, dated as of September 30, 2015, by and among the Company, Capricor, Inc. and the California Institute For Regenerative Medicine (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 13, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416119561/v445821_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Notice of Loan Award, dated as of May 12, 2016 by and between Capricor, Inc. and the California Institute for Regenerative Medicine (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 15, 2016). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416119561/v445821_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease, dated as of May 25, 2016, by and between Capricor, Inc. and The Bubble Real Estate Company, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 15, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416119561/v445821_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Notice of Award, dated as of June 16, 2016, by and between Capricor, Inc. and the California Institute for Regenerative Medicine (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 15, 2016). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">118</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416119561/v445821_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan Election Agreement, dated as of June 16, 2016, by and between Capricor, Inc. and the California Institute for Regenerative Medicine (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 15, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416134169/v452094_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Amended and Restated Exclusive License Agreement, dated as of August 5, 2016, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 14, 2016). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420416134169/v452094_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Exclusive License Agreement, dated as of August 5, 2016, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 14, 2016). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420417001699/v456402_ex4-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Capricor Therapeutics, Inc. 2012 Restated Equity Plan (incorporated by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on January 11, 2017). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420417001699/v456402_ex4-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Capricor Therapeutics, Inc. 2012 Restated Equity Plan (incorporated by reference to Exhibit 4.15 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on January 11, 2017). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420417032230/v468893_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2 to Notice of Loan Award, dated as of June 7, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on June 13, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420417058512/tv478386_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Notice of Award, dated as of August 8, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 11, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420417058512/tv478386_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Facilities Lease, dated as of August 1, 2017, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 11, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.32</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420418016468/tv487725_ex10-58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Exclusive License Agreement, dated as of December 26, 2017, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.58 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 22, 2018). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.33</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420418016468/tv487725_ex10-59.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Exclusive License Agreement, dated as of December 26, 2017, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.59 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 22, 2018). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.34</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420418043686/tv499790_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Amended and Restated Exclusive License Agreement, dated as of June 20, 2018, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2018). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.35</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420418043686/tv499790_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Exclusive License Agreement, dated as of June 20, 2018, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2018). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.36</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420419038387/tv525947_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated and Amended Employment Agreement by and among Capricor Therapeutics, Inc., Capricor, Inc. and Linda Marb&#225;n, dated June 5, 2019 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 8, 2019).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.37</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420419038387/tv525947_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement by and among Capricor Therapeutics, Inc., Capricor, Inc. and Anthony J. Bergmann, dated May 14, 2019 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 8, 2019).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.38</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420419038387/tv525947_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement by and among Capricor Therapeutics, Inc., Capricor, Inc. and Karen G. Krasney, dated May 14, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 8, 2019).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">119</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.39</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000114420419035262/tv525551_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Sales Agreement, dated July 22, 2019, between Capricor Therapeutics, Inc. and H.C. Wainwright &amp; Co., LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 22, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.40</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/tm2022740d1_ex4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Capricor Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on June 17, 2020). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.41</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/tm2022740d1_ex4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement for Capricor Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 4.10 to the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on June 17, 2020). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.42</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465920125153/tm2029532d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amendment to Exclusive License Agreement, dated as of August 20, 2020, by and between Capricor, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on November 11, 2020).+</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.43</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000155837021011587/capr-20210630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Capricor Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2021). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.44</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000155837021011587/capr-20210630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement for Capricor Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2021). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.45</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000155837022003341/capr-20211231xex10d54.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Standard Industrial/Commercial Multi-Tenant Lease, dated as of July 16, 2021, by and between Capricor Therapeutics, Inc. and Altman Investment Company, LLC (incorporated by reference to Exhibit 10.54 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 11, 2022). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.46</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000155837022003341/capr-20211231xex10d55.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">U.S. Commercialization and Distribution Agreement, dated as of January 25, 2022, by and among Capricor Therapeutics, Inc., Capricor, Inc. and Nippon Shinyaku Co. Ltd. (incorporated by reference to Exhibit 10.55 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 11, 2022). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.47</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1133869/000155837023004124/capr-20221231xex10d55.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Japan Commercialization and Distribution Agreement, dated as of February 10, 2023, by and among Capricor Therapeutics, Inc., Capricor, Inc. and Nippon Shinyaku Co. Ltd. (incorporated by reference to Exhibit 10.55 to the Company&#8217;s Annual Report on Form 10-K, filed with the Commission on March 17, 2023). +</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Rose Snyder &amp; Jacobs, LLP. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#SIGNATURES_842538"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page hereof). *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20231231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Capricor Therapeutics, Inc. Policy on Recoupment of Incentive Compensation. *</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial information from Capricor Therapeutics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 formatted in Inline eXtensible Business Reporting Language (iXBRL): (i)&#160;Consolidated Balance Sheets as of December&#160;31, 2023 and 2022, (ii)&#160;Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2023 and 2022, (iii)&#160;Consolidated Statement of Stockholders&#8217; Equity for the period from December&#160;31, 2021 through December&#160;31, 2023, (iv)&#160;Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023 and 2022, and (v)&#160;Notes to Consolidated Financial Statements.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:91.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Filed herewith.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">120</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224; Indicates management contract or compensatory plan or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+ Portions of the exhibit have been excluded because it is both not material and is the type of information that the registrant treats as private or confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_47d953dc_fe7c_4f81_9d97_0322f71686bf"></a><a id="ITEM16FORM10KSUMMARY_363246"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 16.</b></span>FORM 10-K SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">121</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ee9ced6_91a7_426c_8279_1539bd17a35e"></a><a id="SIGNATURES_842538"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;8, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL MEN BY THESE PRESENTS, that we, the undersigned officers and directors of Capricor Therapeutics,&#160;Inc., hereby severally constitute Linda Marb&#225;n, Ph.D. and Anthony J. Bergmann and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to said Annual Report on Form&#160;10-K, and generally to do all such things in our names and in our capacities as officers and directors to enable Capricor Therapeutics,&#160;Inc. to comply with the provisions of the Securities Exchange Act of 1934, and all requirements of the U.S. Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to any and all amendments hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:37.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:26.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anthony J. Bergmann</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anthony J. Bergmann</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Principal Accounting Officer)</i></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Frank Litvack, M.D.</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Chairman and Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Frank Litvack, M.D.</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Earl M. Collier</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Earl M. Collier</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David B. Musket</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David B. Musket</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ George W. Dunbar</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">George W. Dunbar</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Karimah Es Sabar</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Karimah Es Sabar</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Paul Auwaerter</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paul Auwaerter</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Kelliher</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Kelliher</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Philip Gotwals</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;8, 2024</p></td></tr><tr><td style="vertical-align:top;width:31.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philip Gotwals</p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">122</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>capr-20231231xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:28 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The authorized capital stock of Capricor Therapeutics, Inc. consists of 55,000,000 shares, consisting of 50,000,000 shares of common stock, $0.001 par value per share (the &#8220;common stock&#8221;) and 5,000,000 shares of preferred stock, $0.001 par value per share (the &#8220;preferred stock&#8221;). We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934, our common stock, which is listed on the Nasdaq Capital Market under the symbol &#8220;CAPR.&#8221; For purposes of this exhibit, unless the context otherwise requires, the words &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;the company&#8221; refer to Capricor Therapeutics, Inc., a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF COMMON STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our certificate of incorporation, as amended, and our bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Voting Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, and do not have cumulative voting rights in the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Dividend Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Subject to rights that may be applicable to any outstanding shares of preferred stock and the requirements, if any, with respect to the setting aside of sums as sinking funds or redemption or purchase accounts for the benefit of the holders of preferred stock, the holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of assets legally available for dividend payments. Any such dividends shall be divided among the holders of our common stock on a pro rata basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Liquidation Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the event of any liquidation of the Company, the holders of our common stock will be entitled to share ratably in the assets that are remaining after payment or provision for payment of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock are made, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">No Preemptive or Similar Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of our common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights, and our common stock is not subject to any sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fully Paid and Nonassessable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All outstanding shares of our common stock are fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our board of directors has been authorized to designate and issue up to an aggregate of 5,000,000 shares of preferred stock in one or more series without action by the stockholders. Our board of directors can fix the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of delaying or preventing a change in control of our company and might harm the market price of our common stock. As of December 31, 2023, there were no shares of preferred stock issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Certain Provisions of the DGCL and Our Certificate of Incorporation and Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The provisions of the DGCL, our certificate of incorporation, as amended, and our bylaws may be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions, summarized below, are designed to reduce our vulnerability to an unsolicited acquisition proposal and are intended to discourage certain tactics that may be used in proxy fights. Such provisions may also have the effect of preventing changes in our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Section 203 of the DGCL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a Delaware corporation, we are subject to Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. For purposes of Section 203, a &#8220;business combination&#8221; is defined broadly to include, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or, within three years prior, did own) 15% or more of the corporation&#8217;s voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Issuance of Additional Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our board of directors has authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock, in one or more series, and to designate the rights, preferences, privileges and restrictions of each series. The issuance of preferred stock could have the effect of delaying or preventing a change in control of the Company without further action by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, our board of directors has authority to issue the authorized but unissued shares of our common stock, without further action by the stockholders, subject to any applicable stock exchange rules. Under certain circumstances, we could use the additional shares to create voting impediments or to frustrate persons seeking to effect a takeover or otherwise gain control by, for example, issuing those shares in private placement transactions to purchasers who are likely to side with our board of directors in opposing a hostile takeover bid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Special Meetings of Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our bylaws provide that special meetings of stockholders may be called by the Chairman of the Board, the President or our board of directors. A special meeting shall be called by the President or Secretary upon one or more written demands (which must state the purpose or purposes therefor) signed and dated by the holders of shares representing not less than 10% of all votes entitled to be cast on any issue(s) that may be properly proposed to be considered at the special meeting. These provisions may delay or impede the ability of a stockholder or group of stockholders to force consideration of a proposal or stockholders holding a majority of our outstanding capital stock to take a certain desired action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Advance Notice Provisions for Stockholder Proposals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our bylaws provide that the nomination of persons to stand for election to the board of directors at any annual or special meeting of stockholders may be made by the holders of our common stock only if written notice of such stockholder&#8217;s intent to make such nomination has been given to the Secretary of the Company not later than 30 days prior to the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Furthermore, our bylaws require that any stockholder who gives notice of any stockholder proposal shall deliver therewith the text of the proposal to be presented and a brief written statement of the reasons why such stockholder favors the proposal and setting forth such stockholder&#8217;s name and address, the number and class of all shares of each class of stock of the Company beneficially owned by such stockholder and any financial interest of such stockholder in the proposal (other than as a stockholder).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The foregoing provisions may preclude our stockholders from bringing matters or from making nominations for directors at our annual meeting of stockholders if the proposals are not in compliance with the required procedures. Additionally, the requisite procedures may deter a potential acquirer from conducting a solicitation of proxies to elect its own nominees to our board of directors or otherwise attempting to gain control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Filling of Vacancies on the Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our bylaws provide that a vacancy on our board of directors caused by the removal of a director or by an increase in the authorized number of directors between annual meetings may be filled only by a majority of the remaining directors. In addition, the number of directors constituting our board of directors may only be set from time to time by resolution of our board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling any resulting vacancies with its own nominees; thereby making it more difficult to change the composition of our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Amendment of Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our board of directors is expressly authorized to adopt, amend or repeal our bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. Its address is 48 Wall Street, Floor 23, New York, New York 10005, and its telephone number is 800-468-9716.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>capr-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF THE REGISTRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LEGAL NAME</b></p></td><td style="vertical-align:bottom;width:1.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49.05%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">JURISDICTION OF ORGANIZATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capricor, Inc.</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>capr-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Board of Directors and Stockholders&#160;of Capricor Therapeutics, Inc. and Subsidiary<br>San Diego, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the Registration Statements of Capricor Therapeutics, Inc. on Form S-8 (File Nos. 333-152283, 333-175727, 333-194317, 333-215510, 333-239241, 333-253083, 333-262826, 333-269468 and 333-277154), Form S-3 (File Nos. 333-161339, 333-165167, 333- 207149, 333-212017, 333-219188, 333-227955, 333-238088, and 333-254363), and Form S-1 (File No. 333-235358) of our report dated March 8, 2024, relating to the consolidated financial statements, appearing in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Rose, Snyder &amp; Jacobs LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rose, Snyder &amp; Jacobs LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Encino, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 8, 2024</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>capr-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:31 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Linda Marb&#225;n, Ph.D., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1. I have reviewed this Annual Report on Form 10-K of Capricor Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer and Principal Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>capr-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Anthony J. Bergmann, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1. I have reviewed this Annual Report on Form 10-K of Capricor Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anthony J. Bergmann</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Anthony J. Bergmann</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer, Principal Financial and Principal Accounting Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>capr-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PURSUANT TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18 U.S.C. SECTION 1350,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">AS ADOPTED PURSUANT TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Linda Marb&#225;n, Ph.D., the Principal Executive Officer of Capricor Therapeutics, Inc. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), hereby certifies, to her knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">(1) the Annual Report on Form 10-K of the Company for the period ended December 31, 2023 (the &#8220;<b style="font-weight:bold;">Report</b>&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:51.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:51.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Linda Marb&#225;n, Ph.D.</p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer and Principal Executive Officer</p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>capr-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PURSUANT TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18 U.S.C. SECTION 1350,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">AS ADOPTED PURSUANT TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Anthony J. Bergmann, the Principal Financial Officer of Capricor Therapeutics, Inc. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), hereby certifies, to his knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">(1) the Annual Report on Form 10-K of the Company for the period ended December 31, 2023 (the &#8220;<b style="font-weight:bold;">Report</b>&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anthony J. Bergmann</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Anthony J. Bergmann</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer, Principal Financial and Principal Accounting Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>9
<FILENAME>capr-20231231xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 10:04:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 97</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Introduction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Board of Directors (the &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</b>&#8221;) of <b style="font-weight:bold;">Capricor Therapeutics, Inc.</b> (the &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</b>&#8221;) has adopted this Policy on Recoupment of Incentive Compensation (this &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</b>&#8221;), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. &#160;This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (&#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</b>&#8221;) rules and Nasdaq Stock Market (&#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</b>&#8221;) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dodd-Frank Act</b>&#8221;) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Policy shall be administered by the Company&#8217;s Compensation Committee. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals. &#160;The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act. &#160;The Board or Compensation Committee may amend this Policy from time to time in its discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Executives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Policy applies to any current or former &#8220;executive officer,&#8221; within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive</b>&#8221;). &#160;This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recoupment Upon Financial Restatement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Restatement</b>&#8221;), the Compensation Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No-Fault Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Subject to Recovery; Enforcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measure that is derived wholly or in part from such measures, whether or not presented within the Company&#8217;s financial statements or included in a filing with the SEC, including stock price and total shareholder return (&#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TSR</b>&#8221;), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (&#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive-Based Compensation</b>&#8221;). &#160;Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure, is not subject to this Policy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee. &#160;For purposes of this Policy, &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recovery Period</b>&#8221; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company&#8217;s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules). &#160;The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company may use any legal or equitable remedies that are available to the Company to recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive. Executives shall be solely responsible for any tax consequences to them that result from the recoupment or recovery of any amount pursuant to this Policy, and the Company shall have no obligation to administer the Policy in a manner that avoids or minimizes any such tax consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy or any claims relating to the Company&#8217;s enforcement of rights under this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exceptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company&#8217;s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Remedies Not Precluded</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy, whether arising under applicable law (including pursuant to Section 304 of the Sarbanes-Oxley Act of 2002), regulation or pursuant to the terms of any other policy of the Company, employment agreement, equity award, cash incentive award or other agreement applicable to an Executive. &#160;Notwithstanding the foregoing, there shall be no duplication of recovery of the same Incentive-Based Compensation under this Policy and any other such rights or remedies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the extent required by the Compensation Committee, each Executive shall be required to sign and return to the Company the Acknowledgement Form attached hereto as <b style="font-weight:bold;">Exhibit A</b> pursuant to which such Executive will agree to be bound by the terms of, and comply with, this Policy. For the avoidance of doubt, each Executive shall be fully bound by, and must comply with, the Policy, whether or not such Executive has executed and returned such Acknowledgment Form to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date and Applicability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Policy has been adopted by the Board on November 27, 2023, and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8195;<font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DODD-FRANK COMPENSATION CLAWBACK POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACKNOWLEDGEMENT FORM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Capitalized terms used but not otherwise defined in this Acknowledgement Form (this &#8220;<font style="font-style:italic;font-weight:bold;">Acknowledgement Form</font>&#8221;) shall have the meanings ascribed to such terms in the Policy. By signing this Acknowledgement Form, the undersigned acknowledges, confirms and agrees that the undersigned: (i) &#160;has received and reviewed a copy of the Policy; (ii) is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment with the Company; and (iii) will abide by the terms of the Policy, including, without limitation, by reasonably promptly returning any recoverable compensation to the Company as required by the Policy, as determined by the Compensation Committee in its sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;Signature: _______________________________</p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;Print Name: &#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;&#173;______________________________</p></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;Date: ____________________________________</p></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>capr-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $$ G<# 2(  A$! Q$!_\0
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M_9*[*N-UK_DI_AK_ *]+O_V2L*NR]5^:/0P7\27^&?\ Z2SLJ***V. ****
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M2993M'\(XKZW\;_!SPC\1-3MM1UW2C<7]O$8$N8+B6WD,1.?+9HV4LF>=K9
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M!"+;'!50=Q)_2OL[Q3X)T#QQ91V?B'1[+6[2-_,2"_@65%?&-P# \\FOGO\
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MF:!7&_"C_D5I/^OZY_\ 1K5V5<;\*/\ D5I/^OZY_P#1K5C+^)'T?Z'H4_\
M=*O^*/\ [<=E1116QYX5!>7<%E;27%Q,D$$2EGDD8*JCU)->7>.OC+>IXBN?
M"'@72EU[Q/ %^VW=T6CTW2@PR#/(.7?'(B3+'N5'-<L_P?LM7']J?$/7+KQG
M>I\\AU&7R--@/I';*1&J^[[F]35)7$W8B^$NNV</A'Q+XHO;F&QT6_UJ\OX+
MN<B.,V^X(LF3V;82#W!%<E\6O%(^-_P_UKPMX>LI;?0]2B\BY\6ZO_H=G:J&
M#>9%OPTK#&1P![UT_P :/!_B+7-/\+6GA?1M-U/3;"\$]S87MT+6V"HG[DL
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M/TV] 6YCM(0VUYE&=CNSLVS.5&,\Y%>OUF]RUL%%%%(84444 %%%-9@JDD@
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M_P"P]J?_ *5259^)<9TOXY> -14?+?V.HZ5)@\D[8YTX^L+?G5+<E['E^M^
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M3TM Z2GSRZMNW%=N/;K78UU_]B67_/$?F:/[$LO^>(_,T^1B6)BNAR%%=?\
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M\3_#G4]2^(5MK^G7*VX80++<?:I$>%8V)91&/ED#@X.>G6O1SR377?V)9?\
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M">OZ=J\>H2WMQ;'+1W5M$T?RN[Q^2NW]P$\Q@ F!B@#;\,_&G0-<CUC[1/\
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M/2;/7M$OM.U 9LKJ%HIOFVX4CKGM7FWB#X"?\)?9:7;:KXOU2]M;#;Y">5
M55E9"<)@L-N-W4@T =CI?Q3\)ZSIFHZC9ZY;2V6G0BXNIR2JQ1$$B0Y ^4@'
MYAQP?2H+SXK^&[=HXTU. S.L<JK,3"&C8@;U9P PY' ]16*GP,T.V\/ZGI1O
M+T6U]H<&A2R%TW+!%YFUQ\N-W[QLD\<#BLO5/V=])\1^+CXCN-=U&X9G$D,6
M(FC1?D(0';DIF,$#/<^M ';V7Q-\,:@]@D&KQ.U^Q6VRKKYI!(XR!P2#@]#C
MC-8NB_&KP]?ZCXALKZ\CTRYT>[GMI(IB<R)&RJ77CG)=1M&3\PXY%8>B_LWZ
M-HWB"TU@7\EU<0S&5H;BUA:'[Q91&FW$6TD\IBIM2_9XTS4]=N-4DUF_607T
MNJ6486+;9WDCHYE&5RX_=J K9&"WKP 2^*_VB/"WA]94MKA]1NH[=+ORXT95
M,32^63DCAE.<J>>*]#T/7M/\2:='?Z9=)>6DA(61,]0<$$'D$'L:\T?]G72Y
MKJ2XEUF_>6Z5OMQ"1#[3(9A-O^[\GS#&%XQ^==]X0\(6O@S39K*SEEEBEN9;
MHF8@G=(VXC@#B@#=KC=:_P"2G^&O^O2[_P#9*[*N-UK_ )*?X:_Z]+O_ -DK
M&KLO5?FCOP7\27^&?_I+.RHHHK8X#C/&GQ*MO!_B#1M'>V\^ZU-)9(V>X2%%
M6/;NY;J?FZ#TK#\>?';1_"%M9RV?EZTT\;RE+>8#8H7(/3H>1^%=5X@^'^E>
M)O$>F:S?QF>;3X)H(HF"E,2@!CR,@C;P0:\__P"&8="FBD2ZU;49_E:&)E\M
M#%#@@1\+SC)Y/- '?7GQ(\.:5<+;:AJL%G<^0+AXY2<1KL+X9L8!V@G!.2 3
MBGW?Q'\,V6HBPFUJU2[+[#'NSM.T, 2.!PPZ^HKG;_X/:1J?B)KB6_GDLFGA
MO;K2"(VCFFCC\N-V8C>!M RH."5^H.-%^S3X<M9=.ECNIY6MHGAF>]BBN&N%
M+[E8LR_*Z\ ,,' % &QI?QU\+ZIXJGTE-0A6W\F.6WOBQ$4Y8,2 <8&-IZGG
M'%;L7Q0\+3I:.FL1;+NX-I$Y1PIER!L8D84G(QNQG(QG-<?>?L^>&+G34LKF
M]O3;O%;VV#*@+B)751G;U(<YQ69-^RWI%U%80S:W>"VMIHYV@@MX(EF=)%=7
M;:OW\($9QRR@#C% '<^#_B?I?CCQ+K6F:4_VFWTV"WF^V+D++YIDP%! R!Y>
M<C(.>*[2N%^'_P +HOA_=7$ZZO=ZI)+9V]@OVE(U"0P;Q$/D49(#D$GKUKN1
MTH 6BBB@#B?C1I&I:[\,/$%AI#3KJ,]L4B^S %R<C@9KR\ZC\3+3_B0Z;#-;
M1V,PA:XBLD5?(,B!&3C:2$WDX'%?0U)B@#YNUZ]^)=_X7\7Z1=SZS:ZG#8W"
MZ-=6-NH-WM=L.[ ?*^ N ,9S[U??6/']G>:G]FBOTLI)FDTZYCL1YE]+Y-OY
M8G&/D4_O<GCE<<8KZ"QS1CGK0!XCX>O_ (HVQO9KQ);N6>QNY([>:%%C@G64
MB)5(P3E.>>O%9VC:5XN\6?$7PC>:B^H7.@:9<3S>;>VB1EG,"??3'&V0N%8<
M\?C7OY&:!0!\U6:_$'P%INIP6EIJDMGJ%UJ<\:PPH39ROJ3F%@=I)5HW+'(/
M;&*(_$/QE.CQZJ(+HW+-'%)8M:)M2,P@R2@=2P;.!G&>,5]+4FV@#YP^%)\9
M:+\1I!.NJW6AZKJ%Q/(MQ:B%L%<B>0[<;> NT%2#ZU]'KG'- &.]+0 4444
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M<D>M=KI/[1VBM;:IJ>H%ET5=5BL+*Y@3)*26\$BEU)SG=-MPH-2W7[1FCO\
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MKR0PPSB57?:@;:O[R-21CJM<EH7@+Q3H7A^>*&QNH[2XUXWUQ8#4 ;F6V9%
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M3H4DB<95U/4$5Y?+IO@3PMX]T335'V2]MG#V=A%#F(33!P)"V,[ML;#DX %
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M?CCQK%\1M-MM/@MAIME=II\EL^R\:1"!#*L>22DJG>K8 ' &:]P'B2W P('
M_"@>)+<-N$#ANF>,TN9#]C4['S!?_M%:MI.HPZQINM02:!)9:?IUQ?:E#*]O
M;7AC8S':,$R J P]ZG@_:O\ &KZHEJF@6E[JB01S?\(];V\OVNXC>R:?S0V<
M*H=5&",D.!UQ7T%K46A>(6L&U#3//^P7(N[?)VA)0" W!&>IZT[3TT72M;U/
M5[33C%J.IF,W<X8DR[%")P3@84 <8I\R#V-3L>8_"CXQ^.?'GB;0+"]T_2X=
M,NK:ZO;B^M]TA9(S"$C^5BL<FZ5P58D_N^@/ \^T'XQ>*O!FE^*M2C5_$6OI
MK$\,6BRO<RS26XE< JFW;'M4 Y&<J/4BOJ-?$=NOW8'7OP!1_P ));@Y\A\_
MA1S(7L:G8^=K;XT>/HO'>K6%M?:=J37UUHT=C:264RK;PW,8\V<#.2BL&!S_
M !#G%3:7^T'\1]=M)/*\/Z?87$VK+IZQRJTLUCS.&$T2MN'$4;!FQG>>V#7T
M%_PD5MNW?9VW8QNP,XI1XDMP21;N">2>.:.9![&IV/G"+XP?$+Q#!IL=]I20
MWTT<-S;36=M/&L#26\I*NN?G*L@X/]X<5I?"SXX^.-3?X?:)>166N3>(8$G.
MK11.BQQP[A>+(">)%/E =LR>U>^_\)+!_P \'_2LJVBT*T\07&N1:6%U:>%;
M=[H\L(QR%7)PHSR<8R>N:.9![&IV/G^^^+&K> /BCXVMUU'^WVFOA_Q.TEFF
MM=!MGF1/*NK<85#&#PRGY@"3CK6;XX^/WB7Q1KNJ>&].66^M+.6UDCN[&SD@
M=Y4EC+J#N;*.K9&<<'N*^I1X@M07Q:GY_O<#YOKZTH\16RG*VS ^P%',@]C4
M['!_ /XG>)/B7:ZM<:]IMIIJ02*L,4,@\Z(G.Z*5,DJRD=\$YZ5ZU6$OB2W5
MB1 X)Y.,<T[_ (2B'_GC)^E',@]C4[&W16+_ ,)1#_SQD_2D_P"$HA_YXR?I
M1S(/8U.QMT5B?\)1#_SQD_2C_A*(?^>,GZ4N9![&IV-NBL3_ (2B'_GC)^E'
M_"40_P#/&3]*.9![&IV-NN,^%(SX6D_Z_KG_ -&M6R/$\)('DR<_2N1^&'B&
M*W\,.IB<YO;D\8_YZM64I+VD?1_H=].E/ZI55NL?_;CT 6%L  +>(   #8.
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M'_",2_\ /9?RHY6'MJ?<Q**V_P#A&)?^>R_E1_PC$O\ SV7\J.5A[:GW,2N
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MUT+_ ,!)/_CE'_#<OQ$_Y]="_P# 23_XY117C^WJ_P [^]GZ#_9F _Y\0_\
M 8_Y!_PW+\1/^?70O_ 23_XY1_PW+\1/^?70O_ 23_XY111[>K_._O8?V9@/
M^?$/_ 8_Y!_PW+\1/^?70O\ P$D_^.4?\-R_$3_GUT+_ ,!)/_CE%%'MZO\
M._O8?V9@/^?$/_ 8_P"0?\-R_$3_ )]="_\  23_ ..4?\-R_$3_ )]="_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>capr-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $8 :0# 2(  A$! Q$!_\0
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MCC#C+J.I [B@"U12!@:KW>HVU@(C<SQP"6011^8P&YST4>I/I0!9HI"V*6@
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M!.!SD8%?7$.!&H     V]/PKY(\57WC:7QI#9:AJ<>DW]O;?:)[2#68B!#$
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MG16&FVD-C9P@[(($"J,\GCZUYK8_\G.:G_V+D7_HZ@#UFBBB@ HHHH ****
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MS]*[%3HNBZC;OMLK7U\_(Y'4K*JH)*WJ_+R/9 <TM(!@4M<9UA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(PR*6D8X% '
MRC\<=%N]6^(&LC3]$U)9;..2]O\ $QBL[^R%LH<!\<R28,6T'MDU]46)5K.
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MQ#?";1GT6ZTLW.K?9[FZ%V[_ -HR^8''97SD+_LCBIM6^%GA_7]06ZU.";4
MMM]E^S74S20,F,9,9RI;'\6,UV-%-2:=TQ.$7HT>%:U^RMI2Z9';>%/$OB#P
MF8G$B16U\\EN6!R 8R>GL"*KBS\:^!]8U#4O$/A^Y\417=L;2:_\.WT@(CP!
MN^RN?E; R2A)KWVD-=*Q,FK5$I+SW^]:G.\-%.\'R^FWW;'SUJ'C;X6R> F2
MY\1ZAID6B))*+?4+V>"Z5B#Q(&.Y^3C!S4W[-*^#_'_PN,^C:Q=7LEQ#]EU!
M(KV0&!MQ.%7/[LXQR,5N_M-_ JR^-OPTU+3 8+'58P+BWOFB!92G.TGK@CBO
M&OV4_P!G/QE\+? /]O>'?%5F;[5_WTNG75MNMG520H+9W \=17K1IX2I@925
M1QGS+1[?>EZGF2GB:>,C%P4H<KU6_P!S?H?3,'PTTF"30Y%N=2)T?_CWW7\I
M#\Y_>#/[S_@6:;)\,-)D@UN%KC4]FKR"2X(U"4%3G/[LY^0>RXKE1\:=1\)%
M8?'GA:]T0#@ZIIZF[LC[DJ-R#ZBO1/#?BS1?%^GK>Z)JEKJEJ?\ EI:RAP/8
MXZ'V->-.C5IKFDM.^Z^]:'JPJ4JCY5OVV?W&</ &FKJ6E7OG:AYNFQ>3"OVR
M38P]77.'/N:ICX5:.-%O=+%SJOV:[N!<R-_:,OF!@>BOG*CV'%=GN% (-87?
M<WY8]CG/^$&T\>((=8$U]]JBM_LJI]KD\K9C&2F<%L=^M9Y^%>CMH::4;C5?
MLR7/VL-_:$OF;\YP7SG;_L]*[2BB[#E78YG_ (0+3DU?4=2$U^;B^MC:RK]L
MD\L)C&47.%;_ &AS7 ^*=$M_"D6FZ;;^'?%.L6.EDWD=W::BQRQY*NS."X&.
MAXKV2J.M_P#(&O\ _K@__H)K2G)*2YE<SG"\?==CR#P=JEKX_O)]1B\,>*;.
MR\01;9+V:](AC3U50_R'(ZJ*] B^'.F0?V'MGU$_V.<VVZ^D.[_KIS^\_P"!
M9JA\"_\ DDGAK_KV/_H;5WE:8AI5)1@K)-HSH)NG&4G=M)G'GX::48-<B^T:
MGMUE]]R?M\N5.2?W9S^['/1<587X?Z:-1TJ]$VH>;IL7DPK]MDV,N/XUSAS[
MFNHHKGNSHY5V.*/PJT=M$O=*^T:K]FO)_M$C_P!HR^8&]%?.5'L.*OIX#TZ+
M7K?5UFO_ +5!:BT1#>2&(IMVY*9P6Q_%US734478<J['$CX3Z,-%&F?:=6^S
M"Z^U[O[1F\S?GINSG;_L]*TCX'T]M7OM1\Z^^T7MK]DD47;^6$QC*KG"M_M#
MFNDHHNPY5V.-C^&&D)I&F::+C4_(T^<W,3'4)3(S9SAVSEA['BNGL[&.R,IC
M:1O-D,C;W+8)],]![5Q/C[Q;XR\.7LS:)X4MM9TR*#S6NI+\0L&&2R[=IZ #
MGWK.^&OQ#\9^-AI=]>^#[?2]$OH1,+I=0$CJI&1\FVNGZO4=/VEU;U7Y7N<_
MMJ<9^S2=_1_G8]2HHHKE.H**** "BBB@ IDCA$+,P11U9C@"GU4U73H-8TVZ
ML;I-]M<1M%(H."5(P>: /G#XG:WI=K\0/$_AZ[UV;0;#6EA6^67P]/?M<H\0
M0FVN(P5B.T;2'#;3\PQ7TK;1+#!'&F2B*%7/7 '%?/Y\#Z/X2\97]C+\8O$U
MI>21F^.G&ZMR(;>&-<[LPG "C/8X_.OH&!Q)$K*V]2 0WJ/6@"2BF2.RJVT!
MF X!.,FO'->^-/B/POJUWI^H>&[-IE$$5N+:_#[IYY1'!&^5&W=\S9[!?<4
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M*U?7KVT%K!*%)N(LM\G;!!8\ ]Z].T'6;7Q%H>GZK92K-9WMO'<PR*>&1U#
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M7(\V.'3;6\@C5\^68+@;,2$KM&>X!!XKZ]A"K&H080   =A0 ^DQ06 -&:
M]#7D]C_R<[JG_8N1?^CJ]8)KR>P_Y.=U3_L7(O\ T=0!ZS1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&=83*R*JG<?E5N>G%-U?]HCPI!I&A7NJ63,+U/[02,M'+]FB614$V<XSN88
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M>(9]>M[B\L-7GG::2XB<-N#*JLA5@1M(1>,=:** /3(8A!$B#D*H4?A4E%%
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M%2H'9?F8X]234-O\ -#-Q:SWU_J6J7%G-;R6LMU<9,*0N6CC7 'RY//K110
M^;X!Z#_;J:M;75_9W1O+Z[E\N;Y9?M8C$Z$$?=/DIC'3%;'A7X3:)X.O+>YT
MXW*36^F)I,;/*6Q"ARO_  +/>BB@#F$_9TTU-+UFQ_X2;Q&T.JWPU"Y)ON3+
MG)[="<9'0X%>F:%I1T32+6P-W<7WD($^T73;I']V/'-%% %^BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>capr-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $6 :,# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !535!=G3KD6!A6],;>29P3&'QQN
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MHHH **** "BBB@#S;]HT#_A2OBK_ *]?_9A7<>'A_P 2+3O^O:+_ - %</\
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MB?I@5O&A5GK&#?R,)5Z4?BDOO$_:,.?@MXJ_Z]?_ &85W/A[_D!:=_U[1?\
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M_<E5OY&K&XUEMN:)WV'T4T,33J!A1110 4444 %%%% !1110!G^(/^0#J/\
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M4^+MJXVW'A:_0.<[HIHB5_[Z/->G[AZT9%/ZQ+K&/W+]+!]7723^]_J>7_\
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M=,U2"Y<=82VV13Z%3R#70YK>,E)7B[GG5:52C)PJQ<7V:L+129I:HR"BBB@
MHHK#\3>,='\'Q03:SJ,6GQ3.4C:4D!B!G'Y5,I**O)V1I3ISJR4*<6V^BU9R
M_B']GOX>^*]4O-1U;PQ:7UY=MOGDE+'S#TR1G'85H>#O@UX-\ :FVH:!H5OI
MMXT9B,L1;.WTY-5U^.'@64LJ>)K)F!VD*Y.#Z'BNVMYEGC21&W(ZA@?4'H:W
M6,J58\BJ-KM?0FKETL+)3K4>1O9N-OS1-11161(4444 %%%% !1110 4444
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M!)_ 5\^GQ/X"\3^*!9Z=\0+MM*U#5%GFT**RDQ-=%E.WS60%02 2N?YT ?2
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MZ]\5<G)_X2JXY/\ N)7LU !1110 4444 %%%% !1110 4444 %%%% !1110
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MH&"><9- 'UP.E5M2^U_8+C[!Y/VWRSY/VC/E[\<;L<XSZ59%4M<TO^VM&OK
M7,UF;F%X?M%LVV2/<,;E/8CM0!X_:?&+Q5=(-&CT_29_$DVN3:1;7<;R"PF6
M*#SI)1GYOEPR$?WE/-='IOQTT"W\&:9K?B&Y71WNI9;9XPK2*)HG9' (!XRI
MQGM38?@=9V_A;3]&BUO4HY=,N/M.GZ@I436K;2I XP006SGKN-=KX6\+V7A#
M0+32+)6-M;J<-(=S.Q)9F8]R223]: /(?V6]=L?$L_Q,U/39Q<V5QXHN'BE
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MPS7MK]BN67+V^\/L/ID=:RA5C4^'\F=F(P5;"I.K;7M*+WZZ-Z%ZO&/VC?\
MD)_";_L=;#_T&2O9Z\8_:-_Y"?PF_P"QUL/_ $&2MCB1[/5*71=/GE,DEA;2
M2$Y+M"I)/UQ5VB@0@ 4    = **6B@ HHHH 1NU?*=UXDL]!^.>LV:W.K6EW
M-J/G6^C1:Q*'O9]T:LYMP-HB96# YP=ISBOJM@.,]J^;;[QC]K^).I^$%\7V
M.F0G6\21W\$QU4$E)/*MW#;/*;.%8] 2,4 ?28Z4M(.GI2T %(:6D- 'C7[/
M/_(>^*O_ &-5Q_Z E>S5XS^SS_R'OBK_ -C5<?\ H"5[-0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !32N33J* .;\7?#_1O&]K'%JEJ))8CO@N8R4FA;^\CCD&N0^U^,?AJ?],27
MQGX>3_EO"H^WVZ_[2])0/;!^M>ITS8,]36$Z*D^:+L^_^?<]&CCITX>QJ)3I
M_P KZ>CWB_3YIF/X7\9Z/XST_P"V:/?1WD0.UU4X>-NZNIY4^Q%;(;)KB?%?
MPIT[7+\ZQIES/X;\2*/EU73<*S_[,J?=E7V8?0BLB#XCZUX%D2T\>Z>B6V=B
M>(M,5FLY/0RIRT)/OE?0U'M94]*J^?3_ ('Y>9O]3IXGWL#*[_D?Q?+I/Y6E
M_=MJ>GT54L-2M]3M8[FUFCN;>0;DEB8,K#U!%6@<C-=*=]CR&G%V>YYQIW_)
MP>L?]B[;?^CY*](KS?3O^3@]8_[%VV_]'R5Z17/0VEZO\SULR^.E_@A_Z2@K
MQC]HW_D)_";_ +'6P_\ 09*]GKQC]HW_ )"?PF_['6P_]!DKI/)1[/1110(*
M*** "BBB@""^NX;"SFNKAQ%;PHTDCMT50,DG\!7S7X;TWQ-\0_B/J^L:)>S0
M:5/.HN)]2>2&XMH"R/&L<!&!PK ,.H;GI7T;K>E0:]H]]IETK-:WL#VTP0X.
MQU*M@]C@UYYHOP T;0=<@U:#6O$<MU%L&)]5E=)%4Y"L">1R>/>@#U =*AO9
M)XK.=[:(3W"H3'$6VAVQP,]OK4R].:CNX6N+6:))6@=T*B5/O(2.H]Q0!XMH
M?QOU_P 0^&-'%OI-E!XFU76;[28[>29C;Q?9FEWN6 R?EB/ '4UT=E\=_#5G
MX-TS6_$E_#H+7<DMN8Y=S 31N4=00.1E3^%9VC_L\V.CZ"NGP^(=7:XAU&75
M;6_=T,UM/*7,NWC&'\QL@^M=WX=\#Z3X=\.V6CQVL=U;6H.UKI!(S,Q+,YR.
MI))/UH \J_9:UZP\3S?$S5-+N5O+"Y\47#PSIG#C:G(S7NU>*_LY01VVL_%.
M*&-(HU\57 5$4*!\B= *Z_XO?%?2O@YX3EU[5EEFC\P0PV\(^>60]%![?6HG
M.-.+G-V2.C#X>KBZT</0CS3D[)+JSNZ*\<^!'[1^C?'&2^MK6RGTO4;,"1K:
M9@VY"<;@16#XK_::NM!M?$;1Z/#,]C)J-O;!)]SB2UC+[I4ZA&QC/;(]:BE6
MIUX*I3=TS?'8#$Y;7EAL7!PFMTSZ!HKAA\7?#MC<K8ZI>2:=??8OMI$]O(D4
MB!5+^4Y7;(5WKD*2>12:A\7_  [8Q6RRW,UM=7<9>&&ZM)8BIY"^9E1Y>XC
MW8SVK8X#NJ*\F^'G[0&@^)_"46H:K=#3M2BMUGN;4P2+D,Y1?*RO[S+87Y<\
M\5Z!X7\5Z;XPL&O=,G::))&AD22-HI(I!U1T8!E89'!'>@#9HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0C-
M1RV\4T3QR1K)&X(9'&0P]"*EHH#8\UO_ (77/AJ[DU'P-?#1IG.^72ILO93G
MO\O_ "S)]5_*K&A?%>/[>FD>)[-_#.L'Y46X.8)S_P!,Y>A^AYKT*LO7O#VG
M>);"2RU.RBO;5^#'*N1]1Z'WKF]DX.])V\NG_ ^1ZZQL<0N3&QYO[R^-?/[7
MI+7LT<!I>IVC_M$ZQ"+J%IO^$?MD""0;B1/(2,>N"#7J=? WA3]GSQSH_P"T
MNEO'<%([&Y34FU 3YS:%R%ZG)/RE<>U?>Z]>_P"-<F K5*L9^TARVDSW>)\!
MAL#4PZPV(552IQO;I965]7OOW'5XQ^T;_P A/X3?]CK8?^@R5[*P/:O&/B)I
MWB'XD?%+PCHUMX?N;+0/#6K0ZU=Z]=NJQSM&C;(8$!+,27Y)  P>M>H?%GM-
M%(*6@ HHHH **** "BBB@ HHHH *0TM(: /&OV>?^0]\5?\ L:KC_P! 2N@^
M./P>L_C5X+DT&ZO'T^59EN+>Z1=WER#U7C(()&,US_[//_(>^*O_ &-5Q_Z
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M8^(-2\=>'!!>1WNDZS8"^N=/-OM;3T,893Y@/)+'&"!7K(Z4 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >;Z=_P G!ZQ_V+MM_P"CY*](KS?3O^3@]8_[%VV_]'R5Z17-0VEZO\SU
M\R^.E_@A_P"DH****Z3R HHHH **** "BBB@ HHHH *0\4M(>E '&?$/QM?>
M&KC0]+TBU@O-:UJY:WMEN6*Q($C:1W;')PJG@=R*S;#XY>&X?!^FZWX@OX="
M-W));F*4LX$T;E'4$ Y *FMOQUX$B\:PZ>ZWUSI&HZ=/]HL[^T"EXG*E&X8$
M$%68$$=ZN>%_!NG>%/#MGH]O&;BWM@Q$EP [N[,69V..K,23]: /*OV7M;L/
M$ES\3-2TRZ2\L;CQ1</%/&"%<;4Y&>:],^(GPV\/_%3PQ<Z!XDL5O]-G(8HQ
MP58=&4]B/6O']*\)_&#X:^*O&)\*:#X1UC1=9U634H)=0U2>UF0.J@H42%AQ
MCJ#6U_PD7[0G_0E> _\ P?W7_P CU<)RIR4H.S1,HQFG&2NF=1\(?@#X,^!]
MK=Q>%M-^RR79!FGE<O(X'0;CV]JT=2^$'AS5-2U*\>&>'^TT=+Z""=DBN-Z[
M6+*#C)'>O*%^*GQV/C4^%_\ A"/!']H"R^W;_P"WKG9LW[<9^SYSD^E;W_"1
M_M"?]"5X#_\ !_<__(]55JSK3<ZDKM]633I0I14*:LEV/0=;^%/A?Q#-9R7N
MEQN]I"MO%LRN(UD215XZ@-&I'TKJ7MXY2"R*Q'<CFO%?^$C_ &A/^A*\!_\
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M$KP'_P"#^Y_^1Z /;J*\1_X2/]H3_H2O ?\ X/[G_P"1Z/\ A(_VA/\ H2O
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M#^Y_^1Z /;J*\1_X2/\ :$_Z$KP'_P"#^Y_^1Z/^$C_:$_Z$KP'_ .#^Y_\
MD>@#VZHR^&Z@"O%?^$C_ &A/^A*\!_\ @_N?_D>L_7)/CIXCTZ2QU+P%X NK
M60@M$^OW6"1T_P"7>D[VT+BHN24G9?UZ?F=II[_\9 ZR>/\ D7;;_P!'R5Z.
MK[CC-?'B:'X\;X@3>&!\)/AZ-672TU%I_P"W;K:83*8PN[R,YW G'3%>FZ5>
M_'C0["&RL? G@&WM85VQQ+K]UA1_X#UST8SA=22U;>_?Y'IXZKAZW)*C*3:C
M&.J2V5KZ2?W6^9[S17B/_"1_M"?]"5X#_P#!_<__ "/1_P )'^T)_P!"5X#_
M /!_<_\ R/72>2>W45XC_P )'^T)_P!"5X#_ /!_<_\ R/1_PD?[0G_0E> _
M_!_<_P#R/0![=17B/_"1_M"?]"5X#_\ !_<__(]% 'MU%%% !1110 4444 %
M8?C;Q7:^!_"^H:Y>(\EO9Q[V2,?,<D #VY(Y[5N5F^([6XO=%O(+6"VN9I(R
MJPW@S$^>S>U &)I'C^W;1]/N]<2'19[]]EM;FY2;S<XVE60D'.14G_"T?"6P
M./$-@R&<VVX3 CS!U7\._I7FG@[X)>(?!NN:?K5M=:?*PDF272) [6UI#)(K
MXMR>05VGKUS[5ES?LOSVVB^&[2*ZMKU+""]M+VW<&%+F.XN/-WY7D,N /<4
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M ,.?![P]9:G;&TO0DDDD#+M*;Y7<#';AAQVH ]'HHHH **** "BBB@ HHHH
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M!7#?"GP'=>!['6&O98/M.J7S7SV]FI6" E$7:@/;Y-Q]V-=S0 4444 %%%%
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G!"Q%!;C-%% !NX'O2!^,XHHH 7=SBE!R,T44 +1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>capr-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 10:04:47 PM-->
<!--Modified on: 3/8/2024 10:04:47 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" targetNamespace="http://capricor.com/20231231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:capr="http://capricor.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails">
        <link:definition>40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details">
        <link:definition>40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc2) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details">
        <link:definition>40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" id="DisclosureStockAwardsWarrantsAndOptionsTables">
        <link:definition>30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails">
        <link:definition>40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockholderSEquityDetails" id="DisclosureStockholderSEquityDetails">
        <link:definition>40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" id="DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails">
        <link:definition>40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" id="DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails">
        <link:definition>40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" id="DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails">
        <link:definition>40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" id="DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails">
        <link:definition>40305 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" id="DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails">
        <link:definition>40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" id="DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails">
        <link:definition>40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureConcentrationsDetails" id="DisclosureConcentrationsDetails">
        <link:definition>40401 - Disclosure - CONCENTRATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" id="DisclosureGovernmentGrantAwardsDetails">
        <link:definition>40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails" id="DisclosureLicenseAndDistributionAgreementsDetails">
        <link:definition>40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDefaultDetails" id="DisclosureLicenseAndDistributionAgreementsDefaultDetails">
        <link:definition>40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS Default (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockholderSEquity" id="DisclosureStockholderSEquity">
        <link:definition>10201 - Disclosure - STOCKHOLDER'S EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions" id="DisclosureStockAwardsWarrantsAndOptions">
        <link:definition>10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureConcentrations" id="DisclosureConcentrations">
        <link:definition>10401 - Disclosure - CONCENTRATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureGovernmentGrantAwards" id="DisclosureGovernmentGrantAwards">
        <link:definition>10501 - Disclosure - GOVERNMENT GRANT AWARDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10601 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreements" id="DisclosureLicenseAndDistributionAgreements">
        <link:definition>10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10801 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10901 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" id="DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails">
        <link:definition>40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="IncreaseDecreaseFromGrantsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="capr_IncreaseDecreaseFromGrantsReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="StockAwardsWarrantsAndOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_StockAwardsWarrantsAndOptionsAbstract" substitutionGroup="xbrli:item" />
  <xsd:element name="AwardAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_AwardAbstract" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_GovernmentGrantAwardsDisclosureTextBlock" name="GovernmentGrantAwardsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_LicenseAgreementsAbstract" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_CommissionRateOnSalePricePerShare" name="CommissionRateOnSalePricePerShare" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" substitutionGroup="xbrli:item" />
  <xsd:element name="DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" name="MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="GrantorAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_GrantorAxis" substitutionGroup="xbrldt:dimensionItem" />
  <xsd:element name="GrantorDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_GrantorDomain" substitutionGroup="xbrli:item" />
  <xsd:element name="CaliforniaInstituteForRegenerativeMedicineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_CaliforniaInstituteForRegenerativeMedicineMember" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_GrantAwardLiability" name="GrantAwardLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="capr_MinimumExpectedContribution" name="MinimumExpectedContribution" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_CommitmentsAndContingenciesDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element id="capr_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_LicenseAgreementsTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="MilestonePaymentsInPhasesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_MilestonePaymentsInPhasesAxis" substitutionGroup="xbrldt:dimensionItem" />
  <xsd:element name="MilestonePaymentsInPhasesDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_MilestonePaymentsInPhasesDomain" substitutionGroup="xbrli:item" />
  <xsd:element name="JhuLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_JhuLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExosomesLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_ExosomesLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="CsmcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_CsmcMember" substitutionGroup="xbrli:item" />
  <xsd:element id="capr_LicenseAgreementsLineItems" name="LicenseAgreementsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="capr_UpfrontPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="PotentialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="capr_PotentialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="WrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="capr_WrittenNoticePeriod" substitutionGroup="xbrli:item" />
  <xsd:element name="TransactionOtherThanSubawardAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_TransactionOtherThanSubawardAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ConsultingAgreementWithFrankLitvackMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_ConsultingAgreementWithFrankLitvackMember" substitutionGroup="xbrli:item" />
  <xsd:element name="DrEduardoMarbanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="capr_DrEduardoMarbanMember" substitutionGroup="xbrli:item" />
  <xsd:element name="MonthlyConsultingFeesToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="capr_MonthlyConsultingFeesToRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element id="capr_UnrelatedPartyAxis" name="UnrelatedPartyAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_UnrelatedPartyDomain" name="UnrelatedPartyDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_UnrelatedPartyMember" name="UnrelatedPartyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_CsmcLicenseAgreementMember" name="CsmcLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" name="ClassOfWarrantOrRightWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" />
  <xsd:element id="capr_ClinicalTrialExpensePolicyPolicyTextBlock" name="ClinicalTrialExpensePolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" name="CommonStockWarrantsWithExpirationOnDecember2024OneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_ClassOfWarrantOrRightGranted" name="ClassOfWarrantOrRightGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_WeightedAverageExercisePriceGranted" name="WeightedAverageExercisePriceGranted" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" name="CommonStockWarrantsWithExpirationOnDecember2025TwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_FacilitiesLeaseMember" name="FacilitiesLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_RomeLicenseAgreementMember" name="RomeLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_CommonStockSharesAuthorizedValue" name="CommonStockSharesAuthorizedValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="capr_CompletionOfPhaseTwoDueMember" name="CompletionOfPhaseTwoDueMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_AdvisoryServicesAgreementMember" name="AdvisoryServicesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" name="PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="capr_StockOptionPlan2020Member" name="StockOptionPlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" name="UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_AnnualPaymentsForRoyalties" name="AnnualPaymentsForRoyalties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="capr_TermOfAward" name="TermOfAward" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_TerminableNoticePeriod" name="TerminableNoticePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_PeriodOfAgreementWillBeInEffective" name="PeriodOfAgreementWillBeInEffective" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" name="UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_NonPaymentOfRoyaltiesMember" name="NonPaymentOfRoyaltiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_MaterialBreachHasNotBeenCuredMember" name="MaterialBreachHasNotBeenCuredMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_FailsToCureBreachAfterNoticeFromCsmcMember" name="FailsToCureBreachAfterNoticeFromCsmcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" name="FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_ThresholdPeriodToCureBreach" name="ThresholdPeriodToCureBreach" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" name="NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_SeverancePackageToBePaidForPeriodOfBaseSalary" name="SeverancePackageToBePaidForPeriodOfBaseSalary" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_AgreementTerminationPeriod" name="AgreementTerminationPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="capr_StockOptionPlan2021Member" name="StockOptionPlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_June2021AtMarketProgramMember" name="June2021AtMarketProgramMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_NumberOfFinancialInstitutions" name="NumberOfFinancialInstitutions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="capr_PropertyLocatedAt10865RoadToCureInDiegoMember" name="PropertyLocatedAt10865RoadToCureInDiegoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" name="OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="EmployeeRetentionCreditCaresActRevenue" id="capr_EmployeeRetentionCreditCaresActRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeRetentionCreditCaresActReceivable" id="capr_EmployeeRetentionCreditCaresActReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryForwardsIndefinitely" id="capr_OperatingLossCarryForwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryForwardsExpirationYear" id="capr_OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TaxCreditCarryForwardsExpirationYear" id="capr_TaxCreditCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RangeOneMember" id="capr_RangeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RangeTwoMember" id="capr_RangeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RangeThreeMember" id="capr_RangeThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeesNonEmployeeConsultantsAndDirectorsMember" id="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncashLeaseExpenses" id="capr_NoncashLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseBaseLeaseRentPerMonth" id="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentsToAcquireLeaseholdImprovements" id="capr_PaymentsToAcquireLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationNumberOfPlans" id="capr_ShareBasedCompensationNumberOfPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CorporateOfficesLeaseMember" id="capr_CorporateOfficesLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermOperatingLeasesMember" id="capr_LongTermOperatingLeasesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VivariumSpaceLeaseMember" id="capr_VivariumSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePayments" id="capr_MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsultingAgreementMember" id="capr_ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseLeaseRentPerMonth" id="capr_LesseeOperatingLeaseLeaseRentPerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseMonthlyRentEscalationPercent" id="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantIncome" id="capr_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" id="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" id="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" id="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LiborMember" id="capr_LiborMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RegisteredDirectOfferingMember" id="capr_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LockUpPeriodNotToIssueOrSellShares" id="capr_LockUpPeriodNotToIssueOrSellShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AgreementExpiryTerm" id="capr_AgreementExpiryTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MichaelKelliherMember" id="capr_MichaelKelliherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RangeFourMember" id="capr_RangeFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockWarrantsWithExpirationOnDecember2030TwoMember" id="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAndServicesAgreementMember" id="capr_LicenseAndServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseFee" id="capr_LicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TermOfLicense" id="capr_TermOfLicense" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockOfferingRemainingAmountIssuable" id="capr_CommonStockOfferingRemainingAmountIssuable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OverduePaymentObligationsMember" id="capr_OverduePaymentObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentsPercentageOwedToThirdParty" id="capr_MilestonePaymentsPercentageOwedToThirdParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>capr-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 10:04:47 PM-->
<!--Modified on: 3/8/2024 10:04:47 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://capricor.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details" />
  <roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details" />
  <calculationLink xlink:role="http://capricor.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638455322861549918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638455322861549918" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638455322861549918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638455322861549918" xlink:to="us-gaap_MarketableSecuritiesCurrent_638455322861549918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638455322861549918" xlink:to="us-gaap_GrantsReceivableCurrent_638455322861549918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638455322861549918" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638455322861549918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638455322861549918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638455322861549918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638455322861559916" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets_638455322861559916" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638455322861559916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638455322861559916" xlink:to="us-gaap_LiabilitiesCurrent_638455322861559916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638455322861559916" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638455322861559916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638455322861559916" xlink:to="us-gaap_OtherLiabilitiesCurrent_638455322861559916" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638455322861559916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638455322861559916" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638455322861559916" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638455322861569918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638455322861559916" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638455322861569918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638455322861569918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638455322861559916" xlink:to="us-gaap_LiabilitiesNoncurrent_638455322861569918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_638455322861569918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638455322861569918" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_638455322861569918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322861569918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638455322861569918" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322861569918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638455322861569918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638455322861569918" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638455322861569918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638455322861579918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638455322861579918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638455322861579918" xlink:to="us-gaap_PreferredStockValue_638455322861579918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638455322861579918" xlink:to="us-gaap_CommonStockValue_638455322861579918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638455322861579918" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638455322861579918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638455322861579918" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638455322861579918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638455322861579918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638455322861579918" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638455322861579918" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322861589916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638455322861589916" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638455322861589916" xlink:to="us-gaap_NonoperatingIncomeExpense_638455322861589916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638455322861589916" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_638455322861589916" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638455322861589916" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638455322861589916" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_638455322861589916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638455322861589916" xlink:to="us-gaap_OtherIncome_638455322861589916" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638455322861599908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638455322861589916" xlink:to="us-gaap_OperatingIncomeLoss_638455322861599908" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638455322861599908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638455322861599908" xlink:to="us-gaap_OperatingExpenses_638455322861599908" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638455322861599908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638455322861599908" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638455322861599908" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638455322861599908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638455322861599908" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638455322861599908" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638455322861599908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638455322861599908" xlink:to="us-gaap_Revenues_638455322861599908" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638455322861599908" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322861609908" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_ProfitLoss_638455322861609908" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638455322861609908" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638455322861609908" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_ShareBasedCompensation_638455322861609908" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_IncreaseDecreaseFromGrantsReceivable" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable_638455322861609908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="capr_IncreaseDecreaseFromGrantsReceivable_638455322861609908" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638455322861619907" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_638455322861619907" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638455322861619907" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638455322861619907" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322861619907" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NoncashLeaseExpenses" xlink:label="capr_NoncashLeaseExpenses_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322861609908" xlink:to="capr_NoncashLeaseExpenses_638455322861619907" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638455322861619907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638455322861619907" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638455322861629907" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638455322861629907" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsToAcquireLeaseholdImprovements" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322861619907" xlink:to="capr_PaymentsToAcquireLeaseholdImprovements_638455322861629907" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322861629907" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322861629907" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322861629907" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638455322861629907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322861629907" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638455322861629907" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638455322861639904" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638455322861639904" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638455322861639904" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638455322861639904" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638455322861639904" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638455322861639904" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638455322861639904" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638455322861639904" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638455322861639904" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638455322861639904" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details" xlink:type="extended" xlink:title="40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc2) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638455322861649906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638455322861649906" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638455322861649906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638455322861649906" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details" xlink:type="extended" xlink:title="40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc3) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638455322861649906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638455322861649906" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322861649906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322861649906" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>capr-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 10:04:47 PM-->
<!--Modified on: 3/8/2024 10:04:47 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsTables" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockholderSEquityDetails" roleURI="http://capricor.com/role/DisclosureStockholderSEquityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureGovernmentGrantAwardsDetails" roleURI="http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureLicenseAndDistributionAgreementsDetails" roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureLicenseAndDistributionAgreementsDefaultDetails" roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDefaultDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://capricor.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://capricor.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="capr-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityEquityAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantorAxis" xlink:label="capr_GrantorAxis_1" xlink:title="capr_GrantorAxis_1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantorDomain" xlink:label="capr_GrantorDomain_1" xlink:title="capr_GrantorDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="capr_GrantorAxis_1" xlink:to="capr_GrantorDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:capr_GrantorAxis_1 To capr_GrantorDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyAxis" xlink:label="capr_UnrelatedPartyAxis_1" xlink:title="capr_UnrelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyDomain" xlink:label="capr_UnrelatedPartyDomain_1" xlink:title="capr_UnrelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="capr_UnrelatedPartyAxis_1" xlink:to="capr_UnrelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:capr_UnrelatedPartyAxis_1 To capr_UnrelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesAxis" xlink:label="capr_MilestonePaymentsInPhasesAxis_1" xlink:title="capr_MilestonePaymentsInPhasesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesDomain" xlink:label="capr_MilestonePaymentsInPhasesDomain_1" xlink:title="capr_MilestonePaymentsInPhasesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="capr_MilestonePaymentsInPhasesAxis_1" xlink:to="capr_MilestonePaymentsInPhasesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:capr_MilestonePaymentsInPhasesAxis_1 To capr_MilestonePaymentsInPhasesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1 To srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" xlink:type="extended" xlink:title="30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfWarrantActivityTableTextBlock" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_ScheduleOfWarrantActivityTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesTable" xlink:label="capr_AccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="capr_AccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="capr_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="capr_AccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="capr_AccountingPoliciesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="capr_AccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="capr_AccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesLineItems" xlink:label="capr_AccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_AccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActRevenue" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_EmployeeRetentionCreditCaresActRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActReceivable" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_EmployeeRetentionCreditCaresActReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantIncome" xlink:label="capr_GrantIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_GrantIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsExpirationYear" xlink:label="capr_OperatingLossCarryForwardsExpirationYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_OperatingLossCarryForwardsExpirationYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsIndefinitely" xlink:label="capr_OperatingLossCarryForwardsIndefinitely" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_OperatingLossCarryForwardsIndefinitely" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TaxCreditCarryForwardsExpirationYear" xlink:label="capr_TaxCreditCarryForwardsExpirationYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_TaxCreditCarryForwardsExpirationYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" xlink:type="extended" xlink:title="40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockholderSEquityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_June2021AtMarketProgramMember" xlink:label="capr_June2021AtMarketProgramMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="capr_June2021AtMarketProgramMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RegisteredDirectOfferingMember" xlink:label="capr_RegisteredDirectOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="capr_RegisteredDirectOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockSharesAuthorizedValue" xlink:label="capr_CommonStockSharesAuthorizedValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="capr_CommonStockSharesAuthorizedValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommissionRateOnSalePricePerShare" xlink:label="capr_CommissionRateOnSalePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="capr_CommissionRateOnSalePricePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LockUpPeriodNotToIssueOrSellShares" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="capr_LockUpPeriodNotToIssueOrSellShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementExpiryTerm" xlink:label="capr_AgreementExpiryTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="capr_AgreementExpiryTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockOfferingRemainingAmountIssuable" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="capr_CommonStockOfferingRemainingAmountIssuable" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsMember" xlink:label="capr_CommonStockWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="capr_CommonStockWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_CommonStockWarrantsMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_CommonStockWarrantsMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_CommonStockWarrantsMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40305 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeOneMember" xlink:label="capr_RangeOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="capr_RangeOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeTwoMember" xlink:label="capr_RangeTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="capr_RangeTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeThreeMember" xlink:label="capr_RangeThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="capr_RangeThreeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeFourMember" xlink:label="capr_RangeFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="capr_RangeFourMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" xlink:type="extended" xlink:title="40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" xlink:type="extended" xlink:title="40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2020Member" xlink:label="capr_StockOptionPlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="capr_StockOptionPlan2020Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2021Member" xlink:label="capr_StockOptionPlan2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="capr_StockOptionPlan2021Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationNumberOfPlans" xlink:label="capr_ShareBasedCompensationNumberOfPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="capr_ShareBasedCompensationNumberOfPlans" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="capr_CaliforniaInstituteForRegenerativeMedicineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="capr_CaliforniaInstituteForRegenerativeMedicineMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LiborMember" xlink:label="capr_LiborMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="capr_LiborMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantAwardLiability" xlink:label="capr_GrantAwardLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_GrantAwardLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumExpectedContribution" xlink:label="capr_MinimumExpectedContribution" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_MinimumExpectedContribution" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfAward" xlink:label="capr_TermOfAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="capr_TermOfAward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="us-gaap_DerivativeVariableInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeVariableInterestRate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureTable" xlink:label="capr_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyAxis" xlink:label="capr_UnrelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="capr_UnrelatedPartyAxis" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyDomain" xlink:label="capr_UnrelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="capr_UnrelatedPartyAxis" xlink:to="capr_UnrelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyMember" xlink:label="capr_UnrelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_UnrelatedPartyDomain" xlink:to="capr_UnrelatedPartyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FacilitiesLeaseMember" xlink:label="capr_FacilitiesLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="capr_FacilitiesLeaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CorporateOfficesLeaseMember" xlink:label="capr_CorporateOfficesLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="capr_CorporateOfficesLeaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LongTermOperatingLeasesMember" xlink:label="capr_LongTermOperatingLeasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="capr_LongTermOperatingLeasesMember" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_LongTermOperatingLeasesMember" xlink:to="capr_FacilitiesLeaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PropertyLocatedAt10865RoadToCureInDiegoMember" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_LongTermOperatingLeasesMember" xlink:to="capr_PropertyLocatedAt10865RoadToCureInDiegoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_VivariumSpaceLeaseMember" xlink:label="capr_VivariumSpaceLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_LongTermOperatingLeasesMember" xlink:to="capr_VivariumSpaceLeaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_CommitmentsAndContingenciesDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_WrittenNoticePeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_LesseeOperatingLeaseLeaseRentPerMonth" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_SeverancePackageToBePaidForPeriodOfBaseSalary" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_SeverancePackageToBePaidForPeriodOfBaseSalary" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RestructuringReserve" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTable" xlink:label="capr_LicenseAgreementsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="capr_LicenseAgreementsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NonPaymentOfRoyaltiesMember" xlink:label="capr_NonPaymentOfRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_NonPaymentOfRoyaltiesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MaterialBreachHasNotBeenCuredMember" xlink:label="capr_MaterialBreachHasNotBeenCuredMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_MaterialBreachHasNotBeenCuredMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToCureBreachAfterNoticeFromCsmcMember" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_FailsToCureBreachAfterNoticeFromCsmcMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OverduePaymentObligationsMember" xlink:label="capr_OverduePaymentObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_OverduePaymentObligationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesAxis" xlink:label="capr_MilestonePaymentsInPhasesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="capr_LicenseAgreementsTable" xlink:to="capr_MilestonePaymentsInPhasesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesDomain" xlink:label="capr_MilestonePaymentsInPhasesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="capr_MilestonePaymentsInPhasesAxis" xlink:to="capr_MilestonePaymentsInPhasesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CompletionOfPhaseTwoDueMember" xlink:label="capr_CompletionOfPhaseTwoDueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_MilestonePaymentsInPhasesDomain" xlink:to="capr_CompletionOfPhaseTwoDueMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="capr_LicenseAgreementsTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RomeLicenseAgreementMember" xlink:label="capr_RomeLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_RomeLicenseAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_JhuLicenseAgreementMember" xlink:label="capr_JhuLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_JhuLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcLicenseAgreementMember" xlink:label="capr_CsmcLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_CsmcLicenseAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ExosomesLicenseAgreementMember" xlink:label="capr_ExosomesLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_ExosomesLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="capr_CsmcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsLineItems" xlink:label="capr_LicenseAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_LicenseAgreementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AnnualPaymentsForRoyalties" xlink:label="capr_AnnualPaymentsForRoyalties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_AnnualPaymentsForRoyalties" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_WrittenNoticePeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PotentialMilestonePayments" xlink:label="capr_PotentialMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_PotentialMilestonePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePayments" xlink:label="capr_MilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PeriodOfAgreementWillBeInEffective" xlink:label="capr_PeriodOfAgreementWillBeInEffective" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_PeriodOfAgreementWillBeInEffective" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ThresholdPeriodToCureBreach" xlink:label="capr_ThresholdPeriodToCureBreach" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_ThresholdPeriodToCureBreach" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementTerminationPeriod" xlink:label="capr_AgreementTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_AgreementTerminationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UpfrontPayment" xlink:label="capr_UpfrontPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_UpfrontPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsPercentageOwedToThirdParty" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePaymentsPercentageOwedToThirdParty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDefaultDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS Default (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTable" xlink:label="capr_LicenseAgreementsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="capr_LicenseAgreementsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NonPaymentOfRoyaltiesMember" xlink:label="capr_NonPaymentOfRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_NonPaymentOfRoyaltiesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MaterialBreachHasNotBeenCuredMember" xlink:label="capr_MaterialBreachHasNotBeenCuredMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_MaterialBreachHasNotBeenCuredMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToCureBreachAfterNoticeFromCsmcMember" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_FailsToCureBreachAfterNoticeFromCsmcMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OverduePaymentObligationsMember" xlink:label="capr_OverduePaymentObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="capr_OverduePaymentObligationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesAxis" xlink:label="capr_MilestonePaymentsInPhasesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="capr_LicenseAgreementsTable" xlink:to="capr_MilestonePaymentsInPhasesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesDomain" xlink:label="capr_MilestonePaymentsInPhasesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="capr_MilestonePaymentsInPhasesAxis" xlink:to="capr_MilestonePaymentsInPhasesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CompletionOfPhaseTwoDueMember" xlink:label="capr_CompletionOfPhaseTwoDueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="capr_MilestonePaymentsInPhasesDomain" xlink:to="capr_CompletionOfPhaseTwoDueMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="capr_LicenseAgreementsTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RomeLicenseAgreementMember" xlink:label="capr_RomeLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_RomeLicenseAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_JhuLicenseAgreementMember" xlink:label="capr_JhuLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_JhuLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcLicenseAgreementMember" xlink:label="capr_CsmcLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_CsmcLicenseAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ExosomesLicenseAgreementMember" xlink:label="capr_ExosomesLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_ExosomesLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="capr_CsmcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="capr_LicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsLineItems" xlink:label="capr_LicenseAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_LicenseAgreementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AnnualPaymentsForRoyalties" xlink:label="capr_AnnualPaymentsForRoyalties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_AnnualPaymentsForRoyalties" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_WrittenNoticePeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PotentialMilestonePayments" xlink:label="capr_PotentialMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_PotentialMilestonePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePayments" xlink:label="capr_MilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PeriodOfAgreementWillBeInEffective" xlink:label="capr_PeriodOfAgreementWillBeInEffective" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_PeriodOfAgreementWillBeInEffective" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ThresholdPeriodToCureBreach" xlink:label="capr_ThresholdPeriodToCureBreach" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_ThresholdPeriodToCureBreach" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementTerminationPeriod" xlink:label="capr_AgreementTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_AgreementTerminationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UpfrontPayment" xlink:label="capr_UpfrontPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_UpfrontPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsPercentageOwedToThirdParty" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_MilestonePaymentsPercentageOwedToThirdParty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DrEduardoMarbanMember" xlink:label="capr_DrEduardoMarbanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="capr_DrEduardoMarbanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MichaelKelliherMember" xlink:label="capr_MichaelKelliherMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="capr_MichaelKelliherMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_AffiliatedEntityMember" xlink:to="capr_CsmcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementMember" xlink:label="capr_ConsultingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_ConsultingAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementWithFrankLitvackMember" xlink:label="capr_ConsultingAgreementWithFrankLitvackMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_ConsultingAgreementWithFrankLitvackMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TransactionOtherThanSubawardAgreementMember" xlink:label="capr_TransactionOtherThanSubawardAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_TransactionOtherThanSubawardAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AdvisoryServicesAgreementMember" xlink:label="capr_AdvisoryServicesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="capr_AdvisoryServicesAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MonthlyConsultingFeesToRelatedParty" xlink:label="capr_MonthlyConsultingFeesToRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="capr_MonthlyConsultingFeesToRelatedParty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TerminableNoticePeriod" xlink:label="capr_TerminableNoticePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="capr_TerminableNoticePeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://capricor.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RegisteredDirectOfferingMember" xlink:label="capr_RegisteredDirectOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="capr_RegisteredDirectOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAndServicesAgreementMember" xlink:label="capr_LicenseAndServicesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="capr_LicenseAndServicesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockOfferingRemainingAmountIssuable" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="capr_CommonStockOfferingRemainingAmountIssuable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseFee" xlink:label="capr_LicenseFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="capr_LicenseFee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfLicense" xlink:label="capr_TermOfLicense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="capr_TermOfLicense" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>capr-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 10:04:47 PM-->
<!--Modified on: 3/8/2024 10:04:47 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grants Receivable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, ROU asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Lease right-of-use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US">Other Long-term Debt, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US">CIRM liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities, net of current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities, net of current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 6)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 50,000,000 shares authorized, 31,148,320 and 25,241,402 shares issued and outstanding, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Investment income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME (EXPENSE)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Net unrealized gain on marketable securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of shares of common stock outstanding basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of shares of common stock outstanding diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">COMMON STOCK [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">COMMON STOCK</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">OTHER COMPREHENSIVE INCOME [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">OTHER COMPREHENSIVE INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">ACCUMULATED DEFICIT [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of common stock shares issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of fees (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NoncashLeaseExpenses" xlink:label="capr_NoncashLeaseExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_NoncashLeaseExpenses" xlink:to="capr_NoncashLeaseExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_NoncashLeaseExpenses_lbl" xml:lang="en-US">The expense charged against earnings related to noncash lease , which is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_NoncashLeaseExpenses_lbl" xml:lang="en-US">Noncash Lease Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_NoncashLeaseExpenses_lbl" xml:lang="en-US">Changes in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_IncreaseDecreaseFromGrantsReceivable" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_IncreaseDecreaseFromGrantsReceivable" xlink:to="capr_IncreaseDecreaseFromGrantsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in grants receivable (or one business cycle).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable_lbl" xml:lang="en-US">Increase Decrease from Grants Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable_lbl" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" xml:lang="en-US">Increase (Decrease) in Deposits Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Milestone payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsToAcquireLeaseholdImprovements" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_PaymentsToAcquireLeaseholdImprovements" xlink:to="capr_PaymentsToAcquireLeaseholdImprovements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements_lbl" xml:lang="en-US">The cash outflow for acquisition of leasehold improvements during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements_lbl" xml:lang="en-US">Payments to Acquire Leasehold Improvements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements_lbl" xml:lang="en-US">Payments for leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents balance at end of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents balance at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid in cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid in cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDER'S EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDER'S EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract" xlink:to="capr_StockAwardsWarrantsAndOptionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract_lbl" xml:lang="en-US">STOCK AWARDS, WARRANTS AND OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK AWARDS, WARRANTS AND OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">CONCENTRATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AwardAbstract" xlink:label="capr_AwardAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AwardAbstract" xlink:to="capr_AwardAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AwardAbstract_lbl" xml:lang="en-US">GOVERNMENT GRANT AWARDS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GovernmentGrantAwardsDisclosureTextBlock" xlink:label="capr_GovernmentGrantAwardsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_GovernmentGrantAwardsDisclosureTextBlock" xlink:to="capr_GovernmentGrantAwardsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_GovernmentGrantAwardsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure about government grant awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_GovernmentGrantAwardsDisclosureTextBlock_lbl" xml:lang="en-US">Government Grant Awards Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_GovernmentGrantAwardsDisclosureTextBlock_lbl" xml:lang="en-US">GOVERNMENT GRANT AWARDS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsAbstract" xlink:label="capr_LicenseAgreementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseAgreementsAbstract" xlink:to="capr_LicenseAgreementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseAgreementsAbstract_lbl" xml:lang="en-US">LICENSE AND DISTRIBUTION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTextBlock" xlink:label="capr_LicenseAgreementsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseAgreementsTextBlock" xlink:to="capr_LicenseAgreementsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LicenseAgreementsTextBlock_lbl" xml:lang="en-US">The entire disclosure relating to licensing agreements entered into for acquiring intellectual property rights, for the grant of an exclusive, world-wide, royalty-bearing license to develop and commercialize licensed products under the licensed patent rights in all fields and a nonexclusive right to the know-how, Collaboration Agreement and Exclusive License Option, and funding and equipment necessary for conducting clinical trial.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseAgreementsTextBlock_lbl" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="capr_LicenseAgreementsTextBlock_lbl" xml:lang="en-US">LICENSE AND DISTRIBUTION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LiquidityPolicyTextBlock" xlink:label="capr_LiquidityPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LiquidityPolicyTextBlock" xlink:to="capr_LiquidityPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for liquidity position during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" xlink:label="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" xlink:to="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy as it relates to unusual or infrequent items related to the Covid-19 pandemic.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_lbl" xml:lang="en-US">Unusual Or Infrequent Items Or Both Covid 19 Policy Policy Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Uncertainty Related to the Coronavirus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClinicalTrialExpensePolicyPolicyTextBlock" xlink:label="capr_ClinicalTrialExpensePolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ClinicalTrialExpensePolicyPolicyTextBlock" xlink:to="capr_ClinicalTrialExpensePolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ClinicalTrialExpensePolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for clinical trail expense.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ClinicalTrialExpensePolicyPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ClinicalTrialExpensePolicyPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfWarrantActivityTableTextBlock" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ScheduleOfWarrantActivityTableTextBlock" xlink:to="capr_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of all warrant activity during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Summary of warrant activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of outstanding warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of option using Black-Scholes option</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Employee And Nonemployee Service Share-Based Compensation Allocation Of Recognized Period Costs Table Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Schedule of employee and non-employee stock based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of employee and non-employee stock option</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Outstanding And Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Laboratory equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesTable" xlink:label="capr_AccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AccountingPoliciesTable" xlink:to="capr_AccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AccountingPoliciesTable_lbl" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_lbl" xml:lang="en-US">Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., Japan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_lbl" xml:lang="en-US">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_lbl" xml:lang="en-US">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US">General Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Country</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesLineItems" xlink:label="capr_AccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AccountingPoliciesLineItems" xlink:to="capr_AccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AccountingPoliciesLineItems_lbl" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActRevenue" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_EmployeeRetentionCreditCaresActRevenue" xlink:to="capr_EmployeeRetentionCreditCaresActRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue_lbl" xml:lang="en-US">The amount of revenue recognized under Employee Retention Credit, CARES Act.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue_lbl" xml:lang="en-US">Employee Retention Credit, CARES Act, Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue_lbl" xml:lang="en-US">Revenue recognized under "ERC"</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActReceivable" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_EmployeeRetentionCreditCaresActReceivable" xlink:to="capr_EmployeeRetentionCreditCaresActReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable_lbl" xml:lang="en-US">The amount of receivables under Employee Retention Credit, CARES Act.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable_lbl" xml:lang="en-US">Employee Retention Credit, CARES Act, Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable_lbl" xml:lang="en-US">Receivables under "ERC"</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantIncome" xlink:label="capr_GrantIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_GrantIncome" xlink:to="capr_GrantIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_GrantIncome_lbl" xml:lang="en-US">Amount of revenue and income classified as grant income.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_GrantIncome_lbl" xml:lang="en-US">Grant Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsExpirationYear" xlink:label="capr_OperatingLossCarryForwardsExpirationYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_OperatingLossCarryForwardsExpirationYear" xlink:to="capr_OperatingLossCarryForwardsExpirationYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">The expiration year for operating loss carryforwards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating Loss Carry Forwards Expiration Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward limitations on use</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsIndefinitely" xlink:label="capr_OperatingLossCarryForwardsIndefinitely" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_OperatingLossCarryForwardsIndefinitely" xlink:to="capr_OperatingLossCarryForwardsIndefinitely_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_OperatingLossCarryForwardsIndefinitely_lbl" xml:lang="en-US">The amount of the tax credit carryforward, indefinitely before tax effects, available to reduce future taxable income under enacted tax law.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_OperatingLossCarryForwardsIndefinitely_lbl" xml:lang="en-US">Operating Loss Carry Forwards Indefinitely</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_OperatingLossCarryForwardsIndefinitely_lbl" xml:lang="en-US">Operating loss carry forwards indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TaxCreditCarryForwardsExpirationYear" xlink:label="capr_TaxCreditCarryForwardsExpirationYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_TaxCreditCarryForwardsExpirationYear" xlink:to="capr_TaxCreditCarryForwardsExpirationYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_TaxCreditCarryForwardsExpirationYear_lbl" xml:lang="en-US">The expiration year for tax credit carryforwards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_TaxCreditCarryForwardsExpirationYear_lbl" xml:lang="en-US">Tax Credit Carry Forwards Expiration Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_TaxCreditCarryForwardsExpirationYear_lbl" xml:lang="en-US">Tax credit carry forwards expiration Year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Long-lived assets impairment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_June2021AtMarketProgramMember" xlink:label="capr_June2021AtMarketProgramMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_June2021AtMarketProgramMember" xlink:to="capr_June2021AtMarketProgramMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_June2021AtMarketProgramMember_lbl" xml:lang="en-US">Represents the information pertaining to At the Market (ATM) program.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_June2021AtMarketProgramMember_lbl" xml:lang="en-US">June 2021 ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RegisteredDirectOfferingMember" xlink:label="capr_RegisteredDirectOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RegisteredDirectOfferingMember" xlink:to="capr_RegisteredDirectOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to Registered direct offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent event</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent event</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockSharesAuthorizedValue" xlink:label="capr_CommonStockSharesAuthorizedValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockSharesAuthorizedValue" xlink:to="capr_CommonStockSharesAuthorizedValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockSharesAuthorizedValue_lbl" xml:lang="en-US">The maximum value of share authorized.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockSharesAuthorizedValue_lbl" xml:lang="en-US">Common Stock, Shares Authorized, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CommonStockSharesAuthorizedValue_lbl" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommissionRateOnSalePricePerShare" xlink:label="capr_CommissionRateOnSalePricePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommissionRateOnSalePricePerShare" xlink:to="capr_CommissionRateOnSalePricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommissionRateOnSalePricePerShare_lbl" xml:lang="en-US">Percentage of commission on sale price per common shares sold to be paid by the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommissionRateOnSalePricePerShare_lbl" xml:lang="en-US">Commission Rate On Sale Price Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CommissionRateOnSalePricePerShare_lbl" xml:lang="en-US">Commission rate on sale price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Average price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrant to purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Effective warrant terms</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LockUpPeriodNotToIssueOrSellShares" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LockUpPeriodNotToIssueOrSellShares" xlink:to="capr_LockUpPeriodNotToIssueOrSellShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares_lbl" xml:lang="en-US">Period for which issue or sale of shares is not allowed known as lock up period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares_lbl" xml:lang="en-US">Lock Up Period, Not to Issue or Sell Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares_lbl" xml:lang="en-US">Lock up period, not to issue or sell shares</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementExpiryTerm" xlink:label="capr_AgreementExpiryTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AgreementExpiryTerm" xlink:to="capr_AgreementExpiryTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_AgreementExpiryTerm_lbl" xml:lang="en-US">The period for expiry of an agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AgreementExpiryTerm_lbl" xml:lang="en-US">Agreement Expiry Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_AgreementExpiryTerm_lbl" xml:lang="en-US">Agreement expiry term</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockOfferingRemainingAmountIssuable" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockOfferingRemainingAmountIssuable" xlink:to="capr_CommonStockOfferingRemainingAmountIssuable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable_lbl" xml:lang="en-US">The value of shares authorized to be issued under the offering which remain unissued and available at stated date.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable_lbl" xml:lang="en-US">Common Stock Offering, Remaining Amount Issuable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable_lbl" xml:lang="en-US">Amount of stock that may still be sold under the program</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding at Ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding at Beginning</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightGranted" xlink:label="capr_ClassOfWarrantOrRightGranted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ClassOfWarrantOrRightGranted" xlink:to="capr_ClassOfWarrantOrRightGranted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Number of warrants or rights granted during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Class Of Warrant Or Right Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightExercised" xlink:label="capr_ClassOfWarrantOrRightExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ClassOfWarrantOrRightExercised" xlink:to="capr_ClassOfWarrantOrRightExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Number of warrants or rights Exercised during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="capr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:to="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share or per unit of warrants or rights outstanding.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at Ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WeightedAverageExercisePriceGranted" xlink:label="capr_WeightedAverageExercisePriceGranted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_WeightedAverageExercisePriceGranted" xlink:to="capr_WeightedAverageExercisePriceGranted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Exercise price per share or per unit of warrants or rights granted.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:to="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price per share or per unit of warrants or rights exercised.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Right Exercised Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsMember" xlink:label="capr_CommonStockWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockWarrantsMember" xlink:to="capr_CommonStockWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to common stock warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_lbl" xml:lang="en-US">Represents the information pertaining to common stock warrants with expiration on December 2024 one.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_lbl" xml:lang="en-US">Common Warrants with Expiration on December 2024 One</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_lbl" xml:lang="en-US">Represents the information pertaining to common stock warrants with expiration on December 2025 two.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_lbl" xml:lang="en-US">Common Stock Warrants With Expiration On December 2025 Two</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_lbl" xml:lang="en-US">Represents the information pertaining to common stock warrants with expiration on December 2030 two.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_lbl" xml:lang="en-US">Common Stock Warrants With Expiration On December 2030 Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rates, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rates, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeOneMember" xlink:label="capr_RangeOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RangeOneMember" xlink:to="capr_RangeOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RangeOneMember_lbl" xml:lang="en-US">Represents the information pertaining to Range one member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeTwoMember" xlink:label="capr_RangeTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RangeTwoMember" xlink:to="capr_RangeTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RangeTwoMember_lbl" xml:lang="en-US">Represents the information pertaining to Range two member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeThreeMember" xlink:label="capr_RangeThreeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RangeThreeMember" xlink:to="capr_RangeThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RangeThreeMember_lbl" xml:lang="en-US">Represents the information pertaining to Range three member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeFourMember" xlink:label="capr_RangeFourMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RangeFourMember" xlink:to="capr_RangeFourMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RangeFourMember_lbl" xml:lang="en-US">Represents the information pertaining to Range four member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, lower range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, upper range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Outstanding, Options (shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding, Weighted Average Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable, Option (Shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Exercisable, Weighted Average Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at End of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at Beginning of the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted option</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired/Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at Ending of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at Beginning of the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired/Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of stock options outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value of exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:to="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_lbl" xml:lang="en-US">Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2020Member" xlink:label="capr_StockOptionPlan2020Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_StockOptionPlan2020Member" xlink:to="capr_StockOptionPlan2020Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_StockOptionPlan2020Member_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_StockOptionPlan2020Member_lbl" xml:lang="en-US">Stock Option Plan 2020 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_StockOptionPlan2020Member_lbl" xml:lang="en-US">Stock Option Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2021Member" xlink:label="capr_StockOptionPlan2021Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_StockOptionPlan2021Member" xlink:to="capr_StockOptionPlan2021Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_StockOptionPlan2021Member_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_StockOptionPlan2021Member_lbl" xml:lang="en-US">Stock Option Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:to="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_lbl" xml:lang="en-US">Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_lbl" xml:lang="en-US">Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationNumberOfPlans" xlink:label="capr_ShareBasedCompensationNumberOfPlans" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ShareBasedCompensationNumberOfPlans" xlink:to="capr_ShareBasedCompensationNumberOfPlans_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US">Number of share based compensation plans .</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US">Share Based Compensation, Number of Plans</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US">Number of plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_lbl" xml:lang="en-US">Number of stock options available for grant under the stock option plans.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Options Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_lbl" xml:lang="en-US">Number of options available for issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" xlink:to="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_lbl" xml:lang="en-US">The minimum limit of aggregate fair market value will be treated as non-statutory stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_lbl" xml:lang="en-US">Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_lbl" xml:lang="en-US">Minimum limit of fair market value to be treated as non-statutory stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Terms of stock option plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Estimated weighted fair value of option granted (in per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized fair value compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">CONCENTRATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NumberOfFinancialInstitutions" xlink:label="capr_NumberOfFinancialInstitutions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_NumberOfFinancialInstitutions" xlink:to="capr_NumberOfFinancialInstitutions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_NumberOfFinancialInstitutions_lbl" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_NumberOfFinancialInstitutions_lbl" xml:lang="en-US">Number of Financial Institutions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_NumberOfFinancialInstitutions_lbl" xml:lang="en-US">Number of financial institutions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="capr_CaliforniaInstituteForRegenerativeMedicineMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="capr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US">California Institute for Regenerative Medicine</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US">California Institute for Regenerative Medicine</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LiborMember" xlink:label="capr_LiborMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LiborMember" xlink:to="capr_LiborMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LiborMember_lbl" xml:lang="en-US">Interest rate at which a bank borrows funds from other banks in the London interbank market.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LiborMember_lbl" xml:lang="en-US">LIBOR Member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LiborMember_lbl" xml:lang="en-US">LIBOR Member</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantAwardLiability" xlink:label="capr_GrantAwardLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_GrantAwardLiability" xlink:to="capr_GrantAwardLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_GrantAwardLiability_lbl" xml:lang="en-US">Amount of grant liability.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_GrantAwardLiability_lbl" xml:lang="en-US">Grant Award Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_GrantAwardLiability_lbl" xml:lang="en-US">Grant award liability</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumExpectedContribution" xlink:label="capr_MinimumExpectedContribution" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MinimumExpectedContribution" xlink:to="capr_MinimumExpectedContribution_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MinimumExpectedContribution_lbl" xml:lang="en-US">The minimum amount of contribution to be made.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MinimumExpectedContribution_lbl" xml:lang="en-US">Minimum Expected Contribution</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MinimumExpectedContribution_lbl" xml:lang="en-US">Minimum expected contribution</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" xlink:to="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_lbl" xml:lang="en-US">Number of times on total award amount which is the maximum amount of royalty to be payable on commercial revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_lbl" xml:lang="en-US">Number of Times on Total Award Amount, Maximum Royalty on Commercial revenue To be Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_lbl" xml:lang="en-US">Number of times, maximum royalty to be paid on total amount of award</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfAward" xlink:label="capr_TermOfAward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_TermOfAward" xlink:to="capr_TermOfAward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_TermOfAward_lbl" xml:lang="en-US">Term of award.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_TermOfAward_lbl" xml:lang="en-US">Term of Award</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_TermOfAward_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="us-gaap_DerivativeVariableInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeVariableInterestRate" xlink:to="us-gaap_DerivativeVariableInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeVariableInterestRate_lbl" xml:lang="en-US">Derivative, Variable Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeVariableInterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease, ROU liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Included in the condensed consolidated balance sheet:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureTable" xlink:label="capr_CommitmentsAndContingenciesDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable" xlink:to="capr_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyAxis" xlink:label="capr_UnrelatedPartyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UnrelatedPartyAxis" xlink:to="capr_UnrelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UnrelatedPartyAxis_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UnrelatedPartyAxis_lbl" xml:lang="en-US">Unrelated Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyDomain" xlink:label="capr_UnrelatedPartyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UnrelatedPartyDomain" xlink:to="capr_UnrelatedPartyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UnrelatedPartyDomain_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UnrelatedPartyDomain_lbl" xml:lang="en-US">Unrelated Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyMember" xlink:label="capr_UnrelatedPartyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UnrelatedPartyMember" xlink:to="capr_UnrelatedPartyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UnrelatedPartyMember_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UnrelatedPartyMember_lbl" xml:lang="en-US">Unrelated Party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_UnrelatedPartyMember_lbl" xml:lang="en-US">Unrelated Party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FacilitiesLeaseMember" xlink:label="capr_FacilitiesLeaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_FacilitiesLeaseMember" xlink:to="capr_FacilitiesLeaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_FacilitiesLeaseMember_lbl" xml:lang="en-US">Represents information pertaining to facilities lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_FacilitiesLeaseMember_lbl" xml:lang="en-US">Facilities Lease</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_FacilitiesLeaseMember_lbl" xml:lang="en-US">Facilities Lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CorporateOfficesLeaseMember" xlink:label="capr_CorporateOfficesLeaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CorporateOfficesLeaseMember" xlink:to="capr_CorporateOfficesLeaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CorporateOfficesLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to corporate offices under operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CorporateOfficesLeaseMember_lbl" xml:lang="en-US">Corporate Offices Lease [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CorporateOfficesLeaseMember_lbl" xml:lang="en-US">Short-term offices lease</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LongTermOperatingLeasesMember" xlink:label="capr_LongTermOperatingLeasesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LongTermOperatingLeasesMember" xlink:to="capr_LongTermOperatingLeasesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LongTermOperatingLeasesMember_lbl" xml:lang="en-US">Represents the information pertaining to long term operating leases.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LongTermOperatingLeasesMember_lbl" xml:lang="en-US">Long Term Operating Leases [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LongTermOperatingLeasesMember_lbl" xml:lang="en-US">Long Term Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PropertyLocatedAt10865RoadToCureInDiegoMember" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_PropertyLocatedAt10865RoadToCureInDiegoMember" xlink:to="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_lbl" xml:lang="en-US">Represents the information pertaining to Property Located at 10865 Road to Cure in Diego.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_lbl" xml:lang="en-US">Property Located at 10865 Road to Cure in Diego</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_lbl" xml:lang="en-US">Property Located at 10865 Road to Cure in Diego</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_VivariumSpaceLeaseMember" xlink:label="capr_VivariumSpaceLeaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_VivariumSpaceLeaseMember" xlink:to="capr_VivariumSpaceLeaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_VivariumSpaceLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to leases vivarium space.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_VivariumSpaceLeaseMember_lbl" xml:lang="en-US">Vivarium Space Lease [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_VivariumSpaceLeaseMember_lbl" xml:lang="en-US">Vivarium Space Lease</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="capr_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">NA</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Area under lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lease renewal term</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" xlink:to="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_lbl" xml:lang="en-US">The amount of base lease rent per month under the operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_lbl" xml:lang="en-US">Lessee Operating Lease, Base Lease Rent Per Month</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_lbl" xml:lang="en-US">Base rent per month</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_WrittenNoticePeriod" xlink:to="capr_WrittenNoticePeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_WrittenNoticePeriod_lbl" xml:lang="en-US">These lines are represents that notice period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_WrittenNoticePeriod_lbl" xml:lang="en-US">Written Notice Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_WrittenNoticePeriod_lbl" xml:lang="en-US">Notice period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" xlink:to="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_lbl" xml:lang="en-US">Percentage of increase in annual lease rent in an operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_lbl" xml:lang="en-US">Operating Lease Percentage of Increase in Annual Lease Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_lbl" xml:lang="en-US">Operating lease percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LesseeOperatingLeaseLeaseRentPerMonth" xlink:to="capr_LesseeOperatingLeaseLeaseRentPerMonth_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth_lbl" xml:lang="en-US">The amount operating lease rent per month.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth_lbl" xml:lang="en-US">Lessee Operating Lease Lease Rent Per Month</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth_lbl" xml:lang="en-US">Monthly lease payment</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_SeverancePackageToBePaidForPeriodOfBaseSalary" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_SeverancePackageToBePaidForPeriodOfBaseSalary" xlink:to="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_lbl" xml:lang="en-US">Maximum number of months of base salaries used for severance packages for specific full-time employees.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_lbl" xml:lang="en-US">Severance Package To Be Paid For Period Of Base Salary</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_lbl" xml:lang="en-US">Number of months of base salary</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US">Restructuring reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" xlink:to="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_lbl" xml:lang="en-US">The percent of escalation of monthly base rent of lessee's operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_lbl" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Escalation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_lbl" xml:lang="en-US">Monthly rent escalation, percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTable" xlink:label="capr_LicenseAgreementsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseAgreementsTable" xlink:to="capr_LicenseAgreementsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseAgreementsTable_lbl" xml:lang="en-US">LICENSE AGREEMENTS [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" xlink:to="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_lbl" xml:lang="en-US">Until the date of expiration of the last to expire patent within the parent rights.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_lbl" xml:lang="en-US">Patent rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_lbl" xml:lang="en-US">Patent rights</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NonPaymentOfRoyaltiesMember" xlink:label="capr_NonPaymentOfRoyaltiesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_NonPaymentOfRoyaltiesMember" xlink:to="capr_NonPaymentOfRoyaltiesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_NonPaymentOfRoyaltiesMember_lbl" xml:lang="en-US">Non-payment of royalties.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_NonPaymentOfRoyaltiesMember_lbl" xml:lang="en-US">Non Payment of Royalties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_NonPaymentOfRoyaltiesMember_lbl" xml:lang="en-US">Non Payment of Royalties</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" xlink:to="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_lbl" xml:lang="en-US">Information pertaining to failure to undertake commercially reasonable efforts to exploit the patent rights or future patent rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_lbl" xml:lang="en-US">CSMC Agreement Compliance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_lbl" xml:lang="en-US">CSMC Agreement Compliance</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MaterialBreachHasNotBeenCuredMember" xlink:label="capr_MaterialBreachHasNotBeenCuredMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MaterialBreachHasNotBeenCuredMember" xlink:to="capr_MaterialBreachHasNotBeenCuredMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MaterialBreachHasNotBeenCuredMember_lbl" xml:lang="en-US">Material breach has not been cured.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MaterialBreachHasNotBeenCuredMember_lbl" xml:lang="en-US">Material Breach Has Not Been Cured</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MaterialBreachHasNotBeenCuredMember_lbl" xml:lang="en-US">Material Breach Has Not Been Cured</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToCureBreachAfterNoticeFromCsmcMember" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_FailsToCureBreachAfterNoticeFromCsmcMember" xlink:to="capr_FailsToCureBreachAfterNoticeFromCsmcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember_lbl" xml:lang="en-US">Fails to cure that breach after notice from CSMC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember_lbl" xml:lang="en-US">Fails To Cure Breach after Notice From CSMC</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember_lbl" xml:lang="en-US">Fails To Cure Breach after Notice From CSMC</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OverduePaymentObligationsMember" xlink:label="capr_OverduePaymentObligationsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_OverduePaymentObligationsMember" xlink:to="capr_OverduePaymentObligationsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_OverduePaymentObligationsMember_lbl" xml:lang="en-US">Potential overdue payment obligation to CSMC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_OverduePaymentObligationsMember_lbl" xml:lang="en-US">Overdue payment obligations [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_OverduePaymentObligationsMember_lbl" xml:lang="en-US">Overdue payment obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesAxis" xlink:label="capr_MilestonePaymentsInPhasesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MilestonePaymentsInPhasesAxis" xlink:to="capr_MilestonePaymentsInPhasesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MilestonePaymentsInPhasesAxis_lbl" xml:lang="en-US">Milestone Payments in Phases [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesDomain" xlink:label="capr_MilestonePaymentsInPhasesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MilestonePaymentsInPhasesDomain" xlink:to="capr_MilestonePaymentsInPhasesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MilestonePaymentsInPhasesDomain_lbl" xml:lang="en-US">Milestone Payments in Phases [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CompletionOfPhaseTwoDueMember" xlink:label="capr_CompletionOfPhaseTwoDueMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CompletionOfPhaseTwoDueMember" xlink:to="capr_CompletionOfPhaseTwoDueMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CompletionOfPhaseTwoDueMember_lbl" xml:lang="en-US">Represents information pertaining to completion of phase two.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CompletionOfPhaseTwoDueMember_lbl" xml:lang="en-US">Completion Of Phase Two Due</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CompletionOfPhaseTwoDueMember_lbl" xml:lang="en-US">Completion Of Phase Two Due</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RomeLicenseAgreementMember" xlink:label="capr_RomeLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_RomeLicenseAgreementMember" xlink:to="capr_RomeLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_RomeLicenseAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to Rome license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_RomeLicenseAgreementMember_lbl" xml:lang="en-US">Rome License Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_RomeLicenseAgreementMember_lbl" xml:lang="en-US">Rome License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_JhuLicenseAgreementMember" xlink:label="capr_JhuLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_JhuLicenseAgreementMember" xlink:to="capr_JhuLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_JhuLicenseAgreementMember_lbl" xml:lang="en-US">JHU License Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_JhuLicenseAgreementMember_lbl" xml:lang="en-US">JHU License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcLicenseAgreementMember" xlink:label="capr_CsmcLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CsmcLicenseAgreementMember" xlink:to="capr_CsmcLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CsmcLicenseAgreementMember_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CsmcLicenseAgreementMember_lbl" xml:lang="en-US">CSMC License Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CsmcLicenseAgreementMember_lbl" xml:lang="en-US">CSMC License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ExosomesLicenseAgreementMember" xlink:label="capr_ExosomesLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ExosomesLicenseAgreementMember" xlink:to="capr_ExosomesLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ExosomesLicenseAgreementMember_lbl" xml:lang="en-US">Exosomes License Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ExosomesLicenseAgreementMember_lbl" xml:lang="en-US">Exosomes License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CsmcMember" xlink:to="capr_CsmcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CsmcMember_lbl" xml:lang="en-US">CSMC [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CsmcMember_lbl" xml:lang="en-US">CSMC</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_lbl" xml:lang="en-US">Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., United States.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_lbl" xml:lang="en-US">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_lbl" xml:lang="en-US">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsLineItems" xlink:label="capr_LicenseAgreementsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseAgreementsLineItems" xlink:to="capr_LicenseAgreementsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LicenseAgreementsLineItems_lbl" xml:lang="en-US">NA</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseAgreementsLineItems_lbl" xml:lang="en-US">LICENSE AGREEMENTS [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_LicenseAgreementsLineItems_lbl" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AnnualPaymentsForRoyalties" xlink:label="capr_AnnualPaymentsForRoyalties" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AnnualPaymentsForRoyalties" xlink:to="capr_AnnualPaymentsForRoyalties_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_AnnualPaymentsForRoyalties_lbl" xml:lang="en-US">The amount paid for royalties on an annual basis.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AnnualPaymentsForRoyalties_lbl" xml:lang="en-US">Annual Payments For Royalties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_AnnualPaymentsForRoyalties_lbl" xml:lang="en-US">Minimum annual royalty payments</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PotentialMilestonePayments" xlink:label="capr_PotentialMilestonePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_PotentialMilestonePayments" xlink:to="capr_PotentialMilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_PotentialMilestonePayments_lbl" xml:lang="en-US">Amount of milestone payments payable under the JHU License Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_PotentialMilestonePayments_lbl" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_PotentialMilestonePayments_lbl" xml:lang="en-US">Potential milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePayments" xlink:label="capr_MilestonePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MilestonePayments" xlink:to="capr_MilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MilestonePayments_lbl" xml:lang="en-US">Amount of milestone payments during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MilestonePayments_lbl" xml:lang="en-US">Milestone Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MilestonePayments_lbl" xml:lang="en-US">Milestones paid</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" xlink:to="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_lbl" xml:lang="en-US">Milestone payments to be made upon successful completion of certain phases as per License agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_lbl" xml:lang="en-US">Milestone Payments To Be Made Upon Successful Completion Of Certain Phases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_lbl" xml:lang="en-US">Milestone payments to be made upon completion of certain phases</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PeriodOfAgreementWillBeInEffective" xlink:label="capr_PeriodOfAgreementWillBeInEffective" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_PeriodOfAgreementWillBeInEffective" xlink:to="capr_PeriodOfAgreementWillBeInEffective_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_PeriodOfAgreementWillBeInEffective_lbl" xml:lang="en-US">Period for which agreement will be effective.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_PeriodOfAgreementWillBeInEffective_lbl" xml:lang="en-US">Period of Agreement Will be in Effective</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_PeriodOfAgreementWillBeInEffective_lbl" xml:lang="en-US">Agreement effective period</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ThresholdPeriodToCureBreach" xlink:label="capr_ThresholdPeriodToCureBreach" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ThresholdPeriodToCureBreach" xlink:to="capr_ThresholdPeriodToCureBreach_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ThresholdPeriodToCureBreach_lbl" xml:lang="en-US">Threshold period to cure breach.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ThresholdPeriodToCureBreach_lbl" xml:lang="en-US">Threshold Period to Cure Breach</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ThresholdPeriodToCureBreach_lbl" xml:lang="en-US">Threshold period to cure breach</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementTerminationPeriod" xlink:label="capr_AgreementTerminationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AgreementTerminationPeriod" xlink:to="capr_AgreementTerminationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_AgreementTerminationPeriod_lbl" xml:lang="en-US">Represents the agreement termination period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AgreementTerminationPeriod_lbl" xml:lang="en-US">Agreement Termination Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_AgreementTerminationPeriod_lbl" xml:lang="en-US">Agreement termination period</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UpfrontPayment" xlink:label="capr_UpfrontPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_UpfrontPayment" xlink:to="capr_UpfrontPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_UpfrontPayment_lbl" xml:lang="en-US">Upfront Payment made during the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_UpfrontPayment_lbl" xml:lang="en-US">Upfront Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue liability</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsPercentageOwedToThirdParty" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MilestonePaymentsPercentageOwedToThirdParty" xlink:to="capr_MilestonePaymentsPercentageOwedToThirdParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty_lbl" xml:lang="en-US">Percentage of milestone payments received by Capricor and owed to CSMC pursuant to the U.S. Distribution Agreement with Nippon Shinyaku.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty_lbl" xml:lang="en-US">Milestone payments, percentage owed to third party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty_lbl" xml:lang="en-US">Milestone payments, percentage claimed by CSMS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DrEduardoMarbanMember" xlink:label="capr_DrEduardoMarbanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_DrEduardoMarbanMember" xlink:to="capr_DrEduardoMarbanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_DrEduardoMarbanMember_lbl" xml:lang="en-US">Dr Eduardo Marban [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_DrEduardoMarbanMember_lbl" xml:lang="en-US">Dr Eduardo Marban</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MichaelKelliherMember" xlink:label="capr_MichaelKelliherMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MichaelKelliherMember" xlink:to="capr_MichaelKelliherMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MichaelKelliherMember_lbl" xml:lang="en-US">This member represent Michael Kelliher.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MichaelKelliherMember_lbl" xml:lang="en-US">Michael Kelliher [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MichaelKelliherMember_lbl" xml:lang="en-US">Michael Kelliher</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US">Affiliated Entity</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementMember" xlink:label="capr_ConsultingAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ConsultingAgreementMember" xlink:to="capr_ConsultingAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_ConsultingAgreementMember_lbl" xml:lang="en-US">Information pertaining to agreements for consulting and advisory services.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementWithFrankLitvackMember" xlink:label="capr_ConsultingAgreementWithFrankLitvackMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_ConsultingAgreementWithFrankLitvackMember" xlink:to="capr_ConsultingAgreementWithFrankLitvackMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_ConsultingAgreementWithFrankLitvackMember_lbl" xml:lang="en-US">Consulting Agreement with Frank Litvack</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_ConsultingAgreementWithFrankLitvackMember_lbl" xml:lang="en-US">Consulting Agreement with Frank Litvack</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TransactionOtherThanSubawardAgreementMember" xlink:label="capr_TransactionOtherThanSubawardAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_TransactionOtherThanSubawardAgreementMember" xlink:to="capr_TransactionOtherThanSubawardAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_TransactionOtherThanSubawardAgreementMember_lbl" xml:lang="en-US">Transaction other than Sub-Award Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_TransactionOtherThanSubawardAgreementMember_lbl" xml:lang="en-US">Transaction other than Sub-Award Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AdvisoryServicesAgreementMember" xlink:label="capr_AdvisoryServicesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_AdvisoryServicesAgreementMember" xlink:to="capr_AdvisoryServicesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_AdvisoryServicesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to advisory services agreement member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_AdvisoryServicesAgreementMember_lbl" xml:lang="en-US">Advisory Services Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_AdvisoryServicesAgreementMember_lbl" xml:lang="en-US">Advisory Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MonthlyConsultingFeesToRelatedParty" xlink:label="capr_MonthlyConsultingFeesToRelatedParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_MonthlyConsultingFeesToRelatedParty" xlink:to="capr_MonthlyConsultingFeesToRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_MonthlyConsultingFeesToRelatedParty_lbl" xml:lang="en-US">Monthly consulting fees as per consulting agreement entered into with related party.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_MonthlyConsultingFeesToRelatedParty_lbl" xml:lang="en-US">Monthly Consulting Fees to Related Party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_MonthlyConsultingFeesToRelatedParty_lbl" xml:lang="en-US">Monthly consulting fees</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TerminableNoticePeriod" xlink:label="capr_TerminableNoticePeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_TerminableNoticePeriod" xlink:to="capr_TerminableNoticePeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_TerminableNoticePeriod_lbl" xml:lang="en-US">Terminable notice period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_TerminableNoticePeriod_lbl" xml:lang="en-US">Terminable Notice Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_TerminableNoticePeriod_lbl" xml:lang="en-US">Notice period for termination of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" xlink:to="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_lbl" xml:lang="en-US">The cash outflows for the reimbursement of research and development , license and Patent fees and facilities rent expenses which is incurred by the related party on behalf of the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_lbl" xml:lang="en-US">Payments For Reimbursement For Research And Development, License, Patent Fees And Facilities Rent Expenses Incurred Related Party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_lbl" xml:lang="en-US">Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" xlink:to="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_lbl" xml:lang="en-US">Represents information pertaining to employees non employee consultants and directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_lbl" xml:lang="en-US">Employees Non Employee Consultants And Directors</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_lbl" xml:lang="en-US">Employees Non Employee Consultants And Directors</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAndServicesAgreementMember" xlink:label="capr_LicenseAndServicesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseAndServicesAgreementMember" xlink:to="capr_LicenseAndServicesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LicenseAndServicesAgreementMember_lbl" xml:lang="en-US">License and service agreement with Azzur.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseAndServicesAgreementMember_lbl" xml:lang="en-US">License and Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseFee" xlink:label="capr_LicenseFee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_LicenseFee" xlink:to="capr_LicenseFee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_LicenseFee_lbl" xml:lang="en-US">License fee  per month.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_LicenseFee_lbl" xml:lang="en-US">License fee</link:label>
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfLicense" xlink:label="capr_TermOfLicense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="capr_TermOfLicense" xlink:to="capr_TermOfLicense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="capr_TermOfLicense_lbl" xml:lang="en-US">Term of License and Service agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="capr_TermOfLicense_lbl" xml:lang="en-US">Term of License</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>capr-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 10:04:47 PM-->
<!--Modified on: 3/8/2024 10:04:47 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://capricor.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockholderSEquity" roleURI="http://capricor.com/role/DisclosureStockholderSEquity" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptions" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureConcentrations" roleURI="http://capricor.com/role/DisclosureConcentrations" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureGovernmentGrantAwards" roleURI="http://capricor.com/role/DisclosureGovernmentGrantAwards" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureLicenseAndDistributionAgreements" roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreements" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://capricor.com/role/DisclosureRelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://capricor.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsTables" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" roleURI="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockholderSEquityDetails" roleURI="http://capricor.com/role/DisclosureStockholderSEquityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureConcentrationsDetails" roleURI="http://capricor.com/role/DisclosureConcentrationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureGovernmentGrantAwardsDetails" roleURI="http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureLicenseAndDistributionAgreementsDetails" roleURI="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="capr-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://capricor.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://capricor.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638455322862469893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638455322862469893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638455322862559891" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638455322862559891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638455322862559891" order="4" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638455322862559891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638455322862559891" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638455322862559891" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638455322862559891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638455322862559891" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638455322862569891" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638455322862569891" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638455322862569891" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638455322862569891" order="12" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638455322862569891" order="13" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638455322862569891" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638455322862569891" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638455322862569891" order="16" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638455322862569891" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638455322862569891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638455322862569891" order="18" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638455322862579891" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638455322862579891" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638455322862579891" order="21" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638455322862579891" order="22" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638455322862579891" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638455322862579891" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638455322862579891" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638455322862579891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638455322862579891" order="26" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638455322862589891" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638455322862589891" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638455322862589891" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638455322862589891" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638455322862589891" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638455322862589891" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638455322862589891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638455322862589891" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638455322862599891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638455322862599891" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638455322862599891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638455322862599891" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638455322862599891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638455322862599891" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638455322862599891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638455322862599891" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_66" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66" xlink:to="us-gaap_AssetsAbstract_638455322862609900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638455322862609900" xlink:to="us-gaap_AssetsCurrentAbstract_638455322862609900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638455322862609900" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638455322862609900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638455322862609900" xlink:to="us-gaap_MarketableSecuritiesCurrent_638455322862609900" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638455322862609900" xlink:to="us-gaap_GrantsReceivableCurrent_638455322862609900" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638455322862609900" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638455322862609900" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638455322862609900" xlink:to="us-gaap_AssetsCurrent_638455322862609900" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638455322862609900" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638455322862609900" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638455322862609900" xlink:to="us-gaap_OtherAssetsAbstract_638455322862609900" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_638455322862609900" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638455322862609900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638455322862609900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_638455322862609900" xlink:to="us-gaap_OtherAssets_638455322862609900" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_638455322862609900" xlink:to="us-gaap_Assets_638455322862619902" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638455322862619902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" xlink:to="us-gaap_OtherLiabilitiesCurrent_638455322862619902" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638455322862619902" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638455322862619902" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638455322862619902" xlink:to="us-gaap_LiabilitiesCurrent_638455322862619902" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_638455322862619902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_638455322862619902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322862629899" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638455322862629899" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" xlink:to="us-gaap_LiabilitiesNoncurrent_638455322862629899" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638455322862619902" xlink:to="us-gaap_Liabilities_638455322862629899" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" xlink:to="us-gaap_CommitmentsAndContingencies_638455322862629899" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" xlink:to="us-gaap_StockholdersEquityAbstract_638455322862629899" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_PreferredStockValue_638455322862629899" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638455322862629899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_CommonStockValue_638455322862629899" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638455322862639899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638455322862639899" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638455322862639899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638455322862639899" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638455322862639899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638455322862639899" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638455322862639899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638455322862629899" xlink:to="us-gaap_StockholdersEquity_638455322862639899" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638455322862639899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638455322862619902" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638455322862639899" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_248" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638455322862649903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_PreferredStockSharesAuthorized_638455322862649903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_PreferredStockSharesIssued_638455322862649903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_PreferredStockSharesOutstanding_638455322862649903" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638455322862649903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_CommonStockSharesAuthorized_638455322862649903" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_CommonStockSharesIssued_638455322862649903" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638455322862649903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_248" xlink:to="us-gaap_CommonStockSharesOutstanding_638455322862649903" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_453" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_RevenuesAbstract_638455322862659917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638455322862659917" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322862659917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638455322862659917" xlink:to="us-gaap_Revenues_638455322862659917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_OperatingExpensesAbstract_638455322862659917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638455322862659917" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638455322862659917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638455322862659917" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638455322862659917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638455322862659917" xlink:to="us-gaap_OperatingExpenses_638455322862659917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_OperatingIncomeLoss_638455322862659917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" xlink:to="us-gaap_OtherIncome_638455322862659917" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_638455322862659917" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638455322862659917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638455322862659917" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638455322862659917" xlink:to="us-gaap_NonoperatingIncomeExpense_638455322862669909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_NetIncomeLoss_638455322862669909" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638455322862669909" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638455322862669909" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322862669909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638455322862669909" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_EarningsPerShareBasic_638455322862669909" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_EarningsPerShareDiluted_638455322862669909" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638455322862669909" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638455322862669909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_453" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638455322862669909" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_581" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_581" xlink:to="us-gaap_StatementTable_638455322862679907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862679907" xlink:to="us-gaap_StatementEquityComponentsAxis_638455322862679907" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638455322862679907" xlink:to="us-gaap_CommonStockMember_638455322862679907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638455322862679907" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638455322862679907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638455322862679907" xlink:to="us-gaap_ComprehensiveIncomeMember_638455322862679907" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638455322862679907" xlink:to="us-gaap_RetainedEarningsMember_638455322862679907" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638455322862679907" xlink:to="us-gaap_EquityComponentDomain_638455322862679907" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862679907" xlink:to="us-gaap_StatementLineItems_638455322862679907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638455322862679907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockholdersEquity_638455322862679907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_SharesOutstanding_638455322862689910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638455322862689910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322862689910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638455322862689910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638455322862689910" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638455322862689910" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638455322862689910" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_NetIncomeLoss_638455322862689910" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638455322862689910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_StockholdersEquity_638455322862689910" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6384553228626899101" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862679907" xlink:to="us-gaap_SharesOutstanding_6384553228626899101" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_607" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_ProfitLoss_638455322862699911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638455322862699911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638455322862699911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_ShareBasedCompensation_638455322862699911" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NoncashLeaseExpenses" xlink:label="capr_NoncashLeaseExpenses_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="capr_NoncashLeaseExpenses_638455322862699911" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_IncreaseDecreaseFromGrantsReceivable" xlink:label="capr_IncreaseDecreaseFromGrantsReceivable_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="capr_IncreaseDecreaseFromGrantsReceivable_638455322862709912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638455322862709912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_638455322862709912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638455322862709912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638455322862709912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638455322862699911" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322862709912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638455322862699911" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638455322862709912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638455322862709912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638455322862709912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638455322862709912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638455322862719915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsToAcquireLeaseholdImprovements" xlink:label="capr_PaymentsToAcquireLeaseholdImprovements_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" xlink:to="capr_PaymentsToAcquireLeaseholdImprovements_638455322862719915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638455322862709912" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638455322862719915" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638455322862719915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638455322862719915" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862719915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638455322862719915" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638455322862719915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638455322862719915" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638455322862719915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638455322862719915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638455322862719915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638455322862729906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638455322862729906" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384553228627299061" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384553228627299061" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638455322862729906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_607" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638455322862729906" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638455322862729906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638455322862729906" xlink:to="us-gaap_InterestPaidNet_638455322862729906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638455322862729906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638455322862729906" xlink:to="us-gaap_IncomeTaxesPaidNet_638455322862729906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638455322862739913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_646" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638455322862739913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockholderSEquity" xlink:type="extended" xlink:title="10201 - Disclosure - STOCKHOLDER'S EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638455322862739913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_652" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638455322862739913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions" xlink:type="extended" xlink:title="10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="loc_capr_StockAwardsWarrantsAndOptionsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638455322862739913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_StockAwardsWarrantsAndOptionsAbstract_2" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638455322862739913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureConcentrations" xlink:type="extended" xlink:title="10401 - Disclosure - CONCENTRATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_638455322862739913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_5" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_638455322862739913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureGovernmentGrantAwards" xlink:type="extended" xlink:title="10501 - Disclosure - GOVERNMENT GRANT AWARDS">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AwardAbstract" xlink:label="loc_capr_AwardAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GovernmentGrantAwardsDisclosureTextBlock" xlink:label="capr_GovernmentGrantAwardsDisclosureTextBlock_638455322862749904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_AwardAbstract_8" xlink:to="capr_GovernmentGrantAwardsDisclosureTextBlock_638455322862749904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638455322862749904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638455322862749904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureLicenseAndDistributionAgreements" xlink:type="extended" xlink:title="10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsAbstract" xlink:label="loc_capr_LicenseAgreementsAbstract_14" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTextBlock" xlink:label="capr_LicenseAgreementsTextBlock_638455322862749904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_LicenseAgreementsAbstract_14" xlink:to="capr_LicenseAgreementsTextBlock_638455322862749904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10801 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638455322862749904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_17" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638455322862749904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10901 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_20" xlink:to="us-gaap_SubsequentEventsTextBlock_638455322862759901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638455322862759901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638455322862759901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638455322862759901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LiquidityPolicyTextBlock" xlink:label="capr_LiquidityPolicyTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="capr_LiquidityPolicyTextBlock_638455322862759901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock" xlink:label="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock_638455322862759901" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_UseOfEstimates_638455322862759901" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638455322862759901" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_MarketableSecuritiesPolicy_638455322862759901" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638455322862759901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638455322862759901" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638455322862769901" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638455322862769901" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638455322862769901" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638455322862769901" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638455322862769901" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638455322862769901" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClinicalTrialExpensePolicyPolicyTextBlock" xlink:label="capr_ClinicalTrialExpensePolicyPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="capr_ClinicalTrialExpensePolicyPolicyTextBlock_638455322862769901" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638455322862769901" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638455322862769901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638455322862769901" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638455322862779896" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638455322862779896" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638455322862779896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638455322862779896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" xlink:type="extended" xlink:title="30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract_637028551952092221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract_637028551952092221" xlink:to="us-gaap_StatementTable_638455322862779896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862779896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862779896" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862779896" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862779896" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862789895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862789895" xlink:to="us-gaap_EmployeeStockOptionMember_638455322862789895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862779896" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638455322862789895" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638455322862789895" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638455322862789895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638455322862789895" xlink:to="us-gaap_WarrantMember_638455322862789895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862779896" xlink:to="us-gaap_StatementLineItems_638455322862789895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfWarrantActivityTableTextBlock" xlink:label="capr_ScheduleOfWarrantActivityTableTextBlock_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="capr_ScheduleOfWarrantActivityTableTextBlock_638455322862789895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638455322862789895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638455322862789895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:label="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_638455322862789895" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638455322862789895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638455322862789895" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862789895" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638455322862799894" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_104" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_104" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638455322862799894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_104" xlink:to="us-gaap_LeaseCostTableTextBlock_638455322862799894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_116" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_116" xlink:to="us-gaap_StatementTable_638455322862799894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862799894" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638455322862799894" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638455322862799894" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638455322862799894" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638455322862799894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638455322862799894" xlink:to="us-gaap_FurnitureAndFixturesMember_638455322862799894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638455322862799894" xlink:to="us-gaap_EquipmentMember_638455322862809895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638455322862799894" xlink:to="us-gaap_LeaseholdImprovementsMember_638455322862809895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322862799894" xlink:to="us-gaap_StatementLineItems_638455322862809895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862809895" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638455322862809895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862809895" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638455322862809895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322862809895" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638455322862809895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_148" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesTable" xlink:label="capr_AccountingPoliciesTable_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_148" xlink:to="capr_AccountingPoliciesTable_638455322862809895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="srt_RangeAxis_638455322862809895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322862809895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322862809895" xlink:to="srt_RangeMember_638455322862809895" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862809895" xlink:to="srt_MinimumMember_638455322862819894" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862809895" xlink:to="srt_MaximumMember_638455322862819894" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="us-gaap_TypeOfArrangementAxis_638455322862819894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638455322862819894" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322862819894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322862819894" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_638455322862819894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638455322862819894" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638455322862819894" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638455322862819894" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638455322862819894" xlink:to="us-gaap_WarrantMember_638455322862819894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638455322862819894" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638455322862819894" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638455322862819894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember_638455322862819894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638455322862819894" xlink:to="us-gaap_GeneralBusinessMember_638455322862819894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638455322862819894" xlink:to="us-gaap_ResearchMember_638455322862829894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638455322862829894" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638455322862829894" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638455322862829894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638455322862829894" xlink:to="us-gaap_DomesticCountryMember_638455322862829894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638455322862829894" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638455322862829894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638455322862829894" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_638455322862829894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638455322862829894" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638455322862829894" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862829894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638455322862829894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862829894" xlink:to="us-gaap_PrivatePlacementMember_638455322862829894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AccountingPoliciesLineItems" xlink:label="capr_AccountingPoliciesLineItems_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesTable_638455322862809895" xlink:to="capr_AccountingPoliciesLineItems_638455322862839912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638455322862839912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638455322862839912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862839912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActRevenue" xlink:label="capr_EmployeeRetentionCreditCaresActRevenue_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_EmployeeRetentionCreditCaresActRevenue_638455322862839912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeeRetentionCreditCaresActReceivable" xlink:label="capr_EmployeeRetentionCreditCaresActReceivable_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_EmployeeRetentionCreditCaresActReceivable_638455322862839912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638455322862839912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638455322862839912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_Depreciation_638455322862839912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantIncome" xlink:label="capr_GrantIncome_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_GrantIncome_638455322862849899" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_OperatingLossCarryforwards_638455322862849899" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638455322862849899" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsExpirationYear" xlink:label="capr_OperatingLossCarryForwardsExpirationYear_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_OperatingLossCarryForwardsExpirationYear_638455322862849899" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_638455322862849899" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLossCarryForwardsIndefinitely" xlink:label="capr_OperatingLossCarryForwardsIndefinitely_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_OperatingLossCarryForwardsIndefinitely_638455322862849899" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TaxCreditCarryForwardsExpirationYear" xlink:label="capr_TaxCreditCarryForwardsExpirationYear_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="capr_TaxCreditCarryForwardsExpirationYear_638455322862849899" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638455322862849899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638455322862849899" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638455322862859919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638455322862859919" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638455322862859919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638455322862859919" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638455322862859919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638455322862859919" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638455322862859919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_AccountingPoliciesLineItems_638455322862839912" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638455322862859919" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" xlink:type="extended" xlink:title="40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638455322862869918" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638455322862869918" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638455322862869918" xlink:to="us-gaap_FairValueInputsLevel1Member_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638455322862869918" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638455322862869918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638455322862869918" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638455322862869918" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638455322862869918" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638455322862869918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638455322862869918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638455322862869918" xlink:to="us-gaap_AssetsFairValueDisclosure_638455322862869918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockholderSEquityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_206" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_206" xlink:to="us-gaap_ScheduleOfStockByClassTable_638455322862879908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638455322862879908" xlink:to="srt_RangeAxis_638455322862879908" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322862879908" xlink:to="srt_RangeMember_638455322862879908" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862879908" xlink:to="srt_MinimumMember_638455322862879908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862879908" xlink:to="srt_MaximumMember_638455322862879908" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638455322862879908" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638455322862879908" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638455322862879908" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862879908" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_June2021AtMarketProgramMember" xlink:label="capr_June2021AtMarketProgramMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862879908" xlink:to="capr_June2021AtMarketProgramMember_638455322862879908" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RegisteredDirectOfferingMember" xlink:label="capr_RegisteredDirectOfferingMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638455322862879908" xlink:to="capr_RegisteredDirectOfferingMember_638455322862879908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638455322862879908" xlink:to="us-gaap_SubsequentEventTypeAxis_638455322862879908" order="3" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638455322862879908" xlink:to="us-gaap_SubsequentEventTypeDomain_638455322862879908" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638455322862879908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638455322862879908" xlink:to="us-gaap_SubsequentEventMember_638455322862879908" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638455322862879908" xlink:to="us-gaap_ClassOfStockLineItems_638455322862889915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockSharesAuthorizedValue" xlink:label="capr_CommonStockSharesAuthorizedValue_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="capr_CommonStockSharesAuthorizedValue_638455322862889915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommissionRateOnSalePricePerShare" xlink:label="capr_CommissionRateOnSalePricePerShare_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="capr_CommissionRateOnSalePricePerShare_638455322862889915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322862889915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_SharePrice_638455322862889915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322862889915" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638455322862889915" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638455322862889915" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638455322862889915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638455322862889915" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638455322862899903" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638455322862899903" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LockUpPeriodNotToIssueOrSellShares" xlink:label="capr_LockUpPeriodNotToIssueOrSellShares_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="capr_LockUpPeriodNotToIssueOrSellShares_638455322862899903" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementExpiryTerm" xlink:label="capr_AgreementExpiryTerm_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="capr_AgreementExpiryTerm_638455322862899903" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_CommonStockSharesIssued_638455322862899903" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="us-gaap_CommonStockSharesOutstanding_638455322862899903" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockOfferingRemainingAmountIssuable" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable_638455322862899903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638455322862889915" xlink:to="capr_CommonStockOfferingRemainingAmountIssuable_638455322862899903" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638455322862909896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightGranted" xlink:label="capr_ClassOfWarrantOrRightGranted_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_ClassOfWarrantOrRightGranted_638455322862909896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightExercised" xlink:label="capr_ClassOfWarrantOrRightExercised_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_ClassOfWarrantOrRightExercised_638455322862909896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6384553228629098961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6384553228629098961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_638455322862909896" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WeightedAverageExercisePriceGranted" xlink:label="capr_WeightedAverageExercisePriceGranted_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_WeightedAverageExercisePriceGranted_638455322862909896" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_638455322862909896" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:label="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_6384553228629098961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract_637028551953360715" xlink:to="capr_ClassOfWarrantOrRightWeightedAverageExercisePrice_6384553228629098961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="loc_capr_StockAwardsWarrantsAndOptionsAbstract_265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638455322862909896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_StockAwardsWarrantsAndOptionsAbstract_265" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638455322862909896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638455322862909896" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638455322862919892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638455322862919892" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638455322862919892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsMember" xlink:label="capr_CommonStockWarrantsMember_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638455322862919892" xlink:to="capr_CommonStockWarrantsMember_638455322862919892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommonStockWarrantsMember_638455322862919892" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_638455322862919892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommonStockWarrantsMember_638455322862919892" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_638455322862919892" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember" xlink:label="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommonStockWarrantsMember_638455322862919892" xlink:to="capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_638455322862919892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638455322862909896" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638455322862919892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638455322862919892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638455322862919892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_638455322862919892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638455322862919892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_638455322862919892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862929892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862929892" xlink:to="srt_RangeAxis_638455322862929892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322862929892" xlink:to="srt_RangeMember_638455322862929892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862929892" xlink:to="srt_MinimumMember_638455322862929892" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862929892" xlink:to="srt_MaximumMember_638455322862929892" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638455322862929892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638455322862929892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638455322862929892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638455322862929892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638455322862929892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638455322862939891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862929892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638455322862939891" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638455322862939891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638455322862939891" xlink:to="us-gaap_IncomeStatementLocationAxis_638455322862939891" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638455322862939891" xlink:to="us-gaap_IncomeStatementLocationDomain_638455322862939891" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638455322862939891" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638455322862939891" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638455322862939891" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638455322862939891" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638455322862939891" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638455322862939891" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638455322862939891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638455322862939891" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638455322862939891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40305 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638455322862949889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638455322862949889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeOneMember" xlink:label="capr_RangeOneMember_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" xlink:to="capr_RangeOneMember_638455322862949889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeTwoMember" xlink:label="capr_RangeTwoMember_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" xlink:to="capr_RangeTwoMember_638455322862949889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeThreeMember" xlink:label="capr_RangeThreeMember_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" xlink:to="capr_RangeThreeMember_638455322862949889" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RangeFourMember" xlink:label="capr_RangeFourMember_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638455322862949889" xlink:to="capr_RangeFourMember_638455322862949889" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638455322862949889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638455322862949889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638455322862949889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638455322862959894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638455322862959894" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638455322862959894" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638455322862959894" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638455322862959894" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638455322862959894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638455322862949889" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638455322862959894" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" xlink:type="extended" xlink:title="40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862969893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862969893" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862969893" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638455322862969893" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862969893" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322862969893" xlink:to="us-gaap_EmployeeStockOptionMember_638455322862969893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638455322862969893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322862969893" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638455322862969893" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638455322862969893" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384553228629698931" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384553228629698931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638455322862969893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638455322862969893" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638455322862979891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638455322862979891" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638455322862979891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638455322862979891" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384553228629798911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384553228629798911" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638455322862979891" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638455322862979891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638455322862979891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638455322862979891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638455322862979891" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638455322862989889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638455322862969893" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638455322862989889" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" xlink:type="extended" xlink:title="40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockAwardsWarrantsAndOptionsAbstract" xlink:label="capr_StockAwardsWarrantsAndOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_StockAwardsWarrantsAndOptionsAbstract" xlink:to="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" xlink:to="srt_RangeAxis_638455322862989889" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322862989889" xlink:to="srt_RangeMember_638455322862989889" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862989889" xlink:to="srt_MinimumMember_638455322862989889" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322862989889" xlink:to="srt_MaximumMember_638455322862989889" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638455322862989889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638455322862989889" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322863039902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638455322862989889" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322863039902" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638455322863039902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638455322863039902" xlink:to="us-gaap_EmployeeStockOptionMember_638455322863039902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638455322863039902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" xlink:to="us-gaap_PlanNameAxis_638455322863039902" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638455322863039902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638455322863039902" xlink:to="us-gaap_PlanNameDomain_638455322863039902" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2020Member" xlink:label="capr_StockOptionPlan2020Member_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638455322863039902" xlink:to="capr_StockOptionPlan2020Member_638455322863049892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_StockOptionPlan2021Member" xlink:label="capr_StockOptionPlan2021Member_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638455322863039902" xlink:to="capr_StockOptionPlan2021Member_638455322863049892" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems" xlink:label="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable_638455322862989889" xlink:to="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationNumberOfPlans" xlink:label="capr_ShareBasedCompensationNumberOfPlans_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="capr_ShareBasedCompensationNumberOfPlans_638455322863049892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638455322863049892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638455322863049892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant" xlink:label="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant_638455322863049892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock" xlink:label="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock_638455322863049892" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638455322863049892" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638455322863049892" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638455322863049892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638455322863049892" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638455322863059925" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638455322863059925" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638455322863059925" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638455322863059925" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems_638455322863049892" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322863059925" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureConcentrationsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - CONCENTRATIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_380" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NumberOfFinancialInstitutions" xlink:label="capr_NumberOfFinancialInstitutions_638455322863059925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_380" xlink:to="capr_NumberOfFinancialInstitutions_638455322863059925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_380" xlink:to="us-gaap_CashFDICInsuredAmount_638455322863069913" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_380" xlink:to="us-gaap_CashUninsuredAmount_638455322863069913" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AwardAbstract" xlink:label="loc_capr_AwardAbstract_391" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_AwardAbstract_391" xlink:to="us-gaap_StatementTable_638455322863069913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322863069913" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863069913" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863069913" xlink:to="us-gaap_RelatedPartyDomain_638455322863069913" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="capr_CaliforniaInstituteForRegenerativeMedicineMember_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863069913" xlink:to="capr_CaliforniaInstituteForRegenerativeMedicineMember_638455322863069913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322863069913" xlink:to="us-gaap_VariableRateAxis_638455322863069913" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638455322863069913" xlink:to="us-gaap_VariableRateDomain_638455322863069913" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LiborMember" xlink:label="capr_LiborMember_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638455322863069913" xlink:to="capr_LiborMember_638455322863069913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638455322863069913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638455322863069913" xlink:to="us-gaap_StatementLineItems_638455322863069913" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_GrantAwardLiability" xlink:label="capr_GrantAwardLiability_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="capr_GrantAwardLiability_638455322863079910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MinimumExpectedContribution" xlink:label="capr_MinimumExpectedContribution_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="capr_MinimumExpectedContribution_638455322863079910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable" xlink:label="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable_638455322863079910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfAward" xlink:label="capr_TermOfAward_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="capr_TermOfAward_638455322863079910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="us-gaap_DebtInstrumentTerm_638455322863079910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="us-gaap_DerivativeVariableInterestRate_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638455322863069913" xlink:to="us-gaap_DerivativeVariableInterestRate_638455322863079910" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638455322863079910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638455322863079910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638455322863079910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638455322863089912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638455322863089912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638455322863089912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_OperatingLeaseLiability_638455322863089912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638455322863089912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638455322863089912" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638455322863089912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638455322863089912" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638455322863089912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_6384553228630899121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638455322863089912" xlink:to="us-gaap_OperatingLeaseLiability_6384553228630899121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638455322863089912" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638455322863089912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638455322863089912" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_420" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureTable" xlink:label="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_420" xlink:to="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863099909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863099909" xlink:to="us-gaap_RelatedPartyDomain_638455322863099909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863099909" xlink:to="us-gaap_RelatedPartyMember_638455322863099909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyAxis" xlink:label="capr_UnrelatedPartyAxis_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="capr_UnrelatedPartyAxis_638455322863099909" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyDomain" xlink:label="capr_UnrelatedPartyDomain_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_UnrelatedPartyAxis_638455322863099909" xlink:to="capr_UnrelatedPartyDomain_638455322863099909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UnrelatedPartyMember" xlink:label="capr_UnrelatedPartyMember_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_UnrelatedPartyDomain_638455322863099909" xlink:to="capr_UnrelatedPartyMember_638455322863099909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="us-gaap_LeaseContractualTermAxis_638455322863099909" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638455322863099909" xlink:to="us-gaap_LeaseContractualTermDomain_638455322863099909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FacilitiesLeaseMember" xlink:label="capr_FacilitiesLeaseMember_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638455322863099909" xlink:to="capr_FacilitiesLeaseMember_638455322863099909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638455322863099909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638455322863099909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638455322863099909" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638455322863109912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CorporateOfficesLeaseMember" xlink:label="capr_CorporateOfficesLeaseMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638455322863109912" xlink:to="capr_CorporateOfficesLeaseMember_638455322863109912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LongTermOperatingLeasesMember" xlink:label="capr_LongTermOperatingLeasesMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638455322863109912" xlink:to="capr_LongTermOperatingLeasesMember_638455322863109912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FacilitiesLeaseMember" xlink:label="capr_FacilitiesLeaseMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LongTermOperatingLeasesMember_638455322863109912" xlink:to="capr_FacilitiesLeaseMember_638455322863109912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PropertyLocatedAt10865RoadToCureInDiegoMember" xlink:label="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LongTermOperatingLeasesMember_638455322863109912" xlink:to="capr_PropertyLocatedAt10865RoadToCureInDiegoMember_638455322863109912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_VivariumSpaceLeaseMember" xlink:label="capr_VivariumSpaceLeaseMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LongTermOperatingLeasesMember_638455322863109912" xlink:to="capr_VivariumSpaceLeaseMember_638455322863109912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="srt_RangeAxis_638455322863109912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322863109912" xlink:to="srt_RangeMember_638455322863109912" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322863109912" xlink:to="srt_MinimumMember_638455322863109912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322863109912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322863109912" xlink:to="srt_MaximumMember_638455322863109912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureTable_638455322863099909" xlink:to="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_638455322863119915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_NetRentableArea_638455322863119915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638455322863119915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseBaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_LesseeOperatingLeaseBaseLeaseRentPerMonth_638455322863119915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_WrittenNoticePeriod_638455322863119915" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_OperatingLeaseExpense_638455322863119915" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent" xlink:label="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent_638455322863119915" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638455322863119915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638455322863119915" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_OperatingLeaseLiability_638455322863129911" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_OperatingLeasePayments_638455322863129911" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseLeaseRentPerMonth" xlink:label="capr_LesseeOperatingLeaseLeaseRentPerMonth_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_LesseeOperatingLeaseLeaseRentPerMonth_638455322863129911" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_SeverancePackageToBePaidForPeriodOfBaseSalary" xlink:label="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_SeverancePackageToBePaidForPeriodOfBaseSalary_638455322863129911" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="us-gaap_RestructuringReserve_638455322863129911" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LesseeOperatingLeaseMonthlyRentEscalationPercent" xlink:label="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_638455322863129911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_CommitmentsAndContingenciesDisclosureLineItems_638455322863119915" xlink:to="capr_LesseeOperatingLeaseMonthlyRentEscalationPercent_638455322863129911" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsAbstract" xlink:label="loc_capr_LicenseAgreementsAbstract_479" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsTable" xlink:label="capr_LicenseAgreementsTable_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_capr_LicenseAgreementsAbstract_479" xlink:to="capr_LicenseAgreementsTable_638455322863139909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="srt_StatementScenarioAxis_638455322863139909" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638455322863139909" xlink:to="srt_ScenarioUnspecifiedDomain_638455322863139909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember" xlink:label="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_638455322863139909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_NonPaymentOfRoyaltiesMember" xlink:label="capr_NonPaymentOfRoyaltiesMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_NonPaymentOfRoyaltiesMember_638455322863139909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember" xlink:label="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_638455322863139909" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MaterialBreachHasNotBeenCuredMember" xlink:label="capr_MaterialBreachHasNotBeenCuredMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_MaterialBreachHasNotBeenCuredMember_638455322863139909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_FailsToCureBreachAfterNoticeFromCsmcMember" xlink:label="capr_FailsToCureBreachAfterNoticeFromCsmcMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_FailsToCureBreachAfterNoticeFromCsmcMember_638455322863139909" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_OverduePaymentObligationsMember" xlink:label="capr_OverduePaymentObligationsMember_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638455322863139909" xlink:to="capr_OverduePaymentObligationsMember_638455322863139909" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesAxis" xlink:label="capr_MilestonePaymentsInPhasesAxis_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="capr_MilestonePaymentsInPhasesAxis_638455322863139909" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsInPhasesDomain" xlink:label="capr_MilestonePaymentsInPhasesDomain_638455322863139909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_MilestonePaymentsInPhasesAxis_638455322863139909" xlink:to="capr_MilestonePaymentsInPhasesDomain_638455322863139909" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CompletionOfPhaseTwoDueMember" xlink:label="capr_CompletionOfPhaseTwoDueMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_MilestonePaymentsInPhasesDomain_638455322863139909" xlink:to="capr_CompletionOfPhaseTwoDueMember_638455322863149911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="srt_RangeAxis_638455322863149911" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638455322863149911" xlink:to="srt_RangeMember_638455322863149911" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322863149911" xlink:to="srt_MinimumMember_638455322863149911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638455322863149911" xlink:to="srt_MaximumMember_638455322863149911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="us-gaap_RelatedPartyTransactionAxis_638455322863149911" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638455322863149911" xlink:to="us-gaap_RelatedPartyTransactionDomain_638455322863149911" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RomeLicenseAgreementMember" xlink:label="capr_RomeLicenseAgreementMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863149911" xlink:to="capr_RomeLicenseAgreementMember_638455322863149911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_JhuLicenseAgreementMember" xlink:label="capr_JhuLicenseAgreementMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863149911" xlink:to="capr_JhuLicenseAgreementMember_638455322863149911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcLicenseAgreementMember" xlink:label="capr_CsmcLicenseAgreementMember_638455322863149911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863149911" xlink:to="capr_CsmcLicenseAgreementMember_638455322863149911" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ExosomesLicenseAgreementMember" xlink:label="capr_ExosomesLicenseAgreementMember_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863149911" xlink:to="capr_ExosomesLicenseAgreementMember_638455322863159911" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863159911" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863159911" xlink:to="us-gaap_RelatedPartyDomain_638455322863159911" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863159911" xlink:to="capr_CsmcMember_638455322863159911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="us-gaap_TypeOfArrangementAxis_638455322863159911" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638455322863159911" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863159911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863159911" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_638455322863159911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember" xlink:label="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_638455322863159911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863159911" xlink:to="capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_638455322863159911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_638455322863169922" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAgreementsLineItems" xlink:label="capr_LicenseAgreementsLineItems_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsTable_638455322863139909" xlink:to="capr_LicenseAgreementsLineItems_638455322863169922" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AnnualPaymentsForRoyalties" xlink:label="capr_AnnualPaymentsForRoyalties_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_AnnualPaymentsForRoyalties_638455322863169922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_WrittenNoticePeriod" xlink:label="capr_WrittenNoticePeriod_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_WrittenNoticePeriod_638455322863169922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PotentialMilestonePayments" xlink:label="capr_PotentialMilestonePayments_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_PotentialMilestonePayments_638455322863169922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePayments" xlink:label="capr_MilestonePayments_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_MilestonePayments_638455322863169922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases" xlink:label="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases_638455322863169922" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PeriodOfAgreementWillBeInEffective" xlink:label="capr_PeriodOfAgreementWillBeInEffective_638455322863169922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_PeriodOfAgreementWillBeInEffective_638455322863169922" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ThresholdPeriodToCureBreach" xlink:label="capr_ThresholdPeriodToCureBreach_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_ThresholdPeriodToCureBreach_638455322863179915" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AgreementTerminationPeriod" xlink:label="capr_AgreementTerminationPeriod_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_AgreementTerminationPeriod_638455322863179915" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_UpfrontPayment" xlink:label="capr_UpfrontPayment_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_UpfrontPayment_638455322863179915" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="us-gaap_ContractWithCustomerLiability_638455322863179915" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638455322863179915" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MilestonePaymentsPercentageOwedToThirdParty" xlink:label="capr_MilestonePaymentsPercentageOwedToThirdParty_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="capr_MilestonePaymentsPercentageOwedToThirdParty_638455322863179915" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638455322863179915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638455322863179915" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_638455322863189915" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="capr_LicenseAgreementsLineItems_638455322863169922" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_638455322863189915" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_519" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_519" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638455322863189915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638455322863189915" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863189915" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638455322863189915" xlink:to="us-gaap_RelatedPartyDomain_638455322863189915" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_638455322863189915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863189915" xlink:to="srt_BoardOfDirectorsChairmanMember_638455322863189915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_DrEduardoMarbanMember" xlink:label="capr_DrEduardoMarbanMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863189915" xlink:to="capr_DrEduardoMarbanMember_638455322863199920" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MichaelKelliherMember" xlink:label="capr_MichaelKelliherMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863189915" xlink:to="capr_MichaelKelliherMember_638455322863199920" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638455322863189915" xlink:to="srt_AffiliatedEntityMember_638455322863199920" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CsmcMember" xlink:label="capr_CsmcMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_AffiliatedEntityMember_638455322863199920" xlink:to="capr_CsmcMember_638455322863199920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638455322863189915" xlink:to="us-gaap_RelatedPartyTransactionAxis_638455322863199920" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638455322863199920" xlink:to="us-gaap_RelatedPartyTransactionDomain_638455322863199920" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementMember" xlink:label="capr_ConsultingAgreementMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863199920" xlink:to="capr_ConsultingAgreementMember_638455322863199920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_ConsultingAgreementWithFrankLitvackMember" xlink:label="capr_ConsultingAgreementWithFrankLitvackMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863199920" xlink:to="capr_ConsultingAgreementWithFrankLitvackMember_638455322863199920" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TransactionOtherThanSubawardAgreementMember" xlink:label="capr_TransactionOtherThanSubawardAgreementMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863199920" xlink:to="capr_TransactionOtherThanSubawardAgreementMember_638455322863199920" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_AdvisoryServicesAgreementMember" xlink:label="capr_AdvisoryServicesAgreementMember_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638455322863199920" xlink:to="capr_AdvisoryServicesAgreementMember_638455322863199920" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638455322863189915" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_MonthlyConsultingFeesToRelatedParty" xlink:label="capr_MonthlyConsultingFeesToRelatedParty_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" xlink:to="capr_MonthlyConsultingFeesToRelatedParty_638455322863209914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TerminableNoticePeriod" xlink:label="capr_TerminableNoticePeriod_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" xlink:to="capr_TerminableNoticePeriod_638455322863209914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322863209914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" xlink:to="us-gaap_OtherLiabilitiesCurrent_638455322863209914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty" xlink:label="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638455322863199920" xlink:to="capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty_638455322863209914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://capricor.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638455322863209914" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638455322863209914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638455322863209914" xlink:to="us-gaap_SubsequentEventTypeAxis_638455322863209914" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638455322863209914" xlink:to="us-gaap_SubsequentEventTypeDomain_638455322863219910" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638455322863219910" xlink:to="us-gaap_SubsequentEventMember_638455322863219910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638455322863209914" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638455322863219910" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638455322863219910" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638455322863219910" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638455322863219910" xlink:to="us-gaap_PrivatePlacementMember_638455322863219910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_RegisteredDirectOfferingMember" xlink:label="capr_RegisteredDirectOfferingMember_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638455322863219910" xlink:to="capr_RegisteredDirectOfferingMember_638455322863219910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638455322863209914" xlink:to="srt_TitleOfIndividualAxis_638455322863219910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638455322863219910" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638455322863219910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_EmployeesNonEmployeeConsultantsAndDirectorsMember" xlink:label="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638455322863219910" xlink:to="capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_638455322863219910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638455322863209914" xlink:to="us-gaap_TypeOfArrangementAxis_638455322863219910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863219910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638455322863219910" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863219910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseAndServicesAgreementMember" xlink:label="capr_LicenseAndServicesAgreementMember_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638455322863219910" xlink:to="capr_LicenseAndServicesAgreementMember_638455322863229910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638455322863209914" xlink:to="us-gaap_SubsequentEventLineItems_638455322863229910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638455322863229910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="us-gaap_SharePrice_638455322863229910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638455322863229910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_CommonStockOfferingRemainingAmountIssuable" xlink:label="capr_CommonStockOfferingRemainingAmountIssuable_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="capr_CommonStockOfferingRemainingAmountIssuable_638455322863229910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638455322863229910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638455322863229910" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_LicenseFee" xlink:label="capr_LicenseFee_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="capr_LicenseFee_638455322863229910" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="capr-20231231.xsd#capr_TermOfLicense" xlink:label="capr_TermOfLicense_638455322863229910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638455322863229910" xlink:to="capr_TermOfLicense_638455322863229910" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542592848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAPRICOR THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0363465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10865 Road to the Cure, Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAPR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,715,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,399,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Rose, Snyder&#160;& Jacobs LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Encino, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542917232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,694,857<span></span>
</td>
<td class="nump">$ 9,603,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">24,792,846<span></span>
</td>
<td class="nump">31,818,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Receivables</a></td>
<td class="nump">10,371,993<span></span>
</td>
<td class="nump">547,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">995,776<span></span>
</td>
<td class="nump">919,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">50,855,472<span></span>
</td>
<td class="nump">42,888,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, net</a></td>
<td class="nump">5,560,641<span></span>
</td>
<td class="nump">4,588,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets, net</a></td>
<td class="nump">2,050,042<span></span>
</td>
<td class="nump">2,349,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">268,172<span></span>
</td>
<td class="nump">268,172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">58,734,327<span></span>
</td>
<td class="nump">50,094,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,222,762<span></span>
</td>
<td class="nump">4,834,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accounts payable and accrued expenses, related party</a></td>
<td class="nump">27,479<span></span>
</td>
<td class="nump">89,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">749,112<span></span>
</td>
<td class="nump">682,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">24,270,465<span></span>
</td>
<td class="nump">17,980,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">31,269,818<span></span>
</td>
<td class="nump">23,586,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">CIRM liability</a></td>
<td class="nump">3,376,259<span></span>
</td>
<td class="nump">3,376,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current</a></td>
<td class="nump">1,486,783<span></span>
</td>
<td class="nump">1,878,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,467,932<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">4,863,042<span></span>
</td>
<td class="nump">14,722,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">36,132,860<span></span>
</td>
<td class="nump">38,308,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 50,000,000 shares authorized, 31,148,320 and 25,241,402 shares issued and outstanding, respectively</a></td>
<td class="nump">31,148<span></span>
</td>
<td class="nump">25,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">181,701,859<span></span>
</td>
<td class="nump">148,735,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">235,813<span></span>
</td>
<td class="nump">105,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(159,367,353)<span></span>
</td>
<td class="num">(137,079,811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">22,601,467<span></span>
</td>
<td class="nump">11,786,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 58,734,327<span></span>
</td>
<td class="nump">$ 50,094,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344546812720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,148,320<span></span>
</td>
<td class="nump">25,241,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,148,320<span></span>
</td>
<td class="nump">25,241,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344639994448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 25,178,066<span></span>
</td>
<td class="nump">$ 2,551,469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">25,178,066<span></span>
</td>
<td class="nump">2,551,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">36,448,039<span></span>
</td>
<td class="nump">21,816,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,807,886<span></span>
</td>
<td class="nump">10,431,903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">49,255,925<span></span>
</td>
<td class="nump">32,248,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(24,077,859)<span></span>
</td>
<td class="num">(29,697,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">67,657<span></span>
</td>
<td class="nump">190,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">1,728,701<span></span>
</td>
<td class="nump">521,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="num">(6,041)<span></span>
</td>
<td class="num">(34,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
<td class="nump">1,790,317<span></span>
</td>
<td class="nump">677,851<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(22,287,542)<span></span>
</td>
<td class="num">(29,019,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">130,569<span></span>
</td>
<td class="nump">105,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (22,156,973)<span></span>
</td>
<td class="num">$ (28,914,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares of common stock outstanding basic</a></td>
<td class="nump">26,778,360<span></span>
</td>
<td class="nump">24,552,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares of common stock outstanding diluted</a></td>
<td class="nump">26,778,360<span></span>
</td>
<td class="nump">24,552,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344544796288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th"><div>OTHER COMPREHENSIVE INCOME</div></th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 24,185<span></span>
</td>
<td class="nump">$ 139,404,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (108,060,279)<span></span>
</td>
<td class="nump">$ 31,367,966<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">24,185,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of fees</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">4,802,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,803,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of fees (in shares)</a></td>
<td class="nump">830,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,458,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,458,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">70,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">225,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,019,532)<span></span>
</td>
<td class="num">(29,019,532)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 25,241<span></span>
</td>
<td class="nump">148,735,420<span></span>
</td>
<td class="nump">105,244<span></span>
</td>
<td class="num">(137,079,811)<span></span>
</td>
<td class="nump">11,786,094<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">25,241,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of fees</a></td>
<td class="nump">$ 5,813<span></span>
</td>
<td class="nump">25,509,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,515,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of fees (in shares)</a></td>
<td class="nump">5,813,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,392,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,392,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">64,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">93,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,287,542)<span></span>
</td>
<td class="num">(22,287,542)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 31,148<span></span>
</td>
<td class="nump">$ 181,701,859<span></span>
</td>
<td class="nump">$ 235,813<span></span>
</td>
<td class="num">$ (159,367,353)<span></span>
</td>
<td class="nump">$ 22,601,467<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">31,148,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344539741168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (22,287,542)<span></span>
</td>
<td class="num">$ (29,019,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">6,041<span></span>
</td>
<td class="nump">34,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,068,882<span></span>
</td>
<td class="nump">533,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,392,396<span></span>
</td>
<td class="nump">4,458,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_NoncashLeaseExpenses', window );">Changes in lease liabilities</a></td>
<td class="num">(24,282)<span></span>
</td>
<td class="nump">161,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_IncreaseDecreaseFromGrantsReceivable', window );">Receivables</a></td>
<td class="num">(9,824,413)<span></span>
</td>
<td class="num">(155,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(75,884)<span></span>
</td>
<td class="nump">240,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositsOutstanding', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,388,078<span></span>
</td>
<td class="nump">1,718,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses, related party</a></td>
<td class="num">(61,755)<span></span>
</td>
<td class="num">(510,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(3,178,066)<span></span>
</td>
<td class="nump">27,448,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(25,596,545)<span></span>
</td>
<td class="nump">4,916,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(97,441,506)<span></span>
</td>
<td class="num">(114,218,737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">104,597,249<span></span>
</td>
<td class="nump">82,505,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,311,660)<span></span>
</td>
<td class="num">(2,000,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PaymentsToAcquireLeaseholdImprovements', window );">Payments for leasehold improvements</a></td>
<td class="num">(735,873)<span></span>
</td>
<td class="num">(1,359,488)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">5,108,210<span></span>
</td>
<td class="num">(35,072,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="nump">25,515,349<span></span>
</td>
<td class="nump">4,803,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock awards</a></td>
<td class="nump">64,601<span></span>
</td>
<td class="nump">70,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,579,950<span></span>
</td>
<td class="nump">4,873,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">5,091,615<span></span>
</td>
<td class="num">(25,282,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balance at beginning of period</a></td>
<td class="nump">9,603,242<span></span>
</td>
<td class="nump">34,885,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents balance at end of period</a></td>
<td class="nump">14,694,857<span></span>
</td>
<td class="nump">9,603,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid in cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_IncreaseDecreaseFromGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in grants receivable (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_IncreaseDecreaseFromGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_NoncashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings related to noncash lease , which is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_NoncashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_PaymentsToAcquireLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of leasehold improvements during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_PaymentsToAcquireLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344545449520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor Therapeutics,&#160;Inc., a Delaware corporation (referred to herein as &#8220;Capricor Therapeutics&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#8220;DMD&#8221;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (&#8220;Capricor&#8221;), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#225;n, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics,&#160;Inc., a Delaware corporation (&#8220;Nile&#8221;), on November&#160;20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics,&#160;Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple therapeutic drug candidates in various stages of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basis of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities as of December 31, 2023 were approximately $39.5 million, compared to approximately $41.4 million as of December&#160;31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd., a Japanese corporation, (&#8220;Nippon Shinyaku&#8221;), in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). In October 2023, the Company completed a registered direct offering for gross proceeds of approximately $23.0 million (see Note 2 &#8211; &#8220;Stockholder&#8217;s Equity&#8221;). We received our first milestone payment of $10.0 million in the first quarter of 2024, which was triggered upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with our research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase 3 clinical trial of CAP-1002 in DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with potential commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our research programs, including the expansion of our exosomes program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. The Company has incurred significant operating losses and negative cash flows from operations. Based on the Company&#8217;s available cash resources and based upon the Company&#8217;s projections for its operations, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Therefore, there is a substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s plan to address its financial position may include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and from government grants. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company&#8217;s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial and research and development programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Uncertainty Related to the Coronavirus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In light of past uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company submitted for the Employee Retention Credit (&#8220;ERC&#8221;), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021 and $191,463 in 2023. As of December 31, 2023, the Company has recorded a receivable for $366,551 for the remainder of funds expected to be received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Marketable Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company&#8217;s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented as accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. As of December 31, 2023, marketable securities consist primarily of short-term United States treasuries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from <span style="-sec-ix-hidden:Hidden_4p8iOFeSNEmdNJAChajhxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $1,068,882 and $533,131 for the&#160;years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,766,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,206,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,560,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">ASC Topic 842, <i style="font-style:italic;">Leases</i>&#160;(&#8220;ASC 842&#8221;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (&#8220;ROU asset&#8221;). ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases office and laboratory space, all of which are operating leases (see Note 6 - &#8220;Commitments and Contingencies&#8221;). Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company adopted ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i> (&#8220;ASU 606&#8221;), which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#8217;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments were achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the U.S. Commercialization and Distribution Agreement (the &#8220;US Distribution Agreement&#8221;) with Nippon Shinyaku, the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the estimated duration of the HOPE-3 clinical trial, Cohort A arm. Therefore, upon receipt of the upfront payment and achievement of milestones, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the &#8220;CIRM Award&#8221;) from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - &#8220;Government Grant Awards&#8221;). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized during the years ended December 31, 2023 and 2022.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are recognized for the amount of taxes payable or refundable for the current&#160;year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company&#8217;s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion or the entire deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $106.9 million, available to reduce future taxable income, of which approximately $50.7 million will begin to expire in 2027. The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization. As of December&#160;31, 2023, the Company had state net operating loss carryforwards of approximately $147.3 million, available to reduce future taxable income, which will begin to expire in 2028. Utilization of these net operating losses could be limited under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state laws based on ownership changes and the value of the Company&#8217;s stock. Additionally, currently, the Company has approximately $6.2 million of federal research and development credits and approximately $3.7 million of federal orphan drug credits, available to offset future taxable income. These federal research and development and orphan drug credits begin to expire in 2027 and 2035, respectively. Additionally, the Company currently has approximately $2.2 million of California research and development credits available to offset future taxable income which will carryforward indefinitely. Utilization of these credits could be limited under Section 383 of the Code and similar state laws based on ownership changes and the value of the Company&#8217;s stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;382 of the Code, the Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as federal tax credits, in any taxable&#160;year may be limited if the Company has experienced an &#8220;ownership change.&#8221; Generally, a Section&#160;382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of&#160;a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. Similar rules&#160;may apply under state tax laws. We have experienced an ownership change that we believe under Section&#160;382 of the Code will result in limitation in our ability to utilize net operating losses and credits. In addition, the Company may experience future ownership changes as a result of future offerings or other changes in ownership of its stock. As a result, the amount of the NOLs and tax credit carryforward presented in the financial statement could be limited and may expire unutilized. The Company&#8217;s net operating loss carryforwards are subject to Internal Revenue Service (&#8220;IRS&#8221;) examination until they are fully utilized and such tax&#160;years are closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company incurred no interest or penalties for the&#160;years ended December 31, 2023 and 2022. The Company files income tax returns with the IRS and the California Franchise Tax Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, <i style="font-style:italic;">Research and Development</i>. Research and development costs amounted to approximately $36.4 million and $21.8 million for the&#160;years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Comprehensive Income (Loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) generally represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders. The Company&#8217;s comprehensive loss was approximately $22.2 million and $28.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. The Company&#8217;s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the&#160;years ended December 31, 2023 and 2022, the Company&#8217;s other comprehensive income was $130,569 and $105,244, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Trial Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (&#8220;CROs&#8221;), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No.&#160;110,&#160;Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company&#8217;s estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basic and Diluted Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reports earnings per share in accordance with FASB ASC 260-10, <i style="font-style:italic;">Earnings per Share. </i>Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, warrants and options to purchase 13,268,807 and 5,882,621 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive shares of common stock, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:14.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level Input:</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:83.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Input Definition:</p></td></tr><tr><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level I</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level II</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level III</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unobservable inputs that reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the fair value measurements by level at December 31, 2023 and 2022 for assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company&#8217;s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This standard was issued in response to the SEC&#8217;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344545496816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER'S EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDER'S EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDER'S EQUITY</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATM Program </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company established an &#8220;at-the-market&#8221; program (the &#8220;ATM Program&#8221;) on June 21, 2021, with an aggregate offering price of up to $75.0 million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">From June 21, 2021 through December 31, 2023, the Company sold an aggregate of 2,976,154 shares of common stock under the ATM Program at an average price of approximately $5.59 per share for gross proceeds of approximately $16.6 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.6 million. As of the date of this filing, approximately $57.2 million of common stock may still be sold pursuant to the ATM Program. Additionally, subsequent to December 31, 2023, the Company sold shares under the ATM Program (see Note 9 &#8211; &#8220;Subsequent Events&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">October 2023 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On October 3, 2023, the Company entered into Securities Purchase Agreements with its commercial partner, Nippon Shinyaku and funds associated with Highbridge Capital Management, LLC (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), an aggregate of&#160;</span><span style="background:#ffffff;">4,935,621</span><span style="background:#ffffff;">&#160;shares of its common stock, par value </span><span style="background:#ffffff;">$0.001</span><span style="background:#ffffff;">&#160;per share, at a price per share of </span><span style="background:#ffffff;">$4.66</span><span style="background:#ffffff;">&#160;for an aggregate purchase price of approximately </span><span style="background:#ffffff;">$23.0</span><span style="background:#ffffff;">&#160;million. Each share of common stock offered was sold with a warrant to purchase&#160;</span><span style="background:#ffffff;">one</span><span style="background:#ffffff;">&#160;share of common stock at an exercise price of </span><span style="background:#ffffff;">$5.70</span><span style="background:#ffffff;">&#160;per share. Each warrant will be exercisable beginning&#160;</span><span style="background:#ffffff;">six months</span><span style="background:#ffffff;">&#160;after issuance and will expire&#160;</span><span style="background:#ffffff;">seven years</span><span style="background:#ffffff;">&#160;from the date of issuance. As part of the Registered Direct Offering, the Company agreed not to issue or sell shares (subject to customary exceptions for employee stock option issuances and other customary exceptions) for a period of&#160;</span><span style="background:#ffffff;">30 days</span><span style="background:#ffffff;">&#160;following the date of the prospectus supplement that</span> <span style="background:#ffffff;">was used in the Registered Direct Offering. &#160;That prospectus was dated September 29, 2023, and the Company &#8220;lock-up&#8221; expired on October 29, 2023. The Company&#8217;s directors and executive officers also entered into &#8220;lock-up&#8221; agreements with the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">placement agent in the Registered Direct Offering, which agreements expired on the </span><span style="background:#ffffff;">60</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">th</sup><span style="background:#ffffff;"> day following the date of the Securities Purchase Agreements, or December 2, 2023.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outstanding Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At December&#160;31, 2023, the Company had 31,148,320 shares of common stock issued and <span style="-sec-ix-hidden:Hidden_aR2fiAmS1k-ZXTjTa9frtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344543752528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_StockAwardsWarrantsAndOptionsAbstract', window );"><strong>STOCK AWARDS, WARRANTS AND OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK AWARDS, WARRANTS AND OPTIONS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCK AWARDS, WARRANTS AND OPTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all warrant activity for the&#160;years ended December 31, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_inwFgsXzk0-bGk5MAURUnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.61</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all outstanding warrants to purchase shares of the Company&#8217;s common stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/19/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/19/2024</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/27/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/27/2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10/3/2030</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has approved five stock option plans: (i)&#160;the 2006 Stock Option Plan, (ii)&#160;the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the &#8220;2012 Plan&#8221;), (iii)&#160;the 2012 Non-Employee Director Stock Option Plan (the &#8220;2012 Non-Employee Director Plan&#8221;), (iv) the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), and (v) the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan and no longer issues options under the 2006 Stock Option Plan, the 2012 Plan, or the 2012 Non-Employee Director Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company&#8217;s stockholders approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), which authorized 2,500,000 shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.&#160; Pursuant to the &#8220;evergreen&#8221; provision, on January 1, 2021, 823,084 shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, no new shares were added to the share reserve under the 2020 Plan pursuant to its &#8220;evergreen&#8221; provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company&#8217;s stockholders approved the 2021 Plan, which authorized 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards.&#160; The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2024 and 2023, 1,557,416 and 1,262,070 shares were added under the 2021 Plan, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, 1,232,318 options remain available for issuance under the respective stock option plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock option plans are administered by the Board, in conjunction with the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar&#160;year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price not less than equal to the closing price of the Company&#8217;s common stock on the date of grant, and generally vest over a period of <span style="-sec-ix-hidden:Hidden_ncn7a3kMgkO12NbLrZBVLA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years. The term of stock options granted under each of the plans cannot exceed ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated weighted average fair value of the options granted during 2023 and 2022 were approximately $3.85 and $3.04 per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The company used the following assumptions to estimate the fair value of stock options issued during the year ended December 31, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">111</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">123</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">124</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Risk-free interest rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">3.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">4.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">1.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">3.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Employee and non-employee stock-based compensation expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,653,489</p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805,089</p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,392,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,458,578</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes information about stock options outstanding and exercisable at December&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.39 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$2.54 - $3.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,889,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.19</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.61 - $3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,004,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.80</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.11 - $7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.08</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,227,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.39 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,544,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$2.54 - $3.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 845,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.18</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.61 - $3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,601,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.79</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.11 - $7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,248,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.88</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $13.5 million, which is expected to be recognized over a weighted average period of approximately 1.5&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a schedule summarizing employee and non-employee stock option activity for the&#160;years ended December 31, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,817,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (325,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867,854</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (508,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,776,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,420,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (182,405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367,422</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (788,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,227,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,493,414</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,248,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,636,326</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock for each of the respective periods. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_StockAwardsWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_StockAwardsWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344548392000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">CONCENTRATIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company maintains accounts at three financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) for up to $250,000 and/or the Securities Investor Protection Corporation, as applicable. The Company&#8217;s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of December&#160;31,&#160;2023, were approximately $39.2 million. The Company monitors the financial stability of the financial institutions with which it maintains accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. Historically, the Company has not experienced any significant losses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344545645168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOVERNMENT GRANT AWARDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AwardAbstract', window );"><strong>GOVERNMENT GRANT AWARDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_GovernmentGrantAwardsDisclosureTextBlock', window );">GOVERNMENT GRANT AWARDS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">GOVERNMENT GRANT AWARDS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CIRM Grant Award (HOPE)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor&#8217;s Phase 1/2 HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section&#160;100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in the CIRM Loan Policy and CIRM Grants Administration Policy for Clinical Stage Projects (the &#8220;New Loan Balance&#8221;), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. Depending on the timing of our election, additional funds may be owed. If we elect to do so, Capricor would be required to repay the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of December 31, 2023, Capricor&#8217;s liability balance for the CIRM Award was approximately $3.4 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_AwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_AwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_GovernmentGrantAwardsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure about government grant awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_GovernmentGrantAwardsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344545737360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Short-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon 90 days&#8217; written notice to the other party. Commencing in July 2022, the monthly lease payment was $7,869 per month. Effective July 1, 2023, the monthly lease payment was reduced to $7,619 per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred under short-term operating leases for the years ended December 31, 2023 and 2022 were $92,928 and $81,735, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (&#8220;CSMC&#8221;), a related party (see Note 8 &#8211; &#8220;Related Party Transactions&#8221;), pursuant to a lease (the &#8220;Facilities Lease&#8221;) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional 24-month period extending the term through July 31, 2024 with a monthly lease payment of $10,707. Additionally, in September 2023, we entered into an amendment pursuant to which Capricor was granted an option to extend the lease for an additional 24-month period extending the term through July 31, 2026 with a monthly lease payment of $11,028 commencing on August 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (&#8220;Altman&#8221;) for 9,396 square feet of office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the &#8220;San Diego Lease&#8221;). The rent is subject to a 3.0% annual rent increase during the initial lease term of five years, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of five years. The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022, the monthly lease payment was increased to $49,322 per month. Effective December 1, 2022, the monthly lease payment was increased to $51,444 per month. Effective October 1, 2023, the monthly lease payment was increased to $58,409 per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (&#8220;Explora&#8221;), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $4,021 per month for an exclusive large vivarium room located in San Diego, California. The lease term is for one-year and will automatically renew for additional successive one-year renewal terms unless either party provides the other party with 60-day written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of 4.5% bringing the base rent to approximately $4,202 per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of five years. &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The long-term real estate operating leases are included in &#8220;lease right-of-use assets, net&#8221; on the Company&#8217;s Consolidated Balance Sheet and represent the Company&#8217;s right-to-use the underlying assets for the lease term. The Company&#8217;s obligation to make lease payments are included in &#8220;lease liabilities, current&#8221; and &#8220;lease liabilities, net of current&#8221; on the Company&#8217;s Consolidated Balance Sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 886,672</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 910,106</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 676,908</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,473,686</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (237,791)</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,235,895</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in the consolidated balance sheet:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 749,112</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,486,783</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,235,895</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.73 years</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.24%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>As of December 31, 2023, ROU assets for operating leases were approximately $2.1 million and operating lease liabilities were approximately $2.2 million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company&#8217;s operating leases under ASC 842 for the period indicated: &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 663,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632,689</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 129,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,478</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 684,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 470,950</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,478</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company has not recorded any material accruals for loss contingencies as of December 31, 2023. The Company has received a letter from CSMC alleging certain overdue payment obligations and alleged breaches (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Funding Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 - "License and Distribution Agreements").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Severances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability under these severance packages has been recorded as of December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344637369024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND DISTRIBUTION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsAbstract', window );"><strong>LICENSE AND DISTRIBUTION AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsTextBlock', window );">LICENSE AND DISTRIBUTION AGREEMENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">LICENSE AND DISTRIBUTION AGREEMENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights for Capricor&#8217;s Technology&#160;- CAP-1002 and Exosomes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Universit&#224; Degli Studi Di Roma La Sapienza (the &#8220;University of Rome&#8221;), JHU and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">University of Rome License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the &#8220;Rome License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third-party to Capricor. The minimum annual royalties are creditable against future royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party&#8217;s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days&#8217; written notice to the University of Rome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Johns Hopkins University License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">License Agreement for CDCs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the &#8220;JHU License Agreement&#8221;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the FDA. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase 3 study for which a payment of $500,000 will be due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days&#8217; written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">License Agreement for Exosome-based Vaccines and Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor and JHU entered into an Exclusive License Agreement (the &#8220;JHU Exosome License Agreement&#8221;), effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provided for the grant of an exclusive, world-wide, royalty-bearing license of JHU&#8217;s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. The JHU Exosome License Agreement was terminated by Capricor on December 15, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cedars-Sinai Medical Center License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 36pt;">License Agreement for CDCs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Original CSMC License Agreement&#8221;), for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the&#160;percentage of sublicense fees which would have been payable to CSMC. Effective December&#160;30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the &#8220;Amended CSMC License Agreement&#8221;), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty-bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days&#8217; notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents and extend the timing of certain development milestones, among other things. Capricor reimbursed CSMC for certain attorneys&#8217; fees and filing fees incurred in connection with the additional patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We recently received a letter from CSMC alleging that pursuant to the Amended CSMC License Agreement between CSMC and Capricor, Capricor has certain overdue payment obligations to CSMC arising out of a milestone payment received by Capricor pursuant to the U.S. Distribution Agreement entered into between Capricor and Nippon Shinyaku. Capricor has received a milestone payment of $10.0 million under its U.S. Distribution Agreement with Nippon Shinyaku, which CSMC is claiming 10% of this milestone payment is owed to them. The notice letter requests that Capricor cure the alleged breaches of the Amended CSMC License Agreement, and reserves CMSC&#8217;s purported right to terminate the Amended CSMC License Agreement if such alleged breaches are not cured. We dispute the allegations in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the letter from CSMC and intend to vigorously defend our position and pursue all available remedies, but there is no guarantee that any disputes that we have with CSMC will be resolved or if resolved, will not result in our incurring certain payment and other obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 0pt 36pt;">License Agreement for Exosomes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the &#8220;Exosomes License Agreement&#8221;), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#225;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit&#160;percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days&#8217; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and CSMC have entered into several amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights, and converted certain exclusive rights to co-exclusive rights. These amendments also obligated Capricor to reimburse CSMC for certain attorneys&#8217; fees and filing fees in connection with the additional patent applications and patent families.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cell Line License Agreement with Life Technologies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in 2022 and additional milestone fees may become due based on the progress of our development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On January 24, 2022, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;U.S. Distribution Agreement&#8221;) with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S Distribution Agreement, Capricor received an upfront payment of $30.0 million in the first quarter of 2022. The first milestone payment of $10.0 million was paid upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, there are potential milestones totaling up to $90.0 million leading up to and including the BLA approval. Further, there are various potential sales-based milestones, if commercialized, tied to the achievement of certain sales thresholds for annual net sales of CAP-1002 of up to $605.0 million. Further, pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and Capricor will have the right to receive a meaningful mid-range double-digit share of product revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase 3 clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined the transaction price totaled $40.0 million, which was the upfront payment of $30.0 million and $10.0 million milestone payment. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the $40.0 million transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study, Cohort A arm, to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract&#8217;s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the Company recognized approximately $25.2 million as revenue compared to approximately $2.6 million for the year ended December 31, 2022. In relation to the U.S. Distribution Agreement, as of December 31, 2023, the Company recorded approximately $12.3 million as current deferred revenue on the Company&#8217;s consolidated balance sheets. As of December 31, 2023, the Company recorded a receivable of $10.0 million in connection with the interim futility milestone, which payment was received in January 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had no opening or closing contract asset balances recognized. &#160;The difference between the opening and closing balances of the Company&#8217;s contract liability results from the Company performance of services in connection to its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of December 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $12.3 million. At this time, we estimate 100% of the remaining performance obligations are expected to be recognized over the next 12 months. Remaining performance obligations estimates are subject to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2023, Capricor entered into a Commercialization and Distribution Agreement (the &#8220;Japan Distribution Agreement&#8221;) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023 and in addition, Capricor may potentially receive additional development and sales-based milestone payments of up to approximately $89.0 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Subject to regulatory approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. The Company determined the initial transaction price totaled $12.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $12.0 million as current deferred revenue on the Company&#8217;s consolidated balance sheets as of December&#160;31,&#160;2023. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure relating to licensing agreements entered into for acquiring intellectual property rights, for the grant of an exclusive, world-wide, royalty-bearing license to develop and commercialize licensed products under the licensed patent rights in all fields and a nonexclusive right to the know-how, Collaboration Agreement and Exclusive License Option, and funding and equipment necessary for conducting clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344548307520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lease and Sub-Lease Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, Capricor is a party to lease agreements with CSMC (see Note&#160;6&#160;&#8211; &#8220;Commitments and Contingencies&#8221;), and CSMC has served as an investigative site in Capricor&#8217;s clinical trials. Additionally, Dr.&#160;Eduardo Marb&#225;n, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company&#8217;s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consulting Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company&#8217;s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marb&#225;n whereby he was granted an option to purchase 50,000 shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marb&#225;n was granted an additional option grant to purchase 50,000 shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, Capricor entered into a Consulting Agreement with Michael Kelliher, a member of its Board of Directors, related to business development services whereby he was granted an option to purchase 30,000 shares of the Company's common stock. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payables to Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2023 and 2022, the Company had accounts payable and accrued expenses to related parties totaling $27,479 and $89,234, respectively. CSMC accounts for $17,479 and $79,234 of the total accounts payable and accrued expenses to related parties as of December 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the&#160;years ended December 31, 2023 and 2022, the Company paid CSMC approximately $226,400 and approximately $794,000, respectively, for such costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344545641648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SUBSEQUENT EVENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Sales under ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2023 and through March 7, 2024, the Company sold an aggregate of 251,347 shares of common stock under the ATM Program at an average price of approximate $4.50 per share for gross proceeds of approximately $1.1 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to the placement agent in the aggregate amount of approximately $35,900. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company granted a total of 2,203,726 stock options to its employees, certain non-employee consultants, and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License and Service Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2024, we entered into a License and Services Agreement with Azzur Cleanrooms-on-Demand &#8211; San Diego, LLC (the &#8220;Azzur License Agreement&#8221;) pursuant to which we have been granted an exclusive license to use certain space and the non-exclusive right to use certain equipment and property for our early phase clinical and/or pre-clinical manufacturing purposes. Our estimated license fee is approximately $120,500 per month for a term of approximately 6 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344539739408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor Therapeutics,&#160;Inc., a Delaware corporation (referred to herein as &#8220;Capricor Therapeutics&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#8220;DMD&#8221;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (&#8220;Capricor&#8221;), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#225;n, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics,&#160;Inc., a Delaware corporation (&#8220;Nile&#8221;), on November&#160;20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics,&#160;Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple therapeutic drug candidates in various stages of development.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basis of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LiquidityPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities as of December 31, 2023 were approximately $39.5 million, compared to approximately $41.4 million as of December&#160;31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd., a Japanese corporation, (&#8220;Nippon Shinyaku&#8221;), in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). In October 2023, the Company completed a registered direct offering for gross proceeds of approximately $23.0 million (see Note 2 &#8211; &#8220;Stockholder&#8217;s Equity&#8221;). We received our first milestone payment of $10.0 million in the first quarter of 2024, which was triggered upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with our research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase 3 clinical trial of CAP-1002 in DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with potential commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our research programs, including the expansion of our exosomes program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. The Company has incurred significant operating losses and negative cash flows from operations. Based on the Company&#8217;s available cash resources and based upon the Company&#8217;s projections for its operations, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Therefore, there is a substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s plan to address its financial position may include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and from government grants. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company&#8217;s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial and research and development programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock', window );">Business Uncertainty Related to the Coronavirus</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Uncertainty Related to the Coronavirus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In light of past uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company submitted for the Employee Retention Credit (&#8220;ERC&#8221;), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021 and $191,463 in 2023. As of December 31, 2023, the Company has recorded a receivable for $366,551 for the remainder of funds expected to be received. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Marketable Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company&#8217;s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented as accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. As of December 31, 2023, marketable securities consist primarily of short-term United States treasuries. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from <span style="-sec-ix-hidden:Hidden_4p8iOFeSNEmdNJAChajhxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $1,068,882 and $533,131 for the&#160;years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,766,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,206,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,560,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">ASC Topic 842, <i style="font-style:italic;">Leases</i>&#160;(&#8220;ASC 842&#8221;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (&#8220;ROU asset&#8221;). ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases office and laboratory space, all of which are operating leases (see Note 6 - &#8220;Commitments and Contingencies&#8221;). Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company adopted ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i> (&#8220;ASU 606&#8221;), which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 &#8211; &#8220;License and Distribution Agreements&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#8217;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments were achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the U.S. Commercialization and Distribution Agreement (the &#8220;US Distribution Agreement&#8221;) with Nippon Shinyaku, the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the estimated duration of the HOPE-3 clinical trial, Cohort A arm. Therefore, upon receipt of the upfront payment and achievement of milestones, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the &#8220;CIRM Award&#8221;) from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - &#8220;Government Grant Awards&#8221;). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized during the years ended December 31, 2023 and 2022.  </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are recognized for the amount of taxes payable or refundable for the current&#160;year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company&#8217;s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion or the entire deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $106.9 million, available to reduce future taxable income, of which approximately $50.7 million will begin to expire in 2027. The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization. As of December&#160;31, 2023, the Company had state net operating loss carryforwards of approximately $147.3 million, available to reduce future taxable income, which will begin to expire in 2028. Utilization of these net operating losses could be limited under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state laws based on ownership changes and the value of the Company&#8217;s stock. Additionally, currently, the Company has approximately $6.2 million of federal research and development credits and approximately $3.7 million of federal orphan drug credits, available to offset future taxable income. These federal research and development and orphan drug credits begin to expire in 2027 and 2035, respectively. Additionally, the Company currently has approximately $2.2 million of California research and development credits available to offset future taxable income which will carryforward indefinitely. Utilization of these credits could be limited under Section 383 of the Code and similar state laws based on ownership changes and the value of the Company&#8217;s stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;382 of the Code, the Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as federal tax credits, in any taxable&#160;year may be limited if the Company has experienced an &#8220;ownership change.&#8221; Generally, a Section&#160;382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of&#160;a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. Similar rules&#160;may apply under state tax laws. We have experienced an ownership change that we believe under Section&#160;382 of the Code will result in limitation in our ability to utilize net operating losses and credits. In addition, the Company may experience future ownership changes as a result of future offerings or other changes in ownership of its stock. As a result, the amount of the NOLs and tax credit carryforward presented in the financial statement could be limited and may expire unutilized. The Company&#8217;s net operating loss carryforwards are subject to Internal Revenue Service (&#8220;IRS&#8221;) examination until they are fully utilized and such tax&#160;years are closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company incurred no interest or penalties for the&#160;years ended December 31, 2023 and 2022. The Company files income tax returns with the IRS and the California Franchise Tax Board.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, <i style="font-style:italic;">Research and Development</i>. Research and development costs amounted to approximately $36.4 million and $21.8 million for the&#160;years ended December 31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Comprehensive Income (Loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) generally represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders. The Company&#8217;s comprehensive loss was approximately $22.2 million and $28.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. The Company&#8217;s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the&#160;years ended December 31, 2023 and 2022, the Company&#8217;s other comprehensive income was $130,569 and $105,244, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClinicalTrialExpensePolicyPolicyTextBlock', window );">Clinical Trial Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Trial Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (&#8220;CROs&#8221;), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No.&#160;110,&#160;Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company&#8217;s estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basic and Diluted Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reports earnings per share in accordance with FASB ASC 260-10, <i style="font-style:italic;">Earnings per Share. </i>Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, warrants and options to purchase 13,268,807 and 5,882,621 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive shares of common stock, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the years ended December 31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:14.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level Input:</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:83.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Input Definition:</p></td></tr><tr><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level I</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&#160;</p></td></tr><tr><td style="vertical-align:top;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level II</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level III</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unobservable inputs that reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the fair value measurements by level at December 31, 2023 and 2022 for assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company&#8217;s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This standard was issued in response to the SEC&#8217;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ClinicalTrialExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trail expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ClinicalTrialExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity position during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy as it relates to unusual or infrequent items related to the Covid-19 pandemic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344548010576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,766,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,206,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,560,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,792,846</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,818,020</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542826848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Schedule of employee and non-employee stock based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,653,489</p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805,089</p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,392,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,458,578</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Option Outstanding And Exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.39 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$2.54 - $3.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,889,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.19</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.61 - $3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,004,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.80</p></td></tr><tr><td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.11 - $7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.08</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,227,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Ex. Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(yrs.)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.39 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,544,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$2.54 - $3.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 845,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.18</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.61 - $3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,601,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.79</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.11 - $7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,248,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.88</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ScheduleOfWarrantActivityTableTextBlock', window );">Summary of warrant activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_inwFgsXzk0-bGk5MAURUnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.61</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/19/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/19/2024</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/27/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/27/2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10/3/2030</p></td></tr><tr><td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of option using Black-Scholes option</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">111</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">123</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">124</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Risk-free interest rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">3.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">4.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">1.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">3.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of employee and non-employee stock option</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,817,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (325,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867,854</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (508,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,776,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,420,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (182,405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367,422</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (788,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,227,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,493,414</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,248,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,636,326</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all warrant activity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344547382592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 886,672</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 910,106</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 676,908</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,473,686</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (237,791)</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,235,895</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in the consolidated balance sheet:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 749,112</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,486,783</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,235,895</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.73 years</p></td></tr><tr><td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.24%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 663,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632,689</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 129,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,478</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 684,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 470,950</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,478</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344539565024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 7,766,696<span></span>
</td>
<td class="nump">$ 5,769,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,206,055)<span></span>
</td>
<td class="num">(1,181,625)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,560,641<span></span>
</td>
<td class="nump">4,588,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">187,997<span></span>
</td>
<td class="nump">139,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">5,449,597<span></span>
</td>
<td class="nump">4,237,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 2,129,102<span></span>
</td>
<td class="nump">$ 1,393,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344538877840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500,000<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="num">(3,178,066)<span></span>
</td>
<td class="nump">27,448,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,515,349<span></span>
</td>
<td class="nump">4,803,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_EmployeeRetentionCreditCaresActRevenue', window );">Revenue recognized under "ERC"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_EmployeeRetentionCreditCaresActReceivable', window );">Receivables under "ERC"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,778<span></span>
</td>
<td class="nump">$ 738,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,882<span></span>
</td>
<td class="nump">533,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,448,039<span></span>
</td>
<td class="nump">21,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,156,973<span></span>
</td>
<td class="nump">28,914,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward limitations on use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_OperatingLossCarryForwardsIndefinitely', window );">Operating loss carry forwards indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_TaxCreditCarryForwardsExpirationYear', window );">Tax credit carry forwards expiration Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,268,807<span></span>
</td>
<td class="nump">5,882,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember', window );">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_EmployeeRetentionCreditCaresActReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables under Employee Retention Credit, CARES Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_EmployeeRetentionCreditCaresActReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_EmployeeRetentionCreditCaresActRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized under Employee Retention Credit, CARES Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_EmployeeRetentionCreditCaresActRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expiration year for operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_OperatingLossCarryForwardsIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, indefinitely before tax effects, available to reduce future taxable income under enacted tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_OperatingLossCarryForwardsIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_TaxCreditCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expiration year for tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_TaxCreditCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344544551728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details) - Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable Securities</a></td>
<td class="nump">$ 24,792,846<span></span>
</td>
<td class="nump">$ 31,818,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable Securities</a></td>
<td class="nump">$ 24,792,846<span></span>
</td>
<td class="nump">$ 31,818,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344538074240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER'S EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommissionRateOnSalePricePerShare', window );">Commission rate on sale price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,515,349<span></span>
</td>
<td class="nump">$ 4,803,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,148,320<span></span>
</td>
<td class="nump">25,241,402<span></span>
</td>
<td class="nump">31,148,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,148,320<span></span>
</td>
<td class="nump">25,241,402<span></span>
</td>
<td class="nump">31,148,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=capr_June2021AtMarketProgramMember', window );">June 2021 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommonStockSharesAuthorizedValue', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommonStockOfferingRemainingAmountIssuable', window );">Amount of stock that may still be sold under the program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="nump">4,935,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average price</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LockUpPeriodNotToIssueOrSellShares', window );">Lock up period, not to issue or sell shares</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AgreementExpiryTerm', window );">Agreement expiry term</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Effective warrant terms</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Effective warrant terms</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_AgreementExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for expiry of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_AgreementExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_CommissionRateOnSalePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sale price per common shares sold to be paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_CommissionRateOnSalePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_CommonStockOfferingRemainingAmountIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares authorized to be issued under the offering which remain unissued and available at stated date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_CommonStockOfferingRemainingAmountIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_CommonStockSharesAuthorizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum value of share authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_CommonStockSharesAuthorizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LockUpPeriodNotToIssueOrSellShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which issue or sale of shares is not allowed known as lock up period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LockUpPeriodNotToIssueOrSellShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=capr_June2021AtMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=capr_June2021AtMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344544542832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_StockAwardsWarrantsAndOptionsAbstract', window );"><strong>STOCK AWARDS, WARRANTS AND OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding at Beginning</a></td>
<td class="nump">105,782<span></span>
</td>
<td class="nump">105,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClassOfWarrantOrRightGranted', window );">Warrants Granted</a></td>
<td class="nump">4,935,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClassOfWarrantOrRightExercised', window );">Warrants Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding at Ending</a></td>
<td class="nump">5,041,403<span></span>
</td>
<td class="nump">105,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at Beginning</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WeightedAverageExercisePriceGranted', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">5.70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at Ending</a></td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights Exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ClassOfWarrantOrRightWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ClassOfWarrantOrRightWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_StockAwardsWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_StockAwardsWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_WeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_WeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344544523136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">5,041,403<span></span>
</td>
<td class="nump">105,782<span></span>
</td>
<td class="nump">105,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember', window );">Common Warrants with Expiration on December 2024 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Grant Date</a></td>
<td class="text">Dec. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">40,782<span></span>
</td>
<td class="nump">40,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember', window );">Common Stock Warrants With Expiration On December 2025 Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Grant Date</a></td>
<td class="text">Mar. 27,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share</a></td>
<td class="nump">$ 1.5313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration Date</a></td>
<td class="text">Mar. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember', window );">Common Stock Warrants With Expiration On December 2030 Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Grant Date</a></td>
<td class="text">Oct.  03,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">4,935,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration Date</a></td>
<td class="text">Oct.  03,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344538504528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">121.00%<span></span>
</td>
<td class="nump">124.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">111.00%<span></span>
</td>
<td class="nump">123.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rates, Minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rates, Maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344544551984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">$ 7,392,396<span></span>
</td>
<td class="nump">$ 4,458,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">5,476,151<span></span>
</td>
<td class="nump">3,653,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">$ 1,916,245<span></span>
</td>
<td class="nump">$ 805,089<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344538424080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, Options (shares) | shares</a></td>
<td class="nump">8,227,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Option (Shares) | shares</a></td>
<td class="nump">4,248,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower range</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, Options (shares) | shares</a></td>
<td class="nump">1,600,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Term</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Option (Shares) | shares</a></td>
<td class="nump">1,544,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, Weighted Average Term</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower range</a></td>
<td class="nump">2.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper range</a></td>
<td class="nump">$ 3.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, Options (shares) | shares</a></td>
<td class="nump">1,889,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Term</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Option (Shares) | shares</a></td>
<td class="nump">845,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, Weighted Average Term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower range</a></td>
<td class="nump">3.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper range</a></td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, Options (shares) | shares</a></td>
<td class="nump">3,004,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Term</a></td>
<td class="text">8 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Option (Shares) | shares</a></td>
<td class="nump">1,601,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, Weighted Average Term</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower range</a></td>
<td class="nump">4.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper range</a></td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, Options (shares) | shares</a></td>
<td class="nump">1,733,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Term</a></td>
<td class="text">9 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Option (Shares) | shares</a></td>
<td class="nump">255,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, Weighted Average Term</a></td>
<td class="text">7 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=capr_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542561632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 367,422<span></span>
</td>
<td class="nump">$ 867,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">12,493,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 8,636,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at Beginning of the period</a></td>
<td class="nump">5,776,839<span></span>
</td>
<td class="nump">3,793,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,420,979<span></span>
</td>
<td class="nump">2,817,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(182,405)<span></span>
</td>
<td class="num">(325,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired/Cancelled</a></td>
<td class="num">(788,009)<span></span>
</td>
<td class="num">(508,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at End of the period</a></td>
<td class="nump">8,227,404<span></span>
</td>
<td class="nump">5,776,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">4,248,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at Beginning of the period</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">4.32<span></span>
</td>
<td class="nump">3.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.55<span></span>
</td>
<td class="nump">1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/Cancelled</a></td>
<td class="nump">3.82<span></span>
</td>
<td class="nump">4.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at Ending of the period</a></td>
<td class="nump">3.46<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542669808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems', window );"><strong>Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ShareBasedCompensationNumberOfPlans', window );">Number of plans | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant', window );">Number of options available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock', window );">Minimum limit of fair market value to be treated as non-statutory stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted fair value of option granted (in per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized fair value compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,636,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,636,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,493,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,493,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Stock Option Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems', window );"><strong>Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">823,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Stock Option Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems', window );"><strong>Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">1,557,416<span></span>
</td>
<td class="nump">1,262,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems', window );"><strong>Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems', window );"><strong>Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of stock option plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum limit of aggregate fair market value will be treated as non-statutory stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock options available for grant under the stock option plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share based compensation plans .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=capr_StockOptionPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=capr_StockOptionPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=capr_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=capr_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344543919456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONCENTRATIONS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_NumberOfFinancialInstitutions', window );">Number of financial institutions | item</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured deposits</a></td>
<td class="nump">$ 39,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_NumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_NumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344538506288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOVERNMENT GRANT AWARDS (Details) - California Institute for Regenerative Medicine<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2016 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 16, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_GrantAwardLiability', window );">Grant award liability</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MinimumExpectedContribution', window );">Minimum expected contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable', window );">Number of times, maximum royalty to be paid on total amount of award | item</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_TermOfAward', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CaliforniaInstituteForRegenerativeMedicineMember', window );">LIBOR Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_GrantAwardLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_GrantAwardLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MinimumExpectedContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of contribution to be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MinimumExpectedContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of times on total award amount which is the maximum amount of royalty to be payable on commercial revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_TermOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_TermOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CaliforniaInstituteForRegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CaliforniaInstituteForRegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=capr_LiborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=capr_LiborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344543862080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 886,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">910,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">676,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">2,473,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(237,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">2,235,895<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Included in the condensed consolidated balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">749,112<span></span>
</td>
<td class="nump">682,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current</a></td>
<td class="nump">1,486,783<span></span>
</td>
<td class="nump">1,878,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,235,895<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344537921744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth', window );">Base rent per month</a></td>
<td class="nump">$ 58,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,349,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,050,042<span></span>
</td>
<td class="nump">$ 2,349,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, ROU liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,235,895<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_SeverancePackageToBePaidForPeriodOfBaseSalary', window );">Number of months of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_CorporateOfficesLeaseMember', window );">Short-term offices lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth', window );">Base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,928<span></span>
</td>
<td class="nump">81,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_FacilitiesLeaseMember', window );">Facilities Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_PropertyLocatedAt10865RoadToCureInDiegoMember', window );">Property Located at 10865 Road to Cure in Diego</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Area under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth', window );">Base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent', window );">Operating lease percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseLeaseRentPerMonth', window );">Monthly lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_VivariumSpaceLeaseMember', window );">Vivarium Space Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth', window );">Base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseMonthlyRentEscalationPercent', window );">Monthly rent escalation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_VivariumSpaceLeaseMember', window );">Vivarium Space Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_VivariumSpaceLeaseMember', window );">Vivarium Space Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=capr_FacilitiesLeaseMember', window );">Facilities Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth', window );">Base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_UnrelatedPartyAxis=capr_UnrelatedPartyMember', window );">Unrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,684<span></span>
</td>
<td class="nump">632,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,444<span></span>
</td>
<td class="nump">470,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,158<span></span>
</td>
<td class="nump">128,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,772<span></span>
</td>
<td class="nump">$ 128,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LesseeOperatingLeaseBaseLeaseRentPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of base lease rent per month under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LesseeOperatingLeaseBaseLeaseRentPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LesseeOperatingLeaseLeaseRentPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount operating lease rent per month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LesseeOperatingLeaseLeaseRentPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LesseeOperatingLeaseMonthlyRentEscalationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of escalation of monthly base rent of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LesseeOperatingLeaseMonthlyRentEscalationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in annual lease rent in an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_SeverancePackageToBePaidForPeriodOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of months of base salaries used for severance packages for specific full-time employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_SeverancePackageToBePaidForPeriodOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_WrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>These lines are represents that notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_WrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_CorporateOfficesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_CorporateOfficesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_FacilitiesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_FacilitiesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_PropertyLocatedAt10865RoadToCureInDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_PropertyLocatedAt10865RoadToCureInDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_VivariumSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=capr_VivariumSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=capr_FacilitiesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=capr_FacilitiesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_UnrelatedPartyAxis=capr_UnrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_UnrelatedPartyAxis=capr_UnrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344536889840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND DISTRIBUTION AGREEMENTS (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 24, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases', window );">Milestone payments to be made upon completion of certain phases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,178,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,551,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,270,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,980,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember', window );">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases', window );">Milestone payments to be made upon completion of certain phases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember', window );">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, Remaining Performance Obligation, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember', window );">Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember', window );">CSMC | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=capr_RomeLicenseAgreementMember', window );">Rome License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=capr_JhuLicenseAgreementMember', window );">JHU License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ThresholdPeriodToCureBreach', window );">Threshold period to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=capr_CsmcLicenseAgreementMember', window );">CSMC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=capr_ExosomesLicenseAgreementMember', window );">Exosomes License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_WrittenNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Rome License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AnnualPaymentsForRoyalties', window );">Minimum annual royalty payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 605,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | JHU License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePaymentsInPhasesAxis=capr_CompletionOfPhaseTwoDueMember', window );">Completion Of Phase Two Due | JHU License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePayments', window );">Milestones paid</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases', window );">Milestone payments to be made upon completion of certain phases</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember', window );">Patent rights | JHU License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PeriodOfAgreementWillBeInEffective', window );">Agreement effective period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember', window );">Non Payment of Royalties | CSMC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember', window );">Non Payment of Royalties | Exosomes License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ThresholdPeriodToCureBreach', window );">Threshold period to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember', window );">CSMC Agreement Compliance | CSMC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember', window );">CSMC Agreement Compliance | Exosomes License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ThresholdPeriodToCureBreach', window );">Threshold period to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember', window );">Material Breach Has Not Been Cured | CSMC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember', window );">Material Breach Has Not Been Cured | Exosomes License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ThresholdPeriodToCureBreach', window );">Threshold period to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember', window );">Fails To Cure Breach after Notice From CSMC | CSMC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_AgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember', window );">Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_ThresholdPeriodToCureBreach', window );">Threshold period to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=capr_OverduePaymentObligationsMember', window );">Overdue payment obligation | CSMC License Agreement | CSMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseAgreementsLineItems', window );"><strong>LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MilestonePaymentsPercentageOwedToThirdParty', window );">Milestone payments, percentage claimed by CSMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_AgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the agreement termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_AgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_AnnualPaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for royalties on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_AnnualPaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MilestonePaymentsPercentageOwedToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestone payments received by Capricor and owed to CSMC pursuant to the U.S. Distribution Agreement with Nippon Shinyaku.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MilestonePaymentsPercentageOwedToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments to be made upon successful completion of certain phases as per License agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_PeriodOfAgreementWillBeInEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which agreement will be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_PeriodOfAgreementWillBeInEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments payable under the JHU License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_ThresholdPeriodToCureBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period to cure breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_ThresholdPeriodToCureBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment made during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_WrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>These lines are represents that notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_WrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_RomeLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_RomeLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_JhuLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_JhuLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_CsmcLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_CsmcLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_ExosomesLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_ExosomesLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MilestonePaymentsInPhasesAxis=capr_CompletionOfPhaseTwoDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MilestonePaymentsInPhasesAxis=capr_CompletionOfPhaseTwoDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=capr_OverduePaymentObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=capr_OverduePaymentObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542688592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accounts payable and accrued expenses, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,479<span></span>
</td>
<td class="nump">$ 89,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman | Consulting Agreement with Frank Litvack</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_MonthlyConsultingFeesToRelatedParty', window );">Monthly consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_TerminableNoticePeriod', window );">Notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_DrEduardoMarbanMember', window );">Dr Eduardo Marban | Advisory Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_MichaelKelliherMember', window );">Michael Kelliher | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember', window );">CSMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty', window );">Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,400<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember', window );">CSMC | Transaction other than Sub-Award Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accounts payable and accrued expenses, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,479<span></span>
</td>
<td class="nump">$ 79,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_MonthlyConsultingFeesToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly consulting fees as per consulting agreement entered into with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_MonthlyConsultingFeesToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows for the reimbursement of research and development , license and Patent fees and facilities rent expenses which is incurred by the related party on behalf of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_TerminableNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminable notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_TerminableNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_ConsultingAgreementWithFrankLitvackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_ConsultingAgreementWithFrankLitvackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_DrEduardoMarbanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_DrEduardoMarbanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_AdvisoryServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_AdvisoryServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_MichaelKelliherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_MichaelKelliherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=capr_TransactionOtherThanSubawardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=capr_TransactionOtherThanSubawardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344539733488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,515,349<span></span>
</td>
<td class="nump">$ 4,803,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="nump">4,935,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average price</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | License and Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_capr_TermOfLicense', window );">Term of License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Employees Non Employee Consultants And Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,203,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee  per month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_capr_TermOfLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of License and Service agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">capr_TermOfLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>capr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=capr_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=capr_LicenseAndServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=capr_LicenseAndServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=capr_EmployeesNonEmployeeConsultantsAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=capr_EmployeesNonEmployeeConsultantsAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344651572576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (22,287,542)<span></span>
</td>
<td class="num">$ (29,019,532)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140344542909248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/6UQ8WJ&U,KT9&"PM39Z1V\<!%P].=E] ==\._ -J]N<7M*VAOT>6! 8 $8
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M^ZZSS?LVT.DX;;MM.<V\MO5O6[-.)SY0R:7D$=P-D3O S8VM69^+OF$^)ZE
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M97[L=]?P&_+_'L.F\J<RE/8Y4^5,QH[<=4IWG9^D"J-!/E^A( VAS&Z!/];
M!ESFM-.(N&&;IJL;7FUIFH($N]CVS):U<4NPKA+L-YK2/(@+K$$(53=B/ \$
MW\C@N@T4F+BZX[KU3)((ZJ:!/=V0P_5*N-X)N7Y:0GD-#*8'^0Q_-;!-08,0
MTW4M(@>+]8IQ="7<@CKN)J.G X:1$HC>@'!!3-UQ7*N>"%)1S_8<PVV)+3X@
M2*S>J+-[?X(>AL!_/OJRCZV<\? Y=^NYK!V[32JWB7*51GQ%<Q2E\RR19OU>
M_3#DMF-;3GUEFF*0\);;ED45O6(EL_4>TBUE7)00%4BC.;M#7$?'=9A-08M@
MR[!:8%8,B=44^9@QAN"X&D9LG3&H*=D"+:(/"H6%,<J9%+79S&9;-QN8)6*&
M20X([!AS19WX%.[\A;QO4B1VH*KA1C(T!6VQG7$+XHI+L9*[>D-_5IQ(I>AL
M26T@D 262>KX9**>CCW+:,O7BO^P<T(9.3Y$?P970)='5DFJOUQ1SF3M. (5
MJ6(UJP[A4KI)X:X91_]"_B_ACBEV!MP>WR@/7F.*&)UO\HA'5+XM)/QIZ);=
M( ,9SUK$-%N6L*)9K.;9Y@U("M-KG&@AW[ EV*B.5";J>M@DKBL'2RJ6)6J6
M%=&.1?%90QEGJR"G7\5]-YK+,.]MN8= ]$NWCE<FAB]Q&]:*8HF2RZ18PRC>
M\/K%<(\6GX96(J9 6S$C43/C]Z(U0,.+8 NGQ"5%Z29Y!>!0V0OL3#P!(R60
MW'!_G[^A;,,9A\-DE"X5:]!D2B*JHV'K=<<DDJ9E$;LU:RI6)6I6_7^^J=:L
M2;!MWDDDY=YI!VV/A.;+HAO$ -XFY;N^0?FV[#C=%'V6VOM;?-7?]8TJ,[LV
MUE.0+Z.4H9@NP*1^Z<!>S7>=H=V 9^NBN?*:<9XEQ>.*!B'-A0!\7V09_QR(
M"<K^7.\_4$L#!!0    ( -A#:UCJC._'[P4  &@D   8    >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULK5IK<^(V%/TK&MKI;&>610\_MX09UH_&TP320+;3
MCPZ(X(F-J>TDV_[ZRL9KL"P$9/4%;'SOT=4]DJZ.\/ MS9[S-:4%^);$F_RJ
MMRZ*[>?!(%^L:1+FG](MW; GJS1+PH+=9D^#?)O1<%DY)?$ 0V@,DC#:]$;#
MZK>[;#1,7XHXVM"[#.0O21)F_WZA<?IVU4.][S_<1T_KHOQA,!INPR<ZH\7#
M]BYC=X,&91DE=)-'Z09D='75&Z///JX<*HNO$7W+#ZY!V97'-'TN;X+E50^6
M$=&8+HH2(F1?K]2A<5PBL3C^J4%[39NEX^'U=W2_ZCSKS&.84R>-_XJ6Q?JJ
M9_7 DJ["E[BX3]^N:=TAO<1;I'%>?8*WG:W!C!<O>9$FM3.+((DVN^_P6YV(
M P=$CCC@V@%S#M@\XD!J!W*N@U8[:+P#/.*@UP[ZN7TP:@>CROTN656FW; (
M1\,L?0-9:<W0RHN*KLJ;)3C:E"-K5F3L:<3\BI$SG<RF-X$[GGLNF,W9UZTW
MF<_ U ?.]7CRNS<#P80]F#I_7$]O7.]^!KP_'X+YWZ /'F8N^/#SK\-!P0(I
MX0:+NM$ONT;QT49O;Z<UJL#;D7N/73>8!]/)^ ;<C0.WS^)SQG?!?'PCP'+E
M6-/YM7</6#QW]]ZU-YD%7SW67W;O";"\$W$YSL/MPTV52=?S R>8"T!\.<@\
M+<*X[39@E#:\XH977.%H1W"^A'&X65 0%L"EBT^ H(\ 0XQ$9.V0] JI7(E>
M1UA#ECX<O!Z2TK5"Q-:@!@W8MG2ED95+Y>=\&R[H58^MA3G-7FEO],M/R("_
MB7+>;;:/H,4:Q:;=;M?OFA)$#-,VC,:PE4O2Y)*<E<L/T0;DZY %_>M9>=VA
M&GQ>(41<:J7-7Y@P5R68IQ+,5P36XE!K.-2D' 9Y_E*1F*[ (DT25M38VKIX
M_@@VK'RS'U>4YB(2M<Z@L@C/G]8A6K/8^(2$FQC2$"^E1B68+^P!T8DFGCEZ
MDW7]Q[-^.*]$#.B=V"P"+=WB2)!&<NDD4@GFJ03S%8&UZ#0:.@TIG;.2NWZY
MD5N6=++=;1Z6^T,1:U*D"SOM&-WAJ>F6;G)CP%79J*<2S#_=@Q8C9L.(>9H1
MD&Y+%G) O]%L$3%V1(28W2J/^1IO=J(T(>3KK"L-Z=(LJP3S1?$3>&01LYH<
M6^_)\:EER^I6?ZSK&E<3'&G;ERY;*L$\E6"^(K 6@79#H"TE\&'#-'<<_<<X
M>V):&[ JQ%3T,RW"QYB"G"Y>LJB(Q.5?BGSI,J82S+6[^W&H8TUKCR]/99N^
MW1G37)LM?A#<BU H96C"=@/!AI44MLF^27/QA))C7,J%4C17*9I7HQWFN8]M
MB&R=8$[SG&7:9N7@: "]1T-B(3FH6U[8R.!WRK59:P1IEDET#?,J4F0J&N "
MNSXB)BM;%D)\M@28R+0,:!\;PGN]C<X3W!*1*$X<[M:),G$:Q'SN5.IJ5RF:
MIQ3-5X76IG(O]Y%<[[];*]:XAY- MQ!?\9'@7$#7(9NQ!C\%E&IYI6B^N!>(
M24;[R%3:2W6D0*N?VGZAKJ0MN="TSK12*:1=I6B>4C1?%5J;UOU9 )(?!ERB
M'N50%]?Z[A&"26Q,[,Z$4ZK[E:+Y9W2B3<Q>U:,S9/UY(K)&.ESA;(V?4%VM
M:V@Z-/E<*Q7K2M%\81>,@W/;=J;W:AV]2ZZ?7,NZNM8FFFGPB5>II5VE:)Y2
M-%\56IO&_8$ DI\(_(B@E$-?O+(I/3Y W3,+1*!NV/R66^G1P.E6VS3M93^2
MZ_[S5*52A:\4S56*YJ&N>N]CC"U3Y_=$_EFF[?\E]UH?R[7^$55)A/],0L%?
M>DPP\G]-=LV0A4R(+)T_NQ288M+=I'L"NS[2;6(PK<K9^B),S*J%9IA'DK67
MX/@\"2Y1E>+$=85NE3C"RVQ''L"E(U8IFJ<4S5>%MJ-R</#.1?D.SFV8/46L
MJ,=TQ>#A)Y,-AVSW6LONIDBWU6L8CVE1I$EUN:;ADF:E 7N^2M/B^TWY9D?S
M<M'H?U!+ P04    " #80VM8U*! C^H&  !H'   &    'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;*U9;6_;.!+^*X3O<.@"FUHD1;WD$@-ITF(+M$U0=W<_
M,Q(=ZRJ)7I)VDOWU-Y04RY8H)EGD2R+)P]$S,YQY9L2S>ZE^ZK40!CU49:W/
M9VMC-J?SN<[6HN+ZO=R(&GY9255Q [?J;JXW2O"\6525<Q($T;SB13U;G#7/
M;M3B3&Y-6=3B1B&]K2JN'C^(4MZ?S_#LZ<'WXFYM[(/YXFS#[\12F-\W-PKN
MYGLM>5&)6A>R1DJLSF<7^/224KN@D?BC$/?ZX!I94VZE_&EO/N?GL\ B$J7(
MC%7!X=].7(JRM)H QU^=TMG^G7;AX?63]D^-\6#,+=?B4I9_%KE9G\^2&<K%
MBF]+\UW>_R8Z@YC5E\E2-W_1?2<;S%"VU496W6) 4!5U^Y\_=(XX6("CB06D
M6T"&"\*)!;1;T'ANWB)KS+KBAB_.E+Q'RDJ#-GO1^*99#=84M0WCTBCXM8!U
M9G%Y_6UY_>7SU<6/CU=H^0/^??WX[<<277]"EQ?+W]"G+]=_+M$)^GUYA=[]
M^Y>SN8&7VJ7SK'O!A_8%9.(%F*"OLC9KC3[6N<B/%<P![1XR>8+\@7@U7HGL
M/:+X5T0"0AV +E^^G'C@T+T'::./3GF0ZS5:03IHM%*R0I!ABINBOFNW:&$*
MH4]=?FO5AFZU-GU/]89GXGP&^:F%VHG9XC__PE'P7Y?-;Z3LR /AW@.A3_OB
M&U2;4FKM,K)=R9J5MJ3L%B>$D"1F(?A^=VB!2S(-<,IH+WD$C^WA,6^ +O+_
M01Y!Z3$:&0FU)Y-U5I0"U1UN^]1>9S:2&R5W!6Q4=/N(WFTU7!3U+R\/*GO+
MH+Z1LB.O17NO1=Z@?K&.@3J;%WHC-2^17*%5\0#^X%H+XPQVJS$Z"&$4A'@0
MY[$0#4D4N6,<[]'&7K17 ER0%;REAAI 5E*9XN_F@0MJ/$*!@RA)DN&N',LQ
M2C'%;KC)'F[BA;LT,OMY8NDG1YFL@)/U)-)DA""F*:%I-$ ZE@M#EK X<4--
M]U!3+]3+-:_OA(8L0*4 P*@L^&U1-AG@@IN.8)R0D(S\.A;#$8[#P T6!SV=
M!?YJW,,]R-EFQS;[X@"],W\[]6^4P&^E[=@9!]R.O;'[+C)1[/AMZ0Y5M_HH
M5FE"PA#30;1<DIBQA$[%B_00B1?BC1(;7N1(/-@D$&V0I%D+!=V/4E"T/?6F
MTWT$*V9)$@[AC^5(& 0AFT#?4S_V\NKBN@'J 4A'+PZ&V,8B,6-3?NTI&?LY
M^2++Y-8RWH8_V@W0%L4L4UO1.]L).1QG)DV2X*".=, =@C%.*)Z@:]SS-?82
MV\NP_PI$7G(#3S9<F4>G*6R\/:#(,#:TQ"''<(!9.&%)SZ'83Z)78B5@$^>
M=2?JK7"B'!/B"<5Q$D3#"N^0)'$8)FR*CG!/G]C/G]]>W_XX;1G3Y0EA+(U8
M.'+Z6#1,<131>,*6GEMQ\JJ&O*AW0K^D=\->TGYU[7\C;<=>Z&D;^WG[9JNR
MM>5KZ-M@0/\I3)-*6D!9G8Z?@[U3V&*8!:/-Z!#%."0XB:="2'H6)UYB!%:0
MF1!Y%T#H/CMB@+&]0_\JL[JW'7=[(4MC$J8#LQRB"6$!;.&)'",]&Q,_&S]%
MI,$.>08Y91X;L\1?VV)C!Q0G>!?W4@RI,J02ER0)@H"$= )[3]/D&9KFC^T
MM9*J[0/7LH3:4-EZ(9J?G-A=!$T9;)$A=(<@IBP-DXGVE?0<3?P<_4QI<U4'
MIRECG@:.2 @>16$L>$)9$,,NFLJ+GM5)^*K2MBIJ#K/L\Z6->+N%UY:VM])V
M[(6^/R#^_L!&=#.J$#:K8):J8 #4=KQRNF',]$!/F-%Q'1A+ADE 07(BAGU/
M0/P]P7%M$P]"945;IAO8B-]SE;NWH&.^#J-@.& [Q.* !E/ ^QZ!_(,>P;4#
MG=C'= ^>C].4C?+'T1A P4CH5"7H&P/BG[JM 46=J6:,?9>+]LJ6@-8N6XJ;
M"UN/=["EIJK:>-1F ?0N>-CC. 2A'8)A.)CZID5Z?B?/S.53B-$M+R$DT#4;
M="ONBKJVT;&4(U0A<Z=!8RY/(\ X^D;G$*10HAFTH6Y[:$_YU$_Y+[)'V.'0
M9PEU,'T8 8VP>&"*0W)H\[$E/<]3["W2R^UF4S:<R$O[^2PKI=ZJEO:SIP(.
MFZX]@RED[?XZ[&TF7OUY^(VT';ND;Q^HOWWX7!L!>J%LVUF_RS>GU>,^8%@?
MO"+'^ X^X?M[A,\U,(= AC\(_3Q&.OI2/<+H$VDQS@_.;"JA[IJC+(V:R;<]
M"]D_W1^7732'1(/G'_#I97OHU:MIS^"^<@7IKZ%?6X'*X'T,>%1[K-7>&+EI
M3H9NI3&R:B[7@N="60'X?26E>;JQ+]@?+B[^#U!+ P04    " #80VM8Z*2*
MY#PH   !?@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;-4]V7+;2)*_
M@M#T]+HC()JD;KN[(V3Y:.W*MD*RIV/W#02*9(U!@(T")'&^?O.J"P1I>Z9W
M-_;%%G%4967EG5F)GQ_KYHM9*M4F3ZNR,K\<+-MV_>+Y<Y,OU2HSHWJM*K@S
MKYM5UL+/9O'<K!N5%?32JGP^'8]/GZ\R71W\^C-=NVU^_;GNVE)7ZK9)3+=:
M9<WFE2KKQU\.)@?VPIU>+%N\\/S7G]?90MVK]O/ZMH%?S]THA5ZIRNBZ2AHU
M_^7@<O+BU3$^3P_\3:M'$_R=X$IF=?T%?UP7OQR,$2!5JKS%$3+X[T%=J;+$
M@0",/V3, S<EOAC^;4=_2VN'M<PRHZ[J\G==M,M?#LX/DD+-LZYL[^K'WY2L
MYP3'R^O2T+_)(S][.CY(\LZT]4I>!@A6NN+_LR?!0_#"^:X7IO+"E.#FB0C*
MUUF;_?IS4S\F#3X-H^$?M%1Z&X#3%6[*?=O 70WOM;]^O'MW^>'ZORX_77_\
MD%Q^>)W<?W[__O+N/Y./;Y/[ZW<?KM]>7UU^^)1<7EU]_/SAT_6'=\GMQYOK
MJ^LW]S\_;P$ '.9Y+I.]XLFF.R:;3)/W==4N3?*F*E01#_ <('?@3RWXKZ9[
M1WRM\E%R-$F3Z7AZM&>\(X>.(QKOZ'\''3S9\?!DR&\OS#K+U2\'P%!&-0_J
MX-<?_S(Y';_<LY1CMY3C?:/_V4O9/]EDE/P+\R6OE<D;O28^K>?)J\[ ^,8D
M5]FZT7G=))^6JLG6JFMU;M+DNLI':9+!:V7VF#4J@4?6=9/1^\^ K573J")I
MZP1>4QIXWR0__N5\.AV_'!R1[DU>)G"Y72KW:+U:9]4FM7?E\J/J7^G" >1:
MW35R\:<TT0: S0%G.L_*0]."M$MFNFY5OJSJLEYL8 $T5S*O@><!=%@'0E*H
M!Q";:Q""+>*E;;+*L" &49;D(,N2K"H2]52;>J4.43P5^*);&0P(:P)IW>IJ
MD;SN0*97E4I6G<F[,FN28F/:IEXO-\DS ?SU^]<>\"QI$+TX)<X_\-KC4N=+
MD,X&I*!) -7X3(F0+U2E9$L01J!P +MK\%;6+E.Z6".L2:&- L@-B+YVF2Q!
MCB9=M0*%M%(%8BRIE"K,R%$#$X"#V%X.P7Y<UF6Y.:P?*T"(Z69&%QIT#BYB
M!TT]9HBL#N42+@.4V@F2S0XB8TS++NFJJA]X2U %X22ZM:,!M&^*+FN*.GF?
M-;,?_S*=GKRLTN3]Z#70\.T2_DLNYRV@ 6F@5)8',EA]LX#+,]4^*E5YN!%Q
M66]1'S3@_'N81'"'[WF\P8T/]8-:S6#:Z1B%ZN0H]1//5)ZMU'[L$B ((?U!
MM J/)ODRJQ:(6<!+A8, ;^YA[EWWVGJAB&2(4G P/WL:T,<2=FX%%*D!H2$_
M)$73+9(<X--%UBHBV(>LT74'(R%;&EQ#P'6CY%5F-%V]JBM3E_@>(O!CAQMF
MK\#*YKK*JEP#M<) K<*7<?B\[ H" >R/' BBI;'PMX@7Y@,8;0=2@3J RW4%
M%&*%!(F!C*P: TL%LILA@:A2@X% P,"R\A#<47*G\C(S1L^!H6@!5ZIIP68#
MUNW= /  C8#ZM8+_@-16##;BE.99907M'\Q @@'^Q/7D'0A=D%,;!0*"]%G5
MRN0W^H\.5M/R8M_5*(L G;EJ*MQ@APJ<8JG!YFF0[8%L&*E"-SADUH"TP4%"
MR4B6G6XU[!X,\$A2$="\%O$#6Z*>P(A%"0,K ]M3X]!-O4H4P-7::0 J(+$%
M,$!3T;@+P'-K6%*MLPUO*;T'$JMM]*QCZ;9HE.PW/@D669G-+*.MLZ8%.4C2
MRX#4R^%?FO8A*Y4;'6#ZHMIL!M1J%"#2+08V TP<YDAKYL *@9NS];JIGV U
MK8+5_'!T,3H!^[ L8=*4U8FHP-Z#QY/1L7UPQPS3$3 A[>E<-Z9-_@#QA0(*
M'L7YTXA\@7X42#Z@DRKIUH =0)P@"U_X83(=C=U\A+P/>KV&O^^7NMID7SH8
M">3435N0M/KW#$:%C0ZE51J(J^C50,-6Q%]-@>3BI0.-EKQY BXT*)X!:)"J
MR*7Z'UXUO0YW\]+N9O+,* 7RL%7)&6GUB=?X-SI'>MKSMC4)?B)<?LS;FH5J
M'WTB]!%_@,H%C*5PWPH->$4$@BF#W()J?-'4!BFXSE$=DHZ(MW9Z%*#:0S_M
M0W_?UOD7D#:@G.C.V4LPR(D3/-"_*[^S*)V8$F!P!>P)%D2TQ>-@7KV;<HY3
M,1=0UP+.%@M::X=;&BL_UJKPIEXE<\!LR;(C*S<BC/&!WS[>OCD\PH& PQ_1
MTIMMZ ;XGC"<HFD*P&T#8I%Y8::2JFYY2 62M0"A1!*BW,3;LB35C^2"Y(;X
M2NZ!84U 'K#0=9E9:OMM= 5( X'ZV* ?F/R8K=8OD;23FYNKY-F!OW7P$PE/
MM,F @-I#F/:0^=^*(]A4$#TKDY#](#@+H$N9CUK->A3_3T%NE"4HL26PO;$6
M2,[P&X(_)(C#Y" @ O-OLOT'L/&!/';$ 5(3Q.,:T-P9'IW$F)B&NP6S%;L@
M5<D89&LU*V _D&G89/(/Y=E:MU9:P\YTN!1O)J)MA;Q@'VL070USVS#<L,]H
M<&Z--S0"R. -T@=JWA;DOA9H'X&N85$X MI'*[+20>/4C4E%OP-0:0("@&@+
ME7!+U,84-0=U4#_"(R^ _2Y.SRY>TN46=?5"%(9!U6%,#8()7R6"0J;[!HV7
M.K^"&<%88]M=-BU J$)@"0!5-0 9CT9O ,VARP6;BU/7U8+4M##9+3"$2HYZ
MDY%9='E[.!F/I\@/X#N\_+Y5XD. T@XQVI&DD_D!GJ(#">AMM:T%/,%>&Q$8
M^$H\#NQQEB,W 8>8#M1&T])K:^  WMU\2QF$RT'"_O[U?&7TX97%<U0=Z6*<
MP^1@Q-CW'#%8\?!5A(A;:.P;+VG0<"Y>A*X>ZO*!S49X%"V0UBY3H8V'IA%(
M?%P:4$"F5R%;HIPN,<C6P:KA=3"[ .LDZG:P9;UFTY5D1Z8-S>5$L>-.:SP[
MG(*. QGVI?>X,]YZQMUNEC29^"C:F(X,!D"8R%X J5"S-C##^)V2-#X1:,,#
MB(P-G'B/$R +A;:=)X?88G0/BGE(XQ*-=I5,BL^0F-\R2$=;-C-@JJ.(A]&+
MBBQYU,QL_\+()=@-(ODJM9#8 0KP.4@FL6B=M6S(Y?'.;7_SLH=,EV2ITA!
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MPT>'!,"]CL- A!V^7R?UC&(S@]SIX--SB[$"(&O!/N[*@JD]2] G;!B!0 A
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M3G11* 9&-29@P:$ISORVZ#+T^94B]H6;X+[GG-4 YJLX4!Q2")42P&,)F3#
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M]4^(VS#]H!W_\.[&R,.# %CG %1MU'[TR1%Q[+DU4US*X*U#'VA%I3.$*VY
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M8:P].L/34V"56M2MMBW&V-3'SB:,$+<J:<+%1=NB4KVY8O,RW#$MJE#$>KA
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MBZYP?U/<UH6F"1B?*^RE]0L9V-S_3_\#4$L#!!0    ( -A#:UBES_!XB@P
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MSL<FB F]3! .NU!337&$,%J>SO[;0@(C\H<3*!(+@4@Y<@TZ6\90C:Z-STJ
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M+A>"0SA:@/<TR:MNZ(#ZOR5<_ ]02P,$%     @ V$-K6!3:8N%B%0  M50
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MN425I\IW"RQDQ^X>FG05Z<#AR9%8Z91WJ<, S44I_(0>*S3=.>)T%J$1KH[
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M+>SM.ZY(W_XS'>Y!V531)IYR<)C:3);XM2P_*=X-.:\!+TN?#D+<9'-/U+$
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M0?6O=.$ <JWN&KGX-$VT@<7FL&F=9^6A:8$M)3-=MRI?5G59+S:P 9HKF==
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M<)TU+0@I$BT&1%(._]*T]UFIW.BPIJ^JS6; 2HR"<W6; =P Y9#9I54088?
M:K/UNJD?83>M@MW\<G0Q.@$ENRQATI1EO>@GO0>/)Z-C^^".&:8CX)"$8G/=
MF#;Y V0+2@]X%.=/(XH&=%8@E@!MJZ1; W0 < (L?.&7R70T=O,1\#[J]1K^
MOEOJ:I-][6 D$"+OVX)$R7]D,"H<="A*TD"61*\&ZD]%+*<I$%T\ZZ;1DC>/
MP)@,RDY8-(@\9%SZGUYO>!V>YJ4]S>2)40J$5:N2,U*Y)EX=>Z]SQ*<];UM]
M[2G!\E/>UBSQ^N 3B8SP U N8"R%YU9H@"L"$/1,I!;4L19-;1"#ZQQU%1+@
M\=%.CP)0^]5/^ZN_:^O\*S!@T!SHSMD+,&6($ORB?U?^9)%A,R; X K($]2[
MZ(C'P;QZ-^8<IZ++H2($,%LL:*\='FFLF;#* V_J53('R);,.[)R(_()'_C;
MIYLWAT<X$%#X ZKALPW=  L>AE,T30&P;4!2,"W,5%+5+0^I0-@4P)2(0Y2;
M^%B6I)<ANB"Z(;R2.R!8$Z ';'1=9A;;_C:Z J !?W]HT)A._IJMUB\0M9/W
M[Z^2)P?^UL%3XN6H, ,"M8<P[2'3OV5'<*C >E8F(>5.8!:L+F4Z:C4K.?A_
M"GRC+$'#6 +9&ZL>YKQ^0^L/$>(P.0B0P/R['/\!''S CQUR -<$]K@&,'>&
M1R<V)GK[;L9LV2YP5=+4V93("C@/)!K69_U#>;;6K>76<#(=;L7K\*CX(BW8
MQQH$5\/4-KQN.&>T!K;&&QH!>/ &\0.5D1;XOI;5/@!>PZ9P!%1>5V1"@<2I
M&Y.*R@.+2A-@ (1;J)>TA&V,47,0!_4#//(<R._B].SB!5UN47U9B, P*#J,
MJ8$QX:N$4$ATWR'Q4F?T,2$8:PFYRZ:%%:IPL;0 536P,AZ-W@"<0WL8#A>G
MKJL%B6DALAL@")4<]28C3?'RYG R'D^1'L"P>_%CN\2' *0=0K0C3B?SPWJ*
M#CB@5Z2W-O (9VV$8> K\3APQEF.U 048CH0&TU+KZV! OAT\RUA$&X'$?O'
M]_.-T8=W%L]1=22+<0Z3@Q)CWW/(8-G#-P$B-KNQ;[R@0<.Y>!.ZNJ_+>]:D
MX5'40%J[384J)ZI&P/%Q:X !F5Z%9(E\ND1/90>[AM=![0*H$ZO;09;UFK5Y
MXAV9-C278\6..JT]X6 *,@YXV-?>XTYYZREWNTG29&) :F,Z4A@ 8,)[84F%
MFK6!&L;OE"3Q"4$;'D!X;.!A\3 !M%"HVWETB#5&]Z"HAS0NX6A7R:3X#+'Y
M+85TM*4S Z0Z<D<9O:C(L$#)S/HOC%R"WB"<KU(+<>P@ Y\#9Q*-UFG+,/RK
MT//0/[SL/M,E::HT!& EH%HNP[//@@3ZT+N '?]0N3]\A)^?.); 10UCXNF1
MS6>Z^1S]M8B ."U,L,0) ^*VYI ?D.;(X/Q59ICX*_4(?X"% $.NV(?+HA0=
M82B/X5#GH&T018&F<5E5B-6WBF: 2=&=GDS&A_])A] HF$'1ND',D LN%!]%
MW0$F@2W0M<.@G+%BPZ8='%6GV!_$K#=G"VF'2"Y!L47MOBB(;9,WR%GEZ]H0
M>9!0^[^2CO:A/FKZ! V!TC?\$MYI &*1S2*DP1C*B+K:6 45CT.!0DH.'%PV
M:&LA'V?Z9AX-%\V<'11XJ]1\K)I=/Z2/-L"CT7F5 ZD8VO%,W,^\H6_OH:CI
M!.Q1DBNE^$=G6K[=J)))75P#(/X1=!;!2%YM.1WPH09]D;0;YW80#[7].?QN
MN,MVF:%E@%HO.VD]35E-G#1VC0IMSEZ0=A-S,=*R1!V+5;!MN0![G'=5T>,>
M\7C  1%>P'#N-<(+$+1!#)75>ERGB4'M\VP-+ GFT$"*Z!5&=&GH-1"X<_]@
MNG<4-':S>S!@Z4>#.*O6;.&C00++O8X]8P0=OE\G]8Q<18/4Z=:GYQ9B!:RL
M!?VX*PO&]BQ!F[!A  (B -(I,"7S=A=7M_A( UM7.ZH1.^#+<Y7Z*QJ>""5<
M=0%8",8)$#RLOB2HD>V%C!49*/%D:YK$BJ1,.ZSM6H4'EE"+ID.J2 P^TZ$0
M\A 31A0R()Q8/8(D1CB:P "2_:"AT("0R6,<+'39?<NO=N[\:N?[/:P6T%\\
M*8!\*3-FK+*G!G9PKYMN,,ZU=X+A<-P/SDJ.@O'1"S[R3W^_?GTXN0!=!<S1
ME<ZMKU$\MQ9*ZVX&S#U9 J=L^0R!OU0UOI O0>BH"GW?68,A"YH0[+FR&)%S
MV:%?(+Q)"CA>"$/QR488ZEF[!C3(93?WP&OQA N%QCJ@C=W.=04HBWP*7:ZH
M$WA^A(RLZ#AH8#><"9-Q^PB47IJ.%PFOQ.,$>PP,!N$-S)%A 2314"^<H5!8
ML3.01&3-9E@#)( J@>.FMV_>W;ZYNZ/1+M_?_.W2F7S>ZXFTX+5.H0$FJ%D;
M.3I#ZH%S!-%.TD?8_QN0?O5&P:2*!D,'-C :8#/6%_?F]BH,A^5\-UL % "R
M @_T$Z&=F;39(T(&;6%Q2Y(/?Z&1XRF>K*'9_P"-2\_I !\P7!(ZC91!%JK-
M$L809\_5)< DN<S;;;78[^J7LZ/S].SL'"4RK)L5P_4:\)4X[G0\'1.0X(^)
MN.%A7G: X4)^F5Q,TLG%!8?MX!E\F"X>GQ[)Q:-1<CGLL-UV+7G1*Y/0,G!5
MOQR=GJ8G)Q-W$!C3U.0'0MT4\,H0F[*X/O-^NE&RAS]=./YTL9<_?6']Y WP
M2!0A@PQH_PB6V/HCT?&P!N;4B!UQ)!OI0-PEL_K+Z&Z4O+N\O+$2#]TU%6 '
MR0< PRK[JA [9"H6WZ9;B:5)0C]C"<A 17FD?*PEUNE"[89H1YL<J!)]2>C[
M(EU]09Z3'>^TD471?H^*-PH@!31=?VNYPAV,1.<EOE&P\\._1/H\(?0H^>!!
M1GX\Y&T^W")(R0-^K>J'4A4+IYX[#HWQ]^RK3&("H /ZDP<>;J$W-6.'@.74
M:(@4&MW9CI]%+^]!W<G8)P2-]Z+>%7DE8?GTQQL?91E,\OG)L6(]$XY5DP8!
MK(WR"D ?*BG<A6X5915TPF+2RE 9(?Y?(C0!,:OD: RHLME"FS78U>1V8S+O
M1X[V@BS(H9KLW>8''WFZ<YK2(+CVCC.L=@P.'L'/N>?9S** !IB?"(%MHT,3
M'@U&REHK;6/(L:Z@ &(=$9;I0) 4"MTD$OYI$Y7!M5E6D@'+Z81X AR*CL/7
M3EW>L8I&.80@L\K; X? S@Z=O9QG#:B9!<TN% !,(=--@BM%4KHE>Q.NDCAE
M!L->'%'@K>E,8IU80%_=I>4$X8_.6,Y@0'P@8!-8*+ R!^*5:I?()[Y4S;[I
M!S;5F]4KB B#/.]6':N:K#RA]=ZH)?H![C'.0R;B$YS@*?L_# L)14_6E<29
M0H5=3D)VO4?R#I\4G9)I T\'CK\$?GF(\ ((D*/CKF4' ( #F+_&@]E'=%-/
M=-.]1'=CO:0(6&0M9.<,4MW>@8:I;GCT)+JLW&4\+Y)"A([H$$;L6P,R&@E-
MHX.7PO#6Y]VXH$UA71R2NF =D2,X"HQ!:$8L3:&H==?&:-@V&6KCA[@K0;X$
MW18BOAAE/(& S)IW)7#7N9.J)'^M@DC$/? X<.&DP=P@ECQS1+IA8*1@RK86
M.1!=Y]LA'%9N_M7_(TR-?M@G*-*/P?CD;==4%+P2D^B1 UGVP5^2R?E9>G%Q
M%EXYNDB/CDZ3]YR(4#>;X,3M8R?I\?%%>A*\>)Q.C\[2\?E%\AZSY9#6T-)I
M,&&+Q)A;7#J97J23\=1=F:1'%T?P^GAKJV?I&:BTIQ>GP<1GIQ?IZ<D)3&-B
M!E&$:&.??S)-I^/3='QR\M1? WW\?)*>3N':OL/T,#E)3T['Z>GQ)+AVG)Z<
MGZ?C8-7OZVIQ^)["WI>LW(7BRJ4U6>T<[4#=N"@:*(K.]8HB'@=#!+2*XD":
MP@)4!?I%'@QGUKQU*N(ESXE4 _RH*C+4T5[5\)\SQ=Y>WKWRH?OW=M;"3LL*
MQ%*5!:V2TC^1BD&'U.I!K#[4)]G]QYETK(CK!@X';7SG.P-C! 6&XE^P5A!;
M*-#(8B/Y1<H>NM]F@2<2'6:468@>]1)8]L<ZA%[CG1'EUOH?0I/)@A[3GL 6
MHFS*[1P9L>:F^SFV3ZB>[$UR?KF%%H/,^B<2I?\_OOV_A&\^ZWVR/UN=^.\P
MDGW/B\GEW57RN5Z#CG=^/$T3N>J8G,V%9J^UU;197_.>9MBX"R(Z+PRE0S2(
M8Q)SID0HA-:BTI+RUK;]N%5"M2R$&>J18QB!NE7R>M"[CAD7Z.#N>TS@]VH4
M^R7EKKQ<8X"0163II1[16TK&&= ';P$Q,0B.\NL^.^8T.0S2\U>Z]:E]5];R
MQ\H13P ?0"UR>PB28#G.C7MN5*4>V%E(0,/$ ..T&+J+V13BK=#.H.G;':;&
MO'=M\H92I4;))^O@<'/P0FB30<3(*6I;,4C4Z@W[!"HQ2268B5IOS2$)[S2V
M1-B/W,#<E.EF'?#IX&RR-I\P*7E!Y<9&N-"Y0J$/2BT$4PJ="$SEBRY#EZE2
MQ#3@9MOHG(/90/(5QP=##*$,,G@L(5L"B!]+?BAQB]>!<S7DQH7=MINU))WB
M,K!*#,T":S\A%,C*R,2C$?OT*$7MG^)2 9!S3A&L'!"Q(=61UI"Z6H:YD -E
MRCW"\32<#;:=[(5!0^"C/! '+BG#M$6XD8U&D<L@9F?1BC?I$E>U-1Q7-G4X
MQTPRY)&)T2N-11>X64ZF=)><\UM5][JI*1KKP?R63@(]S61#"!5L.SR)_+EP
M!(PNC);FDNA5:,8]]' BUP)^1>YAED*.^PKF8 I#71W:\Q/KT/BL?9(L-L1#
MC(T3UFB"DF1&X+1#?W3N@KP6'YP1GUGZ]2L(+-*JI""F-H,[TIR]8#>.ZXH3
ME."OT,?H]7.4+$7ATG$H60B3'  =0>RAJ%Q]T__C"P<F^S/^;R7(<.L9^*#4
MV3O*L&HS,'2LW!3 \%#ON?N2G()^G]@7$%97CC;):+NB<D+TLX4$;B,D1O04
M&^]%,D4S[Q"LN#4, "A/53.<K$BK^2?1I+R?&3[[NN1D?,!W5%D6=5T0K\$-
M:51(D,ZH0,I5?V52Z:@HTR2K+ T2GXSH? NI/*FC%P9X*_OUK?I$%TM& Y"9
M2[9@B1QJ0,2MQ5%TU/E[W-Y"R4S$'J"0*%AMZ(9#P8&*HF47-@6M'8!W3.<@
M4M%I;V*;F>UM/ CS/'FBGUJGTR8B.3#H=/^>C,>));-2+S@P2(_"LWZKY/KS
M92+HU<D5/G;_U%'X\$.6MG=,97FF7R52ZA,8UF*1APEI+4\0P.9I'%NC!!$B
M\QWS@&!I/?,!\:'66R)4!#5J;4OF='AS&T,=\LH9DG?3C4TN06*..1D0DKK$
M64R-$K]=Z($;7C&IUL%"-D[?"$<7A^AJ1OY'SFJE-WC9E#UCUXT61PD3N_=G
MP+%+TD.LEQ+=2B'_:!'B/0?RU@E;D>O%NVA$IE^M(!(!!L9R+59[8I+MJS[!
MW"0$ZIG-WR!-)NM08D4Y>8@LC:'<QI[ %A<(TDJ/<E'$.Y4X2* 9S*7=L732
MY@PE>0[ ,):"@T1":#2,"^)DE[4:ZY>S2POI@RTR4 _V#0=KM213#&K\3IO<
M586#YJ!P3V1NG"5GTT+<:;LL15B+5NSAH@I46^/ A.42ZJTHMAO"Q'HL"6"
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M'=KYS^]Z<"=-A,7DT.,9XXA5&_+NO1Q.!4=#V9O90#F<#C82Y&*$*P\)>'L
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M[5+2GUPEPRAY%:B@5&AFSY3+3;!-5Q'1Z=7U[8?D$B\[PG1>C"NLQ*B;2F<
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M$SP24BV ^4F>EZL/):!^?C_Y'U!+ P04    " #80VM8,:Q(R/(#  "T"@
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MK%R3'+ &Y(!HU(KG"-"[#;ZI;/8O8K%>:L$4PT]4V8!(SNB2Y<TF+3.BD$)
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M53!M(M<R9W(_YMG#NZ1.N9&H+'E5$I$N(E&\VM= L[90&H72V)IF'/4<+!)
MVQ2B:*I8VG2M9<[73K**2V[5G)06/(N2.K=/"IY$E110E<O)]%8*II*#I'N>
M\9FH]-T0-*,+I5$HC5G[^=P]+>TGD?>T!$WVHFBJEMITKV7.]][R!U'6<IH2
M*J1H*G(SF_&B-C1_N^+I/2^T'J:9>K1FH,E>*(U!:3Z4%D!I(8JF*K'-'5M#
MN)5N0?/'4!J%TAB4YD-I 906HFBJ#-N4M&7.2?\9 \S:SY':CLZ!')L;<;34
MH#EH*,V'T@(H+4315*FUJ6_K0.X[3^4H3L1D7'=\Q8M64M $.)1&H30&I?E0
M6@"EA2B:>NUAFU&W>_ 3K0W-LD-I%$IC4)H/I0506HBBJ3)L<_>V.7=_L^!%
MU*BPSH\I^7OM--6,.UJ"T,P]E,;6-,6Z[PW.=*E[:,4!E!:B:*J^VM2];4[=
MF_1%^/-"%*MKS%]X5&CU!DWG0VD42F,'=J3=LX?:O@W9B !*"U$T57MM_M\V
MY_]?\R43D8JJD5U)I/26I=;2-L./5A[4%X#2V*'=..=DD9<5H3QN<E'K2_>M
M(<EX17+E&RY',0\\J[?P:3U9BQ9R$O<L4OD^>2$_] >G-DE%DM3?^2?Y5STR
M(IORF<A$7?B$W"\KDD8OY)Z3<GG_WSHM5N4DRHC7^_O6023+1?VK$HGXH]EP
MJOV>0"]>A])"%$W]GK2VAVVV/71]--ETTMO'1/L]@9H@4!J%TMB:MCTBZ ]L
M[8  66\ I84HFBJVUC:QS;;)G?S2\L8S^9C'44)^7A:BG(KXM4O/S+BCY07U
M1: T!J7Y4%H I84HFBK!UFVQ!_BI-]1J@=(HE,:@-!]*"Z"T$$539=A:+;;Y
M.OVCI]Y0FP5*HU :LS57S;M#1WNFA7HH4%J(HJGZ:CT4V^RA_.FI-_1J?RB-
M0FGLP(Z44V]/V[=!314H+4315.VUIHIM-E6"9@Z8D _+4OY'?^&=&7&TOJ"F
M"I3&H#0?2@N@M!!%4Y<!:$T5!V^J.%!3!4JC4!J#TGPH+8#20A1-E6%KJCCH
M&R+,P*-%"+55H#3F[-LJCO9^"&BU 906HFBJOEI3Q?EK314S_FBU04T5*(T=
MV)%VS^EK^S:HJ0*EA2B:JKVMI7;,;L M7]^+4W=RXU4G-]X2H%9OV,5VL*OM
M8)?;P:ZW@UUP![OBSE_A63BM9^&X^)$>U*F TBB4QJ T'TH+H+0015-EV+H9
MCMG-^(Z1'M3/@-(HE,:<_9LX]&X9M-H 2@M1-%5?K57AF&\,V=47T0WS?GUM
MF ?U+* T"J6Q WOQM6MGH(T(H+0015.%UYH3SJ%%A,S#//(_^381\ETF(JWX
MH&X%E$:A- :E^5!: *6%*)JJR=;0<#S\F ]J8D!I%$IC4)H/I0506HBBJ3)L
MO0W'[&U\QY@/ZG1 :11*8VN:<N^5?LP'-3&@M!!%4U>3;4T,U[S6TB]25)%>
M2.;(8X4$I5$HC4%I/I060&DABJ:JK?4J7 M^4G6A;@641J$T!J7Y4%H I84H
MFBK#UM)PS9GXD93@5"3+^M$7AY;*AKH74!J%TIB[OVZ3Y=@#S^L-=Y?+WB_9
M]SQ[8.^N20AM8(BBJ:)IO0CWX )/*2]B$7V[\K^YKIB*LBK$_;+9,'HH.&]6
MTWX2U9Q<BT5]L\#=7&0OT=<E&><GY&-])P&?GI"?HT6DO0;9W(RC%0?U+Z T
M!J7Y4%H I84HFBK=K6<&X/T+%^I?0&D42F-0F@^E!5!:B**I,FS]"Q?YT $S
M[&@!:IX4T-.MTT&A]3(HS8?2 B@M1-%4<;7FA6M.NU^)3*3+5*LDJ#4!I5$H
MC4%I/I060&DABJ:JK74L7/S*52[4I(#2*)3&H#0?2@N@M!!%4V78FA2N^68!
M5E;-W<[3^K[RV3(A]7JB)?E1K"['*W6/SOM@9AZM0ZA+ :6Q WNOO]I)6LU!
M'0DH+4315,VUCH1K=B2NHN=73[10ZP%*HU :@])\*"V TD(437U,6>M/]/$W
M6?2AQ@641J$T!J7Y4%H I84HFBK#UKCHFV^R^*X3K9EYM ZAS@64Q@[LO>'K
M)UIH.P(H+4315IKK;CUH.>7%0_/0[9(TW=OJZ;.;K9L'>X^:QUGO;!];[ZFE
MV<ZL]\'JL=TM?O44\:NH>!!921(^DU7U3H=RJEZL'LR]>E/EB^8QS_=Y5>5I
M\W+.HRDOZ@+R_[,\K[Z]J2O8/![]\O]02P,$%     @ V$-K6"F$$'#% @
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M970R-"YX;6RM5FUOVC 0_BM6-DV;U)$W"-!!)%ZZK9I:$'3K9S<Y(%IB,]M
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M\A?:&?[R$_3=7PT](U7/B$E].-:#O.F% $=%X;Z ?QM+6+@N=/U<-\N$EV&
M4(^X9."\-!CR*D/>_H8>\H=-%7WT0KD*CW?U;;)5J =;MG"7^,V>_,J3;_1T
MJ6?^IDC@:+)'C?Q:C0@B <0M?GJ5G][^?@ZH4:]6(]0-@F9/0>4I,'HJIOI8
M3?3OUS1YI+QQJALU#ISJ_<IA_Q,?XKZ%GD%7I[N[1_79TSOOXA@H'%,.\EXV
M9K5;FPNPB_O-<P%NT09:BI52>/N9455R7:\E5R#2GM 'DN6>\J31CUG4 V\T
MY ($("F@!CTP"]],T(&:.M 8_1_.PE)^S\'5R(!F9AP<A[#.#.@1TL.HQ9*&
M!C13PYR(K6-K%JV-;;!S:#51X \@Y9"A]7]D:#58H)DL18[<KYDQQ<TBAX:=
M)@T,/C'(H0U&00TI:"3%!Y*\T,T"?0OK;;&)-%K0H6A9+9<F0ZB.%O4J!EO\
M:+0@6VA!#6@)@K[GM\0/TFA!-M"R0S0HXP<6\:.^;G;%#])D07;)@NIDP5W8
M$C](DP59(@MJ^!HA7K^/6QQIL" ;8-DA6HZL:20U2)!=D* Z2-1(MGP,( T2
MM!=(%IR:/PC,,@>F+=(H09^)$F0#)4BC!%E""6I ">[Z+=&--4JP)93@)I0$
M7HL?C1)L"R6XCA+LNL1';372*,$V4+)#=(,25'VE9"@Q_6-LZS]C=DF"FTC2
M$C]8@P1; @EN^$3Q71AX;HLE31)L@R0[1'N;=P1W,[+^KI<$K-&"[:(%-Z&E
MU_*2@#5:\#YH^<96W$@6L\J!X8LU6?!GD@7;( O69,&6R((;R$*ZL"4UB28+
ML4064B=+KPM;/IJ()@NQ11;2\)'2PQCZO19/FBS$!EEVB/;+ .KMBAVBB4+L
M$H74B>)UW1:DD*V%$DM((76D(,_SVEZGB"8*L4&4':(;HG@;H*"=1"&:*,0N
M44B=*%X7OE]-<;:621/*Y_EBL !3MDIEL6):G:T6G$?%,JN^O%BMO@[Y/%*/
M;DR?5%.WVU/%X\4"<'$@V3)?='UD4K(DWUW0<$9Y=H'Z_8DQN3G(;E MPP__
M U!+ P04    " #80VM8OAP$2F$$   _$@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6RU6-MNVS@0_15"6RQ:H+5$ZNJL;<"QV]U@T=B(T^:9D6A;
MB"1J*3I._GZI2W0SQ;A!^F*)\LR9<T;DC,C)D;*';$\(!T]QE&13;<]Y>J'K
MF;\G,<Y&-"6)^&=+68RY&+*=GJ6,X*!PBB,=&8:CQSA,M-FD>+9FLPD]\"A,
MR)J![!#'F#U?DH@>IQK47A[<A+L]SQ_HLTF*=V1#^(]TS<1(KU&","9)%M($
M,+*=:G-XL4"%0V'Q,R3'K'4/<BGWE#[D@ZM@JADY(Q(1G^<06%P>R8)$48XD
M>/Q7@6IUS-RQ??^"_JT0+\3<XXPL:'07!GP_U3P-!&2+#Q&_H<=_2"7(SO%\
M&F7%+SB6MNY8 _XAXS2NG 6#.$S**WZJ$M%R@,Z  ZH<4-_!&G P*P>S$%HR
M*V0M,<>S":-'P')K@9;?%+DIO(6:,,E?XX8S\6\H_/AL<[M:_ OF=_.;Y>8S
M$)>;^?7M!LROEV"UOKU:76_ %[#AU'\ J[1(_#Q/?,B?P<<EX3B,LD_"XL=F
M"3Y^^#31N>"4(^M^%?^RC(\&XD,$OM.$[S/P-0E(T 70A9A:$7I1=(F4B$OB
MCX )/P-D(%-":'&^.U+0,>L$FP6>.8 WW^T8V6%.P%7"62CFOP]^XNA 9+DJ
MH2PY5+ZB+[(4^V2JB26;$?9(M-F??T#'^$NF\YW .JJM6K6E0I]]?2+,#[/^
M"RU5EJYVX9J7F<>9Z;A6GNW'-O]3,\]Q/=NJS3K,[)J9K62V.O",XR0(DYV,
M6^GLM()"9(U-"UH]=LHH;\RN4VMPSLDNOH^DL\B1),YT3.3T)"B#O%&"6TMP
MU1+B-*+/A'1JBTR,$N97E\0[@744>[5B3UD(K@_Q/6& ;BNQF4RM]YYJWPFL
MHW9<JQV?N\P YN"2[,(DR0="/]\3D!(64FEU&)^L0-MU'<\<]V;OJ9WICDT/
M#=0':#0=T5!2_YOAA,LK5^79"6HA8^SVR4D,D0==TS4&V+7Z-7Q[9:U\VV&_
M0)$2P^[SDQB:R'8<=X ?:OBA5_BE(2.!OL")+S[.!GBBT_"NYQG&21XEAK;A
M.9XWP+-IRU#9__H35'Q]O#XU*\@V&P\AUS+ZS4%BV)_$7=I-7X5G-=:ATE]Y
MMP-;R/*@V:_]ZC!O+ ZP:<+05A;#N^+SF@1@_DB8V"Z EVD-UBSTY=+>J>-6
M^G]'_X9- X?J#O[V\E@!>^W*,AJ[_=<KLW*&%DW3M*&Z:ZM*8^F9%[YFZHW,
M_D>=S,P<6<X LZ:Y0F4W>Z4L>J=!T<@^*8H2,S@RATIBTPJANA>>5Q+'LL1X
M)_F3F%EM*=T]4]/TD+KIG9;#LV9CA3K\.JLMEZ&>M%W232]$9_7"H6)8>7>C
MMCI'Q4T9XU<K@=[:BL>$[8H3B@SX])#P<@];/ZU/0>;%WK_W_!)>+,JSC :F
M/%KYCIFH%AF(R%9 &B-7E#)6GE:4 T[38L-_3SFG<7&[)S@@+#<0_V\IY2^#
M/$!]9C3['U!+ P04    " #80VM89:8+>" (  !P5   &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6S-G%USFT84AO_*CIKI)#.I!>C3J:T9V8" -HDG
M=IN+3B_6TEIB JS"KNRXTQ_?Y<-"R&B-TO<BOK %XCQG@?? +B_>LP>>?A$K
MQB3Y%D>)..^LI%R_ZW;%?,5B*D[XFB7JFSN>QE2JQ739%>N4T44>%$==RS"&
MW9B&26=REJ^[2B=G?".C,&%7*1&;.*;IXP6+^,-YQ^P\K?@4+E<R6]&=G*WI
MDETS^<?Z*E5+W2UE$<8L$2%/2,KNSCM3\UU@C;* ?(L_0_8@=CZ3;%=N.?^2
M+?B+\XZ1M8A%;"XS!%5_[MDEBZ*,I-KQM81VMCFSP-W/3W0WWWFU,[=4L$L>
M?0X7<G7>&7?(@MW1320_\0>/E3LTR'AS'HG\-WDHMS4Z9+X1DL=EL&I!'";%
M7_JM/! [ 99Y(, J ZRV ;TRH-<VH%\&]-L&#,J P5Y ?W @8%@&#/<S' H8
ME0&C_8#3 P'C,F#<=A].RX#3M@&F\73FC%Q!Q2G/]6)322=G*7\@:;:]XF4?
M<M'E\4HF89+5Q[5,U;>ABI.3ZYN/E[^1Z>?I)_OZ+5%_/DT_W%R3Z0>;?+RZ
M\3]^N":_D.EB$69JIA'QDZ(F,VV_MIFD823>G'6E:DH&[,[+M&Z1UCJ0UK3(
M>Y[(E2!.LF"+!H"G!_0,#:"K#L+V2%A/1^+"TA(#FIP0PWQ++,/J$[&B*1,-
M[;IL3^D=IM@O4#:*8A84\S#%:=\6#<754VPV/R&]ISWZX]HFKU^](:%D,7E%
MNB7V,'W6GF[M )L4\3WM/$CS6YR!GO'2L0O:4XQ&2DVJO6W1]G)L[]"NAF(>
M<;%)&;F6?/YEQ:,%2U4I?-V$\O$M$=E*\G&=5:D@TV1!/M,TI8D4ATKYK]]5
M"N*KDRK^;MC-BZ(]_>;V9/?P=V)-Y^R\HV[2@J7WK#/Y^2=S:/S:5$%(F(V$
M.4B8BX3-D# /"?.1L  $JU55?UM5?1U]\F$3W[*4\#NRCJBJFW_SBUQ3-6@Y
MQU8#$F8C80X2YA:P80[+.NWWD\%9]WY7XLAT'A+F(V$!"%:3^& K\4%+B?/R
MYD#O50^.WD:,J)L!"878T&3.FD2O)1\K>B3,1L(<),P=/!.]:?6LGCG>DSXR
MJ=<RJ8],&H!@-54/MZH>:E7]/DS">!.3*(Q#F8G[CH:I&B6E7Y@D]S3:,"(Y
MN56_4T8E6Q J2,*37X2D<B-Y^EAVF/XEKYJ$KTU^K/"1,!L)<Y PMX -=C5H
M9#][ND?F]) P'PD+0+!:<8RVQ3'2%H<C9!CGJG_(GQ6I#WEY%'6QO1.0938^
M4%^^#A.R5O>(?+#R)JL)W9CL0IO\V.) PFPDS$'"W (VWBF.WLEXOS?4M)'1
MKV_D(9OE(V$!"%:3_'@K^;%6\C=<JN'M)DG9G"^3\)^ZY.<\7K-$%./>.1?R
MT'5?F^18:2-A-A+F(&'N^/EUOS=HNO(CLWIML_K(K $(5I/XZ5;BIUJ)?WZZ
MEM-[EM(ERR[9(6]ZCGJA!1TK8R3,1L(<),S5'WR3/#*:DB&)\R?038]KD*WQ
MD# ?"0M L%H)F$9E71C:\S!=+E.V5'T;$B8R#1,1SJMN#?O&TGDH\J'M@0N\
M'G]L:4!I-I3F0&EN2=N]WHZ'O6'/&NY=Y*%IO9(V?"FM#TT;H&AUD>_X<^;W
MB[P8MSX]R^$;J8:TR2),E@<EKTUVM.21-!M*<Z TMZ35NAA6_[37-_O[FD?F
M]5KG]:%Y Q2M+GJK$KW5\CFEZJVKNVPI]-)KS)Y2-GK&%WKLT?)&TFPHS8'2
M7"AM!J5Y)6WWLF^=CH;FX%D%(-,&*%J] BJ'U]1:71,G7D?\D94&;^GEJJMZ
M;?$JHDEN+3?6 M2SA=)L*,V!TEPH;0:E>5":#Z4%*%J]8"KSUNS_8.]$F% ;
M&$JSH30'2G.AM!F4YD%I/I06H&CU JNL8[.M=UQVP^A&KGA:/%Y]P3O6HX\N
M%:A[#*4Y4)H+I<V@- ]*\Z&TP'SN@5M[#X3K55!9S:;>:ZZJ@%9WC6<%T5@#
M4!\92K-+VN[QVGMT[C1L,K9ZQGBO%^Y"&S:#TCPHS8?2 A2MKNO*)39?L(F/
M&6^8C?J&6L%0F@VE.5":"Z7-H#0/2O.AM !%JQ=,Y3&;XQ]MO $UI*$T&TIS
MH#072IM!:1Z4YD-I 8I6+[#*X3;U+NO_&F] 36\HS8;2'"C-A=)F4)H'I?DE
M;;<[V_C*2(!*6_^?M,KCMO0>]_>/-ZSG=JDY&(SZYIY=>MFTH36TC-'>H;#U
M33U6N5":"Z7-H#0/2O.AM !%J\N[<K<MO;M=OKK=J%^H50VEV5": Z6Y4-H,
M2O.@-!]*"U"T>B54EK=E_6#C"0MJED-I-I3F0&DNE#:#TCPHS8?2 A2M7F"5
MHV[I'?4_F9#9FU&'WY35 XXN"*AC#J4Y4)K[PH$O7I=MU#[4'(?2?"@M0-'J
MVJ_,<4OK#4[>TV\'NUE0%QM*LZ$T!TISH;09E.9!:3Z4%J!H]4JH7&QK\*-U
MLZ#>-Y1F0VD.E.9":3,HS8/2?"@M0-'J!589Y);>(&_1S8(:X5":#:4Y4)K[
MPH'OY]VLYBF8H"XZE.9#:0&*5A=_Y:);>A?]AJ6QV/_'C&(ZF<9*@%KF4)H-
MI3E0FOO"63 -32E _7$HS8?2 A2M*(7NSA2#,4N7^926@LSY)I'%''O;M=MI
M,Z?Y9)%[ZUWSW:R8_++"%'-QOJ?I,E2=KHC=*:1Q,E(WLK28WK)8D'R=3V1X
MRZ7D<?YQQ:CJOF4;J._O.)=/"UF"[22CD_\ 4$L#!!0    ( -A#:UC W>G=
M-@(  !,%   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(V476_:,!2&
M_XJ535,K520D0#>61"JPJER,(FBW:Y.<$*O^R&P'.FD_?K83(J:EJ%PD/O9Y
MW_,X'#L^"OFB2@"-7AGE*O%*K:NI[ZNL!(;50%3 S4HA),/:A'+OJTH"SIV(
M43\,@HG/,.%>&KNYM4QC46M*.*PE4C5C6/Z> 17'Q!MZIXD-V9?:3OAI7.$]
M;$$_5VMI(K]SR0D#KHC@2$*1>'?#Z6QL\UW"#P)'=39&=B<[(5YLL,P3+[!
M0"'3U@&;UP'F0*DU,AB_6D^O*VF%Y^.3^[W;N]G+#BN8"_J3Y+I,O,\>RJ'
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MJV\)#JYB*N[0B?\IFWAPY]BS5RUE+UO*7K=4_*2?/NR.KH:#:BZJ>:CFHUJ
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M^W +3T=;>*AFH)J):A:JV:CFH)J+:AZJ^:@6H%I(:?4M0=7"T[$+Q(JESML
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M'-3+H\NBJHKY^J^W-KNR9?,-];]?%T7U^$4SP9>B_&V]F2?_!5!+ P04
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M)4N+KS'!$>&Z@;J^9DR^'.@.ZFW+L_\!4$L#!!0    ( -A#:UALHI::>@8
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MJY]?G_<S%2H7]&<5]KK$TB>P!KGA:;:2Q$WG;-ZA=_5Z\SF]]TQ\^AP@>*8
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MZQ1=Z^LFBM>VW>RYTLW+#DO]MP!A O3SG'-UG)@-AO]/\@902P,$%     @
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M1@S%!=471%QUX/8@)VF2I_,X#(HH1)?!/$@F$<IG453D!J ' 'H' T1'2VQ
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MGV3]T'KYUQ^LVS6I5=D<_%GW5V#V!5!+ 0(4 Q0    ( -A#:U@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ V$-K6.;2.\+N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ V$-K6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #8
M0VM8/0'OJ*T'   Y,@  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ V$-K6%3L\IRA!@  XQL  !@
M         ("!\ \  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( -A#:UC93*-CV0(  /P)   8              " @<<6  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #80VM85I]UC!<%  "K$P
M&               @('6&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ V$-K6.J,[\?O!0  :"0  !@              ("!(Q\  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -A#:UC4H$"/Z@8
M &@<   8              " @4@E  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #80VM8Z*2*Y#PH   !?@  &               @(%H
M+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ V$-K6.,I
M'@QP!@  "Q   !@              ("!VE0  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( -A#:UBES_!XB@P  )0H   8
M  " @8!;  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #8
M0VM80"N7=; #  "<"   &0              @(% :   >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -A#:UCSG9S9Q <  !(3   9
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M970Q-2YX;6Q02P$"% ,4    " #80VM8;-6[_*\I  !HB@  &0
M    @(&+GP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M -A#:UC_34B/=@,  )P)   9              " @7')  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ V$-K6-18XJEB!@  BA<  !D
M             ("!'LT  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #80VM8,:Q(R/(#  "T"@  &0              @(&WTP  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -A#:UCPZ-*(.P,
M *L*   9              " @>#7  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ V$-K6&;@FGRU"P  *GT  !D              ("!
M4ML  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #80VM8
M*800<,4"  !6"   &0              @($^YP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( -A#:UB3_8TV7 D  ,MJ   9
M      " @3KJ  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ V$-K6 Y&$W@2 P  G@H  !D              ("!S?,  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #80VM8_'SH-Y<$   R'
M&0              @($6]P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( -A#:UB&5/V/=P,  #D.   9              " @>3[  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ V$-K6.%FN-(^
M P  V0L  !D              ("!DO\  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " #80VM8D>+#F% %  "2'P  &0
M@($' P$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -A#
M:UB^' 1*800  #\2   9              " @8X( 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ V$-K6&6F"W@@"   <%0  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( -A#:UCV"?9AM@\  /[I   9
M  " @48L 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MV$-K6)59I%ZV!0  PBP  !D              ("!,SP! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " #80VM8;**6FGH&  #Q0   &0
M            @($@0@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( -A#:UC8>W0D0@(  )L%   9              " @=%( 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ V$-K6$Y-(!Y$ @
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M2P$"% ,4    " #80VM80+O#+8<!  "\%P  &@              @ $=5@$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #80VM8_WEJ
MDI\!   =&   $P              @ '<5P$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     +P O , ,  "L60$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>280</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - STOCKHOLDER'S EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockholderSEquity</Role>
      <ShortName>STOCKHOLDER'S EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureConcentrations</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - GOVERNMENT GRANT AWARDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureGovernmentGrantAwards</Role>
      <ShortName>GOVERNMENT GRANT AWARDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureLicenseAndDistributionAgreements</Role>
      <ShortName>LICENSE AND DISTRIBUTION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockholderSEquityDetails</Role>
      <ShortName>STOCKHOLDER'S EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureStockholderSEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40305 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails</Role>
      <ShortName>STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - CONCENTRATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureConcentrationsDetails</Role>
      <ShortName>CONCENTRATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureConcentrations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails</Role>
      <ShortName>GOVERNMENT GRANT AWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureGovernmentGrantAwards</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails</Role>
      <ShortName>LICENSE AND DISTRIBUTION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureLicenseAndDistributionAgreements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capricor.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="capr-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>capr-20231231.xsd</File>
    <File>capr-20231231_cal.xml</File>
    <File>capr-20231231_def.xml</File>
    <File>capr-20231231_lab.xml</File>
    <File>capr-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="capr-20231231x10k.htm">capr-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>capr-20231231x10k005.jpg</File>
    <File>capr-20231231x10k006.jpg</File>
    <File>capr-20231231x10k007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="461">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "capr-20231231x10k.htm": {
   "nsprefix": "capr",
   "nsuri": "http://capricor.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "capr-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "capr-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "capr-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "capr-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "capr-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "capr-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 226,
   "keyCustom": 54,
   "axisStandard": 24,
   "axisCustom": 2,
   "memberStandard": 25,
   "memberCustom": 40,
   "hidden": {
    "total": 22,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 17,
    "http://capricor.com/20231231": 1
   },
   "contextCount": 170,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 547,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 461,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://capricor.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://capricor.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://capricor.com/role/DisclosureStockholderSEquity",
     "longName": "10201 - Disclosure - STOCKHOLDER'S EQUITY",
     "shortName": "STOCKHOLDER'S EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions",
     "longName": "10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://capricor.com/role/DisclosureConcentrations",
     "longName": "10401 - Disclosure - CONCENTRATIONS",
     "shortName": "CONCENTRATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://capricor.com/role/DisclosureGovernmentGrantAwards",
     "longName": "10501 - Disclosure - GOVERNMENT GRANT AWARDS",
     "shortName": "GOVERNMENT GRANT AWARDS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:GovernmentGrantAwardsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:GovernmentGrantAwardsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://capricor.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "10601 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://capricor.com/role/DisclosureLicenseAndDistributionAgreements",
     "longName": "10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS",
     "shortName": "LICENSE AND DISTRIBUTION AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://capricor.com/role/DisclosureRelatedPartyTransactions",
     "longName": "10801 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://capricor.com/role/DisclosureSubsequentEvents",
     "longName": "10901 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables",
     "longName": "30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "capr:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "capr:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails",
     "longName": "40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://capricor.com/role/DisclosureStockholderSEquityDetails",
     "longName": "40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)",
     "shortName": "STOCKHOLDER'S EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:CommissionRateOnSalePricePerShare",
      "unitRef": "Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:CommissionRateOnSalePricePerShare",
      "unitRef": "Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails",
     "longName": "40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:ClassOfWarrantOrRightGranted",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "capr:ScheduleOfWarrantActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails",
     "longName": "40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "capr:ScheduleOfWarrantActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q",
      "name": "us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
     "longName": "40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "unitRef": "Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "unitRef": "Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails",
     "longName": "40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails",
     "longName": "40305 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Stock options outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
     "longName": "40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
     "longName": "40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)",
     "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:ShareBasedCompensationNumberOfPlans",
      "unitRef": "Unit_Standard_item_16395vBjAEypAKpz4atoug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "capr:ShareBasedCompensationNumberOfPlans",
      "unitRef": "Unit_Standard_item_16395vBjAEypAKpz4atoug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://capricor.com/role/DisclosureConcentrationsDetails",
     "longName": "40401 - Disclosure - CONCENTRATIONS (Details)",
     "shortName": "CONCENTRATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "capr:NumberOfFinancialInstitutions",
      "unitRef": "Unit_Standard_item_16395vBjAEypAKpz4atoug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "capr:NumberOfFinancialInstitutions",
      "unitRef": "Unit_Standard_item_16395vBjAEypAKpz4atoug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails",
     "longName": "40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)",
     "shortName": "GOVERNMENT GRANT AWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_8kCOk0e360iW2gA4XW8iYA",
      "name": "capr:GrantAwardLiability",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "capr:GovernmentGrantAwardsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_RVq8CNEcHEiNiTlY9gUr_A",
      "name": "capr:GrantAwardLiability",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "capr:GovernmentGrantAwardsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails",
     "longName": "40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA",
      "name": "capr:LesseeOperatingLeaseBaseLeaseRentPerMonth",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA",
      "name": "capr:LesseeOperatingLeaseBaseLeaseRentPerMonth",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
     "longName": "40701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS (Details)",
     "shortName": "LICENSE AND DISTRIBUTION AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q",
      "name": "capr:MonthlyConsultingFeesToRelatedParty",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://capricor.com/role/DisclosureSubsequentEventsDetails",
     "longName": "40901 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_6_21_2021_To_12_31_2023_fcukxm__uEiN61L1wZ0xDA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_49COgzvYRkSizuPr91icIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ",
      "name": "capr:LicenseFee",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_KtyDuxlZKEaK826l451vFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "capr_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r121",
      "r393"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r77",
      "r127",
      "r389",
      "r405",
      "r406"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADDITIONAL PAID-IN CAPITAL [Member]",
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r418",
      "r624",
      "r625",
      "r626",
      "r666",
      "r688"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "capr_AdvisoryServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AdvisoryServicesAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to advisory services agreement member.",
        "label": "Advisory Services Agreement",
        "terseLabel": "Advisory Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r493",
      "r522",
      "r638",
      "r674",
      "r675",
      "r677"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r551",
      "r561",
      "r587"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r554",
      "r564",
      "r590"
     ]
    },
    "capr_AgreementExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AgreementExpiryTerm",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for expiry of an agreement.",
        "label": "Agreement Expiry Term",
        "terseLabel": "Agreement expiry term"
       }
      }
     },
     "auth_ref": []
    },
    "capr_AgreementTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AgreementTerminationPeriod",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the agreement termination period.",
        "label": "Agreement Termination Period",
        "terseLabel": "Agreement termination period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r555",
      "r565",
      "r582",
      "r591",
      "r595",
      "r603"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation cost",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r296"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "capr_AnnualPaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AnnualPaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for royalties on an annual basis.",
        "label": "Annual Payments For Royalties",
        "terseLabel": "Minimum annual royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r123",
      "r150",
      "r178",
      "r184",
      "r188",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r310",
      "r314",
      "r333",
      "r385",
      "r443",
      "r517",
      "r529",
      "r635",
      "r636",
      "r678"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r150",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r310",
      "r314",
      "r333",
      "r517",
      "r635",
      "r636",
      "r678"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Marketable Securities",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547"
     ]
    },
    "capr_AwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "AwardAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GOVERNMENT GRANT AWARDS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Description of Business",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "capr_CaliforniaInstituteForRegenerativeMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CaliforniaInstituteForRegenerativeMedicineMember",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Institute for Regenerative Medicine",
        "terseLabel": "California Institute for Regenerative Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r119",
      "r498"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents balance at end of period",
        "periodStartLabel": "Cash and cash equivalents balance at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r84",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r84"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, uninsured deposits",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r177",
      "r218",
      "r219",
      "r220",
      "r222",
      "r225",
      "r230",
      "r232",
      "r409",
      "r410",
      "r411",
      "r412",
      "r506",
      "r610",
      "r622"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "verboseLabel": "Grant Date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price per Share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "capr_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights Exercised during the period.",
        "label": "Class Of Warrant Or Right Exercised",
        "negatedLabel": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "capr_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights exercised.",
        "label": "Class Of Warrant Or Right Exercised Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "capr_ClassOfWarrantOrRightGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ClassOfWarrantOrRightGranted",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights granted during the period.",
        "label": "Class Of Warrant Or Right Granted",
        "terseLabel": "Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant to purchase",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants Outstanding at Ending",
        "periodStartLabel": "Warrants Outstanding at Beginning",
        "verboseLabel": "Warrants Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "capr_ClassOfWarrantOrRightWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at Ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "capr_ClinicalTrialExpensePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ClinicalTrialExpensePolicyPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for clinical trail expense.",
        "label": "Clinical Trial Expense, Policy [Policy Text Block]",
        "terseLabel": "Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., Japan.",
        "label": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan",
        "terseLabel": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., United States.",
        "label": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States",
        "terseLabel": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommissionRateOnSalePricePerShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommissionRateOnSalePricePerShare",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on sale price per common shares sold to be paid by the entity.",
        "label": "Commission Rate On Sale Price Per Share",
        "terseLabel": "Commission rate on sale price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r63",
      "r386",
      "r430"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r201",
      "r202",
      "r492",
      "r634"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMON STOCK [Member]",
        "terseLabel": "COMMON STOCK",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r624",
      "r625",
      "r666",
      "r687",
      "r688"
     ]
    },
    "capr_CommonStockOfferingRemainingAmountIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockOfferingRemainingAmountIssuable",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares authorized to be issued under the offering which remain unissued and available at stated date.",
        "label": "Common Stock Offering, Remaining Amount Issuable",
        "terseLabel": "Amount of stock that may still be sold under the program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r431"
     ]
    },
    "capr_CommonStockSharesAuthorizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockSharesAuthorizedValue",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum value of share authorized.",
        "label": "Common Stock, Shares Authorized, Value",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r71",
      "r431",
      "r449",
      "r688",
      "r689"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 50,000,000 shares authorized, 31,148,320 and 25,241,402 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r388",
      "r517"
     ]
    },
    "capr_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants.",
        "label": "Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockWarrantsWithExpirationOnDecember2024OneMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants with expiration on December 2024 one.",
        "label": "Common Warrants with Expiration on December 2024 One"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockWarrantsWithExpirationOnDecember2025TwoMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants with expiration on December 2025 two.",
        "label": "Common Stock Warrants With Expiration On December 2025 Two"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CommonStockWarrantsWithExpirationOnDecember2030TwoMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants with expiration on December 2030 two.",
        "label": "Common Stock Warrants With Expiration On December 2030 Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "capr_CompletionOfPhaseTwoDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CompletionOfPhaseTwoDueMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to completion of phase two.",
        "label": "Completion Of Phase Two Due",
        "terseLabel": "Completion Of Phase Two Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER COMPREHENSIVE INCOME [Member]",
        "terseLabel": "OTHER COMPREHENSIVE INCOME",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedLabel": "Comprehensive loss",
        "totalLabel": "COMPREHENSIVE LOSS",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r132",
      "r134",
      "r140",
      "r380",
      "r397"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureConcentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "CONCENTRATIONS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r499"
     ]
    },
    "capr_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to agreements for consulting and advisory services.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "capr_ConsultingAgreementWithFrankLitvackMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ConsultingAgreementWithFrankLitvackMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement with Frank Litvack",
        "terseLabel": "Consulting Agreement with Frank Litvack"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r247"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r247"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r247"
     ]
    },
    "capr_CorporateOfficesLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CorporateOfficesLeaseMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to corporate offices under operating lease.",
        "label": "Corporate Offices Lease [Member]",
        "terseLabel": "Short-term offices lease"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "capr_CsmcLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CsmcLicenseAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "CSMC License Agreement",
        "terseLabel": "CSMC License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "capr_CsmcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "CsmcMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSMC [Member]",
        "terseLabel": "CSMC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "verboseLabel": "Debt term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r181"
     ]
    },
    "us-gaap_DerivativeVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeVariableInterestRate",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Variable Interest Rate",
        "verboseLabel": "Interest rate",
        "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK AWARDS, WARRANTS AND OPTIONS",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r261",
      "r289",
      "r290",
      "r292",
      "r511"
     ]
    },
    "capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]",
        "verboseLabel": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547",
      "r583"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Country",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "capr_DrEduardoMarbanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "DrEduardoMarbanMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Eduardo Marban [Member]",
        "terseLabel": "Dr Eduardo Marban"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r167",
      "r169",
      "r171",
      "r172",
      "r173",
      "r175",
      "r324",
      "r325",
      "r381",
      "r398",
      "r500"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r171",
      "r172",
      "r173",
      "r175",
      "r324",
      "r325",
      "r381",
      "r398",
      "r500"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "capr_EmployeeRetentionCreditCaresActReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "EmployeeRetentionCreditCaresActReceivable",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of receivables under Employee Retention Credit, CARES Act.",
        "label": "Employee Retention Credit, CARES Act, Receivable",
        "terseLabel": "Receivables under \"ERC\""
       }
      }
     },
     "auth_ref": []
    },
    "capr_EmployeeRetentionCreditCaresActRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "EmployeeRetentionCreditCaresActRevenue",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized under Employee Retention Credit, CARES Act.",
        "label": "Employee Retention Credit, CARES Act, Revenue",
        "terseLabel": "Revenue recognized under \"ERC\""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Total unrecognized fair value compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "capr_EmployeesNonEmployeeConsultantsAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "EmployeesNonEmployeeConsultantsAndDirectorsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employees non employee consultants and directors.",
        "label": "Employees Non Employee Consultants And Directors",
        "terseLabel": "Employees Non Employee Consultants And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r115",
      "r136",
      "r137",
      "r138",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r176",
      "r195",
      "r196",
      "r234",
      "r293",
      "r294",
      "r295",
      "r306",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r349",
      "r401",
      "r402",
      "r403",
      "r418",
      "r474"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r551",
      "r561",
      "r587"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r548",
      "r558",
      "r584"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "capr_ExosomesLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ExosomesLicenseAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exosomes License Agreement",
        "terseLabel": "Exosomes License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "capr_FacilitiesLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "FacilitiesLeaseMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to facilities lease.",
        "label": "Facilities Lease",
        "terseLabel": "Facilities Lease"
       }
      }
     },
     "auth_ref": []
    },
    "capr_FailsToCureBreachAfterNoticeFromCsmcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "FailsToCureBreachAfterNoticeFromCsmcMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fails to cure that breach after notice from CSMC.",
        "label": "Fails To Cure Breach after Notice From CSMC",
        "terseLabel": "Fails To Cure Breach after Notice From CSMC"
       }
      }
     },
     "auth_ref": []
    },
    "capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to failure to undertake commercially reasonable efforts to exploit the patent rights or future patent rights",
        "label": "CSMC Agreement Compliance",
        "terseLabel": "CSMC Agreement Compliance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r331"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r331"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r60",
      "r102"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r328",
      "r361",
      "r362",
      "r363",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r332"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r249",
      "r254",
      "r328",
      "r361",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r361",
      "r362",
      "r363",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r332"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r591"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r591"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r591"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r591"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r591"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of fixed assets",
        "terseLabel": "Loss on disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r631",
      "r632"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r454"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_GeneralBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralBusinessMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Business",
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "capr_GovernmentGrantAwardsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "GovernmentGrantAwardsDisclosureTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure about government grant awards.",
        "label": "Government Grant Awards Disclosure [Text Block]",
        "terseLabel": "GOVERNMENT GRANT AWARDS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_GrantAwardLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "GrantAwardLiability",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of grant liability.",
        "label": "Grant Award Liability",
        "terseLabel": "Grant award liability"
       }
      }
     },
     "auth_ref": []
    },
    "capr_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "verboseLabel": "Receivables",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r547"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Long-lived assets impairment",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r91"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r92"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199",
      "r459"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r459"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r408"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid in cash",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "capr_IncreaseDecreaseFromGrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "IncreaseDecreaseFromGrantsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in grants receivable (or one business cycle).",
        "label": "Increase Decrease from Grants Receivable",
        "negatedLabel": "Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Milestone payment received",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r620"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDepositsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deposits Outstanding",
        "negatedLabel": "Other assets",
        "documentation": "The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Accounts payable and accrued expenses, related party",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r555",
      "r565",
      "r582",
      "r591",
      "r595",
      "r603"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r607"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r607"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r607"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Net",
        "terseLabel": "Interest paid in cash",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Investment income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "capr_JhuLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "JhuLicenseAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JHU License Agreement",
        "terseLabel": "JHU License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "capr_June2021AtMarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "June2021AtMarketProgramMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At the Market (ATM) program.",
        "label": "June 2021 ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Arrangement, Type [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of operating lease cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "capr_LesseeOperatingLeaseBaseLeaseRentPerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LesseeOperatingLeaseBaseLeaseRentPerMonth",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of base lease rent per month under the operating lease.",
        "label": "Lessee Operating Lease, Base Lease Rent Per Month",
        "terseLabel": "Base rent per month"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LesseeOperatingLeaseLeaseRentPerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LesseeOperatingLeaseLeaseRentPerMonth",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount operating lease rent per month.",
        "label": "Lessee Operating Lease Lease Rent Per Month",
        "terseLabel": "Monthly lease payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "capr_LesseeOperatingLeaseMonthlyRentEscalationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LesseeOperatingLeaseMonthlyRentEscalationPercent",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of escalation of monthly base rent of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Monthly Rent Escalation, Percent",
        "terseLabel": "Monthly rent escalation, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Term of Contract",
        "verboseLabel": "Lease term",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r150",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r311",
      "r314",
      "r315",
      "r333",
      "r429",
      "r501",
      "r529",
      "r635",
      "r678",
      "r679"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r105",
      "r391",
      "r517",
      "r623",
      "r630",
      "r668"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r118",
      "r150",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r311",
      "r314",
      "r315",
      "r333",
      "r517",
      "r635",
      "r678",
      "r679"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r66",
      "r67",
      "r68",
      "r69",
      "r150",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r311",
      "r314",
      "r315",
      "r333",
      "r635",
      "r678",
      "r679"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "LONG-TERM LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LiborMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LiborMember",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR Member",
        "terseLabel": "LIBOR Member"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LICENSE AND DISTRIBUTION AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseAgreementsLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "LICENSE AGREEMENTS [Line Items]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseAgreementsTable",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LICENSE AGREEMENTS [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseAgreementsTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure relating to licensing agreements entered into for acquiring intellectual property rights, for the grant of an exclusive, world-wide, royalty-bearing license to develop and commercialize licensed products under the licensed patent rights in all fields and a nonexclusive right to the know-how, Collaboration Agreement and Exclusive License Option, and funding and equipment necessary for conducting clinical trial.",
        "label": "License Agreements [Text Block]",
        "verboseLabel": "LICENSE AND DISTRIBUTION AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseAndServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseAndServicesAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and service agreement with Azzur.",
        "label": "License and Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee  per month.",
        "label": "License fee"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity position during the period.",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "capr_LockUpPeriodNotToIssueOrSellShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LockUpPeriodNotToIssueOrSellShares",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which issue or sale of shares is not allowed known as lock up period.",
        "label": "Lock Up Period, Not to Issue or Sell Shares",
        "terseLabel": "Lock up period, not to issue or sell shares"
       }
      }
     },
     "auth_ref": []
    },
    "capr_LongTermOperatingLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "LongTermOperatingLeasesMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to long term operating leases.",
        "label": "Long Term Operating Leases [Member]",
        "terseLabel": "Long Term Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "capr_MaterialBreachHasNotBeenCuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MaterialBreachHasNotBeenCuredMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material breach has not been cured.",
        "label": "Material Breach Has Not Been Cured",
        "terseLabel": "Material Breach Has Not Been Cured"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r256",
      "r365",
      "r400",
      "r420",
      "r421",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r495",
      "r496",
      "r503",
      "r506",
      "r510",
      "r518",
      "r637",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "capr_MichaelKelliherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MichaelKelliherMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represent Michael Kelliher.",
        "label": "Michael Kelliher [Member]",
        "terseLabel": "Michael Kelliher"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments during the period.",
        "label": "Milestone Payments",
        "terseLabel": "Milestones paid"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MilestonePaymentsInPhasesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MilestonePaymentsInPhasesAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments in Phases [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MilestonePaymentsInPhasesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MilestonePaymentsInPhasesDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments in Phases [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MilestonePaymentsPercentageOwedToThirdParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MilestonePaymentsPercentageOwedToThirdParty",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestone payments received by Capricor and owed to CSMC pursuant to the U.S. Distribution Agreement with Nippon Shinyaku.",
        "label": "Milestone payments, percentage owed to third party",
        "terseLabel": "Milestone payments, percentage claimed by CSMS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments to be made upon successful completion of certain phases as per License agreement.",
        "label": "Milestone Payments To Be Made Upon Successful Completion Of Certain Phases",
        "terseLabel": "Milestone payments to be made upon completion of certain phases"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MinimumExpectedContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MinimumExpectedContribution",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of contribution to be made.",
        "label": "Minimum Expected Contribution",
        "terseLabel": "Minimum expected contribution"
       }
      }
     },
     "auth_ref": []
    },
    "capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum limit of aggregate fair market value will be treated as non-statutory stock options.",
        "label": "Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock",
        "verboseLabel": "Minimum limit of fair market value to be treated as non-statutory stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r256",
      "r365",
      "r400",
      "r420",
      "r421",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r495",
      "r496",
      "r503",
      "r506",
      "r510",
      "r518",
      "r637",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "capr_MonthlyConsultingFeesToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "MonthlyConsultingFeesToRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly consulting fees as per consulting agreement entered into with related party.",
        "label": "Monthly Consulting Fees to Related Party",
        "terseLabel": "Monthly consulting fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r86",
      "r106",
      "r116",
      "r131",
      "r133",
      "r138",
      "r150",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r170",
      "r178",
      "r183",
      "r187",
      "r189",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r325",
      "r333",
      "r396",
      "r451",
      "r472",
      "r473",
      "r502",
      "r527",
      "r635"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Rentable Area",
        "terseLabel": "Area under lease",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r555",
      "r565",
      "r582",
      "r591"
     ]
    },
    "capr_NonPaymentOfRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "NonPaymentOfRoyaltiesMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-payment of royalties.",
        "label": "Non Payment of Royalties",
        "terseLabel": "Non Payment of Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "capr_NoncashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "NoncashLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings related to noncash lease , which is added back to net income when calculating cash provided by (used in) operations using the indirect method.",
        "label": "Noncash Lease Expenses",
        "terseLabel": "Changes in lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "TOTAL OTHER INCOME (EXPENSE)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "auth_ref": []
    },
    "capr_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://capricor.com/role/DisclosureConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions",
        "label": "Number of Financial Institutions",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable": {
     "xbrltype": "integerItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of times on total award amount which is the maximum amount of royalty to be payable on commercial revenue.",
        "label": "Number of Times on Total Award Amount, Maximum Royalty on Commercial revenue To be Payable",
        "terseLabel": "Number of times, maximum royalty to be paid on total amount of award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r187",
      "r189",
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Net",
        "verboseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, ROU liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Included in the condensed consolidated balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current",
        "verboseLabel": "Current portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current",
        "verboseLabel": "Lease liabilities, net of current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345"
     ]
    },
    "capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "OperatingLeasePercentageOfIncreaseInAnnualLeaseRent",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in annual lease rent in an operating lease.",
        "label": "Operating Lease Percentage of Increase in Annual Lease Rent",
        "terseLabel": "Operating lease percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, ROU asset",
        "verboseLabel": "Lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r516"
     ]
    },
    "capr_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration year for operating loss carryforwards.",
        "label": "Operating Loss Carry Forwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "capr_OperatingLossCarryForwardsIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "OperatingLossCarryForwardsIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, indefinitely before tax effects, available to reduce future taxable income under enacted tax law.",
        "label": "Operating Loss Carry Forwards Indefinitely",
        "terseLabel": "Operating loss carry forwards indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r57",
      "r58",
      "r101"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r57",
      "r58",
      "r101"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets",
        "verboseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r122",
      "r384",
      "r529"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]",
        "verboseLabel": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "OTHER COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
        "terseLabel": "Net unrealized gain on marketable securities",
        "verboseLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r193"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income.",
        "terseLabel": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r452",
      "r487",
      "r488",
      "r489"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "terseLabel": "Accounts payable and accrued expenses, related party",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r517"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-term Debt, Noncurrent",
        "terseLabel": "CIRM liability",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r428"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r553",
      "r563",
      "r589"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r544",
      "r556",
      "r566",
      "r592"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r544",
      "r556",
      "r566",
      "r592"
     ]
    },
    "capr_OverduePaymentObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "OverduePaymentObligationsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential overdue payment obligation to CSMC.",
        "label": "Overdue payment obligations [Member]",
        "terseLabel": "Overdue payment obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "capr_PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows for the reimbursement of research and development , license and Patent fees and facilities rent expenses which is incurred by the related party on behalf of the entity.",
        "label": "Payments For Reimbursement For Research And Development, License, Patent Fees And Facilities Rent Expenses Incurred Related Party",
        "terseLabel": "Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "capr_PaymentsToAcquireLeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "PaymentsToAcquireLeaseholdImprovements",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of leasehold improvements during the period.",
        "label": "Payments to Acquire Leasehold Improvements",
        "negatedLabel": "Payments for leasehold improvements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "capr_PeriodOfAgreementWillBeInEffective": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "PeriodOfAgreementWillBeInEffective",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which agreement will be effective.",
        "label": "Period of Agreement Will be in Effective",
        "terseLabel": "Agreement effective period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664"
     ]
    },
    "capr_PotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "PotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments payable under the JHU License Agreement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r218"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r431"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r218"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r431",
      "r449",
      "r688",
      "r689"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r387",
      "r517"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Registered Direct Offering [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock",
        "verboseLabel": "Gross proceeds from sale of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock awards",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r133",
      "r143",
      "r150",
      "r156",
      "r164",
      "r165",
      "r178",
      "r183",
      "r187",
      "r189",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r309",
      "r312",
      "r313",
      "r325",
      "r333",
      "r382",
      "r395",
      "r417",
      "r451",
      "r472",
      "r473",
      "r502",
      "r514",
      "r515",
      "r528",
      "r619",
      "r635"
     ]
    },
    "capr_PropertyLocatedAt10865RoadToCureInDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "PropertyLocatedAt10865RoadToCureInDiegoMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Property Located at 10865 Road to Cure in Diego.",
        "label": "Property Located at 10865 Road to Cure in Diego",
        "terseLabel": "Property Located at 10865 Road to Cure in Diego"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r120",
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "PROPERTY AND EQUIPMENT, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r383",
      "r394",
      "r517"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r109",
      "r113",
      "r392"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives (in years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r248",
      "r256",
      "r284",
      "r285",
      "r286",
      "r364",
      "r365",
      "r400",
      "r420",
      "r421",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r495",
      "r496",
      "r503",
      "r506",
      "r510",
      "r518",
      "r521",
      "r633",
      "r637",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "capr_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Range four member.",
        "label": "Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r248",
      "r256",
      "r284",
      "r285",
      "r286",
      "r364",
      "r365",
      "r400",
      "r420",
      "r421",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r495",
      "r496",
      "r503",
      "r506",
      "r510",
      "r518",
      "r521",
      "r633",
      "r637",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "capr_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Range one member.",
        "label": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Range three member.",
        "label": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Range two member.",
        "label": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r494",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r494",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r548",
      "r558",
      "r584"
     ]
    },
    "capr_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Registered direct offering.",
        "label": "Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r353",
      "r354",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r448",
      "r450",
      "r481"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r353",
      "r354",
      "r355",
      "r356",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r448",
      "r450",
      "r481"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r677"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r459"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r353",
      "r354",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r448",
      "r450",
      "r481",
      "r677"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r357",
      "r414",
      "r415",
      "r416",
      "r457",
      "r458",
      "r459",
      "r478",
      "r480"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r298",
      "r686"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r549",
      "r559",
      "r585"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r538",
      "r550",
      "r560",
      "r586"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r557",
      "r567",
      "r593"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r97",
      "r390",
      "r404",
      "r406",
      "r413",
      "r432",
      "r517"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCUMULATED DEFICIT [Member]",
        "terseLabel": "ACCUMULATED DEFICIT",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r195",
      "r196",
      "r293",
      "r294",
      "r295",
      "r306",
      "r307",
      "r316",
      "r318",
      "r319",
      "r321",
      "r323",
      "r401",
      "r403",
      "r418",
      "r688"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r245",
      "r246",
      "r367"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r497"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "totalLabel": "TOTAL REVENUE",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r150",
      "r179",
      "r180",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r194",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r333",
      "r382",
      "r635"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "REVENUE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONCENTRATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "capr_RomeLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "RomeLicenseAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Rome license agreement.",
        "label": "Rome License Agreement",
        "terseLabel": "Rome License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r257",
      "r611",
      "r627"
     ]
    },
    "capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule Of Employee And Nonemployee Service Share-Based Compensation Allocation Of Recognized Period Costs Table Text Block",
        "terseLabel": "Schedule of employee and non-employee stock based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r455",
      "r456",
      "r459"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Stock Option Outstanding And Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of employee and non-employee stock option",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r46"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of option using Black-Scholes option",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r95",
      "r96",
      "r97",
      "r124",
      "r125",
      "r126",
      "r177",
      "r218",
      "r219",
      "r220",
      "r222",
      "r225",
      "r230",
      "r232",
      "r409",
      "r410",
      "r411",
      "r412",
      "r506",
      "r610",
      "r622"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of outstanding warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "capr_ScheduleOfWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all warrant activity during the period.",
        "label": "Schedule Of Warrant Activity [Table Text Block]",
        "terseLabel": "Summary of warrant activity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "capr_SeverancePackageToBePaidForPeriodOfBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "SeverancePackageToBePaidForPeriodOfBaseSalary",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of months of base salaries used for severance packages for specific full-time employees.",
        "label": "Severance Package To Be Paid For Period Of Base Salary",
        "terseLabel": "Number of months of base salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date",
        "verboseLabel": "Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Expected volatility, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk-free interest rates, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk-free interest rates, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock options available for grant under the stock option plans.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Options Available for Grant",
        "terseLabel": "Number of options available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired/Cancelled",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Granted option",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated weighted fair value of option granted (in per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options outstanding",
        "verboseLabel": "Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at End of the period",
        "periodStartLabel": "Outstanding at Beginning of the period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at Ending of the period",
        "periodStartLabel": "Outstanding at Beginning of the period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired/Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "capr_ShareBasedCompensationNumberOfPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ShareBasedCompensationNumberOfPlans",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share based compensation plans .",
        "label": "Share Based Compensation, Number of Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Prices, lower range",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable, Option (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Outstanding, Options (shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Prices, upper range",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Average price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Terms of stock option plans",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable",
        "verboseLabel": "Aggregate intrinsic value of exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted Average Term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r148"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r19",
      "r115",
      "r136",
      "r137",
      "r138",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r176",
      "r195",
      "r196",
      "r234",
      "r293",
      "r294",
      "r295",
      "r306",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r349",
      "r401",
      "r402",
      "r403",
      "r418",
      "r474"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables",
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r176",
      "r367",
      "r407",
      "r419",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r453",
      "r454",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r522"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r257",
      "r611",
      "r612",
      "r627"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables",
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r176",
      "r367",
      "r407",
      "r419",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r453",
      "r454",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r522"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r540",
      "r552",
      "r562",
      "r588"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "capr_StockAwardsWarrantsAndOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "StockAwardsWarrantsAndOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK AWARDS, WARRANTS AND OPTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of common stock shares issued",
        "verboseLabel": "Issuance of common stock, net of fees (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r71",
      "r97",
      "r409",
      "r474",
      "r490"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails",
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Stock options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r71",
      "r97",
      "r270"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of fees",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r71",
      "r97",
      "r418",
      "r474",
      "r490",
      "r528"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r70",
      "r71",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r19",
      "r97"
     ]
    },
    "capr_StockOptionPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "StockOptionPlan2020Member",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Stock Option Plan 2020 [Member]",
        "terseLabel": "Stock Option Plan 2020"
       }
      }
     },
     "auth_ref": []
    },
    "capr_StockOptionPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "StockOptionPlan2021Member",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Stock Option Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://capricor.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets",
      "http://capricor.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r89",
      "r433",
      "r449",
      "r475",
      "r476",
      "r517",
      "r529",
      "r623",
      "r630",
      "r668",
      "r688"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDER'S EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDER'S EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r149",
      "r217",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r234",
      "r322",
      "r477",
      "r479",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent event",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r360"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockholderSEquityDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "capr_TaxCreditCarryForwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "TaxCreditCarryForwardsExpirationYear",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration year for tax credit carryforwards.",
        "label": "Tax Credit Carry Forwards Expiration Year",
        "terseLabel": "Tax credit carry forwards expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit carryforward limitations on use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "capr_TermOfAward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "TermOfAward",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of award.",
        "label": "Term of Award",
        "terseLabel": "Term of award"
       }
      }
     },
     "auth_ref": []
    },
    "capr_TermOfLicense": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "TermOfLicense",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of License and Service agreement.",
        "label": "Term of License"
       }
      }
     },
     "auth_ref": []
    },
    "capr_TerminableNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "TerminableNoticePeriod",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminable notice period.",
        "label": "Terminable Notice Period",
        "terseLabel": "Notice period for termination of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_ThresholdPeriodToCureBreach": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "ThresholdPeriodToCureBreach",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period to cure breach.",
        "label": "Threshold Period to Cure Breach",
        "terseLabel": "Threshold period to cure breach"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r676"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "capr_TransactionOtherThanSubawardAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "TransactionOtherThanSubawardAgreementMember",
     "presentation": [
      "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction other than Sub-Award Agreement",
        "terseLabel": "Transaction other than Sub-Award Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails",
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "capr_UnrelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UnrelatedPartyAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Unrelated Party [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_UnrelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UnrelatedPartyDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Unrelated Party [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "capr_UnrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UnrelatedPartyMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Unrelated Party",
        "terseLabel": "Unrelated Party"
       }
      }
     },
     "auth_ref": []
    },
    "capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Until the date of expiration of the last to expire patent within the parent rights.",
        "label": "Patent rights",
        "terseLabel": "Patent rights"
       }
      }
     },
     "auth_ref": []
    },
    "capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy as it relates to unusual or infrequent items related to the Covid-19 pandemic.",
        "label": "Unusual Or Infrequent Items Or Both Covid 19 Policy Policy Text Block",
        "terseLabel": "Business Uncertainty Related to the Coronavirus"
       }
      }
     },
     "auth_ref": []
    },
    "capr_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment made during the period",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r107",
      "r108",
      "r110",
      "r111"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "capr_VivariumSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "VivariumSpaceLeaseMember",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to leases vivarium space.",
        "label": "Vivarium Space Lease [Member]",
        "terseLabel": "Vivarium Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r523",
      "r524",
      "r525",
      "r526"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://capricor.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Effective warrant terms",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "capr_WeightedAverageExercisePriceGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "WeightedAverageExercisePriceGranted",
     "presentation": [
      "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights granted.",
        "label": "Weighted Average Exercise Price Granted",
        "terseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average number of shares of common stock outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r173"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://capricor.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average number of shares of common stock outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173"
     ]
    },
    "capr_WrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://capricor.com/20231231",
     "localname": "WrittenNoticePeriod",
     "presentation": [
      "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://capricor.com/role/DisclosureLicenseAndDistributionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These lines are represents that notice period.",
        "label": "Written Notice Period",
        "terseLabel": "Notice period"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001558370-24-002861-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-002861-xbrl.zip
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MHR[Y@$IQWZ2CR5B \+]AA-#*J&ZLH'NN.+$3ER_"1I4$:Z!1RO<VO624B"G
MYK?C:>& K1+458(.YY[M?ZPC_(SN!4*O$TA".+ =IY5U75G+1GDI2AP888=+
MIGHOXB.N(_U2" OTX74M?9 CG\_E!:_XV%HP>*LD>RE)VK6+TX<7S S"Q9ZN
MMK*415R@-&_J*XU& S="8^N(.-# 6RI:[3F ]G0,ESP71(4UT!1HQML]-,,?
M4 M';+6@=E!1(5%1'U&!)OQ2+]!H\P[5#RH< [@,KJ/DGCUD 2E%^#KK.&'4
M[8UFX8645BKY4OE$GS%S1$+CDS JW\)RA*.$5<KH35I&G_0OO<E(Y/>U3Q.9
M?)$6UPJKWEE?%5]:%XU2Q&_3^_2B4[W6B5;6@ $QQ+X%Q ;?^?>R1?"S9-A/
M2N9(O&RWJN>V@S[XV6E/2O>A/YU-^O=/?I+UTZ07'-ZUXMQ'G/).<VVI)GH?
M0[C!$*V0%4*>8$N<F8\1<S<S6#@Y,E0A4!&X4HSOTF*<] ;R/'W<F<S^T" H
M&DT[W38P*MRY>'..OWO :.]9X5GSP)12>I]Q9O%T/^W]ZTF$0[TOK=_,%D[P
MS#/\5^2$('9Q-['H(9!/&4CEY120D1!1^+ T]E'>:I7(XE%+*Z32KT[ LT'S
M"KL$V"G[!"7922FZ:YGW*_D>17N5P-P:VX$N#!SD,H!*SM<'OKC>"K[$T7WQ
MF;U:9"4/ZUM95$ND5DJ6JB5TFR,A94*TE5=!ME.=YE1+I#"_V<Y^N:QFJ72F
M6A;E\YBM4*ID+RMD*-4">EOQ;4$KILHYJ:I9*+7 ZN6=6K&5SC*532^IQ50I
MK]1*IS";5)1&4DNC3/ZH%<*!WFT?<D-;9F-[<^A7$J_"4=ODQH%T(OOYU#ZH
M%/IP>^@7#>U[JSHA:K;,BSLH)?LV+5GUH7DKNWH9DGU>+E1\KE C?P) [1.%
MH[UU/^@S]Y)W80[^POV_0RO$_\1M_0E>:+*2YYTHOOCAC!-[;8F2@?*[E:RE
M*!3E/*P&^6]@]>+%MD(0@5Y1;5/JU>[L! .'*! S4EA2E48!B2QV TIS&1)_
MIET>BBN8SZI<)4700)XL-*_*$W3!5D/9 5.IRLZ.=1V<J5\O=PI !E\DRD3*
M(I' '66NYJ0*O>:4J/3K%P^H(='XT#P/7%:K%!\N8*B N JC;JMREAHU!!<?
MJHVJ*O:;-71F%_%75-OT7'QU?GUS?GM=C?=4<>*2XX<=Q,!O:C.^6_^US. 6
M8XE>@H+W@O7KM_7HR*RXFZ<!13WEW[PT(3FUK)7ZE]GG$ELN#[^IIHT9E;K+
MC1_"^V.+4L'U;2]19[:&U4/?S-&#0M%R^ ]G?4?4:Q=/ /U_'QFUY5$,GV #
MDV>QU3G3?$<LZW/?V=2!.(AM^BZV1?1PIJ$Y=QDRW ]G"V3)8ND2$'PCH>9,
M=C4]%EP-<HAE":0?SESF83\@%-[\W^4H :ZX2UR9W_[$J+<.R2) 3CCRW+^U
M H@9-HF;S[WZ14O 5I)]D5YWEEG,^_S4XKTD'07,YW$I$9^0FYWQ*E,=(<I^
M[!"%]#/\XMY;,'-G :,5X'=H]^<D*D1^YX:@VZDII7G9,Y4GF/#8)CJG.:&0
M%&/7%U@*:4I$2HB?+)08&]\] HYC(S.$FPPF<ML;H5<Y*<Y3F'[>R#E<FN[=
M"G SPYOCOMJ)I3!#W"[[\)_"5VST^O8B\Q]<_,3*! (WW9DB"X\9F,@8L^D*
M,1QJ7!G  M43LPR#'U7Q)"FI*@,=L:(M)=S]9@L2)%:DEPZ7NB7X!1'#]ATA
M14X,68?HE"OQL3FHN89GWO<+2OS%G^M#V!!%$%GOR$[E" Y,[][NXU#TG-+I
M'('F^JXJR(H.B$U<?2'J<0T1^X9=J=XS>H]G_B\U=?B(.N+BM^=2YI,9.K']
M4&2ZM[PMR1Z^;6<+8>*Y:@<A TW*Q(]@G$ C$J/EVX1);/$# ]11VT2 S?_M
MCO2"8<KOC\-!.&9-;]@5/WM#F4-0W_'[BU_&F> E=N1O+3SC(6S\#-#[(;;G
MF)V(N>ID[;$WBG8X X+FQ)(WPV-R334=UW[\M)M;80>^ZUE$.2##Q?(4*+S!
MMN,Y<D!^DF<H2BXH#K=B>](3K<=5B-ECL:TV7FQAJC!E\5X*T>].8X'@J\QR
MZ?W\J:2;-_#>8=.06)B[8$3A*6C?&:\@].4G6O *QM]["<S%?])%L9"*FLOD
M;RMO5S-.NAXJQJ_)4>^%<FJ+W?=/9*N(B+I!#;>-TX8KL0$/F/-+>74E1+,\
M^--ZP6#5">SP- <?NV,>]H@CY5O$1FN(3/RTADV69QB8\X5GB6R'A<60^J*+
MF0O:YKN@ \Q!%!N6=X"5B3SLI(VI"W\09*4(.\ETJ(8_+*-?&7%AK!%U_5PB
M$)GD,-3?0RM]YL U'6?L"87NKC";K1 HS1S)8ZB?LD)4HJCN<D$=[EDB0(XP
M?B7NZA&&_C8@[C,ROIUV-2E/3]T<*.N9'LP@'2(V1\Y)N<L9NR8G0_#W*VNS
MG;)'C,'GQ=\%G6;M*45(-9>3FS#;+G@.B^'W(_E@^<UJV3]"2.\']HL5<C@)
MH_4L7J*V@E.:7>4]:LR3PT>HW%E\1&V-Y$-$M'E1^3;(SH5H)$_B-[M-S\+Z
M(DCRAT5OY1X_=39='KPII^U="W$>D:NS"5FNW*]8_!^;G6?,T!('=:?],\](
MEC4Z%A^2RN.]0V1"4QY:.0?$$;5O9@RBOJ PNG^Y(.<*0I4.C1$TM6WJ_T19
M>%ZU8YP*@$;:9@;!(N8!>1"_M^X\8$.R<'-U\UK?)OYS&2[;OYGSD661\CA"
MW&556.T61K7:"\OD/\4=A6Y$S44<ZJ?SH7*$.R(I!WI\UWD ^=1>-\IB:,HL
M5/(<;V8_Z#Z>)]&_D9[G$1GBH%-<S!*7AY/,YC4VDI,)M;$ZAE5"-)*GF+9)
MZ^ =SUU11OZ#37GY(T,K\^ :=]@;9S+*3LJT)!C-@Y=>\95 C11?QWPF7%S%
MP>P9]([GZ&4Q6".Y"W.K\JH&L><>XQ)"_LTQ8L9*%-81/S-(UZ(AL+TQ$EE:
MD3"!YJV+$<]&@X"<]QW#8Z YR7Q*D&,^^;#--9W8;;8Q]((5YRJI6BJ 1BI5
M[7ND(T^PI2_"NWW/B$CV0"UD*!;-R!$'.&;L&FV/E>DHCWO(TEG?63"_)(\\
M+M39/7577?I,S.OWRNWQ7AB:LE_N.(ZW??4N_ +=(,N5A7 "CZN":*ZYSS"S
M]874QI"3Y%<*TM,'4L>9?$$0<005R3.J+;F9K0V@W*<%)G-[#&-9][CO]!8+
M+)*!4;A5"K(!'#TY+K$>Q,.'16R#LA@@[LZH_"98%<46ACC^9[FKX[NY[/T1
M-7*Y&<&ZZ'L!?1'Y@"3O:I!&<C6$^1?YS7N&D;'ZC#@8VSW&3M<#'Y/DKAQH
M([E\%$5%9E10ZE/?60 OOE\1CV#CUW3"_6R%'DWF^<DQQ36.;[(0C,BS(,O:
M3&"/3J5O!3=$F;@, J9I4>+&[5%G?KF6?&,_\AB-G-?9"J(S\5#$=^UQ'8F6
M+B5( [Q]&*#.B(VY[LRHBRS_2;$MWN -T8LL"21=V$9WMF*=P%[)\5^2@*?S
M;\ &ON^@*!5S1!P7+S$[]A1-L4A.0K@U1L8WM SH(R9$@.&:+N+^*<1D+-IP
M5NW4 %6( I,@WI+[OT0@IH1H  ?IC>MUT<[VNMDNYC?/P8+*CNN_WAHSNF3(
M3G)5!-1(SD(O\0AZY CK#U_Q$%G#-^E*\H".ZAS*;)['?E6BC:P5@LV.>WWU
M[NV;"46!J^\[#P0O=XX#JG9JI/STM7QEY2QEEG_LOW<&1Z<OPMHB?<??,4N
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MY#)N>T8H$:[TQ5/*;4R*5GXXW@6HAH/P .*3+F+'WM5IC7G+/.0F8M*7HCN
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MQ@>B(1>U3')A-\LU8U^O!$DU_.'\T@^\"0K X30#\ MT.==M?=_?%U"<+F?
M1:N >F!3S^H A9%8:@S,?QDWW 8(<P':*I=QFEE*2B9)G0-?V"5Z#1A?FG24
M37BN+#TU3'QAU_8M4,3LS= 4KQRB/5.U&GCS>+-Q\([@"XE274(W.06X* XB
M>JF(?.A"$!X+.08>-1:WE(YW-,C95[M&^N;ZYOKF_!II.GOH3T;_KT]OC)++
MH_GGQ\?^['>::S<?/4Q&]Z-!?[+H]0>#Z>?)8C1YZ#U-QZ/!:#@GO0\@]9S
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M=]753,L!BKO"$%%Z6)X)IU>A/B/EP.)'N 4[_+<:@F"(2!+OH>E&7G,YYXL
M8T1PANQ"K?@,MZ(B6*/"B!\*[PS3S_] R[%/V"./\2E.UE\.[OY.SYN-ZYPL
MZ/,]UNQ('0-YS+IM.RFA4.9BDUT86]$R'&TJ'NF3'T+)1H,)F::&[7ZW"_AM
ML!. !-"O9AENHGC+<P_:N@B98B-6N>TF8*WLK1DJ3AW<+KPU2\I6L(6K GQ2
M(6#/G<R DGI^X@91 JU1>40UOZ1A6YR"'O*M3-[IX\[Q/;8A4\Q) PKS2;"4
MX?J3WQH(TI->"0^2)[L"B@ 8[ZB+_ABW$]N\O%2V7\?68R@MO':^T*1-E9N
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MPD;-Q3)*)[4TD?2H%%+RVYJG.MMC<+WE?'"?J;</>#!M5\B\*V2F=J21%AL
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MTR6&RV8,M3WI^YNU:3;%SI>+F'I^>L&6I3=F7E!91+<Q5L,C;H[;A*AMD%7
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M7$=L;\68\^9)0M/D9QIXS'^JXPZ&N(AU/KH(5ROZ88*(4P'$G+-F.9 "=T8
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MFXM10(JBOV^82WAOUK/)3W6L#Y/8D&>YWM.MR.D5)4)Y"$[1;[L+-GZR@Z&
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M?R(UF<%)W%O&+_7D4Y?Y;<7LFR+C.:-NXE5]C!DFBNOHPEJSCV>.K'[4F!%
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M%WM.3'-"?J708(UZ\Q<:.T_TGFY%*/$B"GDVY-X)H%CC#[K/9@-WMM5M1?M
M[45>)V?-HHJP2+(/[;YK_BIGA62\D((94N%F@FJR9D[>VF^BGU3M]+W#E:"&
M<DZ?_!"F\MQAY%S:K3(W%HN_ES7![%/A+0QZ_GX'JX/)!$R[1-1Q?E?+0J^/
M,<ALGFXXI=)_&2&<(AO]G853U!,\>CBE.?3[":>H9!LIG#)9EW6<<(KQ;%8
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M8>JG;\K]E H09Q^E9SO?/\FA)M\WZ=AHYD,4P$1 CU,T*DSV0<J.N28E,M7
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M/;#(0R+"7[^-P MP_/H4Q=<,Y=N(4@(S'E/G.)U^4EX&[B?7*=8D#(B)CUB
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M%FD7$ERM3]'(LV'4B<8,V"%YV^G9TYR<6N6@<5BD76APM3Y%@V6/N*P!C>1
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M/_>#\7S6F=QV)@^#:6\^Q 4ZO?$-+GG_,!W\.AC/AK\-.J/)K(D X_&YV58
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M=1Z^RED=7&$=:) !K0)\8EPHT(-.7!BL-X[W!L!>:L![L'X"B (_M7SK$"\
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MN8M;^$I^\YE^&O0*[4*[ *-CM 4%5[!A:,*3,E47VW\R6RJCCZL3/<RQ\HC
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M1O')<N3AQ2'6VZ+G^R#P?P7. B\*Z/LKKKHFDJR\X"F)3#("/[IHFPR<W!0
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M+R9N?F3!2L_2"N<2*!5#7%X-NC'@<O[#D\6 W;/>-0,*U" Q.IL,!IR?R&/
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MTQ2OV-QR6@$L"E?6 8Q?/@;,"HXYBN!+6OOH^AM@PR4$"^H-2&I9K6 4 ^,
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MRX9KR_7BX]:,)[O*MNWNJ+7XJ#!>7#>1)B)31[>\VK_K6UALO84$/]H(/<5
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MP RN6]U6WFHLQ5BS7+FMC+,]*[J;?1^QX/A8>IXM8KB78XA8?WPFSL8>QQL
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M?%*+)[AYZ$"=9Q+XB0\BK)AD+BED$O/<759<3;.5Z7T<D\T=/?@B%0/DA=?
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M6EUXW?4O_?BG30QRQAPRI&H6"VO,;*053%. _W^ZA[:*!H'U>V ZXS^[9'Y
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M_J4DN;HN]-J)FK8407W 3=Q).MFWLL\B28;G^/VU$=&,KOD4(?FRJ841@J9
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MIE\91E)0A$"JCA41UN"6GSSR*S*'P![3@AV/<"0YA8BI$BZ 6">!@\DE1MS
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M)3C<$#9RUL[M%*D<RV6X;*=N9ZZFR2(Z>4]JFQUIV1I(B6+1^B3(0.\&+@]
M_@5&STQX(:I9BL#2,NL!)VD\L30G4>+V S1IC\H!&T -5-WIG#29,"N $7G.
MU1>"]1HJRUWH[F)7%%:14U-<(:7-LIJH<JJ'(VHO$^X_O*CS]E#6@5<O;Q!=
MCUJU7$Q*?AAJJ)TOCAYD([!&8UVD(TV& \6,ZRTXBN"+%.ZBY#6*4OC(N33
M[\EKC355.-TYMW0!=T5[ XW$SG1G7+6O<&3\KI",SY2%(:\^@EEIP,M-0P8!
M XUS&K_7T4U4CW8Y-S,T')70/?R+X8LA[<CM,3P:2EN"<5&C<#J%?I >?16Q
MQ]65QTSQ=B$0&9>FH54?[4.5LYT"?(4<,^0/=<^M_\QIO9 YDQT*EPVHQ08N
MGO;50R>/4GA4!"/HG3S_EQSE@ )\K(IV[3%.[2X&-@9^^*06<:W(6]^$B!U@
M9?^&@2]>VF(M;@,.\.[P[;O=H_K7W0-D_9_1_=W457Y1-IQ1%;[ ,?@>,ADP
MMMT^E;XOM YB+I?C,8?AD2:OR@FWO6L$&RLUF?+/@0?&BC(?)F^41\6^HU$S
M5%[(TU](^:FV07)&AD(F)*L(T.3;=>#+1@T!I'_/N>E%_,YV414-H(P&\L$R
M!7S1">TRG?\70"2L_=G)B_ S06R]_O7E\>[^T[TL+#Q4 $8NM;;1Y'K!UK*(
M"I%[*EI=6\J:TQ)>POEW=&1!%L1#,SJW@"749]&7TQ63"[#G]WSM< ,$?9:U
M@4%TTGV$4A?F;/FZ=#2LF].RB)LC[+B]LSU5)A>YH5+D1\RO=^J89VUX3DL#
MB/D\/'20U:<.Y"SW#"'.O$8']P_V!Y'H1"AN4:5&4#@_Y>:8U<RW47K-[% 5
MU[Z4E6^CHQW(N(]1*SVQT$6'*4-B@CSY&?==<Q?B33+MD:7ZVVFC3B:+)EDO
M)4.&N;%!% W)*[_.A=\6]G<,O^UGY_U3IRPGF!T(?J*2QVEY45M/1/R5KH.B
M58IO(3'BXFEZET;[!*52,:A_D%W,QP [P,@/D!7Y"?,4,K=*(#R1NYFI3+3O
M"E_N<WE"6 _ME&?&*9L\@)MB /&^1(?%@S:TZ,&O 9I+JKBJO0+I9% CST5A
MKBKH0F0J]WJ[(&N/+KVS<7V*J,&ZBRP:27*?!;S^FMNLEY'&+(%OQQ&\R??9
MS0N7WECY&)M:^\^S_W&+[(V"Q+<PPD\;ZA=DE#=[[EF@^#XQ:.*QAR;J!C[3
MA=DL[ENCDSNKI5Y''&B^#?IJ++IX!-R77=_M:VJ#NRVF:\S;+]D'06EB=WYZ
M_>;%[H-[V9%Y?^]1Y<5DHVL-[V?X2B:_%J2M/I)\9E@!NQ)4'<"^A<GR.^@!
MBWJ.2"_=9!7]%ULAI_4N4^^"[;C;IS#E#)]=@BH0E0EM7.,[T\:2:I^P09(/
MI4C1'[**@?O<.CV),+#Y:7!2+^Q= ;=")%S3B$#!"("'#O<4QB;?OW2RTD 0
MV?L_>U_7TDA9])_L[.+9Z!^=D=(_4SG-ADW)32:EW1DO(#<8#7K"^D9K4SX_
MT[JQ9358+[#/P.^.N-&RI.5IT ]I,V U1>:2F.O[![OZ"^MKAL[<9(ZE8%YZ
MEXQXK-\(]8-"!6?K/7.^!PQPI[NRA?;4%Q5VGNL;?"#/NI +=OI(OG^HQ32/
M]Z,7.;\\C-%#/>+J]6!*ZOUG^QD?"/,\A$I'E:\01=+7?E"63+0@E::$A](D
M+"G@^.'5H?>.:% :-6)?T5K6<*<:8??31F %6UL($:-'S7PVC$K.F"BAG* G
MC0B"[S";K 0()?G@62((=3V^&%11TMR3\YT<C!/R.V9"L?H#%_-Y:L=W)S\$
M@D6FX18KWBF%=^B]"&I/=',OM"(^:FN,UZDFD'.+XO@Q39C-^)EL/DKH!_T,
MTWT$TVSI^QFOIYL.WV./VG=;#_TMBTP)I5[5:$5TYD#62Y_Q*M^]NVJ;H>MF
MZ!YO,W3;#-VG9^BB%=H_>,J+]@7%^ J%L,Y#?!/URM1+XQ?&/;TJ)Z?9SIM?
M7J'=.\*." G<8W^1KK5TL3&T[_<>37NZ04$5^Y7 6AE I(N^J*<T&C0_IGV8
M3]</.OMR;NNU5G0G]%;02 V[4D)?'N)!][[A$#?"8^D9Z7+\HIR06]@,Z7SE
MTV87YLT^_?\?]^]_N'__T=YOT[._H%CHO__RCR:?DG'RE^Y54E8L8Z?C>OCA
M>>?,R1E]L/]H[Z%BA^Y62.D/A^3ZU*&*=NG1&:O!6G15/5[":[%^V2BLUDNN
M#6+KE$W> X\A+6][&.IK]P[C%6Z &9>Z?O4E>!/QUNR<,-$[J8&#>ULVJT]O
M4!+<X%)I%<C6C+V^'R+07QPP=/S+3JGMPX=IO.,3?61RWD"H, $UA8^K<!+(
MXBWJG5J7;^V[K9Z[RYF2TBI.-7@#3XP##-G^P2"J-7WH^8F,I"V.X(0Q<G8#
MWJ6VCN!0@2X#+V"\:.8XML""%"L=QQ^N=AS?T0N/2W=6![?QKGF-WVBH[QEX
M(5)D\8Z)RUL E=2$U>"!Q)%,F/#!%>:N1C'(ZO5QF(N#O?L#SNE91^)978^%
MB&BD#('^_'!,#+";%A+(,*,=:8[LFGL#5 QD.VY\6E_>L_P<,XU<HG>/QYC<
MRR(XE62D$1I!8QU(_:C))XX9S<@#XHYN]"I?\]<)\4L-PQB3LX?NV>KPNN3C
MMO:KAQ0C\K<BW7Q*JV):E]4LYB?QJ'5?S,4S5M* .V9A?2,9_H6);J 'WIX<
MOE<!\CV%E/VL;+H:1B)_8/;V.98?CP]%R[Y?3-WN#QS[98DX%\2?]>EV10_A
M,-2> E0TN*I(IIB*DB.1,WYHGOWPZA!W@]W7')N<2;<]?J^$)DFWL];F)9GX
M9GO(K6NH#F/Q 7X52)_X/?0LQMK)))V#C+K[Q(@?.9UDH'J+V<3X09CED /A
M^2+N9:)ZF]QYSIOY\'D4TUWB]$SN$8[ \PAU?T(\O'-G)(%/ZZENX\MGY[BV
MZ2NT[KK6C@[U$)B-L\Z6=YC<]5G\(*62SHY.CG3U1G7"*"U\S[0^RDIR@>R*
MES$T'60^O*DKI*,4'@I1"%%J&ZS0LAD9A:0 2RXY&#$3E4B07=)&9F)('>]7
MAZ%M["5ZE_7/-\T2'IBGD^8(GUV=)&3_1']\F0L=S^=D RM(EH@3)QFG\+;+
MF5M#S(?7AH02P\X.]@59UGD\OIE8UI)C=.LRC(V;.A@9T%1DMUZXBELP<68M
M.A]\2?1@6_G$.N",U,#IIB E-\D:N7%G=)&/75)0RZ@]FNR\[2;HGM[_FUE,
M/CEOQK"86:YQ*1A7VZ!%R7RW)NE).E&2G,=N@GL P1Y^!-!!G-%).QWJXZS_
MF]'Q\=5Y64?4_0C13P4L23H(E#9UY791$NQ[G<?N-S^5T5'MN>SP>IG$8\5[
MY@PV?3^XL ,N(I!\J#(=B6S@"@?UWI(W9 :7K36*3-$P9$SZG&9C2&.V97]Y
ME5WL[QUD.]/_OK]W?_]>MSV6SPH&*XXIAVA+^+=DV>IO']ZC[39&GN39IJ##
M."Z5*LX/W4;L>%-EU4(#A1)=$V$3P-",3EP5O+UY:QEC/RQ]!R[/=GYVYEKA
MG_(7A5R#8H]W?[1Z34O?NT^8'/E2?>5&LPP5<DTI(!OWFT+H1HU 6[*=5[^^
M^!$\>@J)B]T-LX:G\\G4F\2DBYQA%:T^73UBED:ARI4,YNE\9A4F_LO^'N1O
M!RDB7_K^]W]C4(\6:JQ"H>>^29MN\?V#>UW#BKMA($L:EECGI^.9V"GO,?EM
M#93)IG ? >&KQW/<7%BP=[\.,OH_Q[_>,YPR8POG#8V6N7GE]VT\Y/!\I4#E
M=LT%$PS'"'D:$FPS+B#A$NRZ.MLEQ3 QAY".^X]B\P!5&D^55I)3YH&&2]?<
M-V_.COYG]^2' ?/N5+\O)HITY,($1J6.96/)PJZTY@&%DRF8*6+G8KM-@ET=
M9N1!^/EL,55GLJIE +I <7?DTW%=%\;+)F490[B%QLVF=B2NC.5A&.++EX R
M+YKV[AQK48Q.F$_Z<D5+WQQ19D(;+!8]$.QTT9[QB@,,T4:&;])2>Q$ :#SP
M1LI8VB51X.]SMQ.ESE>/.*%1RZ/=@SC%BR_U._\R6]9]Q(KI[^S20?F60_-O
M[P#%8#0M':*_,);>:-SDZK SJ,<[O>NZW<;)Q6-JN',AD]?#7X5>,U*/A2//
MU-7IT_321'M&TQ?"NMK&*EX1?700^+'^K@L7HI2G[04M Y4>V-M@FHBIP[SG
MM30U*+H/5L!-_\*>+P"#QWVEU4A;F$$OS.#[+<Q@"S.X'9C!@Z=[WW\AF('Y
ME)V5VC_P*T7BIBA@(=Y1G99Z1!Y=!F4VH:F<A:LEMT(E5,J$(DGS$.RF5"<C
MPY Y4BENE#0K;^/2($6MJ5$/7-IMA@:60 DW6JUU#D6O%.DLWO'%^59OGEU
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M(KTI?8KE3^I??4K+XA6G@X-I ]K0,2I<F**I8$;+K*WK"J8 0VBD4J1Q(#>
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MF = +<7V>U5[SK  ^@NLS@2G8*D]?IC,@>OM%800:N)_/#Y4X<X_BG"?D8C
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MD?>YSX_7N<]_9L/MFFPP:Z!*_)@"71CX%'32&-U/ 1A\!E]CI3/Z(B$*_-6
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M_/8Y-DX/@MY(ZVK"2J#2SSB*46N@F)3K_$X6T3&SR_L52QND$[N%.V%4?D2
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MJ6-G"G(;:@"C+5!QCI9668"#'Y5*7#>=5<]G[&>$]!Y323#A1!RV6"'YT,O
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ML26]T;3!4^\Y'X1N*7X>PUQX&*,#8S7KKL*5)^]<CK14H;@]D-()'E4B8C)
MKYGP48]V L%T%&V(M8&X2@@;UG2]G5F#3KNKKE[OP.ZA70S\YC8F.@CM0#PV
M*.NJ,-XK4O!17G69YT_-E?@6'X3LAK_'^],9RHQ?]><S%/K&,4J0-$IX5TI_
MXDY>$?PN)&Q]\']62ZPZAMQQ#S.ANJ4/'M^7N'Q$/!#JCG25(B[1F.(%+^90
M<<(UFE0M%0[7+EHHH:?V#%H_I7>T VKA=GX=P!B+3,+/+7XFE/18R]#("=8
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M^MX>:R:8SZ)>'KUS)&O!JYVHM?0*651,(C<0"_FE> 2(>P0D?8CFZ .AJ%1
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M6IL9Z=8 48F(/I+<O9U_5FBJ?X-?%_^J1\!DN-*XD7$"A2!"DG!LI\EX-%-
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M:$ME12TX I+7,[W5$2_/&XT,D7Z((/!(0T$\O-4G=G(4'6F6402;&QY]Z[3
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MDMX]G%I1@@$QYPO6@RL_MAJRX-S'^;_4TPAF6W>;84]G"-S6/B&4$<92M#S
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M7  2I(;@[^:[LO/7Y6'5\)94NQ8+OR?%WI)8ION-/];>>%\4*:;IS^36PAN
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MK-:ZHGHG*F>B !"EK0(9<J@![AE\H72O"Y>%XHJY<I7CPFSQ2Q9?>5]Y CH
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MW20=WLQ!&:<:J/)#HI%E?^P&T<)N-LGYS1"MY'BO@+*(C%%MEWZE<D\:Z3*
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M];LY<FW01:Y$2N_H>SZF5;+25W!KG>W8A@I;"YUO2\*(QCM5HE7Q4R =#R>
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M@:RK0NZ2J<T^-9#F:0;29"#-/SV0YNTDY[$)(=4Z9IR13J/8<NC1;:Z0@!3
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M,5:_?/1V!AZ)1RS?04@\I\N ['%=,VZ+,F71P8G;4;3(4?FF::&?XPK;-16
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M@"N_HMSUDCMLKHA^C_A.X "NQ='+2/F63<OI.!SA'3?@Z =2S8MU8NP8UHK
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M_Y4:&,*?%\/@OPT H[+%<E^#BN.*33E>C4>%"LEV&N5##'<B+A=J4:#Y\ ,
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MKTFY>#*6D['&;X^0*:CJR$3'$_OG ]?20V&+9,6B88MK)QK7PEN1(AFD KK
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MR![K27(JJYK2++@H+O&9NCKL_9JRHIA??B$MRQDDQ7Y!< P6'OCJ<O%!95A
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MKNROR&R\E*"0;4PI;N=?;"I0,0C84C>S:ZWIN"&IJAWZ@@BA=V2W#!2S"7?
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MAS)H#?<ST?PI:&_?"(3-P27IT!^*XG$?KK$Z*A%V.38?*7PWRN(,@-R.!):
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M.TW'K/I#C9UTAAOX^*0)*B7A1:W(M72)^1! (7UW/$(>:M5W&MR&GQH0B<5
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M%V= *A9/&Q:&: 4OXT=<T&XGY-J!6[5[WZ>LZ65=!,IO$K?A&C61ZD$@'D7
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M0#]QXG+\!W\E2W#!,%@G'@R#U68>8R D_TK//+?W^0AQ.^U3!XZ7O*_&S@S
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MJTR]R%MM-NF\]S50^RKV3SRS5_2)=A"9"  KWA%B9G>58"=PM@LUQPRIN4G
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M4^U"1@ZVX05S75XT]Z1DP#?+<S-#4=8DJ>E8QXW<Z1KMG/MJWX,I_::DG])
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MO=B_3PIC]^7A:'(L?I68,%4=T,2CY!*6V5)G#XL\"4863EI^\(+B!M2@+OS
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MQ?DU/Y&7PU\P%^AX$= 3*\]]TV93>F0N\=DR\\JH#;)9X9BLR$'&OLFX$I.
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M@UH<X_6VTK^BNRQ',8\VDM"%Q+_1YW]L\=AK(Z#?;*S_&2XN *P/@^JLP7@
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M3ZO>^#/+7".%WXE((GDS$SK!BYOX9K4B4LRCY\QSEL1'3G](&DFW86C@ MA
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M0TNAZ>F6AQRRN25BI\("\U,;K1XBA/)10K$QYKM?PH)VOC1Z&Q5.W!=II1H
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MGC3HUCNQL!&10S#:%$HZ;PD>Y"S!XY<OUO%S:U1ZQQ5V2\4/\3A+YW&R4O(
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M4EV75:G?$Y&@PNYD6^5'L-_(Z@=-F6<U>&@@1;$L*JV[/H::^UY9F4J(U[E
M*P/=-_']8%QVK[9IX<C/_5H>([]B!O_"Q\!+257@R2M Q#+&GQ"I?T0Y<;EK
M10^,)8*&E-]V CP6UFP8II$/E6R=P<?0K"NXIJM"162&R[ I:B:W^A5V@JQF
ML$$W;:[;S),481Q-,3! T:ZT(M*L%'%<-;K&SC-X.<1J$G50*' %1W1:!=#%
MD2HD^R:LHFP*KE]"1YJ$1#8-+M(Y^]TL^=QB2C[3HL?(U:."+L23&5)B$CE\
M)(P&869DBGKSE YZ.7F1=89FHP;C+)A&H5&O["H:9>O=&OH.6GI;-FF^Y?*T
MY\V]J]H\*KX I%.A]0ETL]A\1LEM)L@7,O_4\B/GZ&EHAP#'A* CIZG!9W7(
M>@!J99,=V^.R\?>LG6S<0WL4< '>$!IEFI!79M:Y0@L>#_PU*!)BFW<C(+C&
M=*>>XCJ:GN7CI  !IJ^BC\J;=_[3^3G_CL"S<?#;VW=G6SJX%8(1?G7%+3"2
M*?G3.I(=E!_A2JO$V8<S 5?'"'%9LSS1K9'I60/G9>>-*3A$WNWB8N9T UJ$
MK"*,JU.+!/_TH2DBT4":.KR=(<@@(P-:63C%.4:^A:V;5P05#+A[[$9J/4HK
MQF.'+Z)Q5@_3I)SP*&]/8+Q"N%"%P6;,0-QP\%Q>R=/&@!RB.S6]N<(P##9)
MT.NGW=AI$F]Q=\T8Y"_3J1#\DPOHDE_]/@-','B53(<FV/#N]U<ZP!!<][<'
MP;/9/WK;O?YS"4D91G)V%:^5W<*@RV:W9[-WNFQVE\W^HFSV5[MTVN(I<LN0
M506W/6B$X'JPW1--L"N:8$&%X_Q1/K !"6@M-CW5GP(\'A=LE,M3P)?<]I6U
M. ]@*)316$E+^30%44D5(W+%<\MKUHQBJW_#U$2+'+D+=FR4(_I<-XQ0M?:/
M7%T<9<007 :7$)AOEE7#*.&WK\Z,$L9ISK7"EDN&+P5C0_<']G(C>T"EW)"&
M@HU<MN\;9]:Z^\.]Z(Q.-U<<);!O\I;[CG*RNM$4#)@'R@8P#W/+_!;=B6ML
MKH7AR^95IL5'+CSS:@QWBF#Q56\$$6'=2@0)Y>A8KDH]3O--[LE$ERIFA;!Q
M3DD7!$J98QISTA@AWJ98P[Q,?L:YV"5$33V#U5<9YW$$!TSC!WU(9@(%8V&M
ML7(#C5390O(5AKD\PC4=&,1NYB_SZ[L'Q8X@YNR2'MJ,^[KIE_"JZ[TGEV>>
M8-U2Y/K$>-"X@0Y"[*614 DN!08I;CU[<UEX+$&$!0_;#'10K#*;AHEN1<@*
MB=?[N\ULWY!SOLJ@^YJ ?'&>GI&X[#P/3K1I_![5P0NR'_EO' R0+X3@OX)+
MN\5V"G6XBL%!^!]FNN*\1N,)K-4,?A+1I)XJ!0:0XD7SVPG_H:\QRK&7<:E;
MU6F1%,FBM)XV5=TD'FPU-<M",(;G$),/K*,(QF,0!WQLD#B3G)0K==DK.6*/
M2',X&11WI-9IX)E?I?4H'^'1&.5)##[&&UC5:#K4/;8XVV-^'.9S+A:<8FT@
M.-97 L,(1D5"61!Z*R\@9D%*&W8LU$B1-9Q0K,K,%-U^.?&*7/T=;/%731@=
ML L[@,Z^<YK9Z^H/MN1C[HF&$V=)O6$ ?7@!#S/59UXJPH3%Q2QR97$T<0T&
M,N^;?NI9AMM->L4H .M3<A$T??XX8$S.?M]YD3)K0I$_3"<O7P0*[?5?] .2
M<5MY4W&%#L9F),\=!;]0G F1%*\DZW;,H'PO/?K+JV-[6=9#<'TY3 (>G:[W
MD3(?SZF+G-NNKF"V1D-3E[ADBHDTWGWN%)^4_DK I_FTZ5@=6C%XSZD;79&E
MV*.^Y-/PFEL[XD9SC9^!?5R^_D5/0<*9?-4*6U(PCJY!)["44S@_BR/-4&0O
M>'WQ[LAAC0BC %YY? =-G<_:(BFDILV,;XFK,/K,?)I"9SJR9#$1W(,+HTX.
MBZ+NI_6 _:L6U+QS*&#A2$N#B^7*P"^V):R;@5#TQ2#RCNKNKJ_Q/O/ P$XN
M!@$HO*XUKHBJ)G&2@B0YQM0A$::/):0<HJ2)P(:0M@&U$SIPRET/@J(S'HMC
M)"L21<W+;BN[?MZ:W7+-F\_=*C^&8'L3I><]=[+D9G2B7Z8J(A8QUYC?$;VM
M]^LS(S5@J8:4,]&@4NQB:YC](D:[B(CB;G S7=QD"CT_8^2K*IXCI@$TDTJ'
M^0U[>HC3 %%Y=@,7?R5&8A8_MP'[D*]O,BT1DH6"!>[>5&%?5*R>I$P4O.I&
M11^I#V<C+5?3Y%*<G'[HMEX=6A?NC"NKI_OTL@"Y+H0+U=+>J;$9>,8"R-@8
M,>'B6I3FB]?'[V6/I!FH')2*R.'\<\*7&;I2)J_U\O28=<7[^4QM_4(V#"TZ
M7=@W2F.!5=P&4L-*7F;F$WM!-W_6-)#IG"_72GIRPJVK2^0J?=U6G(BC]_)M
M"QJ*= ^MS]3DX6#O]>V#8S&&JNRY[N@9+'C4_AQXU,TGVGQWD]<5\Z$)=VCU
M,7TTRQ$9=-'<1? 8^!OQ95HST#%3%M+KGC8D2Y)&*/MC3;R&YO/N<HW;UN.+
MJ@G>/? 16'=9:P7G!EZ.G_&WO %@DV<Q'%ZP5R>O3V3UQGGAKE@:P7F94$])
M!P]G@._)E-.:,X4;(Z-#4;"&EQXL)XYT,BVXRC%B09XH.YLL0?JJT2FDFJM"
M;;[)#NU17P5.8U^]F70I.B &$2BI5FYH S3F;@ARC "[&6C@("[J*_<C)!8Z
M0$\[:&#19*([3@K*(J<#Z5QH%*8WHF5)O=!YK,:(&1_$>0?XGZ"GJ4/O!1G%
MP;]SS!(5]@*[^+>YP!@]C=<!A88X6L3/FC$4CW/;,\)7P.M-:M1; 3.T0F&]
M0LD13(I0ESI  Z^EU9&!@G'\DD^%,S/T@LA=)@L<OPB^[LD"D 8UQ:D+8SRV
M,$@Z-$W0)RPU7E2XZ@M_*FGNZA,HIA(7T. C\Z+I.Z] GFYW(+;O',1V)@4)
MO]"1>B<H]>#9NT+I:,[S%P\"7@O./F%#>%!CE!NXAI,[2OW;V.*9$-N,>";[
M*6)>B+)\B^*_8*B";P]NE-J"NSLETAO]60>094!8H%2G",A@)(@TER<N[-$D
MPN2$*B@X#';H+(GA=0([X<\2;(>@7_ W)LV% SM%')49*2.O0-LC<"2C #-3
M%!N\V3!AJF/=TOW:V%EZ+J259D3Z(_HW!N5*@2/V!))"\&&LEA#0-*]@S5+Z
MNX/-V@[.S%K"K;D<]- E;!<2MKM=PK9+V'Y1PK:[@+_5!?S3!G57P"L!:[VR
M*\6L;6+V<UC'(AQ!\#+\ZI"CP3D7PV@P8BE!EFO%D7A,7V;>T^R3]$U$N+RR
M+J[A3DGI[DJ3L0 ZPT4P;@L EVXNN%UPTF& (&H85H;F,Z.DX9/)*)&DCE-W
M@AY:C58%IQ@R6QY)ESPXF5<UHJS<2,(T^DA+,L5,.%B\[$MFL!VC-"IUSD,7
M4C*)9&G=4-N; D.GGV:ZPL49%<@!!I@D&OD)P;J42N""0#"\2RP(^T41PM-'
M4>/0M\9@Q^LRPA$:'Y6^UH=XK/,"_6*,@Z7X#XS*"\&C+B:3P*EX$+"J('BP
M'..HG)C /5$*PLC G0,!&M%DK:-K-Q>#,L.<P Z/%+SHNL-"W>54+3CUDQ$Z
M?Z,$ PE@UL$C%*V@;)"IN70+%@@JAPY;Y7 I4JTG&4Z& ZQ47/RDJ'8)A'N:
MIVI4H[E(CU"?0!F)B<6?*8WQII]A4.:EA9EC0?R,/BW%1F:PR4Q14L4YRL;'
MUT]NE..1[*1I0E+'(9263R# E\"*$1D@5GXU\RDS 0M2[UR+)HWP-ZJSL,6%
MY[_9@L+VK^&WCI%D[8H/_WDV)E /..BGNGK8/N[XW*EA_E<^@2'_EL\^HB$-
M+BL6D.'^Z,__Z[??_=>?*DR3F'B#&E/>SV3*\E/_X[]O7\+Z%].Y/]S+NN##
M?J%72C_A]\OC\\L+OX;R1,5146Y=)EF4!*^E[OF$ZQSU]TXN7Y_8')WF#[5
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MY177%/H BA]WCK;WL. ^M>G&)5B4=4%]O@S>\U60/,)5#(\B!GZZ58PJ%=^
M;Z?6M$1K5N+V30YQ'%=79(I'BZ0'N)H_]GO;/;T]WHIQE@7'_"^X_#%?SPH+
M;"A4SE.CU9C-H=8T'LQ10,H!*:?E1.OC1K^$T\94!T3%JRN-Y"RU95GW9%,8
M_:0+3X48"[_D3V-QIK"@G*+A^LVY7Q&CU4P++41M$OUW2"-%J]-(UOY$OA=-
M_!"[-!FE+>-R4JC(84%9??$PZ4&T[/B@(;I/G,1;10*#<X'3(L02&5;VC>G
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MD3#0K''A[FX?'*+0\%/ URVP(P S/PD=D%%4W&$3P0#5#08Z:E[MW[9/8'O
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MDQ&X[!'<_G,T%6"SYB0&L<*QTWW VP]SJ%-0C+)Y>BZDM$NCXR-V(.@DH3D
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M*5*M6%TK^^C;/QWD]80,J@YV;O0"3Y7ZS[-$L0SJ) CN K,_!+Y"&*DQ11N
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MDU4@T*]>4)(%Q493U=3)2UD6M67P<](R2G"-35(#LG6+)K"IUL(SO43XSZ&
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M5ZOS>_F(.HOH0F\_RA26NZ06PUY5Y.J7%BQ&FKLN[Q2;E<QXXPLX[ 8TH:3
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M<T)3&E-_6<1R^K[.,0QDXE@F[:D32:B 9(MI0#VVOF3"P9J$,KDXEI*Z+6X
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M(/N>:;Z!,R=H%AX:I#PNA+ZF0#&C]J5A!BY+*-@'LXWZ&R)OI\8F)B-B )T
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MAQ )LZ0CT&/-1IBK.6B1NLM>-!R3F-[':Z]&7" [<S/@0N ])'E''&B[P$?
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MSN7]T 9&()F8^@.8@?O:(U8TG5?.'P[.9CRJT",;D LGB<U85VZ3;,6 ;J9
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MO9;GP$^( I8I2N62+.7+V]?!=H$:1#G 9S H=^W0'SE=^A.X2P1^"_S^1.4
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M!2F358A1OBGO1QCD@HH%%;^A09Y Q>U!J5@YF;0SLEH[U&<M1>X\:)= Q5#
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M9&"2M%X5@K\C9!@]Y,L%N=_/%WL#1<WW<K):Z)7[Y4*OKV8U0A=*-J_D8O0
MG2/&/;TQK:CJN)JN5@N^/CMH-"Y[1 -;?E([=XO9AX?<:??::0Z/^HN9?9^Y
M["FK3\YFC_<7#_<W5JW9GMSDO?:U/#V<DR?SRT^>EJJGAJ;>%.1"W:G>N6>R
MT2Q5>KF>O/RD<9VKE^MG^T_CZ_&)\3.7N[@X=(@JMOKD=6__Z.3HMMN257/H
MIZVSTFEF."1/KNSSMF+OE[*GA5)-G3FMWME]:W]1FY,G5_;IU&_+QNFP/)"-
MZZ:>=JKY:9E J;CZ]IO]N7[SDUQ>+;U_?I?;ORM7O.IEK[SZY&5Y-,I:D_FI
MK-S=E4X,;WCN9.>]C+SZZ-'%\=%8WN\==._KD\*M?M6Q)A?DDC*KCW9;_D7V
MOGR0D1<'!Y?ZX_[]R<T5>32[^JAF#XU;??_^3/9=KUYJ:V:K72(;2(#I4>&Q
MU"S7RDIW<7.5SPT6C<,,@50F 0"%RM/D_G"J5L='/V6[EWE0'D?%2B]32KC3
M3F>L^[6SV_&I]Y#QC&&A,2\.>YD$8!5/#>=P-G$GM>:T5]"-ZOQ>/JX0,V'U
MT9+^>'.G%&K%6OO\22TV3[J]TI!@G[+ZZ,'#8>ZR?#L^D],M]=Y]S,TO3K,$
MI1/P3W[J'UT>U(\KXXEU/^X7[-9QOS#L*8751U7=LPHW^M'3N&G<Y>[Z%W?=
MHU.R:@*PAC7-OYMKQ_I8J:FW3_=ZUA@#I21 8.YVS^6661]WC=/B[=V)=>Q.
M#RKPZ I>WY>>2M/+RY8^+IP4)]YQX[IT07" /+J"V-/QH-@].NKG9<7OS\VC
MD[;Y:%V"!;:R@=-[\\1X]*LS^31KM$Z-UO6U8\][V1"NJ'H&&ARU8XGV9JE3
MS_C!_X@R2&!^3-D!L:]1=8%KPJA=J?[,X1]0U0H_B6E@$5.8/2.OJ$TSEV^,
MO3!#N>W+W-9%>:^4W>2BC^@RD?4=LN; <N:<>?-_I\$3\(/JJW,"IV?U1&84
MX(OYHVJ?F$'^S'AE_7"]6RCS"VZAJ++_ARZB8D%<Q$Y<1"$C+F(7+H+P)G$3
MNW 3REY^8\A>7(3@35_L(N2]XL;4!G$3OW83OYAN\:S>^H:I)4G^FS>**FY6
M&3\6#(@=!1_^]UO^V^^*J>)>[M_OF2-<VA0Q8"_IQUX2A=>W?VX-U?6HZ\ZP
M=4-/'1B:,>D;;N#.XSG6_=_/5!*D\WE)1_E=TLDH>[GLAZ8=\'/'Z>+5U-VM
MG/7E)XN.N8V/O.V_!AID/CH:*)^%/;YA>M*N<,,W//)F2^HS'ODY?\HKITSL
M!A1>G;GOX,5_25S?;)]_)%S_/0GVSKVO6[6K6J-;VYIT$BG$0,1?'@I4AGUU
M,% A]M6A($@B(NH^"1AVSEK;V-^V93P8MF\($^P/R'>'.EALI0"&2:BOVJGB
MP'=56*>7Z;'RMXX3+8:S*LV\>KM_=2.W1^=JZ\"]F0PNYK_?F1()\-!U)I"3
M#6>X-F>CJN\1L!MNW=8L'X!;\3R#_'\]N4VW,NSJQ^6?5KG6K)T-^O)C_^@I
M4^GEL;U-7LH42Y)<*+Q&>=R7M48_(=FC%!9DWV-%;E&R5WKI6_GBI'QW]CA.
MMV];F:NC\LW#]>7[DOV9DQL,C+/J;;>=:Y[>U1I#+0-MK7"VH)3/0U.K32.Z
M/H)=OHOT+\QY8;L(<UZ8\X(DA#F_(^9\K*WMMEW7'_'B/I%ZO[V^E,*T?WO3
MWDM0W*VSN]G$ZSKU[N2N8><GS>ZL< =5B\)>%P0MC/;=-MJ3"+K1MAJF5CN2
MY<7/N?(XGE1[6F'>*PI+7%CBPNP0EKBPQ 5)"$O\,UOB9$G6<*=QE*K=7-0:
M[5I;6. [F>[YZA;V^RG<2^46PF+\>@CXRGG#OXN '\'$>297RC-45QNEB)%*
M+,@'PW*FT-92&#(?6&M[?6?KFQ]G=]PQK^U?I?18L?6#D!IKCU/#]HP$'TW>
M=@=Y)^O7:T;?-RX/VH[7R@ZAK5OVVS_9@I3+E20YN\E+(ZPR0=_O:UWM%GV_
MMKOUU^C;RV=O*_W<3:9[W[W73J_N:X79Z!+H&YRP&:F4*4CEW/:]L.^ECQP9
MMN&J%JHCJCXQ;=.;N=AK19B=(DXD K_OII@PPB1\JQ(CR_6LZV?]X;17V+\?
MRH7LH3ZVW9IR7YA#&UFBFF04J207I5))!(0%H8N \ YI*+].Z#-?<=+^9?Y!
M-NZ<Q].N;3S5ATCH,()4EG+9C%26LR)2+"+%G\0 VT$HB$BQ\$D(DGAW7\97
MC10GYVR+X+%0[H45OT-6?'-JP.OL(=/FD](^_73;>RR6T@==\ZIPL']P8;N7
M1@5FNA"[/5>6E'Q>*BMY8;<+TA9V^^[8[2\A[?.;[./M_+[BU=KZJ:(\MAIR
M_W@(I$TL]:PB*;F25,HKPE(7EKHP2X2E+BQU01+"4O^TEGH)UX>AJ:G#5O,\
M,EM56.E?+\/VW5.\4W]]#M.Z;FO.Q#AS/-# R5G_^RV=H(IK6>W8)>^<RHK\
M\WCX\[%H=&Z', X5RJ5SDEPL$E5\-;'GNS"SOQYMOGOV^ZO3YAO9QB^CS9OZ
MX:A0+M<?QW[?NG$+U\>EJUD%:!.2[LI2H5R4LJ75@/9W82<+.UD8!<).%G:R
M( EA)W]L.YDLV>P<UUJI>J/:/*^E_F(A[&THX,(X_F *^+L;QZ+^^6LCX+M;
M@)^T_KDY&QENRD2S4!@P'UA;$S7/']=S"C1(/3,)SIC62?6L,'2/K^7[\=6)
M_O/XMGKH5'J9$CA*"T6ID"^*ZF9!R3MK/^T6);^RGW4C)5<O,]/T>-XLC=7;
MYF3AF<IQ\>@2*!GJA,JRE"]M/_7HO12+NOU@>#,H[MZV=O$%&=#7.O)[FYN?
M2KD(Z9#RI3H,A"6?0 ,&\\$D=Z@GL*K^^/CN,#,X>Y+-12U?LKKGP\HE855E
MK%V6BDI)*LH9D0(M:/R#6O2?2NWX/1JO7#_<*(=W^NGXM',PVS\[RI3<JSG0
M.%%'\DI&RF<W%3E\>-<'1,%3Y*IUTYLZGFJEG$%J8#X:>DKU/&/F"7?(:QM1
M[U@9L8-06NMFV=T"DH^?M7:DFC8P@J9]@&S A%<W!Q7D )MR9&;W<O=&LY6T
M?#16C:<SV=<L^Y)L$=TRDIQ;U8ZVE[HF.(K@*'_B[OG:'.65^\?\+D<QC[+M
MA]O"97-\U.SY?4-N3NO^'#@*%*?E)"5A>- ?9]Q]+8(0_J.O<.17]Q_MWIF%
MU^1+'/G5O28[ENRV$]Z">$>7UTV)$XK][BGV[Y%9L;L*^J<*CC0<VXF7QJSO
M\MCOG1V<96JSZUIS?/#S;GK8N]GO#WO$?J AD;(L93,B%4.PAE=.U1"LX4W,
M^%]A#>=GW=:\655OQV;'O!G(Y:?R1?T26$,!4K2@D'53K%18[L)R%_:-L-R_
MRI&_)F8+R_V].KPT:IT4='D15KI0Q;^(E?[Q _,-8_:R9A57HT.M=G=A]N7[
MH\+$;1ZX#_F3>4_)82,915)*12F?6TVL%M%XP0Z^BF7^\:/J+V8'Q$XO*/JM
M[]2.3IM/B\G%]*)TC.R ]JZ1,V4IG]W(#H0]+NQQ8;4(>_RK'/EK8K:PQ]^\
MDTRU>7[1JAW7&NWZ52T(HH-I+B+HHF+YH_0>",ZWY6XT G,_&>;N7*W]6LS=
M.8MG8^$6L06)\>H:9&=/AIX:JJ8-=5SD^;$Q4_N6D?(,S7?-F6ELKXCK*Y+B
M)W7?B'E;;]O:INI,IJXQ,FS/?#"H%Z<;D.^Q8P%TPZJ)=D"[%9?@NCTD.R;_
MO2!@='1"^LU!1WU,*I\HUXVT_##TQ\;A86G:N'65Q]/+GE+$_*RL+.4+J]W$
MA<$HV(.8V?5N7MTW9 \GE?/T:<Z5VUVE^_3S[/@VW2ZUA\ ><$AW7E)RN0]>
M[;Z+C$*8Y*)YL^AG+FQ]01*[XB/8,<?TNV6%Q9W16\T/^XBWMU5C($L49MWQ
MP17S'M; OU[+3_#VY_K4.5X)FG]$@U^;XF&8B_O)1#F?=I5&I9)Y[,YN+GVB
MRI=9QE<F7Y#*Q8WCB82U+P@\R=+_<@3^NO;];Q*X/9B;WNCXLC9>S&S_6N\T
M?C8[%2!PR.$J2>5,3E)*)3%_3-CKPC@1]KJPUP5)"'O]L]GK+-!O09?6J>&F
MO)'J&E*JKWJFEB):3THW+7]FZ,)J_YA*_3,P27N&EC8?TQ0$/X[Q?WK9@;UO
M/U4JX^[B4O'S1\/SCE>;)\+S-Q&0_@O6(0 C:JY%/YD;H)SSC] "85>Q;7G[
MH>T1VFX:K1&D5Z_7SV;O.Q>WEP]CLW!J3@\:Q^ZQMW6O@_(+1DE-=6T"->_"
M<-O_G[UO;4Y=1];^?GZ%*W/FO'NJ(.,+-F;MF55EP!#"_>(0^.(RM@!C8X,O
MW'[]*\F&D$"RLK)R@:"IFK43(FRIU?VHN_5(C?J818CR4CBR,/.V*@AF15[?
MF3F7GR=7>;J)>L==_42H2#(-%PU*!3#EFMW 4.2NFZH(3:-1 HKT74#I_),D
M[P-*OY\I^5!0LOK!3<4NAFVE6Z@H/7[6S]CW$NH=XC-<,V>?'3GP!KM8V]'U
M_+"OV@A04* #Z!BZP\@W]#_2.?PF/O]'G_$]*;0^J:3)"4/H&REE,9:F,KGZ
M:+/HM:RVN0D;7H8Q]=+R*[>5MD A13A1PS!1'V)<]>MAX*,10/EN,?8IM*[I
MT7"8T]T;FNV$E5O%E#M69JER^*8_5DBDTV*"$VARU1\!FZ\&FU?=1'#A8/.Q
M6UQ_"C9#C[U?,R5N)<^E*G,SFLW"HC]"8(/VNE()GF<3PI&]KB?.W+_QP9?W
M4O.]^9N$?F .U]%'I@-5.?CQLB6\4O??O:<Z0&6O'G64$Y[VM T I>FZ.X7]
M6,-IH1PW@"\,7"H8P[^$AHD\3*A.F.^MH5^&IJ,YNJG9L,/P U1FR[]^QR&\
MGR11)2M;6R,] 7__7I]LTP')<11/OA;HZ-\ .L-<_/P/_&?[%-T&FH<0;OSW
MMM=8@^,7;Z&+35]S/.H._"CN'9[3+0#2_T3=VWONHX<E=6#;?[\4V6R?\%'*
M&(N13>WQSR*99M@]P>S]^S_[HWF ]J3NVJ[W8XO?>^*+Q<)B*!^!Y, #FI74
MAO#U/S1[J:W];127N>:VH?R/W1+ 84H<#<7\3VKO9R24@TF;:JODGMSBE2-I
M@V'P0WSX'4,^_B"N?O+# S:$Y 5X,EGQ7 ?N[ <+U_S'\YR"@1=_,-7O;7)X
M1KB':?F/1HT]M(K\HU//'=7\7V9A.O@((HQ*<VA1<E AN=@0M%\;PU,1'Y.@
MAM<.N)Z!%$BQ:34]8'4U!0::*HH#'OY$&QEA,$@/ 7\5O37Z1JY>:]<KI;S4
MD?/M#ORW*M<Z]8+<5$J=7MSR?>2[+Y>!:QO/6T8D]9S4:)5R]1:%K@F0&K+2
M*>7:B>A03ZF6>T^T_>VN[0F-VDFM3=4+5.Y&JA7E-E6JP3_4<^6;>B4OM]H(
M_ICTWU0DUR_L>B$2*-606Z5ZGBJTZE4J+^?D:E9N1;+EF 0%?2(&-FO5E>+-
M\3]S'[->'_,L#A?LMRR(L8'H=":M"]#M ^S 4%.TQJH#+I-1N52:XSB-S8@B
M>&0@T!UKS\V"<;>NK>E0-QK<:)43)CD)N9+TTZ;+X60QFCH5PYI7!UTGQP43
M/CE"386G3?-*><+767HD=U=!+FNUQX7[L:2R*ONTY4"8%9-.*NS*Y9Q;ZZGB
MS4!4FK!E^FE+AR\UA>ZB.9:+):8;SMLAE\R@9Q[VE,W9I0%#U^IRKII>>*NL
MUF6X$6K*/6UJ+S(E4\FY*Z5<"-5&.K6YN4TO4=.#0?%Z+A6,[>J]+(1\0ZL9
M$IMG8)A\."AGMI"533KCT/.[U')\=ULIN [T<=74TY;U8G@C5%P_J927DW1F
M;->6DQ"U/!A^I6IF*DD1+)1U;JI.M7[9R!70VP^'WUKV6"&SDJLT6"^37)UM
M>_VVA)H>#+^89!V3NPEXR^3\E>H-.K5<'S_U8/@=@U6JN?;RQLJ-@[*NK+E)
MTEBJ@GKP_H6:"9?!8'ZC:*$SL-L-J'X":GDP?"N=&?63,\FR0FF0F5IB<=B
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M+K"U!O"D-0S"BT'#O0O8PDT?O@0V/9"M4+T9UP?^H&&Q=C!7N+DTGS<DU/1
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M:JUH3FN0MWL5HY'&30^[T('K(B^F5Z[2=:W;L9977-.7<-N#+DPFWKPBA?-
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M..V$_$8T_3*FG;#AB*9?R+03>AQ1](N8=L*7(YI^$=-."'1GK>IGR:A3' _
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M/A.9=L)G(II^0=-.^$Q$TR]DV@F?B2CZ14P[X3,13;^(:2=\IK-6];/D,]5
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M@Y0Y )2FPTF!_5BC V^.&\ 7!BX5C.%?0@,:B8%T!9\VT- O\2VXF@T[##]
MZ7;_^@N'\$?"-DQ_9FMKI$K@[]_KMFTZ(#D&R%)__'&_'V1 _P9@&^;BYW_@
M/]NGZ#;0/ 1PX[^W \-V$+]XRRIAT]<<C[H#/XH'@+NWQ3_ZGZA[>\]]]+"D
M#FS[[Y>\^.T3/DH?'HDQD]J3Q=Z__[,_@ <P3^JN[7H_MFR:/8G%DF QNH]
M<N !S4IJ0_C&'YJ]U-;^-DC)7.]*%/S8$7+0=5(47#LX_I_4WL](#@?S--56
MR3U1Q8M)T@;#X$?\M>UG>"78?>CZ)MZW\H - 7L!GLQ3/,V!._O!,M?"XRE.
M,==I_F"6W]L3V89.\4KU'XT:>VB)^4>GGCNJ\^AG:'YP[;"CIRZC[L8?7?WL
M(*5#6W@YM&+AV[=B$] ^%CD?6^O@T5OB3@Y<VT $8ZG1*N7J+:IS([>DAJQT
M2KEV@BK5<A 8!Z?2RUJ]([>I3IW*U6OM>J64ESIRGBJ4:E(M5Y(J5+L#/ZC*
MM4[[$SN-]85A'Q3FI1'DY9Q<S<HMBF,2% HP**F61S^PNQZ_A(E/S>Z8-6G8
M"\&BZM1WLGD0S56D=Y'W40NG<,#ZNX1$CQVE-A26.80 ZP027)Y#!U6%;\ U
M6#>!WX'ORMJXS!!VF09J/VLU,B-A-%8TO[UT U>[F0]&D9-G.B$PI."%=BIJ
MQEQ1 +IB,]B)P O!1T'#_E3O@\%VB3$=O*X.T/ .G*QH\CCAF*:\M7\OHU"L
M>$QLQQ'PO*2B]591JI7Z4J=4KV'M;"O5JM3J4?4"U2X5:Z5"*2?5.I24R]65
M6J=4*U(-:(NYDOQ@=1^M7-G0AS+V_3R<<,_$Q2 DQWB-GK6RQ>HLEV47%EMR
MI"D8ZBNQ)WVMYF E@9&(&XGFR0+_]*](NWY /P!XZ*>#/T>*@)U=A#</ D(+
MT%9N'^JV'PLPGCB/3\61TV9045R/ZHP!C&-!"#TS/Q%MM\*(ZSI!:50>8MQ2
M\P!4)V\6CY;Z"R[-P/.@4P\=?OA=8#J4YE/(U63IOX\^%O^-^9N"'Z,(8=LT
M"B 2V[_&'R_!TT_"_0?$G[FA%W_XKP1E^K"S.IP;[%S""&,$J($)@Q)][,")
M':VI.%B!\:8>^K#K<!RH)P98 -N=H7 $S57@:8X?$WT6<-309\5'@,#*]6$(
MFAQHZ+O!WLA0  N_!C1D E0^U,? <0 U#7T]M#6/,M9^X+FS\9KZ*^YXOII_
MZ+A&>4B\Z)7H_4>^MAR;^ICR@!_:@8_2R*B-C7H^ @Z(IP3U<>8!V.W00W_2
M@G$"?^BBOB)6$[J1S*>69C"FQA!Y8.P_!0$U!0:2&.6@2B_7U';NH!,"%6#7
MX^W'^]U>CEW;7B?=I0,%XH<#WS1,S5MCC^NH8E%+#0D+&1'.AK,TS2.U>4;)
M(DG'LV0ZCKN(IF3I>A9ZB1ELGP9[*QNAYADN5=6\P?_]@V7YOYT$5;W.0QUN
MC.%_* GYXU@';+"U2PV.WAO!CP<@6 +@//0;"4Y[,JB:"67^VY82"Q!]^4%X
M\ \U=P&F ^!%SV!IY)<P7.*A"P.@0_!]6<ZX2ZBO^ >LM; I%5TV9V )(01'
M5OHK6W]NS@)W!+ &8<5!3WSH0F)/7<9P(J=004THWWWSH PO'%'0'S%P&@#K
M[T+S3#?T*6REF&6W9X112N#?C]:RCU_:<KM,!7P47L?6AZM8LA^,NPS3:BA
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M3?5'*90(9Z)@&'[H#^,M=/@G.][_-:-#"GCOU(,.(CIKH4.3]?&(!_%9KFA
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M8_A.1!6(3X@'%-#@9P/-QING_AB  )M%=$?4XWNE=ELDS_3" SLKQ5MZ#WM
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M[ZL'=C)!VZ?E3VK@&!QM-C4C5Z?E*FT6&RO%JD[6"Q;=SH@9+[Q )X34X;U
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M!P'^U#,ANV-S&MSHP!AQ2.@X#O12\(7X>A5?B-K#HWWU_"&/>'&K)[KKBSF
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MMC8*-Z@,]KO-I%6-\\@4B;VD+WM HNDKL,Y%W9HZ4#CBP-ID@AL:!W%@'-I
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ME>SO38%X8:[#BZW&SG[KQ1+*L!PQS!$+TU>_"R#"]-7; $28OGHC@ A9TZT
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MT46T45<J)346FY?@R9-W/B12$[ZS-XQ^MV[.AT.E)?<09PJ@C_53?[W6N8S
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MFT2EOV;C^?HZD7GJ%+8D),_0B4@J?=K!YV(<_-K8_/DCQ8B7Y]KGOLA(L>O
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M;E'HQ"VHIG=FX?@/1X.W4/HKJO[W._!K*O6W._&?A]/?2'J%VEFHG=TX?H=
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M7G0Z]1H^.;ME,EW[Y3'9",;0C5A6I5^9W.WL&7$GP5*"1H1/3A#361M=DWT
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M^:RS:^78#7^>W2M?\J:AZ,&K8AIF6)>0.0/- TP#$?M#)-(68@(4HK\ 9<X
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MT83T%D001(?6D<>JD^<M/6<@.MYEE0UT6.U+\:O"]X(&R.=R@JN6HU@M0UZ
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MH.U"0FQ8;$'#!TC8:$'9Y!VQ:/] ?!NZ.40/)<^$LID316MA89681LU\R'R
MOT]#(:I+N$.O.JG9"2:/NK0KVD$54X&!2=9QA&KR+#3/"@E9:/-13ENE.CN6
M>W> H:M+I@G4B@:%+G#F1[LJ4.;H!=>?A%;M:J*;'B\$-BTOIC]^)6AHW^].
MXD&VO4)MR$V1Y8R(UO9XM3U@7ZC4WB&14&@1T@ZJX LXM63F#'Y"<+DD+:W8
MOOFTQ')L:&^&A@B,N6NBOP!_HS3+Y\>[9+MM->G5M+FHY\31AQLP,"Y+P#
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MU/&ZKWA&!I#[#.(C(;T)#[U&=3LO5!M7E9V,37)?Y_#MH:NCC10T+VH_5$3
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MCN)=0-J1NO.QN/H@Q%6RX=BK;,4T*[34.W0BC+35RVDI[G^H$8JZ.7[_WIQ
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MOK<2,GAG=]LAFYIPL,O[\'-[C_>X,QW2P\R:YE=+>E-L!-=RW^)NTQ#(;Y=
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M6!N/68?,+Z,1N@9A!$$S(!@ ^^E->[JD,<8AK5 7.UR_,8I+%HX-_N/=F:%
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M?YL8!O0!:W9GD_R(R,P[P<Q=?^9PHDS4(35'L12;@H[./Z$,DS)F]"5V(5:
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M$ENZ9*!61A0[AFJJLBJ-NZN)/^.NI8@J7I;-9K@FRK]Q-\N]D2G]/"\?EQN
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M6)\YP!N "P5:=4R;IM9Y$#<P:BH4HO^[["26.U\;DS#C4*W[/P.5/(_PIZ'
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MU.XB;IFV;\3^PCV;>X %!P/N,D^]3 JX9S-*5L7@+BL8W[<,[A>.99L86N?
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M3*NWYI.=9^.;FA0.^<E%B,.!?)Y:F63(WZ+%O?-A>\UNP'VC=?R2#NX\FOM
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M-WJ/VEAKG+R@DAQ>T.AJ^$AO$:YRU.YAK9,BL&7#MI 59"C(.LRVUS?@N5!
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MCZN19"D>)>8.89JYM*@<P#SEM#*7;^[3-+/IC)ST>:ZBDC$X^J@98G))MN(
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M_6;V_%FL,@]VY CYTP =+>ME&C/BIVY3,) ]S+IOSU>?UB.Z:E$>W_"R^O1
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MVL?1HCC:(_'3"RRF!>D^]CF#+MDB0<U=HFM.G6([\=IU3Z1H%OSN5M5-!M"
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MXF4SWO1"8_L4'21DTM(%K;!35_C\5H T<K[$5'K/7!.AR4=W=R9V[I6F,QK
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MN8@&OJMJH(&)HAT(5Q\:L!_[R=( /B6=1 /')>)8IU*Q\U=2V6C@-?@^?)F
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MNM'MR+HZ.[",8SKJ4FP_N;S5X/EM><>KVEB986+O]3#U[N-GHC_)]63R9-G
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M65?7?",YRV,QPY%]"#%I$B0O^/90[O*./7T$U=PN&;L7O;/G%1:#JMF*WE@
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M;[LA#P&GA<^QE4R=LXMWPHM['=JHEBY',+[]T6&#N"<"6-(3S(_',=JA%V+
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M$MD4/E%NO91""'O;,K[/MPOBQQE_SMZ1+OJY&[0]A.7EP*L-P?,FUO44;9B
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M$>0#"WI;CIL.I#))BT8LEB:?,;23ZM.'4#<,@BYWK((ESD>[*MS-/_<Y$MW
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M .XMT ( >+X^C^37P/F297PP')GK--MUWO,<L9QVR*$)M==.VI]<)9>?!=R
M^BXTFWJ7[AR/ EVIXHDB5Y6/,O.C&^T!QW#5L>"*P/)\#;1WN  L ''8'4Q?
M2IYTJXY&H)2>W@)2>;R_G?]-<%;2&T+0[UHR_[-.K$_^;@ @XIO,'2A,KY\[
MT]ZQH_RDR?POHOQM=FS':!B^%7S29''C6$X&JFG? OY^Z;-_,K1+E;APMKF
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MH=98HV#VWX$]XI_LGODWU\C*#&9-/[[WWSJD_Z<-0YQU&<\>"3W*@Y426K<
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M]I<1AX&\-J@XFWY)<"L;OA3Y$C[E9@IS:<0B<V)^3/_75&^V^U )<6XE>&)
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M^D[S8H^\@*6M*@UW_V\=ZY<GF=,S,ALG1(>1TYB4DV1^RCC<=%S+>.+S+U_
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M^^4+5%FE]VD3^F8_RWU6)BJ@;V'[6O@.V<GYV7Z;R?+A3%M1<]<C8C*LY6)
M0HFB4.AF029GPLHNZCY2?6L>Y752YTH:PL!_1YSHO=AVA/=RR*8[?69*QYJX
M\2L-*MZH46PR^S6Q\F1M@XKJ02E>5Z[0>O',AHA,IC[;RE_#\JZUJAH/"CX)
MAJ;XW!3T3B//\I.$FTJV^[RT8S0=GILNHYZMIWG1RHO3Q5$-6O?XRV:OX)8
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MAV;JNH[XE@S4FT\%^,KD9Y"*/JL:W8'75J1()D(>V:Z&O^<E?V8W@5]?]NS
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M\MWZ)NIZ=1"$KSUSUELOJ8WIM8FWP?:NV:@^\T3(E3.RN>!*$J$>FC/93?+
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MMI;CY;.,R([+'@9&2BC)SP,5I:[\$-%UGQ'-KR75]8ZK+J$&I&>"7I)' T
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M*)QE3FEPUAN\NOCD29^\&*F*?J%*X=URIA'?_EN5PC#@LX'BCZ]+C^6+GCD
MF>N?.A[XE-9!;$R)MS"WQDZ7:$VZLB3G*V!5?B9RQ]F>"K>>)405WDF?M&PA
ML!VVV(?59'J<-2DCIW&YZP1*GM$^Q7TK45[[]O%4(YC$6Z>GW1<_/<XBM+3T
M<]#8MU^_E!YTGG'$JTX%2?@AM1'WOJTB48DEMB)LQZ\:$9(='6*%:KO5HFW
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MS([2/)*TO7S!NU( T<7HD+T8]ID;A7P;YF-E1T&+WEZ"0ZLD6?R$D)G'C[!
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M4)"XC0%$JDYP^Z*_*$("UT5CE$,@B# 0E,=_)4@62T%PT(&Y7]Z?)/4V^CY
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MM,'M;OV'<S-$QM]'CW\]1WJ6.38J36$TV^:#*RNA)/'R41];&%X J;-O>%L
M(V]!R^'IY,'[:@)1@6V!O>C82^>TG$#M+?<OK(EIV^T0*K&M-[LKT#VK,;^R
MV$D'C,VQ>9&_W&%@X&R!OO><JNFY][AB53/N(I?X-8PW=&P;!()0;2NE@0=[
M*MX7\H4CV[ J^2GG@!LMN)"?2F5SN&,5_K(K >Q=.F'3NN-\U;?%.3MERO?)
MU0*Z+/=V9)<3K]);8[! P%!KR<HUCVO2J,38V)YU74)'75,^7$Y0N*6[WC_]
M77H(53L\]DDG1_#M?XH<5VF]MS]R"?3XDN=<Q_Y$6.#C%7\B0C7,,FG!=T?L
M_I.N6$W0DFGO*+P>\I$ID/?B]$> C,XTL;IJWV7%97HL9L'AI(CWV^%PK#LY
MW3WW00WB9!8SOAHYJ5#5.].R*8L"&KJ1]9O:>1I1:3Q=74B[]E&E%(.<.W^E
M7!T(D2AW"&$7'FPHARZ#9DA#^/.GV\%I@=H"\1%-W^+RQ-R*.6^Y.+9$ZKAB
M[J+3,:PHJ%;3A(<3B8&IB7'-^?KG\F/REW%IGK19RP<A)J2'!/FPL. LP^W:
M:(8/ Y0.\)/U20_4RK*^,H]W2M\7EES>A) M[S+8HF6Z8!R3JU@8X01K6*U>
M?Z)Y;Y%PH^DSNXVQ]KY7U:SRR+?"5Z-"-.KZ5/_J)-=GN-.)9;>!8UK,)'69
MSZTS3L7!):"@N:&3(9A)]2M;C<)XLRL8UU]]%4J&,NTPH9X,9+:_\*F)[$W5
MB%<V?YN6T/A1V3SCQ9D$^8O'QI&4M,JS?D*[7JU+U[$@E8=D@?C)^%53\"LW
MDR?_QCY[\[_MLS\G,1YKWB4>JE&^-2$NA289E(OVQ.MV=+Z-N713FV9'!D(,
MNMWR\T>OO*'E'P;]L_@C#YKN(\(UPY63C3#M==/IRA\Y*G[$#/]:8GQ)IR#E
MHFVEILBP&0%<\*XL?BVV6:2K+9]ZR[JS3\3Q/$5^'D[AMK$O.31O52O$]VI:
M<7S?R>F>H9^A-TS?TBTH@D!)R$)']V/3XWQ4CVS#Z*F?9=-X69!^YAMIYYMW
MF/V"I5EE\J[<IYM>'NGIV2"1!M53C?>2+5FV'11N&?*UQ:N)"8^?*7PO*U!!
M;609>C]Y.55]SJ02_UO_FKN^CG_-^7&6F;3HE4 !0TD .=)BQ)WAM&_OE'B7
MMQ%N>*DSM3_U4MEB42WV3?+\;<I&4>:P'C.3Q!4HT3:&9N3!2>336H.Y&S2#
MQY6/.2H?2RIQ))QFDG.@DX4&^*F&$4\TQS=L2\K\U9T1XG>?R4_L2;,CH![0
MV^AO/XW=5C-Q >__]HQ345Z.CP:GWSMA)3G<7V/1<3^5<<&SL59*JS] MHS4
M;:T-(W3X=2'3.U2H6&[;K.RA(6LDS_'Y[^:'$>U:=Q:F8AM&3FRM;D>X(%W]
M1^&<'D<M2[RLCJ"NT>S^.XBWH0$KT]O(TO2 0JF6-R<@-=Z&,:$%<9-*Y5+A
M"^)=3V8EISLN%]J%CF,>EG%TSR5HS3[9?Y@,)+6A]^+SRX^,)=MYO@E/D<@G
MX$+G@7@#[TS JH3]!_8A&RAV$P=22,3#A*.SG#.P3\#1B7AS>Y";B4W'JLC[
M1]1[4J(_3)P[]4W-=W^]A1RD-.?X6Q^>;NQL7^08H<QUWN(GU1/56('W1,]!
MF!O=*5"6@OU6\/$<XIZ^HU7:EI &;XG'Y5IN\B![2]&TSB.392,9FIV".R^"
M@ZYVM+\:XV:1%61I?K)=7K>JG3^FMEU@U3RL5"A/Z )1XNH;/C*VP?_UPN7R
MPX6+22&C X 31/"(=TB*!M([CF#"=)AC@><*)HE&,Y:7K:E7L[N_QUR[Q%LK
MR=%L=^5H=-77_E5NXB_BW0-GP@)WP>^7D&(SD"T!W<KIJ,#1UB-JE H6,"\-
MQX1PXBI43B>B(E>O$2N#V0YVO>7KJP<?WLRTX3>O5\3Q,JJX6O(C'&O6:/%
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MS"4K).WNZQ28W,H3<1]$S)"\,C31<S!BOE?[\H(@8B6\:XEL9KXTIM#GWK<
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M\Z00WPO$2CH(+NC>\HYHEJUNL5&O(B0J;K$I*Y#'WU-*2(H>"[QG;P/!;@S
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M[=?R<3J]O5^&B^4GF"]6-_]RL+\=VA\:R1,9H0"54K@21.(=LX$9DS160A9
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M\[29L4SM%_WM?0/_1QE&8:!;0;NPYD>\QN"<[/(1_$QB$15P?7WWO8C_$](
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M8$&R5)6(-B7N+KHM  'FN&TV[JLRQ>[BI,SX.\EK@3&1P8U0MI!]9?(EJY
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M6MGU6L%3Z'/(YTHF332/CWO#T9JV?5G?*8'_=9/[N=3I?P%02P,$%     @
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M:QX.1;]">6E51?2,K],/PU!K4RT09*M$ ZC6AQ)RM&1HM8]7# TYV!A:4$X
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MY/N)SE0I+M527)M,YM_W_"?X62JKI]^?\NA2_UMA:AS/J5O7EZF>87+:J_]
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MR!U@J=/G 22XR 4VV&6"> !EYQ%0I$3[(JG2EI5OIN:94OU)I7IN3!+2",#
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M+,(XR&5V+R(0V#%L"RZ_K$TI]"<BTB#D4C/\5TC@E$HCRU1X U_E]_8M!JW
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MW5P21&O->2LX!7V) /<E-$$W%:A/Q/UFEE^KND:KDQ"TC$2*3CJ:;+S'QF/
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M'/UW=6__"U!+ 0(4 Q0    ( -A#:UAEE&9O]!,  (S%   1
M  "  0    !C87!R+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( -A#:UCYG?DX
M9 L  "&7   5              "  2,4  !C87!R+3(P,C,Q,C,Q7V-A;"YX
M;6Q02P$"% ,4    " #80VM89"KX%>4Q  !G4P, %0              @ &Z
M'P  8V%P<BTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ V$-K6(921465
M:P  'QT& !4              ( !TE$  &-A<'(M,C R,S$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( -A#:U@H!@2T\$8  )@$!0 5              "  9J]
M  !C87!R+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " #80VM8V>B<!%[F
M P"N92$ %0              @ &]! $ 8V%P<BTR,#(S,3(S,7@Q,&LN:'1M
M4$L! A0#%     @ V$-K6##F458'>P  KHT  !@              ( !3NL$
M &-A<'(M,C R,S$R,S%X,3!K,# U+FIP9U!+ 0(4 Q0    ( -A#:UC]3E*0
M"$4  +9*   8              "  8MF!0!C87!R+3(P,C,Q,C,Q>#$P:S P
M-BYJ<&=02P$"% ,4    " #80VM8+$F,VE(Z  !>00  &
M@ ')JP4 8V%P<BTR,#(S,3(S,7@Q,&LP,#<N:G!G4$L! A0#%     @ V$-K
M6'V0':9] P  ? X  !@              ( !4>8% &-A<'(M,C R,S$R,S%X
M97@R,60Q+FAT;5!+ 0(4 Q0    ( -A#:UC0P\)RY ,  %D,   8
M      "  03J!0!C87!R+3(P,C,Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4
M" #80VM8Q-(?+?@'  "G)   &               @ $>[@4 8V%P<BTR,#(S
M,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ V$-K6-,E]-(S"    B8  !@
M             ( !3/8% &-A<'(M,C R,S$R,S%X97@S,60R+FAT;5!+ 0(4
M Q0    ( -A#:U@KOQNJ3@4  .(5   8              "  ;7^!0!C87!R
M+3(P,C,Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    " #80VM8Z,)VED0%  #1
M%0  &               @ $Y! 8 8V%P<BTR,#(S,3(S,7AE>#,R9#(N:'1M
M4$L! A0#%     @ V$-K6-'B//R<$0  M5@  !<              ( !LPD&
M &-A<'(M,C R,S$R,S%X97@T9#$N:'1M4$L! A0#%     @ V$-K6#.T6;J2
M$P  @F\  !8              ( !A!L& &-A<'(M,C R,S$R,S%X97@Y-RYH
8=&U02P4&     !$ $0"-!   2B\&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>capr-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:capr="http://capricor.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="capr-20231231.xsd" xlink:type="simple"/>
    <context id="As_Of_10_3_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_-rsa000sD0a8m5UVTffp1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="As_Of_10_3_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_bQCWtMxE70i-06Cl52c_Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_CaliforniaFranchiseTaxBoardMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_t5-jJPzGkk-S3fnBbEiOcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_hIIPvdfnnkWCVs4dZrEouA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_666ZzRUp-EqzLeKGKVR3Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2021_To_3_15_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_UJ-PEwE3u0eQNWZSzusEPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2021_To_12_31_2023_fcukxm__uEiN61L1wZ0xDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4X-qf24Pnkim2ijfGAzOrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_QonEck6FD0KdgFPM0l4WBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6T-zyWrrmkSBVCPBt8HidA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tf5OikZQFUONNK7Iknfs5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_E2rfLuwSdkG6a9ykiY4nqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J8eFa0zA6kGN_euvLuaNqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HU_mvTo810KMf88JbAhomA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ec85mF__lkWbIVrr9-VJSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i1t2nRzziUyi6BVPUlI6Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_qp1o0pSjSEynST8Sz742XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">capr:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9vSuYHyy80Soi04pDnBeCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">capr:EmployeesNonEmployeeConsultantsAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_MichaelKelliherMember_What73q3UE2-6pZFUmISsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:MichaelKelliherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_m81pZxvbV0ifPEk3pIVFTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:AdvisoryServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:DrEduardoMarbanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_R17I3foYh02N_TLWyWcP4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:AdvisoryServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:DrEduardoMarbanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_60dARrLHYEG7PVahuY09wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_eiRHIQU2P0-iE89u76MZug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_FGAMc8suqEKYI1VbJay2BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_cQDaPBIGKkWSfcAzIJL2Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_6_11_2021_To_6_11_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member__c5YnH6Py0aKqf8BOj9xog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-11</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_DBWOt4gfCES-rIx3f5YORA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">capr:StockOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_B-Y637VwK06PJ8NRgj159g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_3hggLcl2wEOMWMDA2p08QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__dhbnCoFj0mFXSecYuidNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:OverduePaymentObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_YSrt3eyVpUyrEiyR3LkflQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_7DiFd0JLoUiEm79PuGWQEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_uhAlupWMJEW3mHzcohO-jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_bqLzk-PKtkyrIwepnUrEfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_xpiwJvCFFEONVOfrrGbCGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5ZNv_wjOyUmsCoYiegAY_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pKISfRGyWUC5dXwS0_Kalw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RmDL9OhBUESyNzJ0kgQcWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_9P99ospyIU6YpKdhtGl_Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_H_E_Lr6_YUepovFiKb6S1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GkllSxdfAUuGq58nSnX8Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_aYVKDRCxe0SMDBzgeTcNdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:TransactionOtherThanSubawardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__Feo3dGKN0Sy2w8lAyM8Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:TransactionOtherThanSubawardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_0FeZ1sWYakOU07ed4P8ELw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_zfDRweqJO0KyY-n8-mOXUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_KTrLvd7n_kW3fJkJoMqk2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="capr:UnrelatedPartyAxis">capr:UnrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="capr:UnrelatedPartyAxis">capr:UnrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_ztBgOe6LO0utYsvlcIn3LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5BsNuYaQz02q8UT51aO1_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BT9Hpe-z3EmOCGA9Ohlt9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2021_srt_RangeAxis_srt_MaximumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_pZgkKv4xj0G4O10XC-Wx9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_RangeAxis_srt_MinimumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_khGZ9fyPC02WUrVz7NyC4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_5EcEBXyvWkCaPP71aV_17g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_FacilitiesLeaseMember_X5iGALpimEK3OkzCpCCfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_gO-91n0nUE2kR2Y9RTTwLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_QldM9U_12EOep7ZCnuvYiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_1YjBI06wLU-zMo3y3uhc5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_us-gaap_VariableRateAxis_capr_LiborMember_bGOtzNXAZUys8V9CVS72yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">capr:LiborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_oeC63qvRMkKBhVSqouykUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_qQnWowdCk0ycTDEN3vYiFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_d-yKIQOYmUyiV6A4kVWmVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_xrETY022i06_Ku6R6SeboQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2030TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2030TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lcBRc0KVsUmNSWtqubCDrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4jUtqUF9xUW3YXYFwchNdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_b5u34GlNrU6qAr1zibPqjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_b4udqpao7UWs4Wn0sMDiOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P0GvjWMIp0OgB3_UoJ_50A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tpwrEaOXFkyl_lEK9GeKjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ur1NlChm70CaqH2aI7vchQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rSWNvsGxUkyv-s30zMi0YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_381IvcRiHkGNroOTc9xh6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2024_locdSCvZGUSg9uuiWZPwEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:RomeLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_JVh39f55SEWCSfGr2sFfwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_hcCGu4aCq0aWdI1ic9gMFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_r9pBOG-cqUSu0_0p-X_SUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_hUhoFzMYxU2y08SvRW_3Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_l8hYv85mhkiSnt-G1Lj7Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_p6GoxGGgcE2JSpPe0-Rv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:NonPaymentOfRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_G6HBLmII80uwt4M0Xn301w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:MaterialBreachHasNotBeenCuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_fHaPByLkFEWmMCmmItdYUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_Xt587NoPDES43nwHwu-1Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToCureBreachAfterNoticeFromCsmcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ExosomesLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2RTneoE4LUiql_wj_gb_WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_oHpjOTKGoUykLnbV-fTRSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_GyIsPMRQwEid4EesUv_0_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_24_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_f49c96jOM0qAScvbNEBu5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_raj702HzaEWCiJY45rn1UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_I1LoZTPxAU2_UBJz6muQiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_qFit8CulBkqXDIzMZnp4pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ZlaNNG4xJUeX586mgmAzAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_W4VghYTqKU60Dmy4MPpb1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_MLcvLvWUPEyWrlR72udH3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="Duration_6_16_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_2oh6xrIk3U6oGA7dPrVBkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-16</startDate>
            <endDate>2016-06-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:ConsultingAgreementWithFrankLitvackMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_X7Uz7GC3XUmBUEPTyo0nPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-16</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_CwHLfODuHEWscaDC4mM3SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="capr:MilestonePaymentsInPhasesAxis">capr:CompletionOfPhaseTwoDueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_-d6RYF7mlUWi4_x3ZsGV7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:OverduePaymentObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CsmcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_jFLITrcimUyqsFvsZebRCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="capr:MilestonePaymentsInPhasesAxis">capr:CompletionOfPhaseTwoDueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:JhuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">capr:LicenseAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_e9bkzfMXvE6M55FAWBdCdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2023_To_9_30_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_S7NB6S2w7UatfWnNM-rVaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_7_1_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_1IeDcw5S-Emny3Ah0glf7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_gQ0jiQuHOkO7EnvSiVT1AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:PropertyLocatedAt10865RoadToCureInDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_gpq9drB0NkmE4zplTZT6kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">capr:FacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_bD2EIdyBUUuS0qgSmQHcbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:CorporateOfficesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">capr:VivariumSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_RVq8CNEcHEiNiTlY9gUr_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_8kCOk0e360iW2gA4XW8iYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">capr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_t8_RP8tgw0mTuYIP9tOUPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_HyvjpaP4ukelUP5RqqGhUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_22_2021_To_6_22_2021_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_uDaog7QSQEmqbstoEX4SJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="As_Of_3_7_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_ZkaD9BdX-Ue4UjbW-P8o9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:June2021AtMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_nwrh_aVVjkGtRzSmUAp6Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:RomeLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_bybMKDXxsEWCLX8wsTPgbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:NonPaymentOfRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_kNOGvDAtg0KsQmmw19rGSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:MaterialBreachHasNotBeenCuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_vjuMg_ZNqkuHDVxlRGx3Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_2-wubRxozEmpbQcL1C0TJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">capr:FailsToCureBreachAfterNoticeFromCsmcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">capr:CsmcLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">capr:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_EUR_1WG7i0WyeU6pv6Zueih0aw">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_item_16395vBjAEypAKpz4atoug">
        <measure>capr:item</measure>
    </unit>
    <unit id="Unit_Standard_sqft_rMuzb-X9s06FnUhxCkVIgQ">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      id="Hidden__wfulCvmzkqblGrCoRiYMg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      id="Hidden__16vxDQry0ijRuuleSYUWw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      id="Hidden_csn4ML-U40qMKF0mNA918w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      id="Hidden_gJAaLp8guEGZnxuR63MXJg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Hidden_3fnBnzAAkUyQ2u5GgMTsEw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Hidden_Fem3QWtdUEWo4L6QdPIeUA"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">-1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Hidden_Mxnah5-F00iP0zO9JTsDfw"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">26778360</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Hidden_tpsH8HWT8EuA-vvpMBjc_Q"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">24552688</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Hidden_inwFgsXzk0-bGk5MAURUnA"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.00</capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_lsCwHlMnQ0iAdGiQ_cSp1A_2_1">0001133869</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_HHfAbv4-Eki0H5yts5x5RA_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_8gnU6p36rEWmljlmt1QgTw_6_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_03iAY4OVIEu9nYnOMWKkmg_7_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Hidden_4gDhwQPilEiomiZ2dYjYrQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Hidden_84EccO4aFU65I4npzyIOcw"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Hidden_RycXJw99TkuhZ4oIC-N0ZA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Hidden_6QYLGWLrVE2j2Tqkh4daXw"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Hidden_hQRFCNamYUa9BA896rhzWg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31148320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Hidden_sJHoZlsetECWy9vfmM5zoA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">25241402</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_uhAlupWMJEW3mHzcohO-jA"
      id="Hidden_4p8iOFeSNEmdNJAChajhxw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Hidden_aR2fiAmS1k-ZXTjTa9frtQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31148320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA"
      id="Hidden_ncn7a3kMgkO12NbLrZBVLA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_iqlCdMbC8UyzoF4XxRiqBw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_RuWiYAgRQ0uhGqIspXBYVg_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_f6pPLlAsPkuxBCBPIYcmxQ">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_xlO9V5oZqESmretmDmSezQ">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_b6-Y49QCqE2g1UFFLTKoLg_0_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_by3vsobKXEWgT8LPlPqPwQ">001-34058</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_wbjybtmheUmCLYfZ7gow8g">CAPRICOR THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_nJQ9dHkT8kyhhKelcG9nxw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_kCwj3Lgq4kucP3mho1Auqw_1_2">88-0363465</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr__xI94C7R50SWBFrIChcgwg">10865 Road to the Cure, Suite 150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_ru8q-HkmEUWGLF0SaggG0w">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_oyFSLuD_1UCyRJ5N8mIDfw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_JQDWT5MlxEaNb1kuk86YrA">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_buM7vwKmFk6hJwTtFW8Xmg">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_4vCPIhc7qkefF-Rr2QBZEw">727-1755</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_WGewaTB4_0WB7Q0HqNElPQ_1_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_jfUZdayyTEiuj8LtH_yA0w_1_2">CAPR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_-fkmpkMOXUa3QZGQnVqYvw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_bR0uctebnEWpHxcSJGhvug">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_XiRN_NVg5UqTNjSo6Bf52g">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_Qgihjnh3gU6zNh0bU7hn6Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_aHYU80TZlUOvztjITlhzcw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_Dai4pGm7QE-92-v6Qnr7hQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_3aQ96nU-_UCGG95aVsFsKA_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tc_9cENdOTauE6hHLhRdfBzcA_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_1psJ4wYq5UWqBzMmp1S2Ww">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_e9-P2gW50UCHLuRqNmjV6Q">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_NAfFbNcb8kOeAbUcrxWUYg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_381IvcRiHkGNroOTc9xh6Q"
      decimals="0"
      id="Narr_1Z4bFuRjYU6fdtsH3qQdfA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">119715277</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_7_2024_locdSCvZGUSg9uuiWZPwEg"
      decimals="INF"
      id="Narr_-rL2AJCaNUifdyn3jCD3_Q"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31399667</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_o-fhKlqRKkanypQsTiXCAg">468</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_urTguipqV02jpZ-yscJCGw">Rose, Snyder&#160;&amp; Jacobs LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_bYJhIn77-Eq_3q3GOXkbhg">Encino, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc__aYH-cUUvUqvipbRNVFS_A_8_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">14694857</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_jU6q2Inq0kGTq-tPBclD2g_8_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">9603242</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_6d4A_hDWmk2AX_l_pmpOaA_9_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">24792846</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_tECOkVAnXE-XTuXbtC7gwA_9_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31818020</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_kRTViZeFS0Ws-BsUB4KbcA_10_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10371993</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_0SYh7-14Dk2671qNXvFZtg_10_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">547580</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_6QRfGswzyk6elZlIDubZQA_11_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">995776</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_UdXOEqRF5kaZOpYWmoficg_11_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">919892</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_nycmO8PINUmx8by9ZLsimA_13_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">50855472</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_B65bCY_xy0y5NbrI0_p9RA_13_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">42888734</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_N9teVFxKvkWNR4UY0U83YQ_15_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5560641</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_q_mwCGSSwkWNad3X7xOPgw_15_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4588030</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_2dXwRSFYo0mH_c4_zZlNXQ_18_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2050042</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_slfxkD2jZ06KE7iblO-fRA_18_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2349974</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_0NhhpHOIn0qluTvoifkeUw_19_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">268172</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_Tk9PdIpte0aheOLBRkG0aQ_19_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">268172</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_Hf9qZWJ6b0WRDapouufVeg_21_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">58734327</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_F8g3mQQCNUKxXcAYjzpOzw_21_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">50094910</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_NexLYihGlU2XjEbNivQQTQ_26_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">6222762</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_NfhLkFcJjk-wSwqXH654-w_26_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4834683</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_XPCegLiUXUyF9i5uqf-7sg_27_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">27479</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_kjEG9yfOvkeTYjSfapki5A_27_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">89234</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_6uqExRzwl0mHLmPa3dmsCQ_28_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">749112</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_UipC6pjhN0i3_SV3aXGM_A_28_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">682039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_vb8eBVrWXk-5WTZiHzNnMA_29_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">24270465</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_TtwFdzwsqkmqRce8GPrW0w_29_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">17980599</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_s2WmNoRSKEWiRHYHo1hjFQ_31_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31269818</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_BKJa5SjSjk-VI_d3Sp2lkA_31_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">23586555</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_tWiZmKfB2kqq6hT8kMsAbg_34_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3376259</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_ya7GzjIL_0ukBFHsx3UviA_34_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3376259</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_w7Jp_K1tlkmFLTWu3Dn9bQ_35_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1486783</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_r4xmYxL3Fk-wR6S3CafK6Q_35_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1878070</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_IU1RPTcpCU2oDqQGI4GyWw_36_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_XHCzHvd2OkC0SJAm7wQWLg_36_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">9467932</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_EwWiN44Q60aS0etg1iw4rg_38_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4863042</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_ASUbCVQH50i7IDqdXOcMCw_38_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">14722261</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_6-hUv2o0cE-pPwb1gMlE5w_40_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">36132860</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_Sf87AJmS10aEFdtR20TvcQ_40_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">38308816</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Narr_YgW2REiaBkCIecaFOmoXNw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_NBfrYatKJEuTioWxSO2Fng"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Narr_nrhJM12ILkqrscgLbOT0FQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_DqSBzDO_yEa_89sWsiF6Sw"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Narr_Np4yb0C580G6NN7nrP62FA"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_PfEggW4QmkaTN8XCp_56Uw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Narr_tOto2lt0-0yclpUy0F7Dvg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_Y2q8On1QQUqjADW3KsJU3g"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_Cj9xxxWNmUmmhqwO5k16mg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31148320</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="INF"
      id="Narr_UDjVkEWrbU2juirRqnsMxA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">25241402</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_N6E2DVaKu0i-gvJqMOdEOQ_46_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31148</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_PBebyo_3fUCO7G9RYH7jxw_46_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25241</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_eTukbG4V102CTVU_2oaMxg_47_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">181701859</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc__v0TPiCJw0K1X799QKpzrw_47_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">148735420</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_-n3QGr9KEEWbY8eucjvP4Q_48_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">235813</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_pDEvSYx9b0uc8rSlmppwJw_48_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_L8Ikdi1T50Wlmh0-IAhFfg_49_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-159367353</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_4wJHkJ4e60qTwWW-1jok1A_49_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-137079811</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_SVuS1qYR10O2FCakYolY4g_51_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">22601467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_0i422w2waE2yODiTFehPLw_51_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">11786094</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_Ho3-X1xkCEWWoMNfAmXXaQ_53_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">58734327</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_TlWJA1TxlUq3CUq5qxhBiQ_53_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">50094910</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_2gUdH9Zl9EOELfb0xbGz1A_5_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25178066</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_Lo4ffeLCYUS4OKjENgc14g_5_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2551469</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_lLjtmsUoIUmjNn5mOUt6jQ_7_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25178066</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_NSlNicEG00yZw2xkmC_c6w_7_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2551469</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_5nrf5o3uIEebueQDSosR3g_10_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">36448039</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_s53YAb4X1UqUqcKVqE6thQ_10_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">21816949</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_ZIvK_6Bqg063FdknrE2q6w_11_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12807886</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_tu2o-uQ5v0ejoxKUnezIgw_11_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10431903</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_u-Ssx78-DUiV6DBDPnrQeA_13_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">49255925</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_MX3xYwqAsESdK22xRN0bHg_13_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">32248852</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_c3cHrRDrp020ZHgZx7eTYg_15_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-24077859</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_XIFh699IxkublXr6WH8VtA_15_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-29697383</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_RJCL6grHW0qkVJdZHYCFoA_18_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">67657</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_CQ1p-kwO8kaYOmysi2H7GQ_18_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">190582</us-gaap:OtherIncome>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_bkHjF1fLz0iyE58lUMgAQQ_19_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1728701</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_AWvX2FjdKkKTDtBLG18rVw_19_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">521535</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_tq0UXcn2-0GkaezL0uclnQ_20_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-6041</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_iG3SvY6QOkGO_ube0OpIuw_20_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-34266</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_b_LDL1EtWEOkDZjpF_XBbg_22_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1790317</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_MLURwOCaYkiTiXf09z9PIQ_22_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">677851</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_VhFcEjPib0qG6mrODrv5Jw_24_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22287542</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_meE62dYuoEGKOzymPpP8Hw_24_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-29019532</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_i9Ie-0vgukeFF8pNYr2xKQ_27_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">130569</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_JAM-K4r0SU2UzZLHY-S8Sg_27_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_eiyqmm2MpU2NAA1xUtXQug_29_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22156973</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_nfwishHQEkytnuWdTNZOTA_29_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-28914288</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Tc_viDl_66iLEyViCo5q-xD0Q_31_3"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Tc_kZtHLlGuSUWFLUY5pZ9lXA_31_6"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_y0gffCcoH02TuLJUiETk9w_32_3"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">26778360</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_fr2Xy1I3xEqAM1HgppuGsg_32_6"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">24552688</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg"
      decimals="INF"
      id="Tc_c-Oa1RYfkEmKM6S6fWZ6og_6_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">24185001</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8B3AhU0YFkufwGWIOwEvlg"
      decimals="0"
      id="Tc_E_CQ8mtmeEqxNP5oUsn7Dw_6_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">24185</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ec85mF__lkWbIVrr9-VJSA"
      decimals="0"
      id="Tc_YpMEX54IME2SRjs_NQ4JFw_6_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">139404060</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HU_mvTo810KMf88JbAhomA"
      decimals="0"
      id="Tc_TZBNtyBkaUek2X901uoHVg_6_14"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-108060279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"
      decimals="0"
      id="Tc_1gryOBlozki7EfC078TYhA_6_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31367966</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg"
      decimals="INF"
      id="Tc_NpBsnnqDiE67hvX51ZP_sg_8_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">830858</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg"
      decimals="0"
      id="Tc_HvHLpM0FXEG72wdjAxlYMA_8_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">831</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA"
      decimals="0"
      id="Tc_R_9Yz8A4LUOrxH8btgh0QA_8_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4802703</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_DcDqaj100ECxmgbSKYa2ZA_8_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4803534</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA"
      decimals="0"
      id="Tc_Z__9Ovr3bkCtHBG1fKRqEA_10_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4458578</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_aQ_jfzEvlUaAaqxinFUUzw_10_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4458578</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg"
      decimals="INF"
      id="Tc_sZiBhc_i3UKr7sgUdSQEsA_12_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">225543</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uxjLRG91okWLzZv83-zYJg"
      decimals="0"
      id="Tc_Z_J05oW-RUaao-rd4vIuuQ_12_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">225</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KaxVTCopo0S5c0215xsWdA"
      decimals="0"
      id="Tc_JZKvoNphgUSC9ARPalvQVw_12_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">70079</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_fdDKkc1Bd0qhkSAnxTrZuQ_12_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">70304</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_zfDRweqJO0KyY-n8-mOXUw"
      decimals="0"
      id="Tc_CwzqCmIK2kKoAhsDHzRpdA_14_11"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_3v2KWsN78E6UGX4uikC8_w_14_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BT9Hpe-z3EmOCGA9Ohlt9A"
      decimals="0"
      id="Tc_5OEtLAHoK0Oo5kcINMGBKw_16_14"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-29019532</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_9AMah4Tgyka7WoqhGvoTSQ_16_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-29019532</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q"
      decimals="INF"
      id="Tc_gZeFjl2g70it8yotqx1Svw_18_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">25241402</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JnZ1qg_7l0eanan36QAB8Q"
      decimals="0"
      id="Tc_-Z1IHQopsEiEV5_UMoY18g_18_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25241</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J8eFa0zA6kGN_euvLuaNqw"
      decimals="0"
      id="Tc_pwW6PZ9Xd0yfF5nV1FGNIA_18_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">148735420</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_E2rfLuwSdkG6a9ykiY4nqg"
      decimals="0"
      id="Tc_YIwHbesaxUuGitaaU2U8PQ_18_11"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tf5OikZQFUONNK7Iknfs5A"
      decimals="0"
      id="Tc_73FfyBy8uEWvpqUib1FxRg_18_14"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-137079811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_42qlUv4vv0ej67K4tzZIoQ_18_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">11786094</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw"
      decimals="INF"
      id="Tc_uE_gna0t2EqqZORdUoKzHg_20_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5813442</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw"
      decimals="0"
      id="Tc_uDQJK3h980ODA0r45zdmvQ_20_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5813</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww"
      decimals="0"
      id="Tc_662H9QKM2UerxtbjFSNwig_20_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25509536</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_6h7S4HCPLkCzbAgvjQs9iA_20_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25515349</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww"
      decimals="0"
      id="Tc_m8PWxAJiaE-3xZV_FXUpWA_22_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7392396</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_3gKQ58MSjEu-B64MBRavzQ_22_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7392396</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw"
      decimals="INF"
      id="Tc_td5j9_5F90qZTLuaUubSUg_24_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">93476</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oJzbfgpdAk6mQVaWqOHdZw"
      decimals="0"
      id="Tc_07AixAZjFUS-8s0QEuokZw_24_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">94</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_72_Gk_ljukeYEEl-OXBRww"
      decimals="0"
      id="Tc_cINZi7lvIESD_0ezwqojBQ_24_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">64507</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_rBtpBfZjkUOoegtkSq5_1w_24_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">64601</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_0FeZ1sWYakOU07ed4P8ELw"
      decimals="0"
      id="Tc_8575fEpWlkm9XT37-SaIwA_26_11"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">130569</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_0nB9jbvG-02j99lTEaaj_Q_26_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">130569</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5BsNuYaQz02q8UT51aO1_g"
      decimals="0"
      id="Tc_rM2_sPMQ0kiqMQMiEFgt1g_28_14"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22287542</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_rxuErLjTO061OWBWorE3mA_28_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22287542</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q"
      decimals="INF"
      id="Tc_Nsu3rWZPjkqZxVN3Y5mTqA_30_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31148320</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZRKeTiDHMkeMhpfDTC1G1Q"
      decimals="0"
      id="Tc_uFWcMNNSJ0C6R1JK1wfOLg_30_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31148</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6T-zyWrrmkSBVCPBt8HidA"
      decimals="0"
      id="Tc_C2leL5fmykevNX0dlVszdQ_30_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">181701859</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember_QonEck6FD0KdgFPM0l4WBQ"
      decimals="0"
      id="Tc_tG7fc3QB7Uq49nyJqmsqtg_30_11"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">235813</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4X-qf24Pnkim2ijfGAzOrQ"
      decimals="0"
      id="Tc_JP7NkmINLkCkaK87P54VWA_30_14"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-159367353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_llqdDfNtGEqIHSn6uRX1Sw_30_17"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">22601467</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_hswMM86hJk227C6E6Iw6fQ_4_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22287542</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_b5wVIWUOake-8zcSc3YA9Q_4_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-29019532</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_f2sdkdBTnkWzNGIbvUe2sg_6_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-6041</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_xP4yDYRr70GX-jMZcRaqww_6_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-34266</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_DZyIJI43_UuSO7YFmZ8Xbw_7_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1068882</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_IDJZzX5EYEqL8giUr3BY9Q_7_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">533131</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_i_9GfW7RjUeJlnS3vZ3Mpg_8_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7392396</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_a1kCMLHdL0Go-8fMVfySMQ_8_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4458578</us-gaap:ShareBasedCompensation>
    <capr:NoncashLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_jzUUXANuxECz2n8oRUBvFQ_9_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-24282</capr:NoncashLeaseExpenses>
    <capr:NoncashLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_0FSeTaDJ8kuIZYoY1VrNhw_9_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">161740</capr:NoncashLeaseExpenses>
    <capr:IncreaseDecreaseFromGrantsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_2BfhQf8TAUKyd8a5iXl8NA_11_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">9824413</capr:IncreaseDecreaseFromGrantsReceivable>
    <capr:IncreaseDecreaseFromGrantsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_NwZu8y_KNkqyR8ZyRYGK1g_11_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">155830</capr:IncreaseDecreaseFromGrantsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_nuyxDdV0iEKcKjNMBYhbAw_12_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">75884</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_nPosAIpn_k6ElDNea1BgEg_12_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-240045</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositsOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_I3RcjdOgwUeiETgrI2FnVQ_13_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:IncreaseDecreaseInDepositsOutstanding>
    <us-gaap:IncreaseDecreaseInDepositsOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_rntWpPZvRUCqj1qN90h3lw_13_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-7550</us-gaap:IncreaseDecreaseInDepositsOutstanding>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_j4oQUTFkiE6vav3IpiPzFQ_14_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1388078</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_1omlNl-zrUe-ujiHS4ZKBQ_14_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1718312</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_UEc8CDQLZkqVaYoqM7HOiw_15_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-61755</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_2slTEW_G4kC5f20EalyuuQ_15_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-510154</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_8foqdMOnH0uPGyYO1JNV1Q_16_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-3178066</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_xnBeZ2nWe0m3mwCNKXSqZA_16_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">27448531</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_DavmIG5uKkGKX1ahOMMzww_17_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-25596545</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_HpTeix-s70uYENvFS-FOlw_17_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4916637</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_bVLx4LTlE0OrA_f6U4r-vw_20_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">97441506</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_P9tGeAu5G0ypZUgctt0JLw_20_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">114218737</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_Y2klva5jSE6p8l7ig2e5_w_21_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">104597249</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_9aSCO9-XEEOzl5-oJm8sbQ_21_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">82505961</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_L8BLz2bGc0K4XdFhWIDVdA_22_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1311660</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_coyauhbokECfUVTH1T12Pg_22_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2000243</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <capr:PaymentsToAcquireLeaseholdImprovements
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_E4hP3ecX1Ee4z2FvHjfUqQ_23_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">735873</capr:PaymentsToAcquireLeaseholdImprovements>
    <capr:PaymentsToAcquireLeaseholdImprovements
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_BdAAzfz8QEuEtCyy0e8EWw_23_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1359488</capr:PaymentsToAcquireLeaseholdImprovements>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_EF5EGnK21kGDHs-HqzXw3w_24_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5108210</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc__LWLQ79uh0m4wpP1A1Zp7g_24_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-35072507</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_59eL1jGYjkmf90W3IhhJlg_27_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25515349</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_-rqDKA1G3kCCUxBWdfArYg_27_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4803534</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_aosefrpERUaxrzdxqDqMJA_28_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">64601</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_zS06UpLm00CJEmsukx4UNA_28_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">70304</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_VLC5RQ0v9k2oB0ohVBXakw_29_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25579950</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_SSOyQLxRNkS99-K_q_DZjA_29_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4873838</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_sygenxwA1kKA6p8rRUJ_oQ_31_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5091615</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_FwyUBFTZSE-c6clb0UTjfQ_31_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-25282032</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_nBH_BuEykUaGKDMUtq6ZoA_33_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">9603242</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"
      decimals="0"
      id="Tc_DzY8eMwuA0GZKW_FYonEAA_33_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">34885274</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_z2rNtUEnDk6zLmCBnegk3Q_35_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">14694857</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_KMX-TW5RukmGlx9ej6pZPA_35_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">9603242</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_gAOQSb3g906GoxtyfbzTWw_38_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_2pJN88_Dck21dJkzF6uEgw_38_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_9Kr9PklzFk6znXA73qHz8w_39_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_KKVXG5zvfESO5tCQkQIunA_39_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_ZBkP9g6ghUasSwotoaHqbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor Therapeutics,&#160;Inc., a Delaware corporation (referred to herein as &#x201c;Capricor Therapeutics&#x201d; or the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#x201c;DMD&#x201d;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (&#x201c;Capricor&#x201d;), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#xe1;n, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics,&#160;Inc., a Delaware corporation (&#x201c;Nile&#x201d;), on November&#160;20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics,&#160;Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple therapeutic drug candidates in various stages of development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:none;"&gt;Certain reclassification of prior period amounts has been made to conform to the current year presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents, and marketable securities as of December 31, 2023 were approximately $39.5 million, compared to approximately $41.4 million as of December&#160;31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd., a Japanese corporation, (&#x201c;Nippon Shinyaku&#x201d;), in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 &#x2013; &#x201c;License and Distribution Agreements&#x201d;). In October 2023, the Company completed a registered direct offering for gross proceeds of approximately $23.0 million (see Note 2 &#x2013; &#x201c;Stockholder&#x2019;s Equity&#x201d;). We received our first milestone payment of $10.0 million in the first quarter of 2024, which was triggered upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp;amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with our research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase 3 clinical trial of CAP-1002 in DMD;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with potential commercialization of our product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the number and scope of our research programs, including the expansion of our exosomes program; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. The Company has incurred significant operating losses and negative cash flows from operations. Based on the Company&#x2019;s available cash resources and based upon the Company&#x2019;s projections for its operations, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Therefore, there is a substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s plan to address its financial position may include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and from government grants. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company&#x2019;s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial and research and development programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Business Uncertainty Related to the Coronavirus&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In light of past uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company submitted for the Employee Retention Credit (&#x201c;ERC&#x201d;), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021 and $191,463 in 2023. As of December 31, 2023, the Company has recorded a receivable for $366,551 for the remainder of funds expected to be received. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company&#x2019;s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;presented as accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. As of December 31, 2023, marketable securities consist primarily of short-term United States treasuries. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from &lt;span style="-sec-ix-hidden:Hidden_4p8iOFeSNEmdNJAChajhxw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $1,068,882 and $533,131 for the&#160;years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,237,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,766,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,769,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,206,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,181,625)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,560,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,588,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(&#x201c;ASC 842&#x201d;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (&#x201c;ROU asset&#x201d;). ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company leases office and laboratory space, all of which are operating leases (see Note 6 - &#x201c;Commitments and Contingencies&#x201d;). Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company adopted ASU 606, &lt;i style="font-style:italic;"&gt;Revenue for Contracts from Customers&lt;/i&gt; (&#x201c;ASU 606&#x201d;), which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 &#x2013; &#x201c;License and Distribution Agreements&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#x2019;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments were achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under the U.S. Commercialization and Distribution Agreement (the &#x201c;US Distribution Agreement&#x201d;) with Nippon Shinyaku, the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the estimated duration of the HOPE-3 clinical trial, Cohort A arm. Therefore, upon receipt of the upfront payment and achievement of milestones, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grant Income&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the &#x201c;CIRM Award&#x201d;) from the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - &#x201c;Government Grant Awards&#x201d;). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized during the years ended December 31, 2023 and 2022.  &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are recognized for the amount of taxes payable or refundable for the current&#160;year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company&#x2019;s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion or the entire deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $106.9 million, available to reduce future taxable income, of which approximately $50.7 million will begin to expire in 2027. The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization. As of December&#160;31, 2023, the Company had state net operating loss carryforwards of approximately $147.3 million, available to reduce future taxable income, which will begin to expire in 2028. Utilization of these net operating losses could be limited under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state laws based on ownership changes and the value of the Company&#x2019;s stock. Additionally, currently, the Company has approximately $6.2 million of federal research and development credits and approximately $3.7 million of federal orphan drug credits, available to offset future taxable income. These federal research and development and orphan drug credits begin to expire in 2027 and 2035, respectively. Additionally, the Company currently has approximately $2.2 million of California research and development credits available to offset future taxable income which will carryforward indefinitely. Utilization of these credits could be limited under Section 383 of the Code and similar state laws based on ownership changes and the value of the Company&#x2019;s stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Section&#160;382 of the Code, the Company&#x2019;s ability to utilize NOL carryforwards or other tax attributes, such as federal tax credits, in any taxable&#160;year may be limited if the Company has experienced an &#x201c;ownership change.&#x201d; Generally, a Section&#160;382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of&#160;a corporation&#x2019;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. Similar rules&#160;may apply under state tax laws. We have experienced an ownership change that we believe under Section&#160;382 of the Code will result in limitation in our ability to utilize net operating losses and credits. In addition, the Company may experience future ownership changes as a result of future offerings or other changes in ownership of its stock. As a result, the amount of the NOLs and tax credit carryforward presented in the financial statement could be limited and may expire unutilized. The Company&#x2019;s net operating loss carryforwards are subject to Internal Revenue Service (&#x201c;IRS&#x201d;) examination until they are fully utilized and such tax&#160;years are closed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company incurred no interest or penalties for the&#160;years ended December 31, 2023 and 2022. The Company files income tax returns with the IRS and the California Franchise Tax Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. Research and development costs amounted to approximately $36.4 million and $21.8 million for the&#160;years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) generally represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders. The Company&#x2019;s comprehensive loss was approximately $22.2 million and $28.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. The Company&#x2019;s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the&#160;years ended December 31, 2023 and 2022, the Company&#x2019;s other comprehensive income was $130,569 and $105,244, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Clinical Trial Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (&#x201c;CROs&#x201d;), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No.&#160;110,&#160;Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company&#x2019;s estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reports earnings per share in accordance with FASB ASC 260-10, &lt;i style="font-style:italic;"&gt;Earnings per Share. &lt;/i&gt;Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2023 and 2022, warrants and options to purchase 13,268,807 and 5,882,621 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive shares of common stock, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level Input:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:83.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Input Definition:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level I&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level II&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level III&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Unobservable inputs that reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the fair value measurements by level at December 31, 2023 and 2022 for assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company&#x2019;s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This standard was issued in response to the SEC&#x2019;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_RBGMpCB2vk2InAmefcx8YA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor Therapeutics,&#160;Inc., a Delaware corporation (referred to herein as &#x201c;Capricor Therapeutics&#x201d; or the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (&#x201c;DMD&#x201d;), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (&#x201c;Capricor&#x201d;), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marb&#xe1;n, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics,&#160;Inc., a Delaware corporation (&#x201c;Nile&#x201d;), on November&#160;20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics,&#160;Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple therapeutic drug candidates in various stages of development.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_-ZthW11RPUe6POQc59Oblg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_eDfi3uF-3EuIKy82QUdBzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:none;"&gt;Certain reclassification of prior period amounts has been made to conform to the current year presentation.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <capr:LiquidityPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_BDPVq4aCckesjkdEp3PWKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents, and marketable securities as of December 31, 2023 were approximately $39.5 million, compared to approximately $41.4 million as of December&#160;31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd., a Japanese corporation, (&#x201c;Nippon Shinyaku&#x201d;), in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 &#x2013; &#x201c;License and Distribution Agreements&#x201d;). In October 2023, the Company completed a registered direct offering for gross proceeds of approximately $23.0 million (see Note 2 &#x2013; &#x201c;Stockholder&#x2019;s Equity&#x201d;). We received our first milestone payment of $10.0 million in the first quarter of 2024, which was triggered upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp;amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with our research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase 3 clinical trial of CAP-1002 in DMD;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the timing and costs associated with potential commercialization of our product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the number and scope of our research programs, including the expansion of our exosomes program; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. The Company has incurred significant operating losses and negative cash flows from operations. Based on the Company&#x2019;s available cash resources and based upon the Company&#x2019;s projections for its operations, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Therefore, there is a substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s plan to address its financial position may include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and from government grants. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company&#x2019;s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial and research and development programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.&lt;/p&gt;</capr:LiquidityPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_IY_x5zcEB0-8h8n8Dn4Klw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">39500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="-5"
      id="Narr_E3yDNKib4UuDPNYagEtAlA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">41400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_3_31_2023_1YjBI06wLU-zMo3y3uhc5Q"
      decimals="-5"
      id="Narr_paHgITablkOLx5rZDQwi7g"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GkllSxdfAUuGq58nSnX8Jw"
      decimals="-5"
      id="Narr_CxLjQYUiA0mGUMsPa0Ds-w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">23000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_QldM9U_12EOep7ZCnuvYiQ"
      decimals="-5"
      id="Narr_DCC7whZZpUiIoyRjlUZ11w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <capr:UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_TBmhOzVykkqQ1RVVn0UqsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Business Uncertainty Related to the Coronavirus&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In light of past uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company submitted for the Employee Retention Credit (&#x201c;ERC&#x201d;), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021 and $191,463 in 2023. As of December 31, 2023, the Company has recorded a receivable for $366,551 for the remainder of funds expected to be received. &lt;/p&gt;</capr:UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock>
    <capr:EmployeeRetentionCreditCaresActReceivable
      contextRef="As_Of_12_31_2020_HyvjpaP4ukelUP5RqqGhUg"
      decimals="0"
      id="Narr_aYZbf6Pl_026qfe_wmiyIg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">738778</capr:EmployeeRetentionCreditCaresActReceivable>
    <capr:EmployeeRetentionCreditCaresActReceivable
      contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"
      decimals="0"
      id="Narr_4pgbxjzJJku3xnZjNM1uhw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">738778</capr:EmployeeRetentionCreditCaresActReceivable>
    <capr:EmployeeRetentionCreditCaresActRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_t8_RP8tgw0mTuYIP9tOUPg"
      decimals="0"
      id="Narr_8LPsvY52KU6yKENarZh7fw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">191199</capr:EmployeeRetentionCreditCaresActRevenue>
    <capr:EmployeeRetentionCreditCaresActRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_6aqVQD_gSUuAIW9FudQcqg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">191463</capr:EmployeeRetentionCreditCaresActRevenue>
    <capr:EmployeeRetentionCreditCaresActReceivable
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_3-JIkFJOQE-SXk2I62i4Xw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">366551</capr:EmployeeRetentionCreditCaresActReceivable>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_t06zVnV6CEC65J2oYfEQqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_tTbs6-ckxUi-6fpOGwwwhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_9LqHkIGJv0yJP_7IMWqjlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company&#x2019;s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;presented as accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. As of December 31, 2023, marketable securities consist primarily of short-term United States treasuries. &lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_fcTBfA4p5k2Xo2olMuR80w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from &lt;span style="-sec-ix-hidden:Hidden_4p8iOFeSNEmdNJAChajhxw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $1,068,882 and $533,131 for the&#160;years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,237,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,766,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,769,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,206,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,181,625)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,560,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,588,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_bqLzk-PKtkyrIwepnUrEfw"
      id="Narr_WZyV80Ha8UGXLp5lhMKxqA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_kxSGunqXLEOQm8c-i3XKbg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1068882</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Narr_3cHtnfmZ40mHky6EHGFJzw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">533131</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_bYcNBBlbEEurmWaALEdRsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,237,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,766,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,769,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,206,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,181,625)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,560,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,588,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5ZNv_wjOyUmsCoYiegAY_A"
      decimals="0"
      id="Tc_Jlok-6FiYUyLYhBqeaGEXQ_3_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">187997</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_9P99ospyIU6YpKdhtGl_Tw"
      decimals="0"
      id="Tc_egnzxZB4aEOfUxtmcF_JUg_3_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">139336</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pKISfRGyWUC5dXwS0_Kalw"
      decimals="0"
      id="Tc_rFg4bvwVn0Cg5xn7mx1X2A_4_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5449597</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_H_E_Lr6_YUepovFiKb6S1w"
      decimals="0"
      id="Tc_b9_zIxA51kGHAc4TC9f1Cg_4_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4237089</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_xpiwJvCFFEONVOfrrGbCGw"
      decimals="0"
      id="Tc_Wl-fk2UOTEGOVNQZrLlGFQ_5_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2129102</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RmDL9OhBUESyNzJ0kgQcWQ"
      decimals="0"
      id="Tc_eUb8dFnkzkGeamwWfYng9w_5_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1393230</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_fB34ju0ySUSI3ipilrThmg_6_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7766696</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_fCw-VqPu50qcbqnmETjXMQ_6_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5769655</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_We5j-yjWkEej8uOR20yeyA_7_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2206055</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_PfB4gnKQUUi1hYvJ_E8n4A_7_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1181625</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_zzNdCO0EM0iGPxUkMjyv2g_8_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5560641</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_oqe2KPqXWkSoDoiuWrGcrg_8_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4588030</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_OMO4CbYsqU25DJn3vF_lHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company accounts for the impairment and disposition of long-live assets in accordance with guidance issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable, or annually. No impairment related to long-lived assets was recorded for the years ended December 31, 2023 and 2022. &#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Narr_L9wkcYdhmkG_GRaGYIwmNg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_g-Z5x58SOUKFOnR-vc7cVw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_mX1sCN377kSk3eMVB3D60Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(&#x201c;ASC 842&#x201d;), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (&#x201c;ROU asset&#x201d;). ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company leases office and laboratory space, all of which are operating leases (see Note 6 - &#x201c;Commitments and Contingencies&#x201d;). Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For real estate leases,&#160;the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only.&#160;This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_zTgxSmAA6UCbH8iKNKG_SA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company adopted ASU 606, &lt;i style="font-style:italic;"&gt;Revenue for Contracts from Customers&lt;/i&gt; (&#x201c;ASU 606&#x201d;), which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 &#x2013; &#x201c;License and Distribution Agreements&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company&#x2019;s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments were achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under the U.S. Commercialization and Distribution Agreement (the &#x201c;US Distribution Agreement&#x201d;) with Nippon Shinyaku, the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the estimated duration of the HOPE-3 clinical trial, Cohort A arm. Therefore, upon receipt of the upfront payment and achievement of milestones, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grant Income&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the &#x201c;CIRM Award&#x201d;) from the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - &#x201c;Government Grant Awards&#x201d;). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized during the years ended December 31, 2023 and 2022.  &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <capr:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Narr_LGLxXNBos0qtF_Pp1voLaw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</capr:GrantIncome>
    <capr:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_mpH61npuKUimdDaXQP16DQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</capr:GrantIncome>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_iFyQP7JtOUWR3l-I0VXrgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are recognized for the amount of taxes payable or refundable for the current&#160;year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company&#x2019;s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion or the entire deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $106.9 million, available to reduce future taxable income, of which approximately $50.7 million will begin to expire in 2027. The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization. As of December&#160;31, 2023, the Company had state net operating loss carryforwards of approximately $147.3 million, available to reduce future taxable income, which will begin to expire in 2028. Utilization of these net operating losses could be limited under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state laws based on ownership changes and the value of the Company&#x2019;s stock. Additionally, currently, the Company has approximately $6.2 million of federal research and development credits and approximately $3.7 million of federal orphan drug credits, available to offset future taxable income. These federal research and development and orphan drug credits begin to expire in 2027 and 2035, respectively. Additionally, the Company currently has approximately $2.2 million of California research and development credits available to offset future taxable income which will carryforward indefinitely. Utilization of these credits could be limited under Section 383 of the Code and similar state laws based on ownership changes and the value of the Company&#x2019;s stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Section&#160;382 of the Code, the Company&#x2019;s ability to utilize NOL carryforwards or other tax attributes, such as federal tax credits, in any taxable&#160;year may be limited if the Company has experienced an &#x201c;ownership change.&#x201d; Generally, a Section&#160;382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of&#160;a corporation&#x2019;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. Similar rules&#160;may apply under state tax laws. We have experienced an ownership change that we believe under Section&#160;382 of the Code will result in limitation in our ability to utilize net operating losses and credits. In addition, the Company may experience future ownership changes as a result of future offerings or other changes in ownership of its stock. As a result, the amount of the NOLs and tax credit carryforward presented in the financial statement could be limited and may expire unutilized. The Company&#x2019;s net operating loss carryforwards are subject to Internal Revenue Service (&#x201c;IRS&#x201d;) examination until they are fully utilized and such tax&#160;years are closed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company incurred no interest or penalties for the&#160;years ended December 31, 2023 and 2022. The Company files income tax returns with the IRS and the California Franchise Tax Board.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g"
      decimals="-5"
      id="Narr_kDjWtwP9-EO-I7Xo4Yt-xA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">106900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_lebBwGVUJ0GYE1xtWwny7w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">50700000</us-gaap:TaxCreditCarryforwardAmount>
    <capr:OperatingLossCarryForwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA"
      id="Narr_Y0lRSyQzWkWM8O7jHY09Ew">2027</capr:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_THPjM_FI7UKqY_QE2FrfMA"
      id="Narr_I4xQ-SJxmUSDuqG3sOighQ">The post December 31, 2017 net operating losses generated of approximately $56.2 million will carryforward indefinitely, but may be subject to an 80% limitation upon utilization.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <capr:OperatingLossCarryForwardsIndefinitely
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__2AmxjKNtketLh-3hDfX4g"
      decimals="-5"
      id="Narr_ppo0BYUaY0-PEJkjYt0cUg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">56200000</capr:OperatingLossCarryForwardsIndefinitely>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_KTrLvd7n_kW3fJkJoMqk2g"
      decimals="-5"
      id="Narr_0YJdvrR6n0GRbWKmjdB5Rw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">147300000</us-gaap:OperatingLossCarryforwards>
    <capr:OperatingLossCarryForwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ZlaNNG4xJUeX586mgmAzAw"
      id="Narr_vAn-cgGwnU6JuCqMuoDIAg">2028</capr:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_hIIPvdfnnkWCVs4dZrEouA"
      decimals="-5"
      id="Narr_12PkZiVn90G13JTR8FK4Sg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">6200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_666ZzRUp-EqzLeKGKVR3Ow"
      decimals="-5"
      id="Narr_T-UFM-PvlEWIWyxvfPK4aA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3700000</us-gaap:TaxCreditCarryforwardAmount>
    <capr:TaxCreditCarryForwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2RTneoE4LUiql_wj_gb_WA"
      id="Narr__BpVAiR9KUqsrb5MyF9xog">2027</capr:TaxCreditCarryForwardsExpirationYear>
    <capr:OperatingLossCarryForwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_W4VghYTqKU60Dmy4MPpb1A"
      id="Narr_pfSyy0cxvkibEXxKsMrVng">2035</capr:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_CaliforniaFranchiseTaxBoardMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_t5-jJPzGkk-S3fnBbEiOcg"
      decimals="-5"
      id="Narr_8xXqjon9mkenYaW5ykJZgQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Narr_NtEvH80GjEyBwJkCUVbAmg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_8-u2cWkrJE2AYCYyeBvZgg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_FduhOyAWG0muyMs4Y-7LnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. Research and development costs amounted to approximately $36.4 million and $21.8 million for the&#160;years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="-5"
      id="Narr_O3Smk0j0PUahpKmPucVKnw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">36400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="-5"
      id="Narr_ZTP1mGYsxkueEiy90dmQ4A"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">21800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_FTKvPoIQJU6leFkQ82bK6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) generally represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders. The Company&#x2019;s comprehensive loss was approximately $22.2 million and $28.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. The Company&#x2019;s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the&#160;years ended December 31, 2023 and 2022, the Company&#x2019;s other comprehensive income was $130,569 and $105,244, respectively.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="-5"
      id="Narr_oTIEZlJijUmlWHWWu38_ow"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-22200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="-5"
      id="Narr_08YAfLskREidQX6g_wviow"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">-28900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_LcCNkfGMXEGHWajF_GH84g"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">130569</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Narr_0kSMwI-Hj0WoHK7-wcWR8Q"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">105244</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <capr:ClinicalTrialExpensePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_oeDK_ROQ1k2qzGhA7270Wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Clinical Trial Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (&#x201c;CROs&#x201d;), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.&lt;/p&gt;</capr:ClinicalTrialExpensePolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_HyhPf0ehL06RIfufaGdTXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No.&#160;110,&#160;Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company&#x2019;s estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_lOI7jQ6GNEqGoOxqdpc6Vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reports earnings per share in accordance with FASB ASC 260-10, &lt;i style="font-style:italic;"&gt;Earnings per Share. &lt;/i&gt;Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2023 and 2022, warrants and options to purchase 13,268,807 and 5,882,621 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive shares of common stock, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the years ended December 31, 2023 and 2022.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA"
      decimals="0"
      id="Narr_tFPWFycdZECXb76Hmik08Q"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">13268807</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_b4udqpao7UWs4Wn0sMDiOA"
      decimals="INF"
      id="Narr_YPga0z2vj02zqEC8IJPaSA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5882621</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_6qlNxKxlsUK82Yls2MCGsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level Input:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:83.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Input Definition:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level I&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level II&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Level III&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:83.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Unobservable inputs that reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the fair value measurements by level at December 31, 2023 and 2022 for assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company&#x2019;s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_Sva46UZiakmmH3PIUyidUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,792,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;I&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;II&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;III&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,818,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lcBRc0KVsUmNSWtqubCDrQ"
      decimals="0"
      id="Tc_VnwzL1RHEU-bCZbkvoeXiQ_3_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">24792846</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CQIslU6IBEiaHqV7w-PERA"
      decimals="0"
      id="Tc_R8DkG6IMVECOSpiB9MgiwA_3_12"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">24792846</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4jUtqUF9xUW3YXYFwchNdg"
      decimals="0"
      id="Tc_aB-EgJglx0CxxosdPm7g5Q_3_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31818020</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_b5u34GlNrU6qAr1zibPqjg"
      decimals="0"
      id="Tc_gdRQbF6XpUaBsxPU_Hh0VQ_3_12"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">31818020</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_IIrOsD0LMUOucEdAwUzsPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This standard was issued in response to the SEC&#x2019;s disclosure update and simplification initiative, which affects a variety of topics within the Accounting Standards Codification. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact this guidance will have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_laMGFaendkabXKiVzBA-IA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;ATM Program &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company established an &#x201c;at-the-market&#x201d; program (the &#x201c;ATM Program&#x201d;) on June 21, 2021, with an aggregate offering price of up to $75.0 million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;From June 21, 2021 through December 31, 2023, the Company sold an aggregate of 2,976,154 shares of common stock under the ATM Program at an average price of approximately $5.59 per share for gross proceeds of approximately $16.6 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.6 million. As of the date of this filing, approximately $57.2 million of common stock may still be sold pursuant to the ATM Program. Additionally, subsequent to December 31, 2023, the Company sold shares under the ATM Program (see Note 9 &#x2013; &#x201c;Subsequent Events&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;October 2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On October 3, 2023, the Company entered into Securities Purchase Agreements with its commercial partner, Nippon Shinyaku and funds associated with Highbridge Capital Management, LLC (the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;), an aggregate of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;4,935,621&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;shares of its common stock, par value &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.001&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share, at a price per share of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$4.66&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;for an aggregate purchase price of approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$23.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million. Each share of common stock offered was sold with a warrant to purchase&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;share of common stock at an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5.70&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share. Each warrant will be exercisable beginning&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;six months&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;after issuance and will expire&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;seven years&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;from the date of issuance. As part of the Registered Direct Offering, the Company agreed not to issue or sell shares (subject to customary exceptions for employee stock option issuances and other customary exceptions) for a period of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;30 days&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;following the date of the prospectus supplement that&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;was used in the Registered Direct Offering. &#160;That prospectus was dated September 29, 2023, and the Company &#x201c;lock-up&#x201d; expired on October 29, 2023. The Company&#x2019;s directors and executive officers also entered into &#x201c;lock-up&#x201d; agreements with the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;placement agent in the Registered Direct Offering, which agreements expired on the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;60&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;"&gt;th&lt;/sup&gt;&lt;span style="background:#ffffff;"&gt; day following the date of the Securities Purchase Agreements, or December 2, 2023.&lt;/span&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Outstanding Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;At December&#160;31, 2023, the Company had 31,148,320 shares of common stock issued and &lt;span style="-sec-ix-hidden:Hidden_aR2fiAmS1k-ZXTjTa9frtQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <capr:CommonStockSharesAuthorizedValue
      contextRef="Duration_6_22_2021_To_6_22_2021_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_uDaog7QSQEmqbstoEX4SJQ"
      decimals="-5"
      id="Narr_aZgtXZLDM0yI40KHyr0yeg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">75000000.0</capr:CommonStockSharesAuthorizedValue>
    <capr:CommissionRateOnSalePricePerShare
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="3"
      id="Narr_1bFvh26vh0y6An8azW2P5Q"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.030</capr:CommissionRateOnSalePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_21_2021_To_3_15_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_UJ-PEwE3u0eQNWZSzusEPQ"
      decimals="0"
      id="Narr_XtlouaXjakukmzDFi_yW8A"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">2976154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_21_2021_To_12_31_2023_fcukxm__uEiN61L1wZ0xDA"
      decimals="INF"
      id="Narr_riao4cgMX0eas__OLw410g"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">2976154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_qp1o0pSjSEynST8Sz742XQ"
      decimals="2"
      id="Narr_ePOpRHhhcEiw-rTEMLzqwQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.59</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw"
      decimals="-5"
      id="Narr_uB1tlaoQkku1zzf8hUoNNg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">16600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_6_21_2021_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_znWyRBUvH0KSBSWfJb51kw"
      decimals="-5"
      id="Narr_T54zdKLbn0-uoUvyB-UkBw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <capr:CommonStockOfferingRemainingAmountIssuable
      contextRef="As_Of_3_7_2024_us-gaap_SubsidiarySaleOfStockAxis_capr_June2021AtMarketProgramMember_ZkaD9BdX-Ue4UjbW-P8o9Q"
      decimals="-5"
      id="Narr_oYors-pi90yABgZiNpxVHw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">57200000</capr:CommonStockOfferingRemainingAmountIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g"
      decimals="INF"
      id="Narr_S8BTiEiFf0qv5JQC98Ql2Q"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">4935621</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ"
      decimals="3"
      id="Narr_K9I1wbRHnEC80fPLn4IbAw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ"
      decimals="2"
      id="Narr_eXzufi48v0OMuYwhFWN8Wg"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.66</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g"
      decimals="-5"
      id="Narr_iQOm4WOdBE6cg-mSI8pJXQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">23000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ"
      decimals="INF"
      id="Narr_lDcHrXTB6EqSZyPhWeeT5w"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_fq1hs5atxE2kgtPRbAyPYQ"
      decimals="INF"
      id="Narr_vfUUQMdpbUS-mZIo5Z2QIQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_10_3_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_-rsa000sD0a8m5UVTffp1Q"
      id="Narr_LaMZYKtQ6EWXvO84m1C3-w">P6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_10_3_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_bQCWtMxE70i-06Cl52c_Sg"
      id="Narr_kxr39E8WDE-zY7vVEmNvJQ">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <capr:LockUpPeriodNotToIssueOrSellShares
      contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g"
      id="Narr_lNWXmcf8rEy6UgYtEdQQjQ">P30D</capr:LockUpPeriodNotToIssueOrSellShares>
    <capr:AgreementExpiryTerm
      contextRef="Duration_10_3_2023_To_10_3_2023_us-gaap_SubsidiarySaleOfStockAxis_capr_RegisteredDirectOfferingMember_aod-zqphVEiLtfYKG0510g"
      id="Narr_I4xihScmrUy8RAnOWCcN3g">P60D</capr:AgreementExpiryTerm>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_OzDbAMCr5kSajzKzyZLOfA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">31148320</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_rpPQJ0lsWkKDKn1PFo6RRg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;STOCK AWARDS, WARRANTS AND OPTIONS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes all warrant activity for the&#160;years ended December 31, 2023 and 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_inwFgsXzk0-bGk5MAURUnA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,041,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes all outstanding warrants to purchase shares of the Company&#x2019;s common stock:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/19/2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/19/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/27/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/27/2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10/3/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10/3/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,041,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) has approved five stock option plans: (i)&#160;the 2006 Stock Option Plan, (ii)&#160;the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the &#x201c;2012 Plan&#x201d;), (iii)&#160;the 2012 Non-Employee Director Stock Option Plan (the &#x201c;2012 Non-Employee Director Plan&#x201d;), (iv) the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), and (v) the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan and no longer issues options under the 2006 Stock Option Plan, the 2012 Plan, or the 2012 Non-Employee Director Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company&#x2019;s stockholders approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), which authorized 2,500,000 shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.&#160; Pursuant to the &#x201c;evergreen&#x201d; provision, on January 1, 2021, 823,084 shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, no new shares were added to the share reserve under the 2020 Plan pursuant to its &#x201c;evergreen&#x201d; provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June 2021, the Company&#x2019;s stockholders approved the 2021 Plan, which authorized 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards.&#160; The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2024 and 2023, 1,557,416 and 1,262,070 shares were added under the 2021 Plan, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, 1,232,318 options remain available for issuance under the respective stock option plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s stock option plans are administered by the Board, in conjunction with the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar&#160;year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price not less than equal to the closing price of the Company&#x2019;s common stock on the date of grant, and generally vest over a period of &lt;span style="-sec-ix-hidden:Hidden_ncn7a3kMgkO12NbLrZBVLA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to four years. The term of stock options granted under each of the plans cannot exceed ten years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated weighted average fair value of the options granted during 2023 and 2022 were approximately $3.85 and $3.04 per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The company used the following assumptions to estimate the fair value of stock options issued during the year ended December 31, 2023 and 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;111&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;123&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Risk-free interest rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;3.5&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;1.5&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Employee and non-employee stock-based compensation expense was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,653,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,916,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 805,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,392,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,458,578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes information about stock options outstanding and exercisable at December&#160;31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Ex. Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (yrs.)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.39 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,600,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$2.54 - $3.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,889,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.61 - $3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,004,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.11 - $7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,227,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Ex. Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(yrs.)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.39 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,544,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$2.54 - $3.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 845,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.61 - $3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,601,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.11 - $7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,248,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $13.5 million, which is expected to be recognized over a weighted average period of approximately 1.5&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a schedule summarizing employee and non-employee stock option activity for the&#160;years ended December 31, 2023 and 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,793,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,817,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (325,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (508,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,776,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,420,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (182,405)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367,422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (788,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,227,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,493,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,248,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,636,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company&#x2019;s common stock for each of the respective periods. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <capr:ScheduleOfWarrantActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA"
      id="Tb_nDYHbcz-jkGunSgMUFbB_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_inwFgsXzk0-bGk5MAURUnA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,041,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</capr:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"
      decimals="0"
      id="Tc_snqpG5v5IUq24CMq59ZRDw_3_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">105782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <capr:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_Py-PxaQDwk-c7gWaXtjTew"
      decimals="2"
      id="Tc_O2QKfG7IDEO7kEIKsMVJVg_3_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.37</capr:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <capr:ClassOfWarrantOrRightGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_eVU3fUvD_UGCFctrJpkLHw_4_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</capr:ClassOfWarrantOrRightGranted>
    <capr:WeightedAverageExercisePriceGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Tc_UElfHaHl6EePjan3i0fDog_4_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0</capr:WeightedAverageExercisePriceGranted>
    <capr:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_BwGMXfzwrUei5Wbn5Ecrag_5_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</capr:ClassOfWarrantOrRightExercised>
    <capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Tc_8R9AxcLQO0-5cMNiy0xwIw_5_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">0</capr:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_2gcp-P2agEO0fE83PQvVOA_6_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">105782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <capr:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="2"
      id="Tc_dBV5bQB4Mk-zuiuqhMFhQw_6_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.37</capr:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <capr:ClassOfWarrantOrRightGranted
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_Qj4a9OgzVEeD7XSWUb1N3w_7_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">4935621</capr:ClassOfWarrantOrRightGranted>
    <capr:WeightedAverageExercisePriceGranted
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Tc_BYRySpwklEO_fZhixRfzNg_7_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.70</capr:WeightedAverageExercisePriceGranted>
    <capr:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_0MCpZuOY80mQDUx9GFADdQ_8_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</capr:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_NNeaILGtYEejk4PpTCm2_Q_9_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5041403</us-gaap:ClassOfWarrantOrRightOutstanding>
    <capr:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="2"
      id="Tc_x7q9DoQh-USEthAejdyKYA_9_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.61</capr:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_L95AoVvDtkelV-EoTii9FA"
      id="Tb_bV_ekvDHlUa_qnJng1067w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/19/2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/19/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/27/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/27/2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10/3/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10/3/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,041,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q"
      id="Tc_tcp_Pe0fIkmxKpFxo_p6ng_5_2">2019-12-19</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw"
      decimals="0"
      id="Tc_p7Z0RCI_KEemqhTQ3qFsLg_5_4"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">40782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_xrETY022i06_Ku6R6SeboQ"
      decimals="0"
      id="Tc_m9kmr2cynUivC4DgI5Wcvg_5_6"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">40782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_E8-Ay--KRkG2z9oERuPOYw"
      decimals="2"
      id="Tc_hyEDWuwm70mbv2-sSzrXRw_5_9"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_yze3qEY3vkeaM3yID0Yb-Q"
      id="Tc_DLcGfGo3y0K_5gXX7-HOHQ_5_11">2024-12-19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q"
      id="Tc_KASz8Wm7B0C6GvV0NR0Q8w_6_2">2020-03-27</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g"
      decimals="0"
      id="Tc_oNWtjqNAWkCDnKOxrXqJaQ_6_4"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">65000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_d-yKIQOYmUyiV6A4kVWmVQ"
      decimals="0"
      id="Tc_KUaOtC4MEECLkFJzCMWl1A_6_6"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">65000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_5rljoH2yWEKmOWhlyfdC_g"
      decimals="4"
      id="Tc_fQI7GCntZUi0IuU4kULH1A_6_9"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.5313</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember_WqzDeVUnlE254fWkGq3k2Q"
      id="Tc_dyfM-C-5iESD7AwqXuWXrg_6_11">2025-03-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A"
      id="Tc_TgTtNE3S4kGOx3cvKNGmoA_7_2">2023-10-03</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg"
      decimals="0"
      id="Tc_yJnxIlgEP0ifLmT_5uQb0w_7_4"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">4935621</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_LQpmcWZ6UU-CPRPQdFSeJg"
      decimals="2"
      id="Tc_MiX133jzOUukevYqeQVc9Q_7_9"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2030TwoMember_n1SrsjCvIkebAbPTfSQ03A"
      id="Tc_8_URxPzHbUWP6j4qCBtU3g_7_11">2030-10-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_aW6aFISXRkqDMiGzcJa2cw_9_4"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5041403</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Tc_UvXZJlHgMUmzvXabGgxwZA_9_6"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">105782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <capr:ShareBasedCompensationNumberOfPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="INF"
      id="Narr_kVV1sUZu8UWYZZbkrDlv6Q"
      unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug">5</capr:ShareBasedCompensationNumberOfPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_eiRHIQU2P0-iE89u76MZug"
      decimals="INF"
      id="Narr_qcm1ZJKeWkGOyqXwIFJsgg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member_DBWOt4gfCES-rIx3f5YORA"
      decimals="INF"
      id="Narr_PjddboNwQECGJm4pchdAlQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">823084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_11_2021_To_6_11_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2020Member__c5YnH6Py0aKqf8BOj9xog"
      decimals="INF"
      id="Narr_gCygGB81jkS3IJW2tZKUDw"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_60dARrLHYEG7PVahuY09wQ"
      decimals="INF"
      id="Narr_wnpWcXobZ0y215Eion_HLg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_FGAMc8suqEKYI1VbJay2BQ"
      decimals="INF"
      id="Narr_gtGKVbi960iC4THhsg1SBA"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1557416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_capr_StockOptionPlan2021Member_cQDaPBIGKkWSfcAzIJL2Zg"
      decimals="INF"
      id="Narr_5kbPTkdn4UGJZLChNqdaBQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1262070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <capr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Narr_me9wV-1twk2xxLhb5w5cvQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1232318</capr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant>
    <capr:MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Narr_VaGe9wh9iEq9cyymPHL1mw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">100000</capr:MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ"
      id="Narr_qwWcvHvp5UyQHCdO_ERssg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ"
      id="Narr_TX6YDKKvkkmYDJJJS7NP7Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Narr_a09mvnVAXUGD6tOGkdwu5g"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Narr_XbCCzxErAESs5cODW33eyA"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      id="Tb_i50liQD6NEmqnRTFmJQ98Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;111&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;123&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Risk-free interest rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;3.5&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;1.5&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Narr_mu67czyg6EqB5CHExUn_5g"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Narr_q1-yOdHUekGw7sIl54CoSQ"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Narr_T-Ith9QZbESGKe5E8qOLiw"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Narr_msLcE_6RXEeOkG4iu1dXAg"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_OuSuklue5k-caHKqmhXnPA"
      id="Narr_BlHLyak64Eyji3NPcPBsrQ">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_mSAP63REt0u4p7xZ-eOgUQ"
      id="Narr_4DifOeWn1E-pl80I3ioMeQ">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_B-Y637VwK06PJ8NRgj159g"
      id="Narr_wtbKwOg8MkW1RS7xUoIY-Q">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_3hggLcl2wEOMWMDA2p08QQ"
      id="Narr_T0jgNundbECtuY8Cq5C8Jw">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="2"
      id="Tc_CeieMi8ltECW--p8UMNgTA_5_2"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="2"
      id="Tc_xBb7vWjcEEi1TdmB5HSWYg_5_4"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="3"
      id="Narr_SOXNGOSLiEG4sRNjSCWbng"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="3"
      id="Narr_0hBP9bxtB0G0o2VLpm7jlA"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="3"
      id="Narr_DMfoy07zqUipSgaN_MSMNg"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="3"
      id="Narr_2hUnWXfsnUWII5C3Tl148A"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_8342MTHlJkebpWiPk9LlLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,653,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,916,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 805,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,392,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,458,578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tpwrEaOXFkyl_lEK9GeKjA"
      decimals="0"
      id="Tc_Lf8bcIX7f0-MUyZ9jpKwyA_4_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">5476151</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rSWNvsGxUkyv-s30zMi0YA"
      decimals="0"
      id="Tc_NQbv-BdjZU2sApO21t5YxQ_4_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3653489</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P0GvjWMIp0OgB3_UoJ_50A"
      decimals="0"
      id="Tc_ZNvY3DtiGUiJeyU8it17UQ_5_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1916245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ur1NlChm70CaqH2aI7vchQ"
      decimals="0"
      id="Tc_Za2KKdy-ZESg37Ok0nT15g_5_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">805089</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_aj1ooEJwnEufRmvo9nYK7w_6_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7392396</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_dK9gh6rREUa1hxQYVWuH0w_6_6"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4458578</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb__qY2t1WpQUygk7_cE1mzZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Ex. Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (yrs.)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.39 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,600,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$2.54 - $3.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,889,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.61 - $3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,004,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.11 - $7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,227,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Ex. Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(yrs.)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.39 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,544,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$2.54 - $3.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 845,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.61 - $3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,601,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.11 - $7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,248,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ"
      decimals="2"
      id="Narr_PPgEeGX3REWy87f2IpfWwA"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw"
      decimals="INF"
      id="Tc_U1ysn92SS0asjdA3pr4KsQ_4_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1600054</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ"
      id="Tc_xO_m3XPrmUSk-ub9kz-Yew_4_4">P5Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw"
      decimals="2"
      id="Tc_uvyscWqoyky6OGWRd1bxtA_4_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      decimals="2"
      id="Narr_rjTkkNOJ7ka9ipewD0Nyjg"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      decimals="2"
      id="Narr_XOJEHSo-Mkmwl-QdNP-aEQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A"
      decimals="INF"
      id="Tc_y_7z6LeGbEKkPF960bjclQ_5_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1889562</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      id="Tc_2qywSJVSUESCPl_JW40rKg_5_4">P8Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A"
      decimals="2"
      id="Tc_Ngynyb_iYE2698b-K2LCeA_5_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      decimals="2"
      id="Narr_NZ4DCBvPtkOE3r14jBkGxw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.61</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      decimals="2"
      id="Narr_R5Sps_Topkq86PMnfH1x9g"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA"
      decimals="INF"
      id="Tc_qaDiWbocP02-usGR9qU6Dw_6_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">3004621</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      id="Tc_1jrUbMxQGUOB0HkPuZdc1g_6_4">P8Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA"
      decimals="2"
      id="Tc_9DQeUu5pqEKJGqCtJMhnVw_6_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      decimals="2"
      id="Narr_iWjW_8mrz0in03j2ck53PQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      decimals="2"
      id="Narr_sZ4U3zNjK0iZbnwlxSWv_A"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">7.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ"
      decimals="INF"
      id="Tc__j8fTI1OXEu-6ixYUYYVTg_7_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1733167</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      id="Tc_MdbhcSkVdka_OBn5efMgNQ_7_4">P9Y7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ"
      decimals="2"
      id="Tc_yK7EYKVKY0itlf76TuYo_w_7_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Tc_T2koH3ZWM0KuwmHaLWanHQ_8_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">8227404</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="2"
      id="Tc_9kvGgFb6TkawmruelFexWQ_8_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ"
      decimals="2"
      id="Narr_rg8Y7WBjk0GBsbDv_Og_WQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw"
      decimals="INF"
      id="Tc_3JNmHe2b20--MPTm-Nf3_g_4_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1544732</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_W8sOGxCNiUK6TSqNI6lzmQ"
      id="Tc_4wCEr69D40qCEfkWJnOhbA_4_4">P5Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeOneMember_RKUlkKb0oEi29bqGugU2yw"
      decimals="2"
      id="Tc_dT5XT6ASo0an3UVq69d70Q_4_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      decimals="2"
      id="Narr_jIn3g53FmkW1H3YMiYIPQg"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      decimals="2"
      id="Narr__140NcHRF0exm5k39qqZ3A"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A"
      decimals="INF"
      id="Tc_C88cjSL-E0OKxxPYRHF_CQ_5_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">845993</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_FVgcHP_HBEWnDVOHQt9kZw"
      id="Tc_YjEWK_H9pk6J3Zkar0ZZzA_5_4">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeTwoMember_k_XjPlVqU0yVMgYPURk_3A"
      decimals="2"
      id="Tc_0TvjRRO0f0KyET69-h0WQw_5_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      decimals="2"
      id="Narr_s3fnrFg-I0-RGPyPP5W1kw"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.61</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      decimals="2"
      id="Narr_yqNerzxeUUyZf50Vp76sPg"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA"
      decimals="INF"
      id="Tc_42xGA2IwykG0-IvdsB1dFQ_6_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">1601850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_VVUJ1Y33KECazeWS6_dkdA"
      id="Tc_gTkjtaGu0keJuT9cmykm5Q_6_4">P7Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeThreeMember_qdm00rXIT0OfQbus2wt6lA"
      decimals="2"
      id="Tc_Q7SfXRR1fECYiIBz0pJ4pw_6_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      decimals="2"
      id="Narr_xVKxWRI0EUmOPZwBf7RG1g"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      decimals="2"
      id="Narr_3jwJBkc-kkaJTxx8UO3l-g"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">7.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ"
      decimals="INF"
      id="Tc_kmUVLvYickeXzuMEKkgTxg_7_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">255561</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember_FQA4IklfHUOj98YLQtqjXg"
      id="Tc_2oOL9OJIEU2HApEECmUe3Q_7_4">P7Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_capr_RangeFourMember__8VjFkYvekCfn7gre9aixQ"
      decimals="2"
      id="Tc_9WmSyeJHp0-W6vNBMX00tA_7_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">5.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="INF"
      id="Tc_ZVsCHXZXIkqmmSK7XmYUOg_8_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">4248136</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="2"
      id="Tc_T_45hAVp40O9lsDcPmPxzg_8_7"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_YBj8rq7uRU2W1skq31SAjw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">13500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_DOC7d5sJSki-O3N2aMJwUA">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      id="Tb_gpfUJGmwjkWDF7V84fj_QA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,793,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,817,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (325,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (508,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,776,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,420,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (182,405)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367,422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (788,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,227,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,493,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,248,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,636,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA"
      decimals="INF"
      id="Tc_6FGEryBLvEeRolX5zAGMvQ_3_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">3793824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_8KT1vXSuvkeP8ZtRmC89XA"
      decimals="2"
      id="Tc_Tj3XrqU_IkSepPPNCM3CgA_3_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="INF"
      id="Tc__ysKZB5ISEuk4a7uGVu2Hw_4_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">2817370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="2"
      id="Tc_5MhovxDI4EmyAjKdox5Nrg_4_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="INF"
      id="Tc_2RXYh_OKlEO7iy2u7FPT0w_5_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">325667</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="2"
      id="Tc_cnzx4L2jtEqBFSEYcgZFJQ_5_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_-Y0PJ9jLxk-SYR1VG9XvWQ"
      decimals="0"
      id="Tc_ZX4gc-R2mEeYXHfEHBn7qw_5_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">867854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="INF"
      id="Tc_NHHUX2OXI0ShE_Ku4JZTnw_6_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">508688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_XRoSuZFAZEmeLaXBeQv9pw"
      decimals="2"
      id="Tc_vcX_L2AGbkyM0YRxaNzc3w_6_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ"
      decimals="INF"
      id="Tc_0cjv2B39UUS0YwDRC5mLNQ_7_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">5776839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_eh5KO_ppdkeJbA58HfKnqQ"
      decimals="2"
      id="Tc_4sZFFKMbyky5CcQGLFHORA_7_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="INF"
      id="Tc_rLOcVbwneEuZZlXOlqJM0w_8_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">3420979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="2"
      id="Tc_Zt7DW2tYzEyJGeQfACEmsw_8_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="INF"
      id="Tc_FJxbJ20FyUOYpG_bHgQhUg_9_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">182405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="2"
      id="Tc_kn7-Ei9KW0mfchPTJCZJhg_9_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      decimals="0"
      id="Tc_Amzme-7ldUCd_W27HkeQiQ_9_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">367422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="INF"
      id="Tc_5UML-2ksIUGUDb0s2OpJmg_10_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">788009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_Ymwt649o-EmDHrYNuwuMQw"
      decimals="2"
      id="Tc_lpFej_khN0muKSYzfrfdEg_10_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A"
      decimals="INF"
      id="Tc_fCs36ID9PE6HG5jX5pgg1g_11_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">8227404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A"
      decimals="2"
      id="Tc_OkbbVzqAa0-OnI4UPUrJ4w_11_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">3.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_QSziLLvRFU67e4XdjMf-hQ_11_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12493414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A"
      decimals="INF"
      id="Tc_r3rDdlWwfEa81JH5FxPNag_12_2"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">4248136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_4vL2XiHyYkqCebL7HZuJ4A"
      decimals="2"
      id="Tc_657vEGgatkm_JXoanRzYCA_12_5"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">2.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_uG0_5t9lxkWaHQS0PWq8YQ_12_8"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">8636326</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_kbpkcSPOYk-pP3RXsus5EA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;4.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;CONCENTRATIONS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Concentration of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company maintains accounts at three financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (the &#x201c;FDIC&#x201d;) for up to $250,000 and/or the Securities Investor Protection Corporation, as applicable. The Company&#x2019;s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of December&#160;31,&#160;2023, were approximately $39.2 million. The Company monitors the financial stability of the financial institutions with which it maintains accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. Historically, the Company has not experienced any significant losses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <capr:NumberOfFinancialInstitutions
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_D21bKRI0S0WvnZPEXm4Dhw"
      unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug">3</capr:NumberOfFinancialInstitutions>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_3ugJCAg170uTSGKQf4uQJg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_ASEf9Ffq7ku0XOp1HyBcyw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">39200000</us-gaap:CashUninsuredAmount>
    <capr:GovernmentGrantAwardsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_xbwIOVf4YU6KxrIzn31DTg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;5.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;GOVERNMENT GRANT AWARDS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;CIRM Grant Award (HOPE)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June&#160;16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor&#x2019;s Phase 1/2 HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section&#160;100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in the CIRM Loan Policy and CIRM Grants Administration Policy for Clinical Stage Projects (the &#x201c;New Loan Balance&#x201d;), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. Depending on the timing of our election, additional funds may be owed. If we elect to do so, Capricor would be required to repay the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of December 31, 2023, Capricor&#x2019;s liability balance for the CIRM Award was approximately $3.4 million.&lt;/p&gt;</capr:GovernmentGrantAwardsDisclosureTextBlock>
    <capr:GrantAwardLiability
      contextRef="As_Of_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_8kCOk0e360iW2gA4XW8iYA"
      decimals="-5"
      id="Narr_gz4MPvjpr0uEjPOv77AYig"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3400000</capr:GrantAwardLiability>
    <capr:MinimumExpectedContribution
      contextRef="Duration_6_1_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_X7Uz7GC3XUmBUEPTyo0nPg"
      decimals="-5"
      id="Narr_2dg8VPSuDE-b4hnHtRnQyg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2300000</capr:MinimumExpectedContribution>
    <capr:NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable
      contextRef="Duration_6_16_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_2oh6xrIk3U6oGA7dPrVBkg"
      decimals="0"
      id="Narr_2Df72oGTO0KQZUk0et9j_A"
      unitRef="Unit_Standard_item_16395vBjAEypAKpz4atoug">9</capr:NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable>
    <capr:TermOfAward
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ"
      id="Narr_0C3sSP_SrkWnfPJNF8XXeA">P10Y</capr:TermOfAward>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ"
      id="Narr_nWnKT-hasUuR6O47M1z0nQ">P5Y</us-gaap:DebtInstrumentTerm>
    <capr:TermOfAward
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_t0p4VnHdBU6rs_hLSn1kKQ"
      id="Narr_paYLhYRWJE6CLcZP5EyoTA">P10Y</capr:TermOfAward>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_us-gaap_VariableRateAxis_capr_LiborMember_bGOtzNXAZUys8V9CVS72yA"
      decimals="INF"
      id="Narr_yuGz0hHmB0WG-kDaQelLzA"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.01</us-gaap:DerivativeVariableInterestRate>
    <capr:GrantAwardLiability
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_RVq8CNEcHEiNiTlY9gUr_A"
      decimals="-5"
      id="Narr_1sVmuYfGg066SJwmCfhs1w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">3400000</capr:GrantAwardLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_OYWVyI7AnkS-3NHUrw6Qqw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;6.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Short-Term Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon 90 days&#x2019; written notice to the other party. Commencing in July 2022, the monthly lease payment was $7,869 per month. Effective July 1, 2023, the monthly lease payment was reduced to $7,619 per month. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenses incurred under short-term operating leases for the years ended December 31, 2023 and 2022 were $92,928 and $81,735, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Long-Term Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (&#x201c;CSMC&#x201d;), a related party (see Note 8 &#x2013; &#x201c;Related Party Transactions&#x201d;), pursuant to a lease (the &#x201c;Facilities Lease&#x201d;) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional 24-month period extending the term through July 31, 2024 with a monthly lease payment of $10,707. Additionally, in September 2023, we entered into an amendment pursuant to which Capricor was granted an option to extend the lease for an additional 24-month period extending the term through July 31, 2026 with a monthly lease payment of $11,028 commencing on August 1, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (&#x201c;Altman&#x201d;) for 9,396 square feet of office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the &#x201c;San Diego Lease&#x201d;). The rent is subject to a 3.0% annual rent increase during the initial lease term of five years, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of five years. The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022, the monthly lease payment was increased to $49,322 per month. Effective December 1, 2022, the monthly lease payment was increased to $51,444 per month. Effective October 1, 2023, the monthly lease payment was increased to $58,409 per month. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (&#x201c;Explora&#x201d;), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $4,021 per month for an exclusive large vivarium room located in San Diego, California. The lease term is for one-year and will automatically renew for additional successive one-year renewal terms unless either party provides the other party with 60-day written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of 4.5% bringing the base rent to approximately $4,202 per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of five years. &#160; &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The long-term real estate operating leases are included in &#x201c;lease right-of-use assets, net&#x201d; on the Company&#x2019;s Consolidated Balance Sheet and represent the Company&#x2019;s right-to-use the underlying assets for the lease term. The Company&#x2019;s obligation to make lease payments are included in &#x201c;lease liabilities, current&#x201d; and &#x201c;lease liabilities, net of current&#x201d; on the Company&#x2019;s Consolidated Balance Sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 886,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 910,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 676,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,473,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (237,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,235,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Included in the consolidated balance sheet:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current portion of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 749,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,486,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,235,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.73 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.24%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;As of December 31, 2023, ROU assets for operating leases were approximately $2.1 million and operating lease liabilities were approximately $2.2 million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company&#x2019;s operating leases under ASC 842 for the period indicated: &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs, unrelated parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 663,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 632,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 129,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease payments, unrelated parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 684,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 470,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease payments, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Legal Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company has not recorded any material accruals for loss contingencies as of December 31, 2023. The Company has received a letter from CSMC alleging certain overdue payment obligations and alleged breaches (see Note 7 &#x2013; &#x201c;License and Distribution Agreements&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Accounts Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Other Funding Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 - "License and Distribution Agreements").&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Employee Severances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability under these severance packages has been recorded as of December 31, 2023.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A"
      id="Narr_kA0mAYf3qUO9WDdma2Dkmg">P90D</capr:WrittenNoticePeriod>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_bD2EIdyBUUuS0qgSmQHcbg"
      decimals="0"
      id="Narr_fYWBUB03yEGmZ_7A9vxWOw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7869</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_7_1_2023_To_7_1_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_1IeDcw5S-Emny3Ah0glf7Q"
      decimals="0"
      id="Narr_hi6n5v7hBkGMmPT-6zcLMg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">7619</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_uPkh3jGa9kaUE6AoqCVy2A"
      decimals="0"
      id="Narr__yJPwyQsXk-fmWr2StmEFA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">92928</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_CorporateOfficesLeaseMember_ztBgOe6LO0utYsvlcIn3LQ"
      decimals="0"
      id="Narr_inIHpLJQRUiDrqJaCRtijg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">81735</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_7_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_FacilitiesLeaseMember_X5iGALpimEK3OkzCpCCfPA"
      id="Narr_JR5_y2fHMUe2ym7VK0DXtA">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_gpq9drB0NkmE4zplTZT6kg"
      decimals="0"
      id="Narr_QX6LPsJaFUqOVH5KTIeuoQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10707</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_5EcEBXyvWkCaPP71aV_17g"
      id="Narr_8gCXYowXP0GJBtdw3Xc7KA">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_LeaseContractualTermAxis_capr_FacilitiesLeaseMember_S7NB6S2w7UatfWnNM-rVaw"
      decimals="0"
      id="Narr_udbI5QVVoEmXuhIZtvp2Dg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">11028</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <us-gaap:NetRentableArea
      contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg"
      decimals="0"
      id="Narr_miYag-FlKUCvI1b1ovsN1Q"
      unitRef="Unit_Standard_sqft_rMuzb-X9s06FnUhxCkVIgQ">9396</us-gaap:NetRentableArea>
    <capr:OperatingLeasePercentageOfIncreaseInAnnualLeaseRent
      contextRef="Duration_10_1_2021_To_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_MLcvLvWUPEyWrlR72udH3w"
      decimals="4"
      id="Narr_up9kSQ46XUK4sG_pFSQd9g"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.030</capr:OperatingLeasePercentageOfIncreaseInAnnualLeaseRent>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg"
      id="Narr_X44LYl6Vz069l3RrBsqlFg">P5Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_10_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_L8cH1g4-MEOAOLQsAL6iqg"
      id="Narr_ZdUhGaHYB0mM8ZXcT4Zc_g">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <capr:LesseeOperatingLeaseLeaseRentPerMonth
      contextRef="Duration_7_1_2022_To_7_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_e9bkzfMXvE6M55FAWBdCdA"
      decimals="0"
      id="Narr_6E3y6fMoeU2cDG9Zt9vtzA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">49322</capr:LesseeOperatingLeaseLeaseRentPerMonth>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_12_1_2022_To_12_1_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_PropertyLocatedAt10865RoadToCureInDiegoMember_gQ0jiQuHOkO7EnvSiVT1AQ"
      decimals="0"
      id="Narr_BVSZPXUo3EOGNHPV3SIz9A"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">51444</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_10_1_2023_To_10_1_2023_hVssF0k9YkaCVh2VT_moBA"
      decimals="0"
      id="Narr_k8CGgnMufEuiNCH_zmsw3A"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">58409</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw"
      decimals="0"
      id="Narr_Ey_uQgi4H0m25WTuLxrgcg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4021</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="As_Of_11_1_2021_srt_RangeAxis_srt_MinimumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_khGZ9fyPC02WUrVz7NyC4g"
      id="Narr_0i2sugYiu0W9JAIn8_HUeQ">P1Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_gO-91n0nUE2kR2Y9RTTwLQ"
      id="Narr_CD5rtAN7gEqWfR6jrKaxvQ">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <capr:WrittenNoticePeriod
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_vXr19ckNlEODpI1BYL_agw"
      id="Narr_xlcA5DMpxU2oOhc2GG3QSA">P60D</capr:WrittenNoticePeriod>
    <capr:LesseeOperatingLeaseMonthlyRentEscalationPercent
      contextRef="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w"
      decimals="3"
      id="Narr_QZ3ANG47zku7ou3prV094g"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.045</capr:LesseeOperatingLeaseMonthlyRentEscalationPercent>
    <capr:LesseeOperatingLeaseBaseLeaseRentPerMonth
      contextRef="Duration_12_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_EomCxk13tUOZWP7HSoVn-w"
      decimals="0"
      id="Narr_7bCMl1lP3kmHtL3MwV8g6w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">4202</capr:LesseeOperatingLeaseBaseLeaseRentPerMonth>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="As_Of_11_30_2021_srt_RangeAxis_srt_MaximumMember_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_capr_VivariumSpaceLeaseMember_pZgkKv4xj0G4O10XC-Wx9g"
      id="Narr_x_QbhSuPcUKv6m2CCvqhyQ">P5Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_2eMvp0UhakmmtFwMlefbqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 886,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 910,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 676,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,473,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (237,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,235,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Included in the consolidated balance sheet:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current portion of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 749,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,486,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,235,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.73 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.24%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_RI4aIXvz0U6rPR6k0-h-qQ_1_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">886672</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_MD0BCi7lMkepCzg8jhGNQQ_2_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">910106</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_cFQ3X90npEWv9BZiwjVYzw_3_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">676908</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_wTuyZ2vEyk2J00U5qheKhg_6_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2473686</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_ojXHMBKcVEWBPzUQ0FAFCA_7_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">237791</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_sVGZr-fehEa-3mRDEGnA6Q_8_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2235895</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_pgR_mS1EBUKJPLZFrdK0OQ_10_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">749112</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_WAkuxyrGc0621vmz1GDe-w_11_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1486783</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Tc_UF6DW1cp5EiTJUgcWtI-UA_12_3"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2235895</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      id="Narr_WeWsuKRP50KOeTo8iac5VA">P2Y8M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="4"
      id="Tc_ciGkvDpgXkKhIiJY-jeiFQ_16_3"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.0724</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_7U1Sj0uMfUudqcooKvzHOg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="-5"
      id="Narr_lxfsvKXKrkG3LIACnJUO4A"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_jGdSeUl750KJ6zzVMFkZfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs, unrelated parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 663,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 632,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 129,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease payments, unrelated parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 684,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 470,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease payments, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA"
      decimals="0"
      id="Tc_aIA4P6o5vkuOyBGZFvS8Nw_4_2"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">663684</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA"
      decimals="0"
      id="Tc_Dx-dumJH40C0GZZlIbhH4Q_4_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">632689</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw"
      decimals="0"
      id="Tc_PvFl9UXsdUCNL088yLisXQ_5_2"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">129158</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg"
      decimals="0"
      id="Tc_GuFqBn1wEk23S4Td4Gt7Jg_5_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">128478</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_dVg_0_Fv0Eqp0wKR-vkYuA"
      decimals="0"
      id="Tc_R5SDevrZSky_JuXTOAclpg_6_2"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">684444</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_capr_UnrelatedPartyAxis_capr_UnrelatedPartyMember_28KmOe8OGU6amwJAcrbVEA"
      decimals="0"
      id="Tc_t9djnZcOWkOYEkjQaVawyg_6_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">470950</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Lmsg8J4I-UGRywyaErRXQw"
      decimals="0"
      id="Tc_UcBmkLGn7ECloBYK5Df07Q_7_2"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">117772</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m7gB4A2qpk6xbV6R1vlUdg"
      decimals="0"
      id="Tc_b6k2qyelc02t6gw8ak0Xhg_7_5"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">128478</us-gaap:OperatingLeasePayments>
    <capr:SeverancePackageToBePaidForPeriodOfBaseSalary
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_aiksnjBU-0ik1k2sl3mlIg">P6M</capr:SeverancePackageToBePaidForPeriodOfBaseSalary>
    <us-gaap:RestructuringReserve
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_TkvE6l79UEeo71squ8xNGQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">0</us-gaap:RestructuringReserve>
    <capr:LicenseAgreementsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_SKsyafYZsU-kgsiIWME4JQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;7.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;LICENSE AND DISTRIBUTION AGREEMENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Intellectual Property Rights for Capricor&#x2019;s Technology&#160;- CAP-1002 and Exosomes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Universit&#xe0; Degli Studi Di Roma La Sapienza (the &#x201c;University of Rome&#x201d;), JHU and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;University of Rome License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the &#x201c;Rome License Agreement&#x201d;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third-party to Capricor. The minimum annual royalties are creditable against future royalty payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party&#x2019;s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days&#x2019; written notice to the University of Rome.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Johns Hopkins University License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;License Agreement for CDCs&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the &#x201c;JHU License Agreement&#x201d;), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the FDA. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase 3 study for which a payment of $500,000 will be due.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days&#x2019; written notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;"&gt;License Agreement for Exosome-based Vaccines and Therapeutics&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Capricor and JHU entered into an Exclusive License Agreement (the &#x201c;JHU Exosome License Agreement&#x201d;), effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provided for the grant of an exclusive, world-wide, royalty-bearing license of JHU&#x2019;s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. The JHU Exosome License Agreement was terminated by Capricor on December 15, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cedars-Sinai Medical Center License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;License Agreement for CDCs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the &#x201c;Original CSMC License Agreement&#x201d;), for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the&#160;percentage of sublicense fees which would have been payable to CSMC. Effective December&#160;30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the &#x201c;Amended CSMC License Agreement&#x201d;), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#xe1;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty-bearing product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days&#x2019; notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days&#x2019; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor and CSMC have entered into several amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents and extend the timing of certain development milestones, among other things. Capricor reimbursed CSMC for certain attorneys&#x2019; fees and filing fees incurred in connection with the additional patent applications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We recently received a letter from CSMC alleging that pursuant to the Amended CSMC License Agreement between CSMC and Capricor, Capricor has certain overdue payment obligations to CSMC arising out of a milestone payment received by Capricor pursuant to the U.S. Distribution Agreement entered into between Capricor and Nippon Shinyaku. Capricor has received a milestone payment of $10.0 million under its U.S. Distribution Agreement with Nippon Shinyaku, which CSMC is claiming 10% of this milestone payment is owed to them. The notice letter requests that Capricor cure the alleged breaches of the Amended CSMC License Agreement, and reserves CMSC&#x2019;s purported right to terminate the Amended CSMC License Agreement if such alleged breaches are not cured. We dispute the allegations in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the letter from CSMC and intend to vigorously defend our position and pursue all available remedies, but there is no guarantee that any disputes that we have with CSMC will be resolved or if resolved, will not result in our incurring certain payment and other obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 0pt 36pt;"&gt;License Agreement for Exosomes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the &#x201c;Exosomes License Agreement&#x201d;), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr.&#160;Eduardo Marb&#xe1;n on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit&#160;percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third-party for patent rights in connection with the royalty bearing product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i)&#160;if Capricor ceases, dissolves or winds up its business operations; (ii)&#160;in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii)&#160;if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv)&#160;within 30 days for non-payment of royalties; (v)&#160;after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi)&#160;if a material breach has not been cured within 90 days; or (vii)&#160;if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days&#x2019; notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Capricor and CSMC have entered into several amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights, and converted certain exclusive rights to co-exclusive rights. These amendments also obligated Capricor to reimburse CSMC for certain attorneys&#x2019; fees and filing fees in connection with the additional patent applications and patent families.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cell Line License Agreement with Life Technologies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in 2022 and additional milestone fees may become due based on the progress of our development program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On January 24, 2022, Capricor entered into a Commercialization and Distribution Agreement (the &#x201c;U.S. Distribution Agreement&#x201d;) with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S Distribution Agreement, Capricor received an upfront payment of $30.0 million in the first quarter of 2022. The first milestone payment of $10.0 million was paid upon completion of the interim futility analysis of the HOPE-3 trial whereby the outcome was determined to be not futile. Additionally, there are potential milestones totaling up to $90.0 million leading up to and including the BLA approval. Further, there are various potential sales-based milestones, if commercialized, tied to the achievement of certain sales thresholds for annual net sales of CAP-1002 of up to $605.0 million. Further, pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and Capricor will have the right to receive a meaningful mid-range double-digit share of product revenue. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, &lt;i style="font-style:italic;"&gt;Revenue for Contracts from Customers&lt;/i&gt;. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase 3 clinical study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined the transaction price totaled $40.0 million, which was the upfront payment of $30.0 million and $10.0 million milestone payment. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the $40.0 million transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study, Cohort A arm, to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract&#x2019;s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2023, the Company recognized approximately $25.2 million as revenue compared to approximately $2.6 million for the year ended December 31, 2022. In relation to the U.S. Distribution Agreement, as of December 31, 2023, the Company recorded approximately $12.3 million as current deferred revenue on the Company&#x2019;s consolidated balance sheets. As of December 31, 2023, the Company recorded a receivable of $10.0 million in connection with the interim futility milestone, which payment was received in January 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had no opening or closing contract asset balances recognized. &#160;The difference between the opening and closing balances of the Company&#x2019;s contract liability results from the Company performance of services in connection to its performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of December 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $12.3 million. At this time, we estimate 100% of the remaining performance obligations are expected to be recognized over the next 12 months. Remaining performance obligations estimates are subject to change.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 10, 2023, Capricor entered into a Commercialization and Distribution Agreement (the &#x201c;Japan Distribution Agreement&#x201d;) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023 and in addition, Capricor may potentially receive additional development and sales-based milestone payments of up to approximately $89.0 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Subject to regulatory approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, &lt;i style="font-style:italic;"&gt;Revenue for Contracts from Customers&lt;/i&gt;. The Company determined the initial transaction price totaled $12.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $12.0 million as current deferred revenue on the Company&#x2019;s consolidated balance sheets as of December&#160;31,&#160;2023. &#160;&lt;/p&gt;</capr:LicenseAgreementsTextBlock>
    <capr:AnnualPaymentsForRoyalties
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_nwrh_aVVjkGtRzSmUAp6Pw"
      decimals="0"
      id="Narr_OTTcwDg3Xki2z7yEiStsmQ"
      unitRef="Unit_Standard_EUR_1WG7i0WyeU6pv6Zueih0aw">20000</capr:AnnualPaymentsForRoyalties>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw"
      id="Narr_o_rOiVFmBkOpdldl9LffKw">P90D</capr:WrittenNoticePeriod>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_RomeLicenseAgreementMember_rC1Lq1xV_0GEBx1ZHrxUJw"
      id="Narr_9A4q-gNVVkShjX6yzy8vyA">P90D</capr:WrittenNoticePeriod>
    <capr:PotentialMilestonePayments
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_oHpjOTKGoUykLnbV-fTRSQ"
      decimals="0"
      id="Narr_gImTE3OF2ke2kCAPjD0hQw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1850000</capr:PotentialMilestonePayments>
    <capr:MilestonePayments
      contextRef="Duration_3_1_2022_To_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_jFLITrcimUyqsFvsZebRCA"
      decimals="0"
      id="Narr_nxpDMlJtkUuMxsGr5HVC1A"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">250000</capr:MilestonePayments>
    <capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
      contextRef="As_Of_3_31_2022_capr_MilestonePaymentsInPhasesAxis_capr_CompletionOfPhaseTwoDueMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_CwHLfODuHEWscaDC4mM3SQ"
      decimals="0"
      id="Narr_ivkKhHgZZk2FwM6edcLiRw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">500000</capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases>
    <capr:PeriodOfAgreementWillBeInEffective
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_raj702HzaEWCiJY45rn1UA"
      id="Narr_CzDnAe-tBEOo8D3y5PG5qA">P20Y</capr:PeriodOfAgreementWillBeInEffective>
    <capr:ThresholdPeriodToCureBreach
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw"
      id="Narr_Zh6mj-FibECj0b8A0fcFBg">P30D</capr:ThresholdPeriodToCureBreach>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_JhuLicenseAgreementMember_Va50h1hHjEGAMhZeGrZZfw"
      id="Narr_Jv28LHdLIEWD7DJvjVSH3w">P60D</capr:WrittenNoticePeriod>
    <capr:AgreementTerminationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_bybMKDXxsEWCLX8wsTPgbw"
      id="Narr_uzNodOvAhUa1orvpSNKu5w">P30D</capr:AgreementTerminationPeriod>
    <capr:AgreementTerminationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_vjuMg_ZNqkuHDVxlRGx3Dg"
      id="Narr_bW78lFyixUmvvnzQIVjEhw">P90D</capr:AgreementTerminationPeriod>
    <capr:AgreementTerminationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_kNOGvDAtg0KsQmmw19rGSg"
      id="Narr_FXQ-XZe5jUC6OMN2cH030w">P90D</capr:AgreementTerminationPeriod>
    <capr:AgreementTerminationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_2-wubRxozEmpbQcL1C0TJg"
      id="Narr_T7NuhrIOrE6HEpukpwlK3A">P90D</capr:AgreementTerminationPeriod>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_hcCGu4aCq0aWdI1ic9gMFg"
      id="Narr_rA80p8gjLkG1xZSb_exhRw">P90D</capr:WrittenNoticePeriod>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__dhbnCoFj0mFXSecYuidNA"
      decimals="-5"
      id="Narr_aDvGvbX_LEK6elyutWwxRw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <capr:MilestonePaymentsPercentageOwedToThirdParty
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_capr_OverduePaymentObligationsMember_us-gaap_RelatedPartyTransactionAxis_capr_CsmcLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_-d6RYF7mlUWi4_x3ZsGV7g"
      decimals="2"
      id="Narr_wnXWioLYQ0Gksscb5rZ7IA"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">0.10</capr:MilestonePaymentsPercentageOwedToThirdParty>
    <capr:ThresholdPeriodToCureBreach
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_NonPaymentOfRoyaltiesMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_p6GoxGGgcE2JSpPe0-Rv6Q"
      id="Narr_o_HpZg_Y4UuAVtLv0LLvWw">P30D</capr:ThresholdPeriodToCureBreach>
    <capr:ThresholdPeriodToCureBreach
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_fHaPByLkFEWmMCmmItdYUA"
      id="Narr_AFSRstBg_EiP2AD6OkqsKA">P90D</capr:ThresholdPeriodToCureBreach>
    <capr:ThresholdPeriodToCureBreach
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_MaterialBreachHasNotBeenCuredMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_G6HBLmII80uwt4M0Xn301w"
      id="Narr_v8lAuhocW0aveNuulD97iQ">P90D</capr:ThresholdPeriodToCureBreach>
    <capr:ThresholdPeriodToCureBreach
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_capr_FailsToCureBreachAfterNoticeFromCsmcMember_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_Xt587NoPDES43nwHwu-1Rg"
      id="Narr_fDqhlUn6eUCWPRvDWg0z4A">P90D</capr:ThresholdPeriodToCureBreach>
    <capr:WrittenNoticePeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_ExosomesLicenseAgreementMember_JVh39f55SEWCSfGr2sFfwQ"
      id="Narr_PcINGFEjF0qY9m9e5hkWfw">P90D</capr:WrittenNoticePeriod>
    <capr:UpfrontPayment
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_hUhoFzMYxU2y08SvRW_3Vg"
      decimals="-5"
      id="Narr_40-nuVEA7ke5qOJ5DNPOGw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">30000000.0</capr:UpfrontPayment>
    <capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="-5"
      id="Narr_G5P_SCg-O0azBsstZAfCaQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000000.0</capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases>
    <capr:PotentialMilestonePayments
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"
      decimals="-5"
      id="Narr_YIiuivSHA0qcNLlbWk9grQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">90000000.0</capr:PotentialMilestonePayments>
    <capr:PotentialMilestonePayments
      contextRef="As_Of_1_24_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_f49c96jOM0qAScvbNEBu5w"
      decimals="-5"
      id="Narr_BgcDu9kJ7kWp5HvCp9jPfw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">605000000.0</capr:PotentialMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_oeC63qvRMkKBhVSqouykUg"
      decimals="-5"
      id="Narr_8ANsKAcTFEyBZKMExUVjoA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">40000000.0</us-gaap:ContractWithCustomerLiability>
    <capr:UpfrontPayment
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_l8hYv85mhkiSnt-G1Lj7Iw"
      decimals="-5"
      id="Narr_0Wj0JQ-xnkSUmS2nSng3OA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">30000000.0</capr:UpfrontPayment>
    <capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"
      decimals="-5"
      id="Narr_gka0krZgeEqkAujeaExOZw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000000.0</capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_qQnWowdCk0ycTDEN3vYiFQ"
      decimals="-5"
      id="Narr_l9xfH18FJ0yPzEygoSrpRA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">40000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_YSrt3eyVpUyrEiyR3LkflQ"
      decimals="-5"
      id="Narr_8Kx3ziDJd0mu9jWQqxk6VQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">25200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_7DiFd0JLoUiEm79PuGWQEQ"
      decimals="-5"
      id="Narr_tXcOCKGLEEyaE6aeTWZ5fA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">2600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"
      decimals="-5"
      id="Narr_0ffc869l0UKbwuwbKNvYEQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"
      decimals="-5"
      id="Narr_SJ54WGQeHUy05IwyNsGKJQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000000.0</capr:MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_wyAwI7r090ORmSQqIAxKEA"
      decimals="-5"
      id="Narr_7HH-j-xILEK0z1TW4fsz_w"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg"
      decimals="2"
      id="Narr_G9LHAQQHSkKeCAqip2t7Hg"
      unitRef="Unit_Standard_pure_mxuu-W6P0Eer_FHdStMPHQ">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="As_Of_12_31_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_capr_cnst_date_20240701_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_A3SyD96uwUGOwCGjhDyLwg"
      id="Narr_8svmEyqyAUejNPbWkGsDYA">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <capr:UpfrontPayment
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_r9pBOG-cqUSu0_0p-X_SUA"
      decimals="-5"
      id="Narr_b97JJriaW06fuVRTUn2rtg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12000000.0</capr:UpfrontPayment>
    <capr:PotentialMilestonePayments
      contextRef="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_GyIsPMRQwEid4EesUv_0_A"
      decimals="-5"
      id="Narr_6t-PYZOwTUaHyp0_S1yDKg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">89000000.0</capr:PotentialMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw"
      decimals="-5"
      id="Narr_nh_OEK25AkW9IIAVReouWg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember_ozDUVQsxqECxdqLp-_7dsw"
      decimals="-5"
      id="Narr_xpoNYL9T7kShk1Mvy3yhfg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">12000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_VQYJVtbj0U2i92zRO713Pg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;8.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Lease and Sub-Lease Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As noted above, Capricor is a party to lease agreements with CSMC (see Note&#160;6&#160;&#x2013; &#x201c;Commitments and Contingencies&#x201d;), and CSMC has served as an investigative site in Capricor&#x2019;s clinical trials. Additionally, Dr.&#160;Eduardo Marb&#xe1;n, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company&#x2019;s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Consulting Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company&#x2019;s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marb&#xe1;n whereby he was granted an option to purchase 50,000 shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marb&#xe1;n was granted an additional option grant to purchase 50,000 shares of the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, Capricor entered into a Consulting Agreement with Michael Kelliher, a member of its Board of Directors, related to business development services whereby he was granted an option to purchase 30,000 shares of the Company's common stock. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Payables to Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2023 and 2022, the Company had accounts payable and accrued expenses to related parties totaling $27,479 and $89,234, respectively. CSMC accounts for $17,479 and $79,234 of the total accounts payable and accrued expenses to related parties as of December 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the&#160;years ended December 31, 2023 and 2022, the Company paid CSMC approximately $226,400 and approximately $794,000, respectively, for such costs.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <capr:MonthlyConsultingFeesToRelatedParty
      contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q"
      decimals="0"
      id="Narr_3YUDnbXHNUO9SGMoOJBjxg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">10000</capr:MonthlyConsultingFeesToRelatedParty>
    <capr:TerminableNoticePeriod
      contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementWithFrankLitvackMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bQRVRCrOxE-PIKZKhAWr2Q"
      id="Narr_MJqRSLgv80a-QmMWvr24vg">P30D</capr:TerminableNoticePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_R17I3foYh02N_TLWyWcP4Q"
      decimals="INF"
      id="Narr_eCIKoQWKnkqYhxfGUh8h_g"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_AdvisoryServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_DrEduardoMarbanMember_m81pZxvbV0ifPEk3pIVFTQ"
      decimals="INF"
      id="Narr_Da-R3S7PB0KFW-ccX7i3cQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_MichaelKelliherMember_What73q3UE2-6pZFUmISsA"
      decimals="INF"
      id="Narr_ZKSUGhPz1EGihom-6rWcew"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2S_huVsjyUeJPlBGvG9Ong"
      decimals="0"
      id="Narr_7oVyEjhT4E-aZsnM78WtUQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">27479</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QL8AKwNRYE69o6c9cnDAeA"
      decimals="0"
      id="Narr_TQCWQuA0wkScX36vohL-UA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">89234</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_aYVKDRCxe0SMDBzgeTcNdg"
      decimals="0"
      id="Narr_-UE61y9HLkS2rfolpXT9Vw"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">17479</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_capr_TransactionOtherThanSubawardAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember__Feo3dGKN0Sy2w8lAyM8Cg"
      decimals="0"
      id="Narr_7GGjcpbHOEKIA1XazGuhng"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">79234</us-gaap:OtherLiabilitiesCurrent>
    <capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_I1LoZTPxAU2_UBJz6muQiQ"
      decimals="0"
      id="Narr_ghxgSsxiHEi9sWC3ZesVHQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">226400</capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty>
    <capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CsmcMember_qFit8CulBkqXDIzMZnp4pg"
      decimals="0"
      id="Narr_OH82nulXJkW_HTqofQOkyg"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">794000</capr:PaymentsForReimbursementForResearchAndDevelopmentLicensePatentFeesAndFacilitiesRentExpensesIncurredRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Tb_UmF8g0V2SESDatZD5cHFtg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;9.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;SUBSEQUENT EVENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Additional Sales under ATM Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to December 31, 2023 and through March 7, 2024, the Company sold an aggregate of 251,347 shares of common stock under the ATM Program at an average price of approximate $4.50 per share for gross proceeds of approximately $1.1 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to the placement agent in the aggregate amount of approximately $35,900. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Option Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, the Company granted a total of 2,203,726 stock options to its employees, certain non-employee consultants, and directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;License and Service Agreement &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2024, we entered into a License and Services Agreement with Azzur Cleanrooms-on-Demand &#x2013; San Diego, LLC (the &#x201c;Azzur License Agreement&#x201d;) pursuant to which we have been granted an exclusive license to use certain space and the non-exclusive right to use certain equipment and property for our early phase clinical and/or pre-clinical manufacturing purposes. Our estimated license fee is approximately $120,500 per month for a term of approximately 6 months.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA"
      decimals="INF"
      id="Narr_HGjV5w_FAkWPtN9C0kobHQ"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">251347</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i1t2nRzziUyi6BVPUlI6Pw"
      decimals="2"
      id="Narr_xwVIqL5QZUmjEFwre27aaQ"
      unitRef="Unit_Divide_USD_shares_b33qTPYQvki6KipDNHrHsA">4.50</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA"
      decimals="-5"
      id="Narr_fzH2s-4p0USdfZj0SBzddA"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">1100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9kivXfAsQUqTcso9wW9vqA"
      decimals="0"
      id="Narr_a2RhIM3K8EKahzsXYSTZkQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">35900</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_capr_EmployeesNonEmployeeConsultantsAndDirectorsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_9vSuYHyy80Soi04pDnBeCg"
      decimals="INF"
      id="Narr_L5U4-2P6KEykFIKHf3jnEg"
      unitRef="Unit_Standard_shares_49COgzvYRkSizuPr91icIw">2203726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <capr:LicenseFee
      contextRef="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ"
      decimals="0"
      id="Narr_0nN7IEIMyU2i8On29nHwRQ"
      unitRef="Unit_Standard_USD_KtyDuxlZKEaK826l451vFA">120500</capr:LicenseFee>
    <capr:TermOfLicense
      contextRef="Duration_2_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_capr_LicenseAndServicesAgreementMember_duJB4Z8UEkGjgMl82hE6vQ"
      id="Narr_9yTcX-uTUkCtzFKesUjsig">P6M</capr:TermOfLicense>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_1N3UwuJe0kiA2IsKnwJL8A">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_-iYJK5fbo0Ca2XMaJx_mTg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_-ClHLAKz7EWxFANqWfpR6A">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_lAO5aYBVX0ShMaRDrXmfPw"
      id="Narr_Oq8TxgBkW0-JUwAgk-Lk5g">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
